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ABSTRACT
ABSTRACT
Bovine herpesvirus 1 is the cause of a severe 
respiratory disease in cattle known as infectious bovine 
rhinotracheitis (IBR). Restriction endonuclease analysis 
(REA) of thirteen Irish BHV1 isolates indicates that both 
BHV1 genotypes (BHV1.1 and BHV1.2) are present here. 
BHV1.1 has being associated with some of the more severe 
clinical diseases signs in recent years.
A PCR assay to detect BHV1 was developed using 
oligonucleotide primers chosen from the thymidine kinase 
(TK) gene. The assay was sensitive (< 1 TCID50) and
specific for BHV1 and did not detect the live anti-IBR 
vaccine Tracherine (SmithKline Beecham). REA of PCR 
product with the enzymes Hae II and Taq I showed fragments 
of the expected size. Partial sequence data obtained from 
the amplification product also correlated with the 
published sequence data from this region.
The assay was also designed to detect BHV5 (formerly 
known as BHV1.3) which causes fatal encephalitis in young 
calves. Amplified product from BHV5 could be distinguished 
from that of BHV1 on the basis of product size and by 
restriction analysis with the restriction enzyme Taq I.
The PCR assay compared favourably to two other 
routine methods of BHV1 detection (fluorescent antibody 
test- FAT and virus isolation - VI) when applied to 105 
diagnostic submissions from cattle with respiratory 
disease during a winter period (1992-1993). When used to 
detect BHV1 in spiked semen samples, the assay detected 
virus at 1 TCID50 thus offering a very attractive 
alternative technique to V I .
Finally, the study involved the experimental 
inoculation of a BHV1.1 field isolate (associated with an 
outbreak of severe pharyngitis in neonatal calves) into 
calves. Mild clinical IBR infection ensued with little 
sign of the severe pharyngitis. Using REA isolates 
remained genotype BHV1.1 after passage in infected 
animals. PCR detected BHV1 in more nasal secretion samples 
from infected calves than either VI or FAT.
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CHAPTER 1
INTRODUCTION
1 . 1  THE HERPESVIRUSES
Collectively and individually herpesviruses are 
versatile pathogens and cause a variety of clinical 
entities. Extensively studied in man they cause systemic 
diseases such as chicken pox (varicella zoster virus), 
while also associated with such derangements of cellular 
growth as Burkitt's lymphoma (Epstein-Barr virus). In 
animals clinical disease signs caused by herpesviruses 
range from such relatively mild conditions as 
conjunctivitis in cattle (bovine herpesvirus 1) to highly 
fatal malignancies such as encephalitis in pigs 
(Aujeszky's disease virus). The diverse nature of symptoms 
and complex epidemiologic features associated with them 
place herpesviruses as one of the most important as well 
as most interesting viruses in the realms of human and 
veterinary medicine.
The word "Herpes" has been used in medicine for at 
least 25 centuries originating from the greek word to 
creep. In the time of Hippocrates it was used to describe 
shingles and it continued to designate a variety of skin 
conditions up to the 19th century. The modern notion of 
herpes restricted the term to the appearance of localised 
groups of vesicles. While the study of viruses lagged 
behind that of bacteria in the earlier part of the 20th 
century advances in science such as cell culture, 
filtration, crystallisation, ultracentrifugation, negative 
staining and electron microscopy permitted the 
characterisation of viruses with regard to size, shape and 
surface structure leading to the identification of large 
numbers of groups or families of viruses. The 
herpesviruses were the first group of animal viruses to be 
investigated using these techniques.
A comprehensive review of the history of
herpesviruses is given by Wildy (1973). In 1971 The 
International Committee on Nomenclature of Viruses agreed
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that the herpesviruses should be assigned the taxonomic 
rank of genus, named herpesvirus and given the following 
definition:
Virions contain one molecule of linear DNA having Mr 70-150 
x 106 and 35- 75% G+C. There are more than 20 structural 
polypeptides, Mr 12-220 x 103. The proportion of lipid is 
uncertain; carbohydrate is largely covalently linked to 
proteins in the envelope; there are at least 6 
glycoproteins. The Mr of the virion is 1000 x 109. Buoyant 
density in CsCl is 1.20-1.29 g/ml. Characteristic 
morphology is spherical enveloped particle, 120-200 nm in 
diameter comprising (a) core capsid consisting of protein 
spool round which DNA is wrapped, (b) capsid 100-110 nm in 
diameter comprising 162 hollow prismatic capsomers 
arranged in accordance with icosahedral symmetry, (c) 
tegument composed of globular material surrounding the 
capsid, (d) envelope with surface projections comprising 
a lipid bilayer in which is embedded the glycoproteins 
which form the surface antigens and which are important 
immunogenically.
FIGURE 1.1
THE SCHEMATIC ARCHITECTURE OF A  HERPESVIRUS
Envelope with 
projections
Tegument
Capsid
Figure 1.1 Typical herpesviral architecture consisting of 
the capsid, tegument and envelope (Adapted from Minson 
1989).
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Since 19 71 more than 100 herpesviruses have been 
characterised and have been found in insects, reptiles, 
amphibia, as well as in virtually every species of bird 
and mammal that has been investigated. A comprehensive 
list of herpesviruses, their host species and associated 
diseases are reviewed by Roizman et al. (1991). 
Herpesviruses spread from host to host by direct contact 
or by the transfer of infected droplets via the 
respiratory route. An important attribute governing their 
propensity to perpetuate in nature is their ability to 
become latent in vivo with subsequent reaction in some 
cases after prolonged intervals.
Although alike in their virion structure 
herpesviruses display a remarkable degree of diversity in 
the following: (i) properties of their DNA, (ii) gene
content and linear arrangement of genes in their viral 
genomes, (iii) host range and duration of reproductive 
cycle and (iv) the mechanism by which the viruses maintain 
a latent state in the host. They have been subdivided by 
the International Committee on Taxonomy of Viruses (ICTV) 
(Roizman et al., 1991) into three groups based on their 
biological and molecular properties - Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae.
Alphaherpesvirinae: The members of this family are
classified on the basis of a moderately wide host range, 
rapid growth and lysis of infected cells (hours rather 
than days) and the capacity to establish latent infections 
primarily, but not exclusively, in nerve ganglia. Examples 
include herpes simplex virus 1 (HSVl), bovine herpesvirus 
1 (BHV1), and equine herpesvirus 1 (EHV1). 
Betaherpesvirinae: Most members have a restricted host
range. Their replicative cycle is long and the infection 
progresses slowly in culture, with cell lysis occurring 
several days after infection. Infected cells often become 
enlarged. The virus can be maintained in the latent form 
in secretary glands, lymphoreticular tissue, kidneys, and 
other tissues. Examples include equine herpesvirus 2 
(EHV2) and mouse cytomegalovirus (MCV).
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Gammaherpesvirinae: Members of this group have a narrow 
host range. All members replicate in lymphoid cells and 
some also cause cytocidal infections in epithelial and 
fibroblastic cells. Viruses in this subfamily are specific 
for either T or B lymphocytes which may be transferred to 
tumours. Examples include the Epstein-Barr virus (EBV) and 
bovine herpesvirus 4 (BHV4).
1.2 THE BOVINE HERPESVIRUSES
Those herpesviruses that infect cattle have been 
divided into five main groups: bovine herpesvirus 2
(BHV2), (what was previously called BHV3 has been 
reclassified as alcelaphine herpesvirus 1*)/ bovine 
herpesvirus 4 (BHV4), bovine herpesvirus 5 (BHV5),
pseudorabies virus (PRV) and finally the subject matter of 
this thesis bovine herpesvirus 1 (BHVl).
1.2.1 Bovine Herpesvirus 2 (BHV2)
Bovine herpesvirus 2 is a member of the 
alphaherpesvirus family and has been reviewed by Scott 
(1989). It exhibits two different clinical forms: 
mammallitis and pseudo-lumpyskin disease. Pseudolumpyskin 
disease is a generalised skin disease of cattle 
characterised by mild fever and the appearance of nodules 
on the skin. Mammallitis is predominantly a disease of 
dairy cattle associated with lesions localised to the 
teats, which occasionally spread to the udder of cows and 
heifers. The virus has a worldwide distribution and it was 
first isolated in Ireland in 1979 (Lenihan et al., 1985).
1.2.2 Bovine herpesvirus 4 (BHV4)
The classification of BHV4 was, until recently, a 
matter of dispute. Characteristics, such as being highly 
cell associated, slow growth in tissue culture with 
minimal detectable cytopathic effects in cell culture led 
to it being originally classified as a cytomegalovirus and 
referred to as bovine cytomegalovirus (Ludwig et al.,
1983). Genomic data, including its genomic organisation
designates it as a member of the B group of herpesviruses 
and it has since been classified as a gammaherpesvirus and 
is now known as BHV4 (Thiry et al., 1992). Despite a high 
prevalence of antibodies in the cattle population of the 
United States of America and other countries little 
information is available on the pathogenesis of BHV4 (Naeem 
et al., 1991). BHV4 has been isolated from cows with 
various clinical conditions including ocular and 
respiratory diseases, reproductive or genital diseases, 
skin lesions and enteric diseases while it has also been 
isolated from healthy cattle (Osorio and Reed, 1985). 
Because of its slow growth it is often difficult to detect 
in clinical samples by the conventional technique of virus 
isolation.
1.2.3 Bovine herpesvirus 5 (BHV5)
BHV5 is the newest member of the bovine herpesviruses. 
It was originally referred to as BHV1.3 and is responsible 
for encephalitis in young calves. The first isolation of 
the virus was from an outbreak of fatal encephalitis in 
calves in Australia (French 1962). The course of disease is 
rapid and fatal. The disease is characterised by ataxia and 
depression, followed by frenzied movements, frothing from 
the mouth and nostrils, convulsions and death. The disease 
has since been reported in Australia, The United States, 
Canada and Argentina (Straub 1990). Apart from one reported 
isolation of the virus in Hungary from calves suffering 
from encephalitis (Bartha et al., 1969), there have been no 
other reports of the isolation of the virus in Europe. 
Theoretical calculations (Mayfield et al., 1983) and cross 
hybridisation studies (Seal et al., 1985) suggest that 
there is a genetic homology of 85% between BHVl and BHV5.
1.2.4 Aujeszky's disease virus (ADV)
Aujeszky's disease virus also known as pseudorabies 
virus (PRV) is primarily associated with pigs. Aujeszky's 
disease has been comprehensively reviewed by Wittmann 
(1989), and is characterised by a fatal non purulent
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encephalomyelitis. ADV may also cause similar disease signs 
in cattle and sheep with infected animals rarely 
recovering. Such an infection in cattle has been reported 
in Ireland (Power et al., 1990).
1.3 BOVINE HERPESVIRUS 1 (BHV1)
Bovine herpesviruses (BHV1) is an important pathogen 
of cattle. It is a member of the genus Varicellovirus in 
the subfamily of alphaherpesvirinae (Roizman, 1992). The 
virus is primarily associated with respiratory tract 
infections and causes a condition known as infectious 
bovine rhinotracheitis (IBR). Cattle of all ages are 
susceptible to BHV1 infection. With increasing stress of 
high stocking density, respiratory disease has become 
considered as the single greatest risk in many intensive 
cattle farms, especially feedlots (Healy et al., 1993).
The virus is also associated with a variety of other 
disease manifestations and possesses one of the broadest 
tissue tropisms of any virus that infects domestic animals 
(McKercher, 1973). As a result, BHV1 has been designated a 
number of synonyms after the diseases syndromes with which 
it has been associated. These include the following: 
infectious bovine rhinotracheitis virus (IBRV), infectious 
pustular vulvaginitis virus (IPW), infectious pustular 
balonoposthisis virus (IPBV). The spectrum of diseases it 
can cause in cattle also includes conjunctivitis and 
abortion (Wyler et al. , 1989 ). The virus has also been
isolated from young calves with systemic disease signs 
(Higgins and Edwards 1986; personal communication Power, 
1996) .
1.3.1 The History of BHVl
The history of BHVl has been comprehensively reviewed 
(Yates et al., 1982). Classical infectious bovine
rhinotracheitis was first identified in the 1940s when 
respiratory disease, characterised by severe laryngitis and 
tracheitis swept through cattle in feedlots in Colorado 
(Miller et al. , 1955). Later, the same infection assumed
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epizootic proportions in Western American feedlots in the 
1950's and some outbreaks in Europe in the 1960's could be 
traced to imports of cattle from Northern America. The 
causative agent was isolated (Madin et al. , 1956) and
identified subsequently as a herpesvirus making BHV1 the 
first viral agent shown to cause respiratory disease in 
cattle. The virus was soon isolated from cattle infected 
with conjunctivitis, vulvovaginitis, and from aborted 
fetuses. Much to the surprise of many virologists the virus 
isolated was identical to that causing IPV-IPB (infectious 
pustular vulvovaginitis-balanopostitis. IPV-IPB had existed 
in Europe for at least 100 years and was regarded as a 
venereal disease of old world cattle, which had reached 
America and Australia by the importation of infected cattle 
(Me Kercher et al., 1973).
1.3.2 Pathogenesis and clinical manifestations of BHV1
The clinical effects of BHV1 infection may be 
separated into respiratory and non-respiratory 
manifestations and have been described in review articles 
by Yates et al. (19 82); Kahrs et al. (1977): Fenner et al. 
(1988); Wyler et al. (1989) and Straub (1990).
(A1) Infectious bovine rhinotracheitis (IBR):
IBR is a rapid necrotising infection of the trachea, 
larynx, nasal and conjunctival surfaces. In mild 
uncomplicated IBR, the changes consist of a slight to 
moderate rhinitis with slight serous exudation into the 
nasal cavity. In more severely affected animals the 
inflammation also involves the pharynx and the trachea. The 
exudate, at first serous, becomes catarrhal and eventually 
fibrinous in nature as necrosis of the inflamed surfaces 
occurs. This then adheres to the walls of the nasal 
passages, the larynx and the trachea in which it forms a 
yellowish fibrinous pseudomembrane.
Signs of respiratory infection vary from unapparent to 
severe. Infection is characterised by the onset of high 
fever with rectal temperatures in excess of 40°C. 
Clinically, cattle become dull and anorectic; coughing,
nasal discharge, foaming salivation, hyperpnoea and 
dyspnoea are the most evident clinical signs. 
Conjunctivitis frequently accompanies the respiratory signs 
or it may occur as an almost exclusive sign. It may be 
either uni- or bilateral with excess ocular secretions 
changing from clear to mucopurulent as the disease 
progresses. As nasal secretions increase milk production of 
dairy cows drops and animals go off their feed with a 
consequent loss of weight. The most severe clinical signs 
are seen 3-4 days after infection. In the course of an 
uncomplicated infection, clinical signs last from 7-10 
days.
Bronchopneumonia is sometimes found in advanced cases 
particularly when secondary bacterial disease occurs such 
as that caused by Pasteurella heamolyitca. Superimposed 
viral infections such as bovine respiratory syncytial virus 
(RSV) or bovine parainfluenza virus 3 (PI3) can also give 
rise to more serious clinical signs.
On histopathologic examination, the mucosa is found to 
contain migrating neutrophils while lymphocytes, 
macrophages and plasma cells infiltrate the submucosa. 
Cellular desquamation and diffuse necrosis occur at the 
attachment of the membrane to the underlying epithelium. 
Eventually the entire epithelial surface is eroded. This is 
accompanied by the congestion of the underlying blood 
vessels. Inclusion bodies are present in the tracheal 
epithelium after 36 hours, while after 48-60 hours they are 
found in the cells of the turbinates and bronchi.
While the infection principally concerns the upper 
respiratory tract the virus may spread directly to the lung 
or by viraemia thus gaining access to a broader range of 
tissue and organs including the digestive tract or 
reproductive organs and cause a variety of diseases.
(B1 Genital diseases:
BHV1 causes genital disease in both males and females 
causing infectious pustular vulvovaginitis (IPV) in cows 
and infectious balonoposthithis (IPB) in bulls.
IPV is most commonly recognised in dairy cows. It has
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a short incubation period lasting 24 - 7 2  hours and is 
followed by an undulating febrile response of several days 
duration. Infection may be sub-clinical and may go 
unnoticed. The vulva may be slightly swollen while vesicles 
may be present with a small amount of tenacious discharge. 
Affected cattle usually stand with their tail slightly 
elevated and make obviously painful attempts to urinate. 
The acute stage of the disease lasts 4 - 5  days and 
uncomplicated lesions heal by 10-14 days although many 
cases are subclinical or go unnoticed. Infection may lead 
to a drop in fertility or infected cows or heifers may go 
on to produce still born calves (Miller et al. , 1988).
The clinical symptoms of IBP are limited to the 
preputial, penile and sometimes the distal portion of the 
urethral mucosa. The progress of the disease is similar to 
that described for IPV, but healing of the epithelial 
lesions often requires more time. During the first days 
post infection (p.i.) bulls serve normally, but usually at 
days 3 or 4 p.i., probably due to the discomfort caused by 
the preputial swelling. Temperatures may be as high as 
40.5°C - 41.5 °C. During the peak of the inflammation
process some animals go completely off their feed leading 
to considerable weight loss. Four weeks p.i. small 
hyperaemic nodules may still be visible on the penile 
mucosa. A sequel may be that some bulls are reluctant to 
start servicing again while those that are used may spread 
of the disease.
(CM Abortion:
BHV1 has been isolated from cases of abortion often in 
the first trimester.
(PI Other diseases:
In young calves the infection may be more systemic 
involving many organs systems (Ross et al., 1983; Higgins 
and Edwards, 1986). Metritis, dermatitis, diarrhoea and 
mastitis have been associated with BHVl infections, while 
BHV1 has infrequently been reported to cause fatal 
encephalitis in cattle (d'Offay et al., 1993).
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The following properties of BHV1 have been summarised 
by Wyler et al. (1989).
1.4.1 The architecture of BHV1
The BHV1 virion is an enveloped entity with typical 
herpetic structure. Innermost, the DNA genome is wrapped 
around a fibrous spool-like core, the fibres of which are 
anchored to the inner side of the surrounding capsid. The 
capsid is an icosahedron of lOOnm in diameter, composed of 
162 hollow capsomers, of which 150 are hexomers and 12 are 
pentamers. Between the capsid and the envelope lies the 
tegument which carries the glycoprotein peplamers. The 
entire contents described above are contained within the 
lipid envelope (see Figure 1.2). Embedded within the 
envelope are the glycoproteins which allow interaction with 
the host cells.
1.4.2 Physicochemical properties
Bovine herpesvirus 1 has a buoyant density of 1.22 g/1 in 
potassium tartrate gradient and 1.249 in caesium chloride 
and its sedimentation coefficient is 1680-1830.
1.4.3 Biological properties
Host and cell range; The virus can be recovered from many 
animals following infection however distinct clinical 
manifestations have only been found in cattle. BHV1 may be 
propagated in vitro using primary and continuous cell lines 
of known susceptibility. The virus grows in a wide variety 
of cell cultures prepared from a range of adult and foetal 
bovine tissues including kidney, lung, skin, adrenal, 
thymus and lymph node. It also replicates in cell lines 
derived from goat, lamb, mouse, pig and rabbit kidney. 
Madin Darby Bovine Kidney (MDBK), a continuous cell line, 
and foetal bovine kidney (FBK), are most frequently used to 
propagate the virus in many laboratories.
1.4 PROPERTIES OF BHV1
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Virus propagation: The path of BHV1 infection in bovine 
cells has been described by Mohanty and Dutta (1982). For 
infection to occur, the virion particles must absorb and 
penetrate the cell membrane. This requires a receptor in 
the cell membrane and a corresponding attachment protein in 
the virion envelope. Initial interaction between virus and 
the cell is electrostatic in nature as is fusion between 
the virus and the cell membrane. Entrance of the viral 
nucleocaspids into the cytoplasm results in an interaction 
with intracellular lysosomes. The lysosomal proteolytic 
enzymes dissolve the protein capsid and release the viral 
DNA. The lysosomal vacuoles release the viral DNA into the 
nucleus.
The replication mechanism of BHV1 is similar to that 
of the extensively studied alphaherpesvirus herpes simplex 
virus (HSV) and has been described by Fenner (1988). 
Following adsorption to host cell receptors via the 
glycoprotein peplomers of the envelope, the nucleocapsid 
enters the cytoplasm either by fusion of the envelope to 
the cell membrane or via a phagocytic vacuole. A DNA- 
protein complex is then freed from the nucleocapsid and 
enters the nucleus. Three classes of mRNA are transcribed 
by the cellular DNA-dependant polymerase II in a 
coordinated, regulated and sequentially ordered cascade. 
Thus alpha or immediate early (IE) RNAs, when appropriately 
processed to mRNAs, are translated to alpha proteins, which 
initiate transcription of beta (early) mRNAs, whose 
translated products beta (early) proteins, suppress the 
production of further alpha mRNAs. Viral DNA replication 
then commences, this utilises some of the alpha and beta 
protein as well as host cell proteins. The programme of 
transcription then switches on once again, and the 
resulting gamma (late) mRNAs, which are transcribed from 
genes scattered throughout the genome, are translated into 
gamma proteins. Many of the alpha and beta proteins are 
enzymes/nonstructural proteins while most of the gamma 
proteins have structural functions. Intricate controls must 
regulate this sequential gene expression at the level of
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both transcription and translation.
Viral DNA is replicated in the nucleus utilising a 
rolling circle mechanism: circularisation of the genome is 
brought about by bonding of the terminal sequences. 
Concatemeric DNA is cleaved and packaged into preformed 
immature capsids. Host cell DNA, RNA and protein synthesis 
decline concomitantly with viral biosynthesis and ceases 
after 3-5 hours.
Maturation involves the encapsidation of DNA into 
nucleocapsids and the association of nucleocapsids with 
altered areas of the inner layer of the nuclear membrane. 
An envelope develops around the nucleus during the process 
of budding. Mature virions accumulate within vacuoles in 
the cell cytoplasm and may be released slowly by vacuolar 
membrane fusion and exocytosis or by cytolysis. Virus 
specific proteins, possibly similar to those that become 
associated with the nuclear membrane and determine the 
sites of nucleoprotein binding, are also found in the 
plasma membrane, where they are involved in cell fusion. 
These may act as targets for antibody binding, and are 
presumed to be targets for immune cytolysis. Each infected 
cell produces up to 105 virus particles.
Infection of cells produces pronounced cytopathic 
effect (CPE) within 24-48 hours with ballooning degradation 
and polykcryocytosis. Regardless of the type of cell 
culture employed in the laboratory, the cytopathic effects 
produced are morphologically similar. Inclusion bodies 
known as Cowdry type A are present in infected cells in 
vivo and in cell cultures in vitro. These are 
characteristically recognised when appropriately fixed and 
stained and these may be observed in fluorescent antibody 
staining. Soon after CPE small aggregates of finely 
granular acidophilic material appear from among the nuclear 
chromatin and collect slowly into a mass which eventually 
occupies the major portion of the nucleus. The nucleolus 
slowly disappears or is displaced to the nuclear margin 
where it remains as a small basophilic body. The mature 
inclusion body is round, oval or irregular in contour
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although it conforms generally to the shape of the nucleus. 
It is separated from the nuclear membrane by a clear zone 
or halo.
The production of empty envelopes in some BHV1 strains 
has been reported (Moussa, 1993). These envelopes are 
derived from the inner layer of the nuclear membrane by a 
mechanism similar to that involved during the envelopment 
of nucleocapsids at nuclear membrane level. They accumulate 
in the perinuclear spaces and in endoplasmic reticulum 
until liberated outside the cell. The envelopes are usually 
round in shape and can exist in the non closed circle with 
a diameter ranging from 110-130 nm.
1.5 GENOMIC PROPERTIES OF BHVl
1.5.1 The BHVl genome
BHVl has now been extensively studied at both the 
molecular and clinical level. As the analysis of other non­
human herpesviruses is much less advanced, BHVl now serves 
as the prototype member of the ruminant herpesviruses. The 
genome of BHVl has a molecular weight of 140 Kbp with a GC 
content of 72% (Roizman and Baines, 1991). The
configuration of the genome places it in group D of the 
herpesviruses. In this group the sequences from one 
terminus are repeated in an inverted orientation
internally. The domain consisting of the stretch of unique 
sequences flanked by inserted repeats (Small or s component) 
can invert relative to the remaining sequences (Large or L 
component) such that the DNA extracted from the virions or 
infected cells consist of two equimolar populations
differing solely in the relative orientation of the S 
component relative to the L component (Roizman, 1982).
13
FIGURE 1.2
THE D CONFIGURATION OF BOVINE HERPESVIRUS 1
UL URg Us IRS
Figure 1.2 shows the genomic configuration of the BHVl 
genome which consists of a unique (U) long (L) and a unique 
short (s) segment; the latter which is flanked by inverted 
repeat sequences and can invert its orientation relative to 
its L component to yield two isomeric forms (Farley et al., 
1981).
The nucleotide sequence of the BHVl genome has been 
determined (Schwyzer and Ackermann, 1995). The available 
sequence comprises 60 unique genes and 2 genes, both 
duplicated, in the inverted repeats. Genes are nominated 
according to their position on the UL and Us position on the 
genome. It has been postulated (Engels et al., 1995) that 
the herpesviruses contain at least 2 sets of genes, one 
involved in gene expression and viral replication and a 
second set responsible for functions which may affect 
pathogenesis, latency and virus/host interactions.
1.5.2 BHVl genotypes
BHVl is associated with a variety of clinical entities 
described in 1.3.2. Since these manifestations are 
clinically very different and because respiratory 
infections are rarely found in conjunction with genital 
lesions, it was originally suggested that different types 
of BHVl viruses were responsible for specific syndromes. 
Attempts to characterise BHVl genital and respiratory 
isolates into subtypes on the basis of their antigenic and 
polypeptide properties proved difficult and revealed little 
if any differences between isolates (Bagust 1972, Pastoret 
et al., 1980; Gregersen et al., 1985). It was only with the 
advent of restriction endonuclease analysis (REA) of the 
BHVl genome that more precise characterisation of BHVl
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strains was possible. Using REA, BHV1 could be 
differentiated into two basic genotypes based on the 
restriction patterns given by the restriction endonucleases 
Hind III and Eco R1. These genotypes were known as the 
Copper and the K22 type (Engels et al., 1981:, Mayfield et 
al., 1983) and have also referred to by others as IBR and 
IPV-like respectively (Misra et al., 1983) and finally as 
BHVl.1 and BHVl.2 (Metzler et. al, 1985). Genotype BHV1.2 
could can further differentiated into BHVl.2a and BHVl.2b 
using the enzyme Hind III or Hpa 1 (Edwards et al., 1990).
The BHVl genome and its identified genes are also 
often described in terms of its Hind III genomic map. Hind 
III divides the genome into 16 fragments which are named A 
- P in order of decreasing magnitude of size (see Table 
1 .1 ) .
Both BHVl.1 and BHVl.2 have been recorded in Europe 
(Engels et al., 1981, Mayfield et al. , 1983) and Canada
(Misra et al., 1983). Whether or not clinical disease was 
related to the newly elucidated BHVl genotypes has been the 
subject of much investigation. Some initial studies linked 
BHVl.1 to respiratory disease and BHVl.2 to genital disease 
(Engels et al., 1981, Mayfield et al., 1983). However
BHVl. 1 has been shown to be linked with a variety of 
clinical signs including rhinitis, diarrhoea, pneumonia, 
abortions, peritonitis and conjunctivitis (Wyler et al. , 
1989) indicating that this strain is not exclusively 
involved in respiratory disease. It also shown that further
strains isolated from respiratory and genital disease
displayed BHVl.2 restriction patterns (Metzler et al. , 1985 
and Edwards et al. , 1990). With earlier evidence that
genital isolates could cause respiratory infections and
vice versa, and that combined respiratory and genital 
infections, although rare, do occur (House et al. , 1972) it 
is more likely that it may be routes of infection and/or 
other environmental factors such as social habits and 
management that determines whether a particular isolate 
causes a specific disease syndrome. Thus in densely crowded 
fattening feedlots the mainly sexually inactive animals
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would be more likely to acquire respiratory infections 
whereas in Europe the practice of natural servicing and 
relatively uncrowded pastures would favour the genital 
form.
TABLE 1.1 
THE BHV1 HIND III GENOMIC MAP
Assigned 
Hind III Letter
Sizes in Kilobases (Kb) of BHVl 
restriction fragments
BHVl.1 BHVl.2
A 21.20 21.20
B 18.95 18.95
C 16.35 16 . 35
D 15.80 15.80
E 14.00 14.00
F 13.00 13.00
G 12.25 12.25
H 12.25 12.25
I 11.95 10.85
J 9 .30 9.15
K 8.55 7.87
L 8.03 7.27
M 3.75 3.75
N 2.55 2.55
0 1.90 1.90
P 1.50 1.50
Table 1.1 presents the sizes in kilobases of the Hind III 
fragments of BHV1. Cleavage of the BHVl genome followed by 
the separation of fragment using gel electrophoresis 
permits the distinction of BHVl. 1 from BHVl. 2 by the 
mobility of fragments K and L (Adapted from Data presented 
in reports by Bulach and Studdert 1990 and Engels et al., 
1986/97). BHVl. 2 can be further divided into fragments 
BHVl. 2a and BHVl. 2b due to the mobility of fragment I. This 
fragment size approximates to 11.95 Kb in BHVl.2a isolates
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and 10.8 kb In BHV1.2b isolates.
The virulence of the disease, however, does appear to 
be associated with the genotype (Msolla et al., 1983). From 
197 7 onwards a more virulent form of the disease emerged 
and spread rapidly to most regions of Britain (Wiseman et 
al, 1978; Edwards, 1988). Studies indicated that a change 
in the predominant genotype of BHV1 in Scotland (Nettleton 
1986) and in the United Kingdom (Edwards et al., 1990) 
coincided with an the increase in the number of BHV1.1 
isolates. Further studies on calves experimentally infected 
with BHVl.1 and BHV1.2 genotypes proved that those infected 
with BHVl.1 had a higher clinical score reflecting more 
severe clinical signs than those infected with BHVl.2 
(Edwards et al., 1991).
In Australia the more severe BHVl outbreaks that have 
historically plagued farming communities in the USA and 
Europe have not occurred to date. REA of Australian BHVl 
isolates have shown only the existence of subtype BHVl.2 
(Smith et al., 1993).
1.6 THE GLYCOPROTEINS OF BHVl
The BHVl genome is now known to consist of 9 
glycoproteins (gB, gC, gD, gE, gG, gH, gl, gK, and gL), 
(Schwyzer and Ackermann, 1995). In general, these genes 
exhibit strong homology at the amino acid sequence level to 
those of other alphaherpesviruses (Herpes Simplex Virus 
(HSV), Varicella Zoster Virus (VZV), Equine herpes virus 1 
(EHV1), Aujeszky's disease virus (ADV) and are arranged in 
similar order. As in other herpesviruses the glycoproteins 
are synthesised and incorporated into the BHVl envelope. 
Glycoproteins located on the viral envelope and on the 
surface of infected cells play an important role during 
viral infection such as recognising receptor sites for 
attachment and penetration of virus in cell attachment, 
cell penetration, cell-to-cell spread and cell egress. As 
a result, glycoproteins have received much attention in 
order to elucidate their importance in initiating virus 
infection as well as further defining the role of the host
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cell mediated immunity. The comparison of these proteins at 
nucleotide and amino acid level with their counterparts in 
other herpesviruses should reveal which of these may be 
suitable targets for diagnosis, vaccine development or 
antiviral treatment.
Four glycoproteins (gB, gC, gD gE) have been studied 
extensively to date and the function of the others has also 
been elucidated but had not been published at the time of 
writing. Table 1.2 shows the sizes, putative functions and 
homologies to the glycoproteins in HSV1.
TABLE 1.2
BHV1 GLYCOPROTEINS AND THEIR PUTATIVE FUNCTIONS
GLYCO­
PROTEIN
SIZE FUNCTION HSV HOMOLOG
gB1 2 3 130 Kda Attachment 
and penetration
gB 56%
gC4 9 OK 10 Haemagglutination gC
gD5 71 kd 10 Penetrates 
cells/cell 
to cell spread
gD 12
(PRV) 75% 
(HSV1)65%
gE6 108 Kda Cell to cell spread gE ■
gH7 ■ ■ gH ■
1 Mlsra et al., 1988, 2 Lawerance et al., 3 1986 Whitbeck et
al., 1988, 4 Misra et al., 1981, 3 Tikoo et al., 1990, 6
Baronowski et al., 1995, 7 Meyer et al., 1991. ■ = No
available information. No published information is
available on glycoproteins gG, gl, gK, gL
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1.7 BOVINE HERPESVIRUS 1 THYMIDINE KINASE ENZYME
The thymidine kinase (TK) gene has been extensively 
studied in the alphaherpesviruses including BHV1. [A 
comprehensive review on the herpesvirus TK enzyme 
[(ATP:thymidine 5' phosphotransferase;EC 2..7.1..21) is 
given by Kit et al., 1985].
Many eukaryotic cells contain both cytoplasmic and 
mitochondrial forms of the TK enzyme. In synchronised 
populations of cells, cytoplasmic TK activity is low in 
resting or G1 phase cells. It increases dramatically with 
the onset of DNA synthesis (S phase), and then declines to 
very low levels in the G2 phase. In terminally
differentiated cells, such as cardiac muscle or nerve 
cells, the cessation of DNA synthesis and withdrawal from 
the cell cycle are accompanied by the loss of cytoplasmic 
TK activity. However, mitochondrial TK activity persists 
and accounts for the low level of residual TK activity. 
Cytoplasmic TK activity is readily induced following 
release of resting phase cells from G1 arrest by serum 
stimulation or by viral infection. Virally encoded TK 
enzymes duplicate and augment the activity of cellular 
enzymes. Consequently deoxythymidine salvage is more
efficient, dTTP pools expand and virus DNA synthesis is 
facilitated. The enzyme can be distinguished from host cell
TK by its ability to use CTP in place of ATP as the
phospahte donor in DNA synthesis.
From the study of HSVl which is considered to be the
prototype alphaherpesvirus, it is well established that 
following infection a number of virus induced enzymes are 
produced within the host cell (Kit, 1985). Herpesvirus TK 
genes are transcribed in the cell nucleus by an RNA
polymerase II enzyme and they belong to the kinetic class 
of early genes. Studies with HSV indicate that virus
induced TK is not essential for virus replication in cell 
cultures (Dubbs and Kit, 1964; Field and Wildy 1978) and 
the enzyme appears to be more important in the 
establishment and maintenance of neural latency (Field and 
Owen, 1988).
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Like HSV1, BHV1 codes for a viral thymidine kinase TK 
(Weinmaster et al.f 1982; Kit and Qavi, 1983) while the 
nucleoside sequences have been published for the TK genes 
of Equine Herpesvirus 1 (EHV1) (Robertson and Whalley,
1988):, HSV1 (Wagner et al, 1981):, HSV2 (Swain and 
Galloway, 1983):, Varicella zoster virus (VZV) (Davidson 
and Scott, 1986): Marmoset Herpes (MarHV) (Otsuka and Kit
1984), EBV (Baer et al. , 1984), herpes saimiri (Honess et 
al 1989) and herpesvirus of Turkeys (HVT) (Scott et al,
1989) .
The location and nucleoside sequences of the TK gene 
of both North American and European BHV1 strains have also 
been reported (Kit and Kit 1986; Bello et al., 1987: Mittal 
and Field 19 89). Smith et al. (1990) undertook a study to 
extend the sequence data available on the TK gene of 
different BHV1 subtypes to determine the degree of sequence 
variation between four BHV1.2a virus isolates. They found 
that all four Australian BHV 1.2a had identical nucleotide 
sequences, however significant variation was found when 
compared to BHVl.1 TK gene sequences. The sequence data 
obtained was used to compare the BHVl TK primary amino 
acids sequence with those of other herpesvirus TKs. Based 
on this study the amino acid sequence of the BHVl TK gene 
can be divided into four regions of strong homology which 
can be numbered I to IV. Region I has been reported to have 
homology with the proposed nucleotide-binding sites of 
other herpesvirus TKs, other TKs and other enzymes as 
diverse as adenylate kinase and myosin. Regions II and IV 
have a high degree of conservation among different 
herpesvirus TKs but similar sequences were not seen in 
poxvirus or mammalian TKs or adenylate kinases. Region III 
is a conserved sequence which in HSV has been implicated in 
the determination of substrate specificity of the enzyme.
The TK gene has received much attention because it 
encodes a potential target for chemotherapy or attenuation 
of vaccine strains and provides a useful selective marker 
for genetic diseases. Virally encoded TKs also have an 
important role in the mode of action of several nucleoside
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analogues which are potential inhibitors of virus 
replication. The selective antiviral activity of many 
nucleoside analogues depends on either (i) a unique or 
preferential activation by virus-encoded TKs e.g. acyclovir 
or (ii) the preferential trappings of drugs e.g. 
iododeoxyuridine due to the augmentation of total 
intracellular TK by viral TK activity.
Other gene products
Herpesviruses code for a number of genes capable of 
encoding several enzymes that catalyse reactions in the 
pathway of nucleoside metabolism. Four virally encoded 
enzymes thymidine kinase, DNA polymerase, ribonucleotide 
reductase and dUTPase have been described in the literature 
to date while several others have been reported in the 
proceedings of meetings (Unpublished). The gene coding the 
BHV1 deoxyuridine triphosphase dUTPase has been identified 
and sequenced (Liang et al., 1993). The gene has a homolog 
in the HSV1 genome (UL49.5). The dUTPase enzyme is a 
component of the de novo dTMP synthesis pathway, its 
function being to catalyse the degradation of dUTP into 
dUMP and PPi, dUMP then can be converted to dTMP by 
thimidylate synthetase. DNA sequence analysis of this 
region revealed an open reading frame (ORF) of 975 bp 
capable of encoding a 325 amino acid protein. The deduced 
polypeptide sequence exhibits significant homology with 
dUTPases of other herpesvirues (including human herpes 
simplex virus, varicella-zoster virus and Epstein-Barr 
virus) and it contains five conserved amino acid motifs 
characteristic of all dUTPases identified to date.
The nucleotide sequence of the UL 27 - UL 31 region 
encompassing about 1200 nucleotides in the long unique 
region of the BHVl Cooper strain has been determined (Meyer 
et al., 1995). This region contains three genes coding for 
the major DNA-binding protein (MDBP), the DNA polymerase 
and the ICP 18.5 homologous putative assembly protein.
The MDBP gene codes for a protein of 1204 amino acids 
with a predicted molecular mass of 127.4 kDa. The protein
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shares a homolog in the proteins of EHV1, PRV, VZV and HSV. 
Comparison of the amino acid sequences of the predicted 
proteins of BHV1 with the respective proteins in the above 
herpesviruses reveal a high homology ranging from 53.2% 
(HSV), 53.6% (VZV) to 61.3% (EHV1).
The BHV1 DNA polymerase which is located on the Hind 
III G fragment (Owen and Field, 1988). With the ICP18.5 
ORFs it translates into two polypeptides of 1247 and 827 
amino acids respectively with a calculated molecular mass 
of 134.2 kDa and 86.9 kDa. The overall conserved amino acid 
identity between the polymerase primary sequences was 59.5% 
(VZV), 61% (HSV-1), 69% (EHVl) and 68% (PrV) while that of 
ICP 18.5 was 46.5% (VZV), 53.2% (HSV1) and 58.2% (PRV). 
Both have been studied extensively as enzymes regulating 
nucleic acid metabolism and constitute important virulence 
determinants since mutants defective in them often impair 
infectivity In vivo.
Finally a group of regulatory proteins BICPO, 4, 22,27 
and B-TIF have been identified. Only information on BICPO 
has been published to date. Its role as an immediate-early 
transactivator protein BCIPO has been shown as a key 
element in the regulation of the replicative cycle of BHV1 
(Koppel et al., 1995).
1.8 IMMUNE RESPONSES TO BHV1
The bovine immune response to BHV1 is broad and 
complex with the exact mechanism not yet elucidated 
(Babiuk, 1995). In all reported cases exposure to BHVl has 
induced non-specific and specific responses which are 
capable of neutralising virus. These responses have been 
discussed in detail by Wyler et al.,1989, Straub 1990) and 
may be divided into humoral and cellular.
The Humoral Response
When born to BHVl seropositive dams calves possess 
maternal antibodies to BHVl which persist for about six 
months. These antibodies are acquired through colostrum 
ingestion while calves which do not receive colostrum
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produce their own antibodies sooner.
Immunogobulins made in the blood plasma and derived 
from B-lymphocytes are also produced following infection 
with class IgA and IgM antibodies present in the serum 
approximately 10 days post infection. More specific IgGl 
are produced later after primary infection while IgG2 are 
produced if cattle are re-exposed. In addition to including 
neutralising antibodies which prevent virus attachment and 
penetration, these antibodies can precipitate in antibody 
complement lysis of infected cells or in dependant cell 
cytotoxicity. Antibodies to BHV1 have been shown to persist 
for periods up to 3 years (Kasshoek et al., 1995). No 
correlation exists between the levels of immunoglobulin, 
virus excretion and the severity of clinical signs. Higher 
titres are usually the result of an infection of the 
respiratory tract, lower titres are found after genital 
infection.
Cell Mediated Immunity
In addition to an antibody response BHV1 infection 
induces a myriad of specific cellular responses termed cell 
mediated immunity (CMI) which plays an important role in 
the bovines defense against infection. This response
involves the production of cytokines which directly or 
indirectly inhibit virus replication by the activation of 
effector cells. These effector cells include phagocytic 
cells such as polymorphonuclear neutrophils, macrophages 
and natural killer (NK) cells which act with a complement 
mediated system. These effector cells can kill virus 
infected cells either directly or by interacting with 
antibody to induce death by antibody dependant cell
cytotoxicity. Another class of lymphocyte the T-cell also
plays a role in cell mediated immunity. T-helper cells 
release gamma-interferon which blocks viral replication in 
adjacently infected cells and while also activating
macrophages. Cytotoxic T cells have the ability to kill 
virus infected cell while they too release gamma- 
interf eron .
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1.9 LATENT BHV1 INFECTION
Despite a pronounced immune response, BHVl is not 
eliminated from the host following infection, due to the 
capacity of this virus to establish latent infection. Once 
infected with BHVl, a animal becomes a lifelong carrier and 
potential shedder of the virus. The virus can remain latent 
in infected but clinically normal animals and is harboured 
for long periods in ganglia and may be re-excreted at 
intervals with or without clinical signs of disease (Sheffy 
et al., 1972,: Snowdon et al., 1965,: Huck et al., 1973). 
It is this characteristic which is probably mainly 
responsible for the perpetuation of the virus in nature. It 
is also the most significant property of the virus from a 
disease control point of view, as virus present in latently 
infected cattle may reactivate under different conditions 
and spread throughout the environment. Ultimate disease 
control strategies must not only prevent clinical disease 
but must also interrupt the transmission of the virus in 
nature.
Though less well studied than some other members of 
the alphaherpesvirus group, available data on BHVl latent 
infection is generally consistent with the generic 
description of the path taken by herpesviruses after 
infection (Rock, 1994). Following infection, virus 
replicates at a mucocutaneous surface prior to entry into 
nerve axons. Direct uptake into axons may occur if the 
infecting dose of virus is sufficiently high. Virus then 
travels centripetally via retrograde, fast axonal transport 
to the cell bodies of neurons in sensory and autonomic 
nerve ganglia, and in some cases from there to the central 
nervous system. Neurons support both lytic and latent 
infection with alphaherpesviruses. The exact physical state 
of the viral particle during translocation is unknown. In 
the acute state of ganglionic infection, evidence of lytic 
virus infection in sensory neurons and accessory cells is 
observed and infectious virus may be recovered from 
ganglionic homogenates. Viral nucleic acids and proteins 
associated with lytic viral replication are easily detected
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in tissue samples, and ultrastructural examination of 
ganglionic neurons reveals evidence of reproductive virus. 
After the acute ganglionic infection subsides, virus 
persists as a DNA copy in neurons, probably for the life 
time of the host. Infectious virus is not recoverable from 
ganglionic homogenates during the latent phase. The 
molecular functioning of the virus during latency is a 
topic currently being researched. Lytic infection occurs in 
cells where lytic cycle genes, beginning with immediate- 
early (IE) genes, are expressed efficiently. During 
latency, restricted transcription (latency associated 
transcription - LAT) of the BHV1 genome occurs (Rock, 
1994). Transcription appears restricted to a 1.9 kb region 
contained completely within the unique long region to the 
inverted repeat of the viral genome. These LAT transcripts 
are anti-parallel to and overlapping an IE gene. Latent 
infection results where the efficient expression of viral 
IE genes and subsequent steps in the lytic cycle are 
prevented, perhaps by the presence of a repressor or 
absence of a positive regulator for IE gene expression.
Because virus can be reactivated from latently 
infected neurons, conditions must exist for shifting a non- 
permissive virus-cell interaction to a permissive one. It 
has been suggested that virus may be non-permissive under 
normal conditions (Lillycrop at al., 1991; Kemp et al.,
1990). If so, specific stimuli (which perhaps rarely occur) 
may be required for shifting them to a permissive state. 
Glucocorticoid-mediated BHV1 reactivation is likely to be 
a significant mechanism underlying the survival of BHV1 in 
natures naturally occurring stressful conditions may lead 
to increases in endogenous corticosteroids and subsequent 
viral reactivation followed by shedding in latently 
infected animals. Glucocorticoids are known regulators of 
both cellular and viral gene expression. LAT is 
transiently down-regulated in a significant proportion of 
latently infected cells following dexamethasone treatment 
(Sheffy et al., 1972). However virus is only reactivated 
in a small number of cells. Periodically, latent virus is
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reactivated spontaneously or can be induced to reactivate 
by a variety of stimuli (stress, dexamethasone, U.V. 
irradiation, nerve root section, epinephrine, hypothermia 
or explant culture of ganglia). During reactivation, virus 
(or perhaps a subviral particle) is transported 
centrifugally via the nerve axon to the original peripheral 
infection site where virus replication can occur, thus 
providing a source of infection to other susceptible hosts. 
Recurrent lesions at the peripheral site may or may not 
develop following viral reactivation. The quantities of 
virus shed after reactivation are not related to antibody 
titre (Straub et al., 1990). Maximum titres however do not 
reach the same levels as after the first infection while 
recrudescence of virus appears possible only from the site 
of original inoculation.
The current methods for the identification of latent 
carriers are indirect methods based on the theory that 
animals will have BHV1 antibodies. Such testing is 
important when the animal being used for artificial 
insemination or embryo transfer programmes or when new 
cattle are being introduced to an BHV1 free herd. Tests 
include the serum neutralisation test (SNT) and ELISA 
techniques. Alternatively virus isolation may be undertaken 
following reactivation by treatment of the animals with 
dexamethazone (Sheffy et al. , 1972), thus demonstrating
that the animal has been infected at some stage in the 
past. Some animals may escape identification as being 
latently infected by serological testing alone. This may 
happen if the animal had become infected while in the 
presence of maternal antibodies as such infection may not 
be followed by seroconversion (Lemaire et al., 1995). 
Investigations on the ability to distinguish calves with 
passive colostral immunity from those with active immunity 
on the basis of antibody isotypes have not been successful 
(Bradshaw and Edwards 1995).
Definitive identification of latent carriers has been 
possible in the trigeminal ganglia of animals after 
slaughter (Kasshoek et al., 1995).
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1.10 DIAGNOSTIC PROCEDURES
1.10.1 Clinical Diagnosis
While BHV1 can be diagnosed clinically by observation 
of typical clinical signs of IBR or IPV/IPB, a definitive 
confirmatory diagnosis by laboratory examinations on 
specimens is necessary in most cases. Laboratory detection 
of BHVl infection is readily achieved provided the samples 
are correctly taken and submitted under appropriate 
conditions.
1.10.2 Laboratory Diagnosis
Detection may be based on direct or indirect 
diagnostic methods. In direct methods, the virus particles 
or some of their components (viral nucleic acids or viral 
proteins) are detected in the specimens submitted to the 
diagnostic laboratory. For this reason infected tissue, 
nasal/ocular secretions from outbreaks of respiratory 
disease or semen from bulls in or entering AI stations are 
submitted for analysis. The most common conventional direct 
methods are virus isolation (the "gold standard" 
technique), electron microscopy, and the detection of viral 
antigens by antigen enzyme linked Immunosorbent assay 
(ELISA) or immunoflouresent techniques.
Tests to demonstrate antiviral antibodies in serum 
samples may be indirectly used to detect BHVl infections. 
Virus neutralization and ELISA tests are the most commonly 
used indirect methods and are applied to paired sera 
samples (i.e. samples taken during the acute and 
convalescent periods ( 2 - 4  weeks apart) of infection. A 
seroconversion from negative to positive or a fourfold (or 
greater) increase in antibody titre is considered 
indicative of recent infection. A retrospective diagnosis 
of be exposure to BHVl may also made on the basis of a 
positive antibody single serum sample. This test may also 
be applied to identify a latently infected animal e.g. a 
bull entering an AI station. In general, a secure diagnosis 
may be made by the simultaneous application of direct and
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indirect methods. The most routinely used methods for BHV1 
detection are virus isolation (VI), fluorescent antibody 
tests (FAT), paired serology and ELISA based immunoassays.
1.10.2.1 Virus Isolation (VI); Virus isolation is regarded 
as the gold standard diagnostic technique. BHV1 isolation 
on tissue culture was described by Snowdon et al. (1964). 
It involves the inoculation of sample (tissue, nasal/ocular 
or genital swabs) onto a monolayer of bovine cells lines 
and their subsequent monitoring for characteristic CPE 
which is indicative of herpesvirus infection (see 1.4). 
Specific characterisation is then made by means of 
neutralisation using a reference BHV1 antiserum. This 
method still remains one of the most favoured means of BHV1 
detection and has the advantage of propagating the 
causative BHV1 agent which can be used for further research 
and/or in epidemiology studies.
1.10.2.2 Fluorescent Antibody Test (FAT): The fluorescent 
antibody test is based on the detection of virus antigen in 
infected cells. This technique may be used on nasal and 
tissue samples which have been smeared on slides (Gunn,
1991) (outlined in Figure 1.3). These samples are incubated 
with specific antiserum which has been conjugated to a 
fluorescent dye (fluorescein isothyocynate) and is 
incubated on the slide where in a moist chamber for 1 hr -
1.5 hrs. BHV1 antigen in the test cells are bound by the 
specific antiserum. The unbound antibody is removed by 
washing while any bound BHV1 antigen present is visualised 
by fluorescence for characteristic inclusion bodies etc.. 
Fluorescence is detected using an incidence light 
microscope with an ultraviolet light source and filters 
facilitating a transmitted wavelength of 490 nm. (A similar 
general procedure using specific antiserum conjugated to 
horse radish peroxidase can performed on fixed tissue 
sections in order to locate viral antigen on fixed 
samples).
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FIGURE 1.3
THE PRINCIPLE OF THE FLUORESCENT ANTIBODY TEST
X Nasal secretions/tissue smears 
fixed on glass microscopeslides 
and incubated with BHV1 antiserum 
conjugated to a FITC dye
Removal of unbound antiserum 
by washing slides with PBS
Slides are mounted for microscope 
examination using a fluorescent microscope
Figure 1.3 outlines the principle of the FAT test.
1.10.2.3 Serological Tests
Virus neutralisation (VN) tests and various ELISAs are 
routinely used for the detection of antibodies.
Serum Neutralisation Test (SNT): The principle of virus
neutralisation has been described by Rossi et al. (1971). 
Virus of known titre (working dilution) is incubated with 
test serum. Antibodies to the virus, if present, bind to 
the virus. Various cells may then be used to examine the 
presence of free virus which are present due to the absence 
of antibodies. If present, CPE is an indication that there 
are no antibodies in the serum therefore the animal is 
seronegative. The antibody levels may be determined by 
performing a series of titrations on dilutions of the test 
serum.
Enzyme Linked Immunosorbent Assay (ELISA): ELISAs for the 
detection of BHV1 antigen or BHV1 antibody may be used
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instead of or in conjunction with SNT. ELISAs are based on 
the use of enzyme-labelled antigens and antibodies where 
the resulting conjugates have both immunological activity. 
Several types of ELISA are available, including direct 
ELISAs and indirect ELISAs (Voller et al. , 1976 ). In direct 
ELISAs one component (antigen or antibody) is labelled with 
an enzyme and bound to an immunoadsorbent support 
immobilising the antigen-antibody complex. A colour 
reaction developed following the addition of a specific 
substrate upon which the enzyme acts. In indirect ELISAs 
the addition of the enzyme-conjugated anti-immunoglobulin 
follows that of the test serum. A colour reaction only 
develops when the conjugated immunoglobulin has bound which 
indicates the absence of antibodies in test serum.
1.10.2.4 DNA BASED METHODS
1.10.2.4a Differentiation of subtypes using Restriction 
Endonuclease Analysis: Differentiation of BHVl subtypes may 
be useful in epidemiological studies. Restriction 
endonuclease analysis of viral BHVl as discussed in 1.5 
makes it possible to differentiate between all recognised 
BHVl subtypes (Metzler et al., 1985). This technique is 
quite labour intensive and may not be practical on a 
routine basis.
1.10.2.4b Nucleic acid hybridisation: Advances in molecular 
biology has contributed to the development of highly 
sensitive, new diagnostic approaches. Synthetic 
oligonucleotide probes have been developed to detect a 
variety of infectious agents. In the last decade various 
molecular biological methods have been introduced into 
diagnostic virology, the first being the nucleic acid 
hybridisation technique. The principle of nucleic acid 
hybridisation is that labelled nucleic acid molecules bind 
specifically to stretches of homologous target nucleic acid 
sequences present in the clinical samples. The nucleic acid 
sequence of the probe is complementary to the target 
sequence. Accordingly, the probe will only bind to the
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target if it contains the appropriate viral nucleic acid. 
In order to demonstrate hybridisation the probes are 
labelled with radioactive isotopes or more recently with 
non-radioactive labels such as digoxigenin. The deployment 
of various nucleic acid hybridisation techniques has 
considerably increased the arsenal of the diagnostic 
virologist. The detection of many viral infections, for 
example that of latent herpesviruses, has become more 
reliable and more rapid. Various sensitive and specific 
nucleic acid hybridisation methods have been used to detect 
BHV1 (Dorman et al. , 1985, Dunn et al., 1986, Andino et
al., 1987, Belak et al., 1988).
1.10.2.4c The Polymerase Chain Reaction (PCR): Between 1985 
and 1987 the first reports emerged on the use of polymerase 
chain reaction (PCR) marking an important landmark in the 
history of molecular biology (Saiki, et al 1985: Mullis and 
Faloona, 1987). PCR is based on the principle of DNA 
replication in vivo and is defined as the site directed in 
vitro amplification of target DNA. The DNA sequence to be 
amplified is selected by choosing oligonucleotide primers 
which flank the target region. This sequence is then 
amplified in an exponential fashion resulting in a several- 
million-fold amplification of the sequence within a few 
hours. An aptly mentioned statement regarding the 
amplification rate of the PCR is that "the PCR finds a 
needle in a haystack and then produces a stack of needles" 
(De Marchi, 1990). These large amounts of PCR product can 
then be easily detected and identified. This technique has 
huge implications for all areas of biological sciences from 
virology to zoology for the study of specific sequences of 
DNA and has been one of the most rapidly adopted techniques 
in diagnostic medicine. Theoretically a single target DNA 
sequence of a pathogen may be amplified several million 
fold to produce such quantities of DNA which may be visible 
by gel electrophoresis or colorimetric methods.
The use of the PCR assay has several advantages over 
many standard viral detection techniques:
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(I) It is sensitive and should in theory detect down to one 
pathogenic agent. (H) It is specific - provided the 
sequence of the oligonucleotide primers is only present in 
the pathogen to be detected. (Ill) It is rapid - the assay 
may be performed in the same day that samples as received 
in the laboratory. Such rapid diagnosis may influence the 
course of treatment and ultimate outcome of the disease.
(IV) It may be used to detect viral DNA of non-infectious 
particles increasing the chance of diagnosis in cases where 
infectious particles are below the limit of detection.
(V) It is suitable for the identification of pathogens that 
are difficult to grow or culture. The assay may also be 
used for the detection of pathogen in substances that are 
inhibitory to test systems eg. the detection of BHVl in 
semen is often inhibitory on tissue cell culture.
(VI) Finally primers may be chosen that are common to 
related pathogens for a general detection system. 
Differences in the sequence within this region may allow 
differentiation between strains on the basis of product 
size (eg Stratagene's Mycoplasma test kit) or by using 
restriction endonuclease analysis (Lawerence et al. , 1994).
First reports of the use of the PCR in veterinary 
diagnostics were in the late 1980s (Belak et al, 1989: 
Deacon and Lah, 1989) and many PCR assays for the detection 
of animal viruses followed (for a list of some of the PCR 
assays that have been developed for use in veterinary 
medicine see Tables 1. 3A and 1. 3B adopted from Belak et 
al., 1993). Some of the methods can provide a result within 
24 hours thus aiding rapid intervention strategies aimed 
at the reduction and control of the devastating effects of 
virus spread.
A number of PCR assays for BHVl detection have been 
developed to date (Vilcek et al., 1993, Weidemann et al., 
1993, Kibenge et al. , 1994, Vilcek et al. , 1994, Xia et
al., 1995, and more recently Mweene et al., 1996, Santrude 
et al., 1996, Masri et al., 1996).
32
TABLE 1.3a
DETECTION OF DNA VIRUSES USING THE POLYMERASE CHAIN 
REACTION
VIRUS GENE REGION
Porcine parvo
Bovine papilloma type 1
Bovine papilloma type 2
VP 2
Nt 3759-4002 
Nt 3759-4002
Bovine polyoma 
Avian polyoma 
Bovine herpes 4 
Alcelaphineherpes type 1
Nt 436-721 
VP1
EcoRl L 
Nt 1549-2576
Pseudorabies gll gll; gX 
gp5 0 
TK 
gX
Equine herpes 1 (and 4) gpi3
gß
Feline herpes
Infectious laryngotracheitis
Channel catfish 
African swine fever 
Duck hepatitis 
Chicken anaemia
TK
BHI1.4 
gB
EcoR I A 
Ca. Nt% 52-56 
Nt 2594-300 
cap
Abbreviations: BH1.4 BamHl 1.4 Kb fragment, cap capsid
protein, Ecorl 1 Ecorl cleavage fragment, Nt nucleotide 
number, g and gp glycoprotein, TK thymidine kinase, VP 
Virus protein,
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TABLE 1.3b
DETECTION OF RNA VIRUSES USING THE POLYMERASE CHAIN 
REACTION
VIRUS GENE REGION
Foot and Mouth RNA pol VP1
Rabbit Haemorrhagic Disease Nt 57-74; 645-
628
Bluetongue VP 7
Bovine rota Gene no. 3, 11
Infectious bursal disease Ca.Mu 570-620
Nt 170-1879
Bovine viral diarrhoea gp48
gp53, p80
Hog Cholera gp55
Equine arthritis LS; pol, N
Duck influenza HA
Newcastle disease fb
Porcine distemper fb,P
Rabies NPC, PC
Bovine corona N
Infectious bronchitis M,N
Me,N
Bovine leukaemia pol
pol, pX
Feline leukaemia U3
Avian Leucosis gp85
Bovine immunodeficiency disease pol
Feline immunodeficiency disease gag/pol
Maedi visna Nt 180-1370
Caprine-arthritis-encephalitis gag/pol
Equine infectious anaemia gag
Abbreviations: Pol polymerase, Fb fusion protein, N
nucleocapisd, PG pseudogene.
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1.11 EPIDEMIOLOGY OF BHV1
1.11.1 Geographical Distribution
Descriptions of clinical signs and antibody prevalence 
studies indicate a worldwide distribution of BHV1 
infections (Straub et al. , 1990). Low sporadic to enzootic 
disease occurrence have been reported from many countries 
including America, Europe, Asia, Australia and New Zealand. 
The prevalence of BHVl throughout the world varies. Most 
reports present results from serological testing of a 
representative number of herds and often the number of 
affected animals varied from herd to herd. One report from 
Australia indicated that 11.5 % of animals in herds tested 
in Queensland were BHVl seropositive (Norton et al., 1989). 
In New Zealand more than 94% of a beef herd were BHVl 
seropositive while on average 90% of dairy cattle in a herd 
were seropositive (Neilson et al., 1988). In Southern Chile 
20.3% of herds were BHVl antibody positive (Hochstein- 
Mintzel et al., 1985).
Within Europe, Norway, Finland and Denmark have 
achieved eradication of BHVl on a countrywide basis. 
Countries such as Austria and Sweden are approaching an IBR 
free status. In Sweden only two isolated outbreaks have 
ever been recorded with both these cases originating from 
contaminated bovine semen (Ackermann et al., 1990). 
Countries such as France (Departement du Morbihan) and 
Germany organise eradication programmes on a regional basis 
by the elimination of seropositive animals. In most other 
European countries IBR/IPV infection are enzootic with 
serological values being high where vaccination programmes 
have been undertaken. In Belgium and the Netherlands 80% of 
herds are seropositive for BHVl, most of which is due to an 
extensive programme of vaccination. The prevalence of BHVl 
positive animals in Great Britain increased steadily from 
below 5% in 19 70 to over 15 % in breeding herds and 40 - 
50% on commercial farms in 1988. (Ackermann et al.,1990).
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1.11.2 Transmission (Infective dose)
Infectious bovine rhinotracheitis is easily 
transmitted directly from one animal to another because 
large quantities of the virus are shed in respiratory and 
ocular excretions. The infective dose required to establish 
infection has been difficult to establish and it is quite 
likely that the amount of BHV1 needed to induce infection 
in susceptible animals will depend on the virulence of the 
strain. A dose of 102 TCID50 or lower can be adequate to 
establish infection (Straub et al, 1990). The subtype 
BHV1.1 is spread more rapidly in a herd and is excreted at 
higher titres in nasal secretions than BHV1.2 (Edwards et 
al.7 1991). Virus may be transmitted by direct contact and 
by aerosol droplets over a relatively short distance inside 
buildings by coughing or sneezing. Animals excreting virus 
from the vagina or prepuce (IPV or IBP) transmit the virus 
less efficiently. This may occur during natural mating or 
artificial insemination and virus may also be spread the 
swishing of the tail whereby an infected droplet may be 
transmitted from an infected animal to its neighbour. BHV1 
may also be transmitted due to reactivation of the virus in 
latent carriers. Latently infected cows or heifers can re- 
excrete virus during delivery and transmit virus to their 
newborn calves. After transport, carriers may transmit 
virus to other groups on the same farm or to other herds 
(Thiry et al., 1987). The possibility of interspecies 
transmission between animals is also possible. Spontaneous 
and successful experimental infections with BHV1 to sheep 
and goats have been recorded (Wentik et al. , 1995). However 
goats do not seem to play a significant role in the 
transmission of BHV1. Sheep can be infected with BHV1 and 
during the infectious period they may infect other calves 
and sheep. BHVl may be reactivated in latent infected 
sheep, however such animals may not transmit infection 
(Hage et al., 1995).
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1.12 BHV1 IN IRELAND
The first isolation of BHV1 in Ireland was made in 
19 71 from a case of contagious conjunctivitis (Timoney and 
O'Connor, 1971). Eleven more isolations of BHV1 were made 
between 1971 and 1981 (Lenihan, 1981). Since then the 
number of reported IBR outbreaks has steadily increased and 
the virus has since been isolated routinely from cases of 
respiratory disease, some cases of conjunctivitis and one 
case of infectious pustular vulvovaginitis (IPV) (Collery, 
1974). The number of BHV1 isolations at the VRL in the 
winter period September 1993 - March 1994 was 102
(Laboratory data). There is little evidence to suggest that 
BHV1 has been associated with infectious balonposthithis or 
abortion in Ireland.
In Ireland the prevalence of seropositive cattle was 
reported to be 6%-17% in older cattle (Lenihan et al.,
1985) with this figure likely to have increased, 
particularly since the introduction of live vaccines which 
are being used in the face of an outbreak to confer rapid 
immunity to cattle.
The total financial costs of IBR outbreaks cannot be 
solely estimated from the loss of the relatively small 
number of animals that die during infection. The final cost 
will ultimately be influenced by the quality of the herd 
and herd management. Indirect costs to herdowners due to 
the veterinary care and treatment, and considerable loss of 
profits eg. due to reduced milk yields are usually more 
financially damaging than the losses due to fatalities or 
enforced salvage. Exact costs of BHV1 outbreaks are 
difficult to determine and estimates of loss may vary. One 
report on the financial loss caused by 15 outbreaks of IBR 
estimated that accounting for culling and extra feeding, 
the cost per animal was £27 at the time of publishing 
(Wiseman et al., 1979). That figure has since increased and 
information on economic loss in Ireland indicates that 
bovine respiratory disease in general incurs losses of £35 
million annually to the farming community (Smithkline 
Beecham Animal Health), BHV1 infections contributing a
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large percentage in this cost. The cost of one outbreak on 
an Irish farm in a fattening unit of 1,240 cattle was 
estimated to be £129,000 (£104 per head) (Gunn, 1994). In 
terms of financial return a non return rate of 3.6-13% was 
reported in seropositive cows (Bartha et al., 1978).
Ireland now conforms to the two EU directives 
controlling the spread of BHV1 and prevent its transfer via 
AI. EU directive 88/407/EEC states that all bulls used as 
a source of semen sold commercially in AI stations must be 
free from BHV1. A later directive 92/65/EU made the same 
provision for cows used as a source of embryos in embryo 
transfer programmes. Cattle being used for such programmes 
are screened using serological testing for the presence of 
antibodies while semen from those animals whose antibody 
status is in doubt are tested using virus isolation 
techniques.
Until the end of 1992, imports of cattle to Ireland had 
to undergo a quarantine. During quarantine animals were 
serologically tested for exposure to a range of viruses 
including BHV1. Cattle being imported from Britain were 
tested before shipping. Such measures theoretically 
eliminated the risk of the importation of new and more 
virulent strains of BHV1 which were prevalent in Europe at 
that time. Since the introduction of the European Single 
Market at the end of 1992 which abolished border controls 
allowing the free movement of stock throughout Europe these 
measures are no longer implemented, thus exposing the Irish 
cattle population to an increased risk of more severe and 
virulent strains. As a result new and more rapid techniques 
for BHV1 detection are necessary to facilitate meticulous 
surveillance in the future.
Since 1992 licences have been issued to companies to 
allow the sale of live vaccines (see 1. 14). The use of
these vaccines had not been permitted in the Republic of 
Ireland despite their widespread use in Europe. Such 
modified live vaccines may be used in the face of severe 
outbreaks when administered intranasally and therefore be 
included as part of control measures to reduce virus spread.
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1.13 CONTROL AND ERADICATION OF BHV1
Bovine herpesvirus 1 currently receives much attention 
with regard to its control and possible eradication. 
Control may take place at local and national/international 
levels.
In attempting to control the disease at local level, 
factors influencing the spread of the disease must be 
assessed so that they may then be reduced to a minimum. 
Those factors contributing to disease spread within a farm 
are (i) the disease organism itself, (ii) the immune status 
of the host animal, (iii) farm management practises. 
Generally it is only the third that can be directly 
controlled by the farmer.
A number of precautionary measures may be adopted on 
farms to prevent and control outbreaks of BHV1 which 
include the following: (i) mixing animals, especially new
stock of unknown BHV1 status with those already on the farm 
should be avoided (Gunn, 1995). The stress associated with 
the transport or movement of animals may reactivate BHV1 in 
latently infected cattle which may then spread the virus 
(Thiry et al., 19 87), (ii) adequate housing and ventilation 
are crucial in the control of respiratory disease. Cattle 
sheds should be designed to provide good air circulation, 
therefore reducing the viral infective dose in the shed. 
The number of animals in each shed should be kept to a 
minimum and overcrowding avoided to reduce stress and the 
likelihood of reactivation of latent virus in infected 
cattle. Results have shown that under the right 
circumstances the establishment of an IBR seronegative herd 
is practicable (Corkish et al., 1988).
At a national and international level disease control 
strategies vary. Ultimate BHVl control programs aim for the 
complete elimination of virus and latent infection. 
Different control strategies exist in different European 
countries. Alternative approaches are that of and virus 
eradication by the elimination of infected animals or else 
vaccination. The possibility and feasibility of eradication 
of BHVl within Europe is a topic currently under much
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discussion (Mettenleiter, 1995). Eradication programmes may­
be based on the assumption that all BHV1 seropositive
cattle are virus carriers and they are thus slaughtered. 
This approach may only be adopted in countries where there 
is a low prevalence of BHV1 seropositive cattle. Slaughter, 
however is neither feasible nor realistic if a high 
percentage of animals in a region or country have been 
infected. In such a situation there is no practical 
alternative except vaccination with marker vaccines.
1.14 VACCINES AGAINST BHV1
Vaccination provides a means of IBR control,
particularly in situations whereby virus is easily
transmitted between cattle, such as when cattle populations 
are changing for example as in intensive feedlots. Although 
vaccines do not prevent or terminate virus latency,
properly immunised animals do show much reduced viral 
excretion as well as inducing antibodies which protect the 
animal if infected. In countries where the incidence of 
BHV1 antibodies in the national herd is high, vaccination 
is the preferred strategy as a means of control with a view 
to eradication.
There are three types of vaccine currently available 
against BHV1, (I) Inactivated vaccines, (II) Live
attenuated vaccines (III) and Subunit vaccines.
(I) Inactivated vaccines against BHV1 are safe and 
have no chance of reversion to virulence. However, they are 
expensive to produce, require multiple injections and 
depend upon the use of adjuvants to be effective. The 
immunity produced by killed vaccine viruses is less 
effective and of shorter duration than that produced by 
vaccination with live vaccines (Mozaria et al., 1990).
(II) Live vaccines consist of naturally occurring 
avirulent strains or strains of low virulence which are 
attenuated by successive passaging in the laboratory. 
Examples of such vaccines available in Ireland are 
Tracherine (SmithKline Beecham) and Inbovac (Intervet). 
Tracherine is an attenuated vaccine with the added
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advantage of being a temperature sensitive (ts) mutant. 
This vaccine grows only at 32 °C and therefore can be 
administered intranasally. Intranasal administration of the 
ts BHV1 vaccine elicits a rapid immune response providing 
some protection almost immediately and complete protection 
within 24-48 hours after administration (Kucera et al., 
1978), and diminishes the risk of abortion.
Live vaccines may also be a virulent strain that has 
been genetically engineered by the removal of a gene that 
codes for a component essential for viral pathogenicity. 
This component is usually a glycoprotein or regulatory 
protein. The repertoire of live BHV1 vaccines is 
continually growing. A number of BHV1 thymidine kinase 
negative live vaccines have been reported (Kit et al. , 
1985; Kit et al., 1986; Smith et al., 1994). A glycoprotein 
E (gE) negative live vaccine is also available on the 
market. Other gE deleted vaccines have been investigated in 
clinical trials (Strube et al., 1995; Kaashoek et al.,1995; 
Rijsewijk et al. , 1995). In addition live vaccine lacking 
the gl, gE, gC and gG have been assessed for their efficacy 
(Rijsewijk et al., 1995).
Live vaccines have the advantage of being less 
expensive to produce, confer rapid protection and activate 
both cell-mediated and humoral components of the immune 
system. The major disadvantage of these vaccines is their 
ability to establish latent infection. Earlier live 
vaccines were also reported to cause abortion in pregnant 
recipients (Wyler et al., 1979). However some of the gE- 
vaccines have been reported not to establish latent 
infection and therefore eliminating the risk of re­
excretion of virus (Kaashoek et al., 1996).
(Ill) Subunit vaccines consist of only one component 
of the virus to which an immune response is illicited: 
Subunit D is currently being evaluated (Basca-Estrada et 
al., 1995). Subunit vaccines have the advantage of being 
safe and eliciting no disease signs. They also guarantee 
that latency cannot be established. Unfortunately they are 
expensive to produce and require multiple injections to be
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effective. Their efficacy is still to be determined (Smith 
et al., 1994 ) .
Marker vaccines allow the differentiation of 
vaccinated cattle from those that have been naturally 
infected. They are usually vaccines that have used 
recombinant DNA technology to insert or delete a gene 
encoding a marker protein. Such vaccines may be described 
as positive or negative markers. A negative marker lacks a 
gene for a specific antigen, in this case vaccinated cattle 
will lack antibodies to the antigen while naturally 
infected cattle will possess such antibodies. A positive 
marker contains a gene that codes for an antigen to which 
only vaccinated animals will develop antibodies. 
Corresponding ELISA kits can be developed to allow 
serological differentiation between vaccinated animals and 
those infected with field strains. This selective property 
is extremely important when eradication programmes are 
based on slaughter of all cattle seropositive for wild type 
virus.
1.15 THE PURPOSE OF THIS THESIS
The vast research and increasing body of literature on 
BHV1 is proof itself of the economic and scientific 
importance of this agent. BHV1 infection has important 
economic implications not only due to loss of revenue as a 
result of illness, but as a trade issue in artificial 
insemination and embryo transfer programmes.
The advances in vaccine development that may be used 
in the face of an outbreak of respiratory disease has 
placed emphasis on more rapid and sensitive techniques for 
the detection of respiratory pathogens. PCR is one such 
technique which fulfils the required criteria. In addition, 
changing farming towards more intensive cattle rearing as 
well as new trading agreements within the EU have meant 
that the effects of BHV1 may become more significant in the 
future necessitating more rigorous surveillance of BHV1 
using sensitive detection methods.
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This study was undertaken for the following purposes:
(I) To determine the genotypes of a number of BHVl field 
isolates that have been made in Ireland (at the VRL, 
Abbotstown) between 1971 and 19 92.
(II) To develop, validate and optimise a PCR assay to 
detect BHVl.
(III) To evaluate the use of the PCR assay for the 
detection of BHVl in routine diagnostic samples and 
evaluate it with the other routine techniques such as VI 
and FAT for the detection of BHVl.
(IV) To examine one isolate which had been made from an 
atypical severe pharyngeal BHVl infection in young calves 
by the reinoculation of the virus into calves and 
monitoring the clinical serological and haematological 
outcome.
( V) To evaluate PCR, FAT and VI as BHVl detection methods 
following the experimental IBRV infection of cattle.
(VI) To assess the use of PCR as an alternative to virus 
isolation to detect BHVl in semen samples for use in 
artificial insemination.
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CHAPTER 2
MATERIALS AND METHODS
2.1 WATER
Distilled water was used in the preparation of media and 
solutions. Water used for PCR and silver sequencing was 
purified by passing it through an Maxima Ultra Pure Water 
System (Elga, UK). This process involves a pretreatment 
step and utilises activated carbon, prefiltration and 
antiscaling, followed by a reverse osmosis step. This was 
followed by organic absorbtion, ion exchange, 
ultrafiltration, photo-oxidation and ultra filtration. A 
measure of 18 megohms/cm3 reactivity at 25°C was considered 
acceptable.
2.2 GLASSWARE
All glassware and bottle caps were soaked for 1-2 hr in a 
detergent (Pyroneg, Diversey IRL) solution, the bottles 
were scrubbed manually, bottle and bottle caps were rinsed 
in warm water and machine washed. Bottles and caps were 
rinsed twice in double distilled water, once with 
ultrapure water and autoclaved before use. Glassware 
containing spent virus suspensions was autoclaved, rinsed 
with tap water and cleaned as above.
2.3 STERILISATION
Water, glassware and solutions containing thermostable 
compounds were sterilised by autoclaving at 121°C for 20 
min at 15 lbs psi pressure. Temperature labile compounds 
were filtered through a 0.2 2 pm sterile filter (Lida, USA 
5003-06) .
2.4 CHEMICALS
The following Suppliers provided the chemicals that were 
used regularly throughout the project. Chemicals were 
AnalaR grade unless otherwise stated. All other chemical 
sources and codes are listed as cited.
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BRITISH DRUG HOUSE - UK
Disodium ethylenediamine tetra-acetate. 2HZ0 - EDTA (10093) 
Sodium Chloride - NaCl (10241)
Sucrose (10274)
Potassium Acetate (10350 4X)
Glacial Acetic acid (10001 4M)
Sodium Acetate - Na (10236)
Dimethyl sulfoxide (DMSO) (28216)
SIGMA - UK
Dithiothreitol -DTT (D7 79)
Mineral oil (M5904)
Dimethyl Sulfoxide - DMSO (D4818)
Bromophenol Blue (B5525)
Ethidium bromide (E8751)
GibcoBRL - IRL
Tris Ultrapure (5505-UB)
Sodium Dodeycl Sulphate (SDS) (15525-025)
Boric Acid (5705-032)
Phenol (5509-UA)
Merck- UK
8-hydroxyquinoline (7098)
2.5 BUFFERS AND SOLUTIONS
All solutions used for DNA manipulation were prepared as 
described by Sambrook et al. (1989) in distilled water, 
autoclaved at 121 °C for 20 min and stored at room 
temperature except where stated otherwise.
2.5.1 Solutions used for DNA extraction
lOx TE Buffer pH 8.0 
Tris-HCl 10 mM
Na2-EDTA 1 mM
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0.5 M EDTA (pH 8.0)
Disodium ethylene diamine tetraacetate.2HZ0 (181.6g) was 
added to 800 ml of H20 and stirred vigorously. The pH was 
adjusted to 8.0 with 1M NaOH and the volume made up to 1 
litre with distilled water.
3M Sodium Acetate (pH 5.2)
Sodium acetate. 3H20 (408. lg) was dissolved in 800 ml HzO, 
the pH adjusted to pH 5.2 with glacial acetic acid and the 
volume brought to 1 litre.
Phenol:chloroform
Twenty five millilitre quantities of buffered phenol 
stored under 100 mM Tris-HCL pH 7.5, was dissolved in 24 
ml of chloroform. To this, 1 ml of isoamylalcohol and 0.2 
g of 8-hydroxyquinoline were added and the mixture was 
either stored in a dark bottle at 4°C for immediate use, 
or at -20°C for long term storage.
2.5.2 Solutions used for DNA gel electrophoresis
lOx Tris Borate Electrophoresis buffer (TBE) pH 8.3
Tris 108.0 g
Na2-EDTA 9 . 3 g
Boric acid 55.0 g
H20 to 1 litre
lOx Tris Acetate Electrophoresis buffer (TAE) pH 8.3
Tris 48.40 g
Glacial acetic acid 11.42 ml
0.5 M Na2-EDTA (pH8.0) 20.00 ml
H20 to 1 Litre
6x Bromophenol blue
Bromophenol blue 0.25% (w/v)
Sucrose in H20 40.00% (w/v)
DNA samples were mixed in a 5:1 ratio with bromphenol blue
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prior to loading on agarose gels.
2.5.3 Solutions for the preparation of plasmid DNA from 
E . c o l i  
Solution 1
0.5M glucose 1.0 ml
0.1M Na2EDTA 1.0 ml
1.0M Tris-HCL (pH 8.0) 0.25 ml
H20 7.75 ml
Solution 2
IN NaOH
10% (w/v) SDS
H20 7.75 ml
Solution 3 pH 4.8
5M potassium acetate* 30.00 ml 
Glacial acetic acid 5.75 ml
H20 1.42 ml
* 5M potassium acetate, 11.5 ml of glacial acetic acid and
28.5 ml H20 were added together. This solution was 3 molar 
with respect to potassium and 5 molar with respect to 
acetate.
2.5.4 Solutions used for DNA ligations 
lOx ligation buffer
300 mM Tris-HCL pH 7.8 
lOOmM MgCl2 
100 mM DTT 
5 mM ATP
2.5.5 Solutions used for PCR 
lOx PFU buffer
200 mM Tris-HCL pH 7.5 
80 mM MgClz 
400 ng/ml BSA
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10X Taq polymerase buffer:
500 mM K
100 mM Tris (pH 8.3 at room temperature)
15 mM MgCLz 
0.1% gelatin.
2.5.6 Solutions used for single stranded DNA preparation 
using Dynabeads
Binding and washing buffer
10 mM Tris-HCL, pH 7.5 
1 mM EDTA 
2.0 M NaCl
Melting solution
0.1 M NaOH
Neutralising solution
0 . 2 M HCL
2.5.7 Solutions used for non-isotopic sequencing
USB Sequenase Imagestm Non isotopic DNA sequencing and 
detection Kit:
IX Post-SAAP Wash Buffer
0.10 M NaCl, 0.05 M Tris-HCL pH 10.0
IX Post-SAAP Wash buffer
+ 0.1% SDS
Silver sequencing:
Fix stop solution: 10 % glacial acetic acid 
Developing solution: 60 g sodium carbonate was dissolved
in 2 L ultra pure water and chilled on ice to 10 °C. 
Immediately before use 3 ml of 37% formaldehyde (Sigma 
F1643) and 400 |0.1 of sodium thiosulphate (Sigma S1643) (10 
mg/ml) were added.
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2.6 ENZYMES 
DNAse free RNAse:
RNAse A (Boehringer Manheim, Germany 109142) was dissolved 
at a concentration of 10 mg/ml in Tris-HCL (pH 7.5) and 15 
mM NaCl, heated to 100°C for 15 min, allowed to cool 
slowly to room temperature, dispensed into aliquots and 
stored at -20°C. RNAse was used at a working concentration 
of 500 ng/ml.
Proteinase K:
Proteinase K (Gibco-BRL-510-5530UB) was prepared at a 
concentration of 20 mg/ml in a reaction buffer of 0.01M 
Tris (pH 7.8), 0.01M EDTA, 0.5%(w/v) SDS at 37°C.
All other enzymes were purchased in a ready to use form 
and are detailed in Table 2.1
TA B L E  2.1
R E S T R IC T IO N  A N D  M O D IF Y IN G  E N Z Y M E S  U S E D
R E S T R IC T IO N
E N Z Y M E S
M A N U F A C T U R E R C O D E E N Z Y M E
A SSA Y
T E M P E R A T U R E
H in d  III P rom ega, U K R 6045 37°C
H a e  II P rom ega, U K R 6661 37°C
R sa  I P rom ega, U K R 6371 37°C
T a q  I S tratagene, U K 501100 65°C
Sm a I P rom ega , U K R 126 32°C
M O D Y F IN G  E N Z Y M E S
P F U Stratagene, U K 600153 74°C
T aq
polym erase
P rom ega, U K M 1861 72°C
T 4 D N A  L igase P rom ega, U K M 1801 16°C
Table 2.1 lists the enzymes used In this study, their 
suppliers and optimum reaction conditions.
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2.7 CELL CULTURE MEDIA
Medium Preparation: Minimal Essential Medium (MEM) with 
Earle's balanced salt (Gibco-BRL-11700-069) was used for 
the maintenance and growth of all cell lines. It was 
supplemented with 5 - 10% foetal calf serum (FCS) (Sigma- 
F7399) for the initiation of cellular growth and 1% FCS 
for maintenance of cell growth (all FCS used were shown to 
be free of antibodies to common bovine viruses such as 
bovine diarrhoea (BVDV) and cell growth inhibitors). Media 
for cell culture was prepared by dissolving 9.35 g (a 10X 
packet) of MEM, 12 g of sodium bicarbonate, 1 g of sodium 
pyruvate and 100 ml of non essential amino acids in 8800 
ml of distilled H20 (dH20) . As most field specimens
submitted for virological examination are contaminated 
with bacteria and fungi all media were supplemented with 
the following antibiotics, Penicillin (Sigma-S0774) 100
unit/ml, Streptomycin (Sigma-P8306) 100 unit/ml, Polymyxin 
B (Sigma-N4014) 20 unit/ml and Nystatin (Sigma-N6386) 25 
unit/ml. Foetal Calf Serum (FCS) was then added to a final 
overall concentrations of 0%, 5% or 10% FCS. The pH was 
adjusted to 7.45-7.55 by the addition of 1.5 M NaOH and 
the volume adjusted to 10 litres. The medium was then 
filtered through a sterile 0.22 (Jim filter by positive 
pressure (Lida, USA 5003-06) into sterile 500 ml bottles. 
The medium-containing bottles were labelled, dated and 
stored at 4°C until required. The addition of L-glutamine 
(BDH - 37107) to a concentration of 0.029 mg/ml was made 
just before use.
2.8 CELL TISSUE CULTURE
2.8.1 Cell Lines.
All cell lines used throughout this project are outlined 
in Table 2.2. These cell lines are anchorage dependant 
growing as a monolayer attached to the bottom of flasks. 
Cells were grown in 75 cm2 or 150 cm2 plastic flasks 
(Costar, UK -25115 or (Costar-25120) at 37°C. Separate 
medium bottles were kept exclusive to each cell line to 
prevent cross contamination.
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T A B L E  2.2  
C E L L  L IN E S
C E L L  L IN E S G R O W T H
M E D IU M
C E L L  TYPE C EL L
SO U R C E
M a d in  D arby  
B o v in e  K idney  
(M D B K )
M E M  5% C ontinuous A T C C
F o eta l B ov in e  
K idney (F B K )
M E M  10% Prim ary/
S econ d ary
V R L
P orcin e  K idn ey  (P K 15) M E M  5% C on tin u ou s A T C C
E q u in e  K idney
(E Q )
M E M  10% Prim ary/
S econ d ary
V R L
Table 2.2 shows the cell lines used, their origin and the 
growth medium used for their propagation.
2.8.2 Routine Management of Cell Cultures
Routine management of cultured cells involved feeding, 
sub-culturing, freezing and thawing. All procedures were 
performed in a re-circulating laminar flow cabinet (Faster 
BHA72) which had been swabbed with 70% IMS (Industrial 
Methylated Spirits). All articles entering the cabinet 
were also swabbed with 70% IMS to ensure that a sterile 
atmosphere was maintained. Gloves were worn at all times 
during these procedures.
2.8.3 Sub-Culture of Cell lines
Upon reaching confluency, or when required, the cells were 
sub-cultured by enzymatic detachment. This involved 
removing the growth medium from the flask of cells and 
rinsing the cells with 2 ml of 0.25% acid trypsin versene 
(ATV) (Gibco 043-05090) which had been preheated to 37°C. 
A further 5 ml of ATV was added, left for 20-30 sec and 
approximately 4 ml decanted. Cells were incubated with the 
remaining 1 - 2 ml ATV at 37°C to allow the breakdown of 
intracellular bonds and disassociation of cells. When the
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monolayer was observed to be detached from the vessel 9 ml 
of MEM 5 was then added to the cell suspension to 
neutralise the action of the ATV. Cells were now ready to 
use for further cell propagation, or for serum 
neutralisation, virus titrations and virus isolation.
2.8.4 Cell Counting
A sample of single cell suspension was mixed in a ratio of 
3:1 with trypan blue dye (Gibco-525) for 2 min after which 
a sample of cell suspension was applied to a Neubauer 
chamber. The concentration of cells per ml was determined 
by multiplying the average number of cells in the four 
outer grids by 10A. Cells were then diluted with MEM 0 to 
give the required concentration for either neutralisation 
or virus isolation tests.
2.8.5 Cell Thawing
The required vial of cells was removed from the liquid 
nitrogen storage at -130°C and thawed rapidly in a 37°C 
water bath. The thawed cell suspension was resuspended in 
ml of MEM 10 and transferred to a 25 cm2 (Costar-25100) 
flask containing medium and incubated at 37°C where growth 
was monitored at 24 hr intervals.
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TABLE 23
VIRUSES USED IN THIS STUDY, THEIR ORIGIN AND THE 
CELL LINES USED FOR THEIR PROPAGATION
2.9 VIRUSES
VIRUS CELL LINE SOURCE
B H V 1  - O xford  
strain
M D B K / P K 15 C V L , W eybridge
B H V 2 PK 15 V R L
B H V 3  A lcep h a lin e M D B K C V L , W eybridge
B H V 4 M D B K C V L , W eybridge
B H V 5  (T K  g en e ) ---- Q u een slan d  A gricultural 
C entre, A u stra lia
A ujeskys D ise a se  
V irus (P R V )
PK 15 V R L
E H  V I E K V R L
E H V 4 E K V R L
B H V 1  579 M D B K V R L
B H V 1  H 607 M D B K V R L
B H V 1  J302 M D B K V R L
B H V 1  D 4 6 3 M D B K V R L
B H V 1  D 868 M D B K V R L
B H V 1  D 731 M D B K V R L
B H V 1  H 984 M D B K V R L
B H V 1  J702 M D B K V R L
B H V 1  0909 M D B K V R L
B H V 1  W 145 M D B K V R L
B H V 1  W 199 M D B K V R L
B H V 1  X 35 M D B K V R L
B H V 1  X 313 M D B K V R L
2.9.2 Virus Titration
The protocol used to perform a virus titration was based 
on that described by Villegas and Purchase 1991. Ten fold 
serial dilutions (10_1 to 10‘8) of the virus to be titered 
were prepared using MEM 1 and 25 ni of each dilution was
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placed in four wells of a flat-bottomed 96 well microtitre 
plate. Fifthy microlitres of MEM 10 was then added to each 
well. The plate was incubated at 37°C for 1 hr. Meanwhile 
cells were prepared as in 2.2.1.1 to give a cell 
suspension of 3 x 105 cells/ ml and 25 p.1 of cell
suspension was then added to all wells. Plates were 
incubated at 37°C in a 5% C02 incubator (Forma Scientific, 
USA) and examined daily for up to 5 days for cytopathic 
effect (CPE) under an incident light microscope (Leitz, 
Germany). Once CPE had stopped progressing the viral titre 
or endpoint where 50% of the cell cultures are infected 
(TCID50) was estimated using the Karber Method (Payment and 
Tundel, 1993) as shown below.
TCID50 = L - D ( S- 0.5) 
where L = log10 of the lowest dilution with 100 positive 
culture (CPE)
D = log10 of the dilution factor 
S = Sum of proportion of cells showing CPE 
0.5 = a constant
Negative cell controls were also included in the titration 
in which medium replaced virus in the above procedure. 
Positive controls consisted of the addition of virus of 
known titre.
2.10 DIAGNOSTIC SAMPLES
Diagnostic samples were submitted in five basic forms for 
examination for the presence of BHVl at the VRL : (I)
Tissue, (II) Nasal secretions, (III) Ocular secretions,
(IV) Semen, (V) Blood. (I) Tissue samples (usually lung 
and/or trachea) were submitted from the VRL and Regional 
Veterinary Laboratories (RVLs) following post mortem 
examinations on cattle where respiratory disease had been 
associated with the cause of death.
(II) Nasal secretions obtained from cattle exhibiting 
signs of respiratory disease and were submitted to the VRL 
from veterinary practitioners and research officers at the
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RVLs. These were submitted as nasal secretions, nasal 
secretions on swabs, or as nasal smears fixed on slides.
(III) Ocular secretions, taken from cattle suffering from 
conjunctivitis, were submitted on swabs or as secretions 
fixed on slides.
The above sample types are routinely tested for the 
presence of BHV1 by virus isolation and/or fluorescent 
antibody tests.
(IV) Deep frozen extended semen samples were submitted in 
straws from AI stations and tested for BHVl by virus 
isolation.
(V) Single sera samples were also examined for the 
presence of antibodies to BHVl using the SNT to establish 
whether animals had ever been infected and were thus 
possible latent carriers of the virus. These sera were 
usually submitted from bulls in AI stations. For the 
serological diagnosis of a recent infection, paired acute- 
and convalescent- phase sera (taken 2 to 4 weeks apart) 
were tested together in the same test. A fourfold (or 
greater) rise in BHVl antibody titre was indicative of 
recent infection.
2.10.1 Processing of diagnostic samples
Tissue; Tissue samples were prepared for testing by FAT by 
smearing a freshly cut section of tissue in a circular 
motion onto alcohol washed glass microscope slides. Slides 
were then air dried and fixed in acetone at room 
temperature for 30 min (Gunn et al., 1991). For virus 
isolation approximately 3 g of tissue sample was ground in 
5 ml of MEM 0 using a sterile pestle and mortar. The 
homogenate was then centrifuged at 197 g (Megafuge 1.0, 
Heraeus) for 5 min and the supernatant used for virus 
isolation.
Nasal secretions; Submissions of nasal secretions were 
added to a universal container and 15-20 glass beads 
(approximately 3 mm in diameter) in 5 ml of PBS were 
added. Nasal secretions were mixed thoroughly using a 
vortex to release cell from the mucous. The mixture was
then centrifuged at 197 g (Heraeus Megafuge 1.0) for 5 
min. The supernatant was used for virus isolation while 
the cell pellet were used to make a smear on alcohol 
washed glass microscope slides which were then air dried, 
fixed in acetone for 30 min used for FAT.
Swabs: Swabs of nasal secretions were suspended in MEM 0
and used for virus isolation. When swabs were sufficiently 
damp they were used to make slides for FAT.
2.11 ROUTINE DIAGNOSTIC TESTS FOR BHV1
2.11.1 Virus Isolation (VI)
2.11.1a VI from routine samples: The protocol used for 
virus isolation was based on that described by Snowdon et 
al., 1964. Monolayers of FBK or MDBK cells in plastic 
tissue culture tubes (Costar-25200) were inoculated with 
100 |il of sample supernatant as prepared in 2.10 and 
maintained in 1 ml of MEM 1. Cultures were monitored daily 
for up to one week for the appearance of typical 
herpesvirus cytopathic effect (CPE). If at the end of this 
time there was no CPE, the sample was passaged once more 
after which if there were no signs of CPE the sample was 
interpreted as being negative.
2.11.1b VI from semen: Cells prepared (section 2.8) at a 
concentration of 1 xlO5 cells/ml were grown in 48 well 
microtitre plates (Corning, USA 2583-48) for 2 days at 
37°C in a 5% C02 incubator. Cells were overlaid with 50 nl 
of seminal fluid and incubated at 37 °C for 1 hr. The 
seminal fluid was removed and cells were washed three 
times with MEM 1. Finally, 75 (il of MEM 5 was added to 
each well and plates were incubated at 37°C in a 5% C02 
incubator and monitored for CPE daily for seven days. A 
virus positive control and negative control were included 
on the plate.
2.11.2 The Fluorescent Antibody Test (FAT): The FAT is
used to detect the presence of viral antigen in cells.
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Samples are probed a monospecific labelled antiserum. 
Fluorescence is detected at the site of viral antigen 
using an incident light microscope with ultraviolet light. 
The test system is based on one described for the 
detection of EHV1 (Gunn, 1991).
Monospecific BHV1 hyperimmune serum was obtained by 
immunising a BHVl, BVD, respiratory syncytial virus (RSV) 
and parainfluenza virus 3 (PI3) seronegative bovine to
BHVl. Approximately two weeks after exposure serum with a 
high antibody titre to BHVl was collected, purified and 
tested for antibodies to a wide range of pathogens. The 
antiserum was then conjugated to a fluorescent dye (FITC) 
and the appropriate working dilution determined. Prior to 
use in routine diagnostic tests rigorous specificity 
testing were undertaken on laboratory and clinical 
material.
Testing by FAT was performed by incubating the FITC- 
hyperimmune antiserum on samples for 90 min in a moist 
chamber at 37°C. Areas of sample to be tested were 
outlined using a ring of paint (Texpen) approximately 2 cm 
in diameter. Unbound antiserum was removed by washing the 
slides in 0.01 M PBS (Oxoid, UK pBrl4a) for 30 min. Slides 
were mounted for microscope examination using a 90% 
glycerol:10% PBS solution. Fluorescence was detected using 
an incident light microscope with ultraviolet light and 
filters facilitating a transmitted wavelength of 490nm 
(Ploemopak, Leitz).
2.11.3 The Serum Neutralisation Test (SNT): The serum
neutralisation test was used to measure the amount of 
neutralising antibodies in sera. The protocol used to 
perform each serum neutralisation test was based on that 
described by Rossi et al. (1971). Serum was obtained from 
blood samples collected into vacucontainers and 
centrifuged at 1,139 g (Heraeus Megafuge 1.0) for 15 min. 
Serum was inactivated by heating at 56°C for 30 min. Each 
serum sample was diluted 1/4 to 1/256 or further if 
necessary. Twenty five microlitres of each dilution were
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placed in four wells of a 96 well microtitre plate 
followed by 25 |j l1 of MEM5. Twenty five raicrolitres of 
virus at 100 TCID50 was added to all wells except the 
negative control to which 12 |il of MEM 1 was added. Plates 
were shook gently and incubated at 37°C for 1 hr. A MDBK 
cell suspension at a concentration of 2.5 x 105 cells/ml 
(25 (J.1) was then added to all wells. Plates were incubated 
at 37°C in a 5% C02 incubator and examined for CPE after 
two and three days. The neutralising antibody titre of 
serum (neutralising dose 50%) was determined by applying 
the Karber formula (2.9.2). The titre was expressed as the 
highest serum dilution which neutralises the viral 
cytopathic effect in half of the wells.
2.12 DNA PREPARATION
2.12.1 Total Viral DNA preparation
The technique used for the preparation of viral DNA was 
based on methods described by Christensen et al. (1992) 
and Wheatstone et al. (1989). Viral DNA was prepared from 
BHV1 isolates previously isolated at the VRL from routine 
diagnostic samples. MDBK cells were grown to 90% 
confluency in tissue culture flasks with MEM 5. Cells were 
infected with virus by decanting the medium and adding 
virus at a titre of 10z TCID50/50 jo.1. In order to allow 
cells to absorb virus they were incubated for 1 hr at 37°C 
and then washed twice with MEM 0. Flasks were then 
incubated at 37 °C with MEM 1 until extensive CPE was 
observed, usually after 4 8-72 hr. Virus was released into 
the supernatant fluid by repeated freezing and thawing of 
the cultures. Cell debris was pelleted by centrifugation 
at 1,14 0 g (Heraeus Megafuge 1.0) for 10 min. The 
supernatant was removed and centrifuged at 18,000 g 
(Beckman L8-M Ultracentrifuge) for 30 min after which the 
virus pellet was further purified by resuspending it in 2 
ml of MEM 0 and passing it through a 40% sucrose cushion 
for 2 hr at 18,000 g (Beckman L8-M Ultracentrifuge). This 
pellet was resuspended in 2.5 ml of 100 mM NaCl, lOmM
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EDTA, 0.5%N-Lauryl sarcosine, 50 mM Tris-HCL. (Pipette 
tips with the tip ends cut were used for all manipulations 
in order to prevent damage to DNA associated with 
shearing). Proteinase K was added to a final concentration 
of 200 ug/ml followed by a 3 hr incubation at 37°C. The 
proteinase K treatment was repeated once. DNA was then 
extracted by repeated phenol:chloroform:isoamyl alcohol 
25:24:1 treatment followed by 1 treatment with 
chloroform:isoamyl alcohol 24:1. Viral DNA was then 
ethanol precipitated by the addition of 1/10 volume of 0.2 
M NaCl and two volumes of ice cold absolute alcohol. The 
DNA was precipitated overnight at -20°C. After 
centrifugation at 12,000g for 30 min the DNA pellets were 
washed twice with 7 0% ethanol to remove any traces of 
excess salt and the residual ethanol removed using a 
desiccator. DNA Pellets were allowed to dry at 55°C and 
then dissolved in 50 |il TE pH 8.0 containing 2[il of DNAse 
free pancreatic RNase (500 (ig/ml). Extracted DNA was 
stored at - 20°C.
2.12.2 Template DNA preparation for PCR
Nasal secretions. Tissue and nasal swabs: Twenty five
microlitre aliquots of supernatants prepared as described 
in Section 2.10 were added to 150 jil 5% Chelex 100 (Bio­
rad, Hercules, CA USA) solution and incubated at 56°C for 
15 min. After a brief mix using a vortex, tubes were 
placed on a heat block at 100°C for 8 min and centrifuged 
for 3 min at 12,000 g (ALC microcentrifuge 4214). A 20 jil 
aliquot was used in each PCR reaction.
2.12.3 Preparation of white blood cells (WBC) from whole 
blood
Preparation of white blood cells using ammonium chloride 
Whole blood samples were collected into vacucontainers 
containing EDTA in order to prevent clotting. Eight 
hundred microlitres of 0.8% ammonium chloride was added to 
200 nl of whole blood and mixed by gentle inversion for 5 
min to allow lysis of RBC. Tubes were then centrifuged for
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20 min at 1500 rpm. The pellet of white blood cells was 
resuspended in 0.83% ammonium chloride and the 
centrifugation step repeated. The pellet was washed in PBS 
until all traces of haemoglobin had disappeared. It was 
then resuspended in 500 |a.l of PBS and frozen at -70 °C 
until use.
Preparation of WBC using a Ficoll-Plaque (Pharmacia, 
Sweden 17-0840-02) gradient. An equal volume of MEM 0 was 
added to 7 ml whole blood and mixed. The diluted blood 
sample was then underlaid with a 7 ml of Ficoll-Plaque 
(research grade density = 1.077 ± 0.001 g/ml). The tubes 
were centrifuged at 1500 rpm for 25 min. The layer of 
white cells was removed and washed with PBS to remove 
Ficoll. Washing was repeated three times and the cell 
pellet was resuspended in 500 \il of PBS and frozen at - 
70°C until use.
2.12.4 Preparation of WBCs for PCR
White blood cells prepared as in 2.12.3 were treated with 
0.2 mg/ml proteinase K for 2 hr at 55°C. Samples were then 
either (i) boiled for 8 min and a 10 |il aliquot used 
directly as D N A  template for PCR or (ii) boiled for 8 min 
and followed by a phenol:chloroform D N A  extraction and 
ethanol precipitation. Extracted D N A  was resuspended in 
the 200 ul of sterile dHz0 and a 10 nl aliquot was used in 
the PCR assay.
2.12.5 Restriction endonuclease analysis of total viral 
D N A
The viruses were classified by the scheme of Metzler et 
al., 1985 by which BHV1 was subdivided into subtypes 
BHV1.1 and BHV1.2. DNA quantities of 1 ug were 
photometrically determined (Quantspec-Pharmacia). 
Restriction endonuclease digestion of 1.0 ug of purified 
viral DNA in 20 jil digest buffer E (10 mM Tris-HCL pH 7.4, 
50 mM NaCl, 0.2 mM EDTA, 1 mM DTT, 0.5 mg/ml BSA, 50 % 
glycerol) was performed using Hind III at 37°C for 2 hr.
60
Restricted DNA was then resolved using electrophoresis and 
visualised on a transilluminator (Viller Laurmat, France 
>2500 |j.W/cm2) .
2.13 ELECTROPHORESIS AND VISUALISATION OF DNA
2.13.1 Electrophoresis of DNA
Agarose (Promega V3121) was dissolved in TAE (0.04 mM Tris 
Acetate, 0.002 mEDTA) buffer at an appropriate 
concentration depending on the molecular weight of DNA to 
be resolved (Table 2.4). DNA gels were run using mini gel 
(Hybaid, UK) or Midi gel Horizonaltm 11.14 system (BRL).
T A B L E  2 .4
P E R C E N T A G E  A G A R O SE  G E L  U S E D  F O R  D N A  A N A L Y SIS
A G A R O SE
C O N C E N T R A T IO N
D N A  S O U R C E T IM E  R U N
0.7% V iral 1 - 2  hr
1% P lasm id 2 hr
2% P C R  P rod u cts 1 hr
3-4% * R estr ic ted  P C R  P rod u cts 2 hr
* In the case where PCR products were being further
manipulated such as by restriction endonuclease analysis 
or DNA sequencing, a low melting point agarose (Gibco-BRL 
15517-014) was used. These were resolved on 4% (w/v)
Nusievec GTG (FMC) gels at 80 volts for 1.5 hr. Nusiever 
GTG agarose is a low gelling (<30°C) and low melting 
(<65°C) temperature agarose. It finely resolves nucleic 
acid fragments less than lOOObp in size.
2.13.2 Visualisation of DNA
All nucleic acid gels were stained in ethidium bromide 
(0.5n.g/nl) for 25 min, destained in water for 5 min and 
viewed on a UV transilluminator.
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2.13.3 Preparation and Disposal of Ethidium Bromide
Ethidium bromide (Sigma E8751) was diluted to 100 ng/ml in 
H20. The container was wrapped in tin foil and stored at 
4°C. This solution was further diluted just before use to 
0.5(j.g/M.l. Gloves were worn at all times when handling EtBr 
containing solutions. EtBr waste was collected, treated 
with 100 mg activated charcoal/ 100 ml and filtered 
through 3 MM Watmann filter paper (AW 3030/917). The 
solids concentrated on the filter paper were incinerated 
at 262 °C while the filtrate was disposed of normally.
2.13.4 Photography of Gels
Photographs were taken using a Polaroid Ds-34 (Kodak) and 
Polaroid film 667. This film was used with A003 red filter 
(Kodak) which blocks UV light.
Some photographs were also taken with an OLYMPUS SLR 
camera using a red filter. The film was then developed by 
removing the roll of film in a dark room and placing it in 
a light proof box. Developer (Ilford, UK Hypam 758120) was 
added for 15 minutes stirring continuously. Developer was 
removed and the film was washed by rinsing with water. 
Fixer (Ilford Hypam 758120) was added for 12 minutes after 
which the film was washed in water for a minimum of 30 
min. The negatives were then dried and printed on to F4 
printing paper.
2.14 POLYMERASE CHAIN REACTION
2.14.1 Using Data bases to check the uniqueness of 
primers. The most critical element in the choice of 
primers for PCR is that the primers are unique i.e. that 
they do not hybridise with sequences present in the DNA of 
the bovine cells or other viruses. This involved choosing 
primers using guidelines as described in chapter 4.2.1 and 
checking if similar sequences exist. European Molecular 
Biology Laboratory (EMBL) DNA data bases were accessed 
easily via E-mail by linking to large mainframe computers 
(e.g vax). This system allows the primers chosen to be
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compared with all other sequences available in gene data 
bases in order to asses their uniqueness or specificity. 
Using software KERMIT IBM-PCs were used as vax terminals 
for E-mail. Once E-mail had been accessed on the PC 
through the use of KERMIT commands the appropriate user 
number and password, primer sequences were sent to EMBL be 
checked by the following procedure as outlined in Table
2.5. Depending on the pressure on the EMBL faculty at the 
time a list of related sequences were sent back via Email 
in minutes or hours.
TABLE 2.5
THE USE OF EMBL FACILITIES TO COMPARE AN OLIGONUCLEOTIDE 
SEQUENCE WITH OTHER AVAILABLE SEQUENCES IN THE GENEBANK
User name: xxxxxxxxx [R]
Password; yyyyyyy [R]
$ mail
To: in % "Fasta@embl-heidelberg.de" [R]
Subj: (not necessary to chose subject) [R]
Enter your message below Press CTRL/Z when complete or CTR/C to quit
Lib email [R] chose to check a particular library in this way
Align 20 [R] (can chose how many alignments required. Default is 30)
Seq ??????????? (GGT GAA TTC CGC AGG CAT GGT primer IB) [R] 
end [R]
To access returned mail:
mail > dir [R] (will give a list of your directory of returned messages)
Mail 3 [R]( chose the number of any of the listed return messages eg no 3) by pressing [R] you can 
read the message or mail> prompt [R] CTRL/Z to print message 
After use, when you have exited by using CTR/Z command 
$ lo (to exit the system).
Note: Bold = to be type in;
[R] = return;
???? = type in actual nucleoside sequence. 
Accession no. = type in actual accession number 
CTRL/Z = press " control" and "z" simultaneously.
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All primers were costumed ordered form Genosys 
Biotechnologies Inc, Cambridge UK.
2 . 1 4 . 2  PCR c o n t r o l  p r o c e d u r e s
In order to avoid sample or PCR "carryover" contamination, 
procedures described by Swok and Higuchi (1989) and 
Heinrich (1991) were implemented within the laboratory. 
Different rooms were used for (i) dispensing, storing and 
preparing reagents for PCR, (ii) sample preparation, (iii) 
DNA addition, and (iv) DNA analysis. Each area was 
equipped with designated lab coats and disposable gloves 
which were changed frequently. Test sample or DNA was 
added last using disposable plugged tips (Elkay, USA-AER- 
2Ref-S96). A "no DNA" negative control tube containing all 
other reaction components was set up with each set of 
amplifications. When testing diagnostic samples, a second 
negative control was included. This sample had been 
previously negative on PCR and did not contain target 
sequence. A tube was also included to which target BHV1 
DNA was added. This acted as the positive control.
2 . 1 4 . 3  S e t t i n g  up PCR a s s a y s
All the PCR assays were set up in a class two laminar air 
flow cabinet under sterile conditions in a clean room 
dedicated to the storage and dispensing of PCR assay 
components. In a typical PCR assay the following were 
mixed in the order cited in 0.5 ml sterile microfuge
10x Amplification buffer 5 Hl
dNTP (lOmM) 5 Hl
Sterile water 13.5 Hl
Primer 1 (see 4.2) 1 Hl
Primer 2 (see 4.2) 1 Hl
Enzyme (1.25u) 0. 5|al
Template DNA 20 Hl
Paraffin oil 40 Hl
All reaction components were kept on ice prior to and 
following amplification. Amplification took place using a 
Omnigene thermocycler (Hybaid) and on a DNA Thermocycler
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480 (Perkin Elmer, USA) . Following amplification, 15 p.1 
samples of the PCR assay were examined on a 2% gel and the 
remainder stored at -20°C.
2.14.4 Wizard1™ PCR Preps DNA purification system for rapid 
purification of DNA fragments
The Wizard1” PCR preps purification system (Promega-A717 0) 
provided a simple, reliable and effective way to purify 
PCR amplified DNA for restriction analysis, sequencing and 
cloning. The PCR sample was purified "directly" from the 
microfuge tube following electrophoresis.
Direct purification of PCR products
Each PCR reaction mix was transferred to a 1.5 ml clean 
microfuge tube containing 100 nl of Wizard direct 
purification buffer. The contents were mixed using a 
vortex and 1 ml of Wizard PCR Preps resin was added. The 
tube was mixed by vortex 3 times over a one minute period, 
the contents were pipetted into a 1 ml syringe and the 
plunger depressed slowly to push the slurry into the mini­
column. The syringe barrel was re-attached and 1 ml of 80% 
isopropanol inserted into the syringe and gently pushed 
through the mini column. The isopropanol wash was 
repeated. In order to remove all of the isopropanol the 
mini columns were transferred to a 1.5 ml tube and 
centrifuged for 20 sec at 12,000g. Minicolumns were then 
transferred to another microcentrifuge tube, 50 (il of 
water applied and left for one minute to allow the elution 
of DNA. The eluate was recovered by centrifugation at 
12,000g for 30 sec. Purified DNA was then stored at -20°C.
2.14.5 Purification of PCR product from agarose gels
PCR products were separated on low melting point agarose 
gels (Gibco-BRL 15517-014) by electrophoresis and stained 
in ethidium bromide. The position of the DNA on the gel 
was identified quickly under UV light and the DNA was 
sliced out using a sterile blade and placed in a 1.5 ml 
eppendorf. It was then heated to 75°C until the agarose 
was completely melted. One millilitre of Wizard Prep
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purification resin was added and mixed gently for 20 sec. 
Wizard Prep mini columns were then used to purify the 
sample as described above in 2.14.4.
2.14.6 Restriction endonuclease analysis of PCR products
PCR products from isolates of known genotypes were cleaned 
using Wizard preps. Restriction endonuclease analysis of 
cleaned PCR product was performed using Taq I and Hae II 
in 20 p.1 volumes. Digests using Taq I proceeded at 65°C 
for 1 hr in digestion buffer (10 mM Tris-HCL pH 7.4, 50 mM 
NaCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mg/ml BSA, 50% glycerol) 
while those using Hae II proceeded at 37°C for 1 hr in 
digestion buffer B (10 mM Tris-HCL, 0.1 mM EDTA, 1 mM DTT, 
0.5mg/ml BSA, 50% glycerol). The digests were analysed by 
electrophoresis using TBE 4% Low Nu sieve agarose (FMC).
2.14.7 Amplification of a region of the bovine IGF gene 
from routine diagnostic samples using PCR
As an endogenous internal control, an equal aliquot of 
sample was used in a PCR assay with primers to detect an 
insulin growth factor (IGF-1) gene ubiquitously present in 
bovine cells (primers were provided by the National 
Diagnostic Centre, Galway, Ireland). The sequence of the 
primers was as follows 
IGF Is 5' CTCACTGTCACTHCTAAA 3'
IGF 2: 5' AAGAAATCACAAAAAGCAGC 3'
Each 50 (J.1 reaction was set up as follows:
Reaction mixes were overlaid with mineral oil and heated 
to 94 °C for 5 min for initial dénaturation of the
10 x Taq buffer 
MgCl2 (25 mM) 
dNTPs (1.25 mM)
IGF primer 1 (lOOng) 
IGF primer 2 (lOOng) 
Taq (Promega)
H20
10 j il  
16 nl 
1 2  yil  
1  Hi 
1  n l
0.5 units 
9.5 (il
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template. Samples were then subjected to 35 cycles of 94°C 
for 30 sec, 50°C for 30 sec followed by 72°C for 60 sec. 
On completion of PCR, 10|a.l of reaction mixture was loaded 
onto a 2% agarose gel for electrophoresis.
2 . 1 5  CLONING PCR FRAGMENTS
Cloning PCR fragments by their insertion into vector 
plasmids followed by their transformation and propagation 
in bacterial cultures provides a means of generating large 
quantities of the PCR fragment which can be manipulated 
further by DNA sequencing. All protocols used in DNA 
cloning were followed according to the method outlined by 
Sambrook et al. (1989).
2 . 1 5 . 1  E n d - P o l i s h in g  o f  PCR p r o d u c t s
In order for PCR fragments to be suitable for blunt-ended 
cloning they must be end polished or treated to remove all 
extensions or overhangs (Costa and Weiner, 1994).
The following were added to a 1.5 ml microcentrifuge tube.
18 jjiI  of PCR product 
4 M.1 lOx PFU buffer 
2 nl dNTPs (10 mM),
1 unit PFU 
16 M-l sterile water 
Tubes were incubated at 74°C for 45 min.
2 . 1 5 . 2  P la s m id  l i g a t i o n
For the cloning experiments the plasmid pGem 3Zf ( + ) 
(Promega-P2271) was used. The plasmid was cut with Smal at 
32°C for 2 hr and run on a 1 % agarose gel to verify that 
complete digestion of plasmid had occurred. Plasmid DNA 
was then purified by a phenol/chloroform extraction, a 
chloroform extraction and an ethanol precipitation. 
Digested plasmid DNA was resuspended at a final 
concentration of 450ng/(j.l. The following were mixed in the 
order cited in a 0.5 ml sterile microfuge tube
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1 |il of plasmid (450 ng),
8 |-il of purified PCR product (500 ng),
1.1 |il ligase buffer 
1 jjlI (u) T4 ligase.
The ligation reactions were incubated overnight at 16°C. 
As a control a tube which lacked PCR product was set up 
with similar ligation conditions.
2.15.3 Transformation of competent cells
Tubes containing 200 p.1 of cold competent E. coli DH5- 
alpha cells (ampicillin sensitive) were allowed to thaw on 
ice. The ligation mix was added to the competent cells 
which were heat shocked by placing them at 42°C for 90 
seconds. These were transferred immediately to ice for 2 
min, 0.8 ml of SEC was added and samples incubated at 37 
°C for 60 min for outgrowth to occur. Luria Broth (LB) 
(lOg tryptone, 8 g NaCl, lOg agar) plates with ampicillin 
(25ug/jil) (Gibco-BRL 13075-015), 4 jj.1 20 mg/ml X-gal
(Gibco-BRL 15520-018), 4 [il 200 mg/ml IPTG (Bibco-BRL
15529-019) were inoculated (neat and 1:10) with 
transformed cells by spread plating. Plates were incubated 
overnight at 37°C. All plates were examined for white 
colonies, which if present, were picked off using a 
sterile tooth pick and transferred to 5 ml LB broth with 
ampicillin (50ug/ml) and placed in a shaker at 37 °C 
overnight.
2.15.4 Mini prep analysis
The cells from 1.5 ml of the bacterial culture were 
pelleted in a microcentrifuge tube by centrifugation at 
12,000 rpm for 30 sec. The remainder of the culture was 
stored at 4°C. The supernatants were removed using a 
sterile syringe and cells were lysed by alkali treatment, 
by resuspension in 100 (a.1 of cold solution I (see 2.5.3). 
Two hundred microliters of freshly prepared cold solution 
II (see 2.5.3) was added and the contents mixed rapidly 
ensuring that the entire contents of the tube came in
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contact with the solution. The tubes were stored on ice 
for 5 min. One hundred and fifty microlitres of solution 
III (see 2.5.3) was then added and the tube mixed by 
vortex for 10 seconds to disperse solution III through the 
bacterial lysate. Tubes were then stored on ice for 5 min 
and centrifuged for 15 min at 12,000g and the supernatant 
transferred to a new tube. The supernatants were treated 
with an equal volume of phenol:chloroform and centrifuged 
at 12,000 rpm for 2 min. Plasmid DNA was then precipitated 
with 2 volumes of ethanol for 2 hr at -7 0°C. Pellets were 
washed twice with 7 0% ethanol and any residual ethanol was 
removed with a syringe. Pellets were allowed to dry at 
55°C, dissolved in 50 p.1 TE pH 8.0 and 2|j.l of DNase free 
pancreatic RNase (5000 p.g/ml) and stored at - 20°C.
2 . 1 6  DNA SEQUENCING
The Macrophor sequencing system (Pharmacia LKB) was used 
to run sequencing gels. Two non-radioactive sequencing 
kits were used: a Silver sequencing kit and USB's non
radioactive Sequenase kit (USB-71350).
2 . 1 6 . 1  P r e p a r a t io n  o f  g l a s s  p l a t e s
Plates were cleaned with Alkanox (Alkanox Inc, USA) twice 
and rinsed with distilled water. Plates were allowed to 
dry, swabbed with meths and rinsed with distilled water. 
The thermal or longer plate was cleaned in the same manner 
by using white lint free tissues. Five mililitres of Repel 
Silane (Pharmacia-80-1129-42) was spread over the top of 
the plate in a fume hood, left to dry and polished. This 
was repeated once, the plate was then polished with 
ethanol, rinsed with distilled H20 and polished with 
ethanol again. In the case of silver sequencing the 
shorter plate was treated by wiping the entire plate using 
lint free tissue with 3p.l Bind Silane: 1 ml 95%
ethanol:0.5% glacial acetic acid. The plate was then 
allowed to dry for 4-5 min and polished with 2ml of 95% 
ethanol. This method was repeated three times using a
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fresh tissue each time. Spacers and combs were rinsed in 
ethanol.
2 . 1 6 . 2  P r e p a r a t io n  o f  s e q u e n c in g  g e l
Sequagel Sequencing System (National Diagnostics: SequaGel
Concentrate- EC830, SequaGel Diluent EC840, Buffer EC835)
was used to prepare gels. This is supplied as a 3-part
system consisting of concentrate, diluent and buffer.
Depending on the required concentration of the gel
required, Sequagel concentrate, Sequegel dilulent and
Sequagel Buffer (see Table 2.6 below) were added to a
beaker followed by the addition of 480 ul (1 mg/ml) of
ammonium persulpahte (National Diagnostics EC 504) and 240
ul of Temed (National Diagnostics EC 503). All components
were mixed gently and the gel poured immediately. Various 
« ««ylamiaa wav* uaad tom «ha «•■«lutlen a« «ha DMA
sequencing products (see Table 2.6).
TABLE 2.6
PERCENTAGE GELS USED FOR DNA SEQUENCING GELS
DNA % monomer Volume of Sequagel Fragment Size
(in nucleotides)
> 200 4 16 ml SequaGel Concentrate 
74 ml SequaGel Diluent 
10 ml Buffer
80 -200 5 20 ml SequaGel Concentrate 
70 ml SequaGel Diluent 
10 ml Buffer
60-150 6 24 ml SequaGel Concentrate 
66 ml SequaGel Diluent 
10 ml Buffer
Pouring the gel
The short plate with notched side was faced towards the
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large plate and set on the macromould at a slant. Spacers 
were clamped in place. The gel was poured in front of the 
notched plate at an upward slant. When the whole gel was 
poured the short plate was clamped to the longer one and 
the comb inserted. Any air bubbles were removed. The gel 
was allowed to polymerise for at least 60 min, sealed with 
household clingfilm to prevent drying and stored on the 
bench until required.
2.16.3 Running sequencing gels
Prior to sample loading the thermoplate was heated to 
58°C, thus ensuring high temperature across the gel. The 
gel was pre- electrophoresed for 15 - 60 min at 2,500 
volts using TBE buffer. All wells were thoroughly washed 
out with buffer using a Pasteur pipette. Samples were 
heated to 98 °C immediately before loading and 3 - 5 jj.1 of 
samples applied to the gel. The gel was allowed to run for
2.5 hr.
2.16.4 Silver sequencing
This procedure was performed using a Silver sequencing Kit 
(Promega-Q4160).
2.16.4.1 Sequencing reactions: All the following were
performed on ice. For each set of sequencing reactions, 
four 0.5 microcentrifuge tubes were labelled G,A,T,C and 
2 |il of appropriate d/ddNTP mix added to each tube. One 
drop of mineral oil was added to each tube. The following 
were added to each tube in the order cited
Plasmid DNA 2 pmol
DNA sequencing buffer 1 p.1 
Primer 4.5 pmol
Water 5.5 m.1
One microlitre (5 u) of sequencing grade taq DNA 
polymerase was added to the primer/template mix, followed 
by the addition of 4 |il of this enzyme/primer/template to 
each labelled tube containing d/ddNTP. Tubes were
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centrifuged briefly and placed on a preheated thermocycler 
and the following cycle initiated 96°C for 2 min, 96°C for 
30 sec, 60°C for 30 sec and 74°C for 1 minute. This cycle 
was repeated 45 times after which tubes were cooled to 4°C 
and 3 pil of DNA sequencing stop solution was added. 
Samples were then run on a 5% polyacrlamide gel (see Table 
2 . 6 ) .
2.16.4.2 Development of silver sequenced product:
Ultra pure water was used for silver staining in all
procedures
Staining procedure
Plates were separated with the gel remaining attached to 
the shorter plate. The gel was then fixed onto the shorter 
plate by placing it in fix/stop solution and agitating for 
20 min. The gel was rinsed 3 times (2 min each) with 
ultrapure water, transferred to staining solution and 
agitated well for 30 min. The gel was rinsed in a tray in 
ultra pure water for 5-10 sec and placed immediately in a 
tray containing developing solution and agitated for 5 min 
or until the bands began to appear.
2.16.5 USB non radioactive sequenase kit (USB-71350)
2.16.5.1 Generation of single stranded DNA using Dynabeads
The use of dynabeads M280 (Accu Science•112.05) as a 
magnétisable solid phase for the capture and purification 
of PCR product allows simple preparation of immobilised 
single stranded template (Hultman et al., 1989; Lewis et 
al., 1992). This is achieved by end-labelling one of the 
PCR oligonucleotide primers with biotin thus providing a 
means of biotinylating the PCR product. The biotinylated 
PCR product is then captured by incubation with stepavidin 
coated magnetic beads, these are immobilised using a Dynal 
Magnet particle concentrator (MPC). Strands are 
disassociated using a 0.4 M Naoh permitting the removal of 
the unbiotinylated strand while the biotinylated strand 
remains attached to the MPC.
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Preparing Dynabeads for use.
Dynabeads were stored in PBS containing 0.02% sodium azide 
(NaN3) as a preservative, which was removed before use. For 
each PCR product to be sequenced 20 |il of beads were 
placed in a 1.5 ml eppendorf, immobilised using a magnet, 
Dynal MPC-E-L (Accu Science 120.07), and the supernatant 
discarded. The beads were then washed by the addition of 
an equal volume of 2x wash & binding (W&B) buffer (2.5.7) 
and the supernatant discarded after mixing. The above step 
was repeated once. This was followed by the addition of a 
double volume of 2x W&B buffer, which was mixed and the 
supernatant discarded. The beads were resuspended in a 
double volume of W&B buffer allowing 40 p.1 available per 
sample to be sequenced. PCR product to be sequenced was 
added to the washed beads and incubated at room 
temperature for 15 min. The beads were immobilised and the 
supernatant was removed. Beads were washed twice with 40 
M-l of 2x W&B buffer. This process was repeated with 40 |il 
of TE buffer. Single stranded DNA was obtained by the 
addition of 8 |j.l of 0.1 M NaOH to the beads which were 
mixed and incubated at room temperature for 10 min. This 
supernatant was then removed and transferred to another 
tube and neutralised immediately by the addition of 4 nl 
of 0.2 M HCL followed by 1 p.1 1M Tris-HCL pH 7.5. The 
beads were then washed with 50 p.1 of 0.1 NaOH in order to 
remove any unbiotinylated ssDNA followed by a wash with 40 
|il of 2 x W&B mix and a final wash with 40 p.1 of TE. The 
beads were then resupended in 12 \xl of PCR quality sterile 
water. Two microlitres of neutralised and dynabead 
suspension sample were run on a gel in order to verify the 
presence of DNA.
2.16.5.2 Direct sequencing of PCR products
Prior to sequencing PCR products were cleaned using PCR 
magic preps and the concentration of PCR product 
determined photometrically and by gel electrophoresis. 
Single stranded DNA was generated using the dynabeads 
described in 2.16.1.
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7 nl DNA (0.5pmoles)
2 nl 5 X sequencing buffer
1 jj.1 biotinylated primer (20 ng) ( 2 . 8pmoles )
2.16.5.3 Sequencing reactions
Annealing reaction
10 |il
Tubes were heated to 65°C for 2 min using a heat block and 
then let cool slowly to a termination temperature (which 
varied between 37°C and 60°C) for 20 - 30 min period and 
chilled on ice.
While the annealing mix was cooling 4 tubes were labelled 
G,A,T and C. Two and a half microlitres of each ddNTP mix 
was added to the appropriate tube and left on ice. 
Sequnase enzyme was diluted in ice cold enzyme dilution 
buffer (1:8) dilution and kept on ice.
Chain Termination reactions
The four termination tubes were heated for 1 min at the 
required termination temperature. Meanwhile the following 
were added to the annealing reaction mix and centrifuged 
briefly in a tube.
1 |il DTT (0.1M)
2 nl Hz0
2 nl diluted sequenase
To the prewarmed termination tubes (G,A,T and C) 3.5 |il of 
the above mixture was then added and mixed. The tubes were 
incubated at the chosen termination temperature for 5 min.
The reactions were stopped by adding 4 |il of stop 
solution. The tubes were then stored at -20°C until 
electrophoretic separation. Variations on the method ere 
performed as described in Table 8.3.
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2 . 1 6 . 5 . 4  T r a n s f e r  o f  DNA t o  t h e  S e q u e n a se  Im a g es membrane
After electrophoresis the glass plates were separated 
allowing the gel to remain on one. Clean rinsed disposable 
gloves were worn while performing the following procedure. 
A Hybond N+ membrane (Amersham, USA -203B) was pre-wet 
with Hz0 and was placed on the gel. If necessary, any air 
bubbles were rolled out with a clean 25 ml pipette. The 
top left hand corner was cut to serve as an orientation 
marker. Two sheets of 3 MM of Watmann filter paper were 
placed on the nylon and these were covered with a glass 
plate. A 2 kg mass was then evenly distributed over the 
glass plate and left for 1 hr. The nylon membrane was then 
placed DNA side up on another sheet of Watmann filter 
paper and baked at 80°C for 30 min in a hot air oven. The 
membrane was then sealed in a development bag with one 
corner left open to facilitate the addition of developing 
solutions.
2 . 1 6 . 5 . 5  The d e t e c t i o n  o f  s e q u e n c e  on  m em brane
Two hundred millilitres of blocking buffer was added to 
the bag which was resealed and agitated at 100 rpm for 30 
min. Two hundred microlitres of strepavidin alkaline 
phosphatase conjugate (SAAP) was then added directly to 
the blocking buffer, mixed immediately and agitated for 30 
min. The bag was drained and the membrane rinsed with 
distilled water. Three hundred millilitres of IX post- 
SAAP/0.1% SDS wash buffer was added to the bag which was 
then agitated for 10 min at 100 rpm and drained. This step 
was repeated three times. The membrane was given a final 
wash with 300 ml IX post-SAAP wash buffer. All excess 
liquid was squeezed out. Using a sterile pipette, 6 ml of 
Lumniphos 530 was added to the bag and the liquid 
distributed over the entire membrane for 2-3 min. The bag 
was then sealed, dried thoroughly with tissue paper and 
exposed to Hyperfilm MP multipurpose Autoradiogaphy film 
(Amersham RPN34) in a Cassette (Amersham 1644) for 90-120 
min at room temperature and developed.
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2.16.6 Cycle sequencing using USB kit
This involved the use of Stratagenes' Cyclist Kit 
(Stratagene- 200325) in conjunction with a biotinylated 
primer and using USB's Sequenase development kit to detect 
product.
2 . 1 6 . 6 . 1  C y c le  s e q u e n c in g  r e a c t i o n s
DNA
Primer biotinylated
Sequencing buffer
Enzyme
DMSO
Water
4 |il (0.1 ug/nl) 
2(il (40 ng)
4 |il
1 |il (2.5 units) 
4 |il 
8  n l
23 |il
Meanwhile 5 |a1 of the appropriate ddNTP was added to each 
of the 4 termination reaction tubes and these were then 
kept on ice. Five microlitres of DNA/primer/enzyme mix was 
added to each termination tube containing dddNTPs which 
were then overlaid with mineral oil. Tubes were placed on 
a preheated thermocycler and the optimised PCR programme 
was run after which 5 |~il of stop dye mix was added.
2 . 1 6 . 6 . 2  D i r e c t  PCR p r o d u c t s
The DNA source was (i) Direct PCR product (ii) Direct PCR 
product which had been cut from the gel (iii) or Purified 
viral DNA. PCR product which had been cut from the gel was 
placed in 50 |il of sterile distilled water and heated to 
7 0°C and 10 h1 was used in the sequencing.
2 . 1 6 . 6 . 3  C lo n e d  PCR p r o d u c t s
The DNA source was PCR product which had been cloned as 
described in 2.15. Reactions were as described as above.
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CHAPTER 3
THE RESTRICTION ENDONUCLEASE ANALYSIS OF BHV1 
ISOLATES FROM IRISH CATTLE
3 . 1  INTRODUCTION
Since the first isolation of BHV1 in Ireland was made
in 1971 (Collery, 1974) the number of reported IBR
outbreaks has increased steadily and the virus has been 
isolated routinely from cases of respiratory disease and 
some cases of conjunctivitis. Unlike the United Kingdom 
and mainland Europe where there was an emergence of severe 
BHV1 in the field coinciding with the appearance of the 
more virulent BHV1.1 genotype in the late 1970s and early 
there were no such reports of severe IBR infection in 
Ireland at this time. Some severe outbreaks were recorded 
in the late 1980s however the isolates were not
characterised using restriction endonuclease analysis. A 
number of BHV1 isolates made in Northern Ireland were 
analysed and shown to be BHV1.2. (Edwards et al. , 1990) 
and the assumption prevailed that like Northern Ireland 
the Republic remained free from the more virulent BHV1 
genotype.
This study was undertaken for two reasons:
(I) For epidemiological purposes to investigate if both
BHV1 genotypes were present in the Republic of Ireland.
( I I )  To confirm that the PCR assay developed in chapter 4 
(see below) would detect a range of BHV1 field isolates 
including, if present, both BHV1.1 and BHV1.2.
3 . 2  VIRUSES
Thirteen BHV1 isolates that had been made at the
Veterinary Research Laboratory were chosen for analysis
using REA. These had been submitted to the laboratory as 
diagnostic samples from cattle suffering from clinical
signs of IBR including conjunctivitis, respiratory disease 
and pharyngitis. Submissions were made from veterinary 
practitioners around the country and from the Regional 
Veterinary Laboratories. The isolates included the first 
BHV1 isolate made at the VRL and 12 others made between 
1971 and 1992. Isolates are referred to using the
reference letter and number assigned to them upon entry to 
the laboratory. Virus was propagated on cell culture, DNA
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extracted and REA performed according to the methods 
described in Chapter 2.10.
3 .3  RESULTS
FIGURE 3.1
THE RESTRICTION ENDONUCLEASE ANALYSIS OF 9 BHV1 ISOLATES 
MADE AT THE VRL FROM DIAGNOSTIC SUBMISSIONS
Fragment
LI L2 L3 L4 L5 L6 L7 L8 L9
Lane 1: lambda DNA size markers (Hind III digest: Marker 
sizes in base pairs 23,130; 9,426; 6,557; 4,361; 2,322; 
2,027; 564; 125), Lanes 2 - 9  Hind III digests from viral 
DNA prepared from BHVl isolates,
Lane 2: Severe IBR (1989; D463),
Lane 3: Severe IBR (1989; D686),
Lane 4: Severe Pharyngitis (1991; J702),
Lane 5: Severe IBR (1989; D7 31),
Lane 6: Conjunctivitis (1971; 579),
Lane 7: Mild IBR (1992; X313),
Lane 8: Lambda DNA size markers (as lane 1),
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Figure 3.1 shows the restriction pattern obtained from REA 
of 9 isolates. The REA pattern obtained in lanes 6 and 7 
corresponds to those previously obtained from BHV1.2 
isolates while that obtained in lanes 2 - 5  and lane 9 
corresponds to that previously obtained from BHV1.1 
isolates (Metzler et al., 1985).
It can be concluded that BHV1.1 and BHV1.2 have been 
isolated from diagnostic submissions to The Veterinary 
Research Laboratory.
Table 3.1 (overleaf) shows the clinical history, year of 
isolation, nature of outbreak and genotype resulting from 
REA analysis on 13 BHV1 isolates. Results show that BHV1.2 
was in Ireland since at least 1971 and that BHV1.1 has 
been present and has been the causative agent of outbreaks 
of pharyngitis, and some outbreaks of severe respiratory 
disease since 1989.
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TABLE 3.1
CLINICAL HISTORY, AGE AND DISEASE SIGNS CAUSED BY BHV1 ISOLATES ANALYSED BY REA
YEAR OF 
ISOLATION
LABORATORY
REFERENCE
CLINICAL
SIGN
SEVERITY AGE GENOTYPE
1971 579 Conjunctivitis MiJd Adult BHV1.2
1979 H607 Conjunctivitis Mild Unknown BHV1.2
1986 J302 Conjunctivitis Mild Adult BHV1.2
1989 D463 Respiratory Severe Adult BHV1.1
1989 D863 Respiratory Severe Adult BHV1.1
1989 D731 Respiratory Severe Adult BHV1.1
1990 H984 Respiratory Severe Adult BHV1.1
1991 J702 Respiratory
Pharyngitis
Severe Weanling BHV1.1
1991 0909 Respiratory Severe Unknown BHV1.1
1992 W145 Pharyngitis Severe Neonatal BHV1.1
1992 W199 Pharyngitis Severe Neonatal BHV1.1
1992 X35 Respiratory Severe Adult BHV1.2
1992 X135 Respiratory Mild Adult
Neonatal
BHV1.2
8 0
FIGURE 3.3
THE FARM LOCATIONS FROM WHICH BHV1 ISOLATES EXAMINED IN THIS 
STUDY WERE MADE.
Donagal
Cavan
Roacommon
W aaim aath
G a l way
Klldara
C arlo '
Kilkenny
Tipperary
Watarfori
H 6 0 7
J7 02
D 4 6 3
D 6 8 6
D 7 3  1
Figure 3.3 shows a map of the locations from which the BHV1 field 
isolates were chosen for analysis.
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3 .4  DISCUSSION OF RESULTS
The purpose of this investigation was to determine if 
both BHV1.1 genotype were present in the Republic of 
Ireland.
Restriction endonuclease analysis was performed on 
purified viral DNA from a number of BHV1 isolates, made at 
the VRL, according to the system described by Metzler et 
al. (1985). The restriction enzyme Hind III was used to 
classify the strains as it permits the differentiation 
between BHVl.1 and BHV1.2 as well as distinguishing 
between BHVl.2a and BHVl.2b. The Hind III genomic map has 
been described for both BHVl genotypes in chapter 1.5 
Table 1.1. Based on the MW of fragments K and L, virus can 
be assigned to BHVl type 1 (K - 8.55 Kb; L - 8.03 Kb) or 
BHVl type 2 (K - 7.87 Kb; L - 7.27 Kb). These fragments 
are visibly smaller using gel electrophoresis (see Figure
3.3 lanes 2 - 5  for a typical restriction pattern from 
BHVl.1 isolates, while lanes 6 and 7 depict those from 
BHVl.2 isolates). Hind III also allows the differentiation 
between BHVl.2a and BHVl.2b genotypes on the basis of the 
size of fragment I. This fragment has a lower molecular 
weight in BHVl.2b (10.8 Kb) in contrast to (11.95 Kb) in 
BHVl.2a and BHVl.1 isolates.
A total of 13 strains which had been isolated between 
the years 1972 - 1992 were investigated and their
laboratory reference number, age, clinical manifestation 
and severity of disease are presented in Table 3.1. The 
isolates were chosen on the basis of clinical signs and 
the importance or severity of the outbreak and included 
the following:
■ The first recorded BHVl isolate made from a case of 
conjunctivitis in Wexford in 1971 and two subsequent cases 
of conjunctivitis in 1979 and 1986 (579, H607, J302; Table
3.1),
■ Isolates made from rare cases of pharyngitis in neo­
natal calves (W145, W199; Table 3.1) as well as isolates 
made from outbreaks of respiratory disease (D463, D868, 
D7 31, H984, X35, X313; Table 3.1).
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As the purpose of the investigation was to determine 
if genotype BHV1.1 was present in the Republic of Ireland, 
isolates from some of the more severe clinical cases of 
IBR were deliberately chosen for analysis. Data from the 
submissions used for this study must be viewed with 
caution as it was based on clinical histories reported by 
the farmer and/or veterinary practitioner. The absence of 
a record of a sign does not necessarily imply that it was 
absent from a particular incident.
The analysis of the first BHV1 isolate made at the 
VRL from a case of conjunctivitis revealed it to be a 
BHV1.2 genotype (57 9 Figure 3.1 lane 6). Two other cases 
of conjunctivitis also were shown to be BHV1.2. (H608 and 
J302; Table 3.1). Based on the size of fragment I in their 
restriction patterns all isolates were designated BHV1.2b. 
This finding was consistent with that previously reports 
suggesting that BHV1.2b is associated with conjunctivitis 
(Edwards et al., 1990). There was no evidence of BHV1.2a 
in this study which has also not been recorded in Britain 
(Edwards et al., 1990).
BHV1 isolates were made from outbreaks of severe 
respiratory disease in mature cattle on large feedlots in 
the North East and midlands of the country during the 
years 1989, 1990 and 1991 (D463, D683, H984, J702, 0909; 
Table 3.1). All animals had classical IBR signs, which in 
some cases resulted in eventual mortality or slaughter. 
The causative isolates were identified and again 
classified as BHV1.1 (Figure 3.1; lane 2,3 and 5), thus 
indicating that BHV1.1 had either entered or circulated 
throughout another part of the country.
A report of severe BHV1 infection was recorded in 
1991, when BHV1 was shown to be the causative agent of 
death in neonatal calves on a farm in the South of Ireland 
(Table 3.1; Figure 3.2). These animals had been suffering 
from severe pharyngitis and post mortem examined revealed 
systemic infection similar to that described in previous 
reports (Kahrs et a.,1977., Ross et al., 1983; Higgins et 
al.,1986). The outbreak resulted in a high mortality rate.
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This case was distinctive in that such outbreaks seem to 
be a rare clinical sign of BHVl. (Two previous cases 
similar to this had been recorded in 1987 and 1989 (Power 
et al., 1996)). The affected animals did not show clinical 
signs of respiratory disease such as nasal or ocular 
secretions. Older animals in close proximity also showed 
no apparent clinical disease signs. The REA of the 
isolate revealed it to be BHVl.1 genotype (Figure 3.1 lane
4 ) .
Another case of necrotic pharyngitis in neonatal 
calves was reported in 1992 within the same region as that 
of 1991 however there was no apparent link between the 
farms in question and those involved in the 1991 outbreak. 
The outbreak was associated with systemic disease with 
similar post mortem reports as that described for previous 
cases (Power et al., 1996). It was unknown whether the 
severe disease was due to the fact that neo-natal calves 
have been shown to suffer from systemic disease similar to 
that of fetuses (Higgins and Edwards 1986 ) or if the
disease was caused by the more virulent BHVl.1 genotype
(Attempts to elucidate this are described in chapter 6).
The causative agent was identified as a BHVl.1 genotype 
(Figure 3.1, lane 9: W145).
Restriction analysis on DNA prepared from a further 
two isolates made on a farm which had the clinical form of 
IBR revealed BHVl isolates as the causative agents (X313 
and X35, Table 3.1). In the latter case, BHVl.2 was
associated with severe respiratory disease which had 
serious economic reprocussions for the farm. This result 
appeared inconsistent with the results above and those 
already found. However, the housing and environmental 
conditions of the farm in question were conducive to 
disease spread. All the animals were housed in one large 
slated shed with little air ventilation while the stocking 
density was high. As a result the virus could spread 
rapidly to all animals. This finding suggests that the 
impact of disease may be accentuated or decreased 
depending on the farm management policies and highlights
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the importance of proper housing, reduction in stocking 
density and environmental conditions of the farm in 
disease control and prevention of virus spread (Chapter
1.13) .
From Figure 3.1 and Table 3.1 it can be concluded 
that as expected, the earlier BHV1 isolations made in this 
country were BHV1.2 and were associated with 
conjunctivitis, unfortunately no isolates from cases of 
mild respiratory disease in the years 1971 - 1985 were 
available for analysis. This study also has provided 
evidence that BHV1.1 has entered this country and has been 
associated with cases of severe pharyngitis and systemic 
disease in young calves as well as cases of severe 
respiratory disease in older cattle.
How and when BHV1.1 entered Ireland is unknown and 
difficult if not impossible to ascertain. The genotype may 
have been present for many years prior to 1989 and may 
only have come to play a more important role in animal 
health due to (i) greater circulation of the virus, (ii) 
changing farming patterns resulting in more intensive 
feedlots, (iii) greater awareness of respiratory disease 
on the part of farmers and veterinary practitioners or 
(iv) a combination of some or all the above factors. This 
may only be determined by further restriction analysis of 
more isolates. At this time animals were being imported 
from United Kingdom, Mainland Europe, Canada, England and 
Scotland. Prior to 1992 cattle entering Ireland from 
Europe and Canada were quarantined and tested for BHV1 
antibodies. Under an agreement with Britain cattle were 
tested there before importation. Seropositive cattle were 
denied entry therefore the introduction of the virus to 
the country by importation should not have been possible. 
If latently infected cattle did enter the country the 
stress associated with the transport or movement of 
animals (Thiry et al., 1987), would have increased the 
possibility of virus reactivation in any of those which 
were carriers and virus may have been shed soon after 
arrival. However another alternative is that the virus
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strain present in Ireland in the 1970s mutated to become 
more virulent.
These results are consistent with those obtained in 
previous reports on the relationship between BHV1 genotype 
and disease signs (Edwards et al., 1991). However, it is 
difficult to make any definitive conclusions based on the 
number of REAs performed. The cases of conjunctivitis were 
caused by BHV1.2 and all the severe outbreaks of 
respiratory disease were associated with BHV1.1 with the 
exception of the outbreak from which virus X313 was 
isolated. This was classified as BHV1.2.
3.5 CONCLUSION
Clinical and molecular studies indicate the presence of 
both BHV1 genotypes in Ireland. Genotype BHV1. 2 has been 
present since at least 1971 and was the genotype of the 
first recorded outbreak of conjunctivitis. Genotype 
B H V l. 1 , which has been associated with more severe 
clinical signs, has been shown to be the causative agent 
of some of the more severe and economically significant 
outbreaks in recent years.
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CHAPTER 4
THE DEVELOPMENT AND OPTIMISATION OF A 
PCR ASSAY TO DETECT BHV1
4.1 INTRODUCTION
The polymerase chain reaction PCR was first described 
by Saiki et al. (1985) and is defined as a selective in 
vitro method for the amplification of specific DNA 
sequences. The use of PCR to select and amplify small 
regions of DNA has been used as a revolutionary new tool 
in the quest for a fast and specific method for the 
detection of pathogenic animal viruses (Belak et al., 
1993). This chapter describes the development of a PCR 
assay to detect a BHV1 DNA.
The principle of PCR is based on that of DNA 
replication in the cell which occurs before cell division 
to permit the conferring of the same hereditary 
information to the two daughter cells.
DNA replication occurs as follows (and outlined in Figure
4.1); (I) DNA strand separations New DNA can only be
synthesised when a single-stranded matrix DNA ("template") 
is present. In a living cell this strand separation is 
achieved by enzymes and other proteins. In a test tube - 
as is the case for PCR - strand separation is normally 
performed by heat. Reaction mixtures are heated to 
approximately 90 to 95°C or up to 98°C when target 
sequences are high in GC content as in the case of 
herpesviruses (Moore et al., 1995). At this temperature, 
the double-stranded (ds) DNA is denatured to form single 
strands.
(II) Annealing of primers The hybridisation of a single 
stranded primer is necessary for DNA polymerisation. This 
takes place at the 3' end of an existing single-stranded 
starter DNA segment ("primer-site"). In vivo this is a 
short stretch of RNA synthesised within the cell. In a PCR 
assay the primer is artificially synthesised to contain a 
sequence complementary to the region to be amplified. To 
allow specific annealing between the primers and the 
single bands of target DNA a temperature is selected that 
allows only specific annealing between exact matches of 
primer and target sequences. This temperature usually lies 
between 45°C and 70°C. The optimal annealing temperature
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mainly depends on the length and on the guanine/cytosine 
(GC) content of the primers: accordingly it is empirically 
determined for each primer pair (See 4.2.1).
(iii) Strand extension: DNA synthesis takes place using 
DNA polymerase and proceeds in a 5'— > 3' direction
beginning at the site of the annealed primer. Taq 
polymerase extends the primers by using each single 
stranded target as a template for the construction of a 
complete complementary strand. In vivo this occurs at 37°C 
while in a PCR assay polymerase enzymes that function at 
75°C are chosen which can withstand the high temperatures 
used for denaturation. Strand extension results in 
duplication of both original DNA strands.
The components of PCR, as described in the reaction, 
are mixed in reaction tubes and placed into the 
thermoblock of a DNA thermocycler. These thermoblocks are 
available to allow automation of the process and are 
controlled by a microprocessor which increases and 
decreases the temperature rapidly, in accordance with a 
preselected programme. One PCR cycle is typically 
completed within 3 - 5  minutes. On completing the first 
cycle, the thermoblock is reheated and begins the second 
round of amplification. In this cycle the double strands 
of DNA will separate and serve yet again as templates for 
new DNA synthesis. Accordingly, each PCR cycle results in 
the duplication of the DNA target. If the number of cycles 
is n, then the amplification results in a 2n exponential 
increase in DNA. By performing 25 to 30 cycles, a 109 
million fold amplification of the target could 
theoretically be achieved within 3 hr. However, due to 
decreasing enzyme activity and other factors, one cannot 
expect more than an approximately 106 fold amplification of 
the target in a single PCR assay.
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FIGURE 4.1 
THE PRINCIPLE OF THE PCR ASSAY
3'
5' 3'
5'
DOUBLE STRANDED
D N A  t a r g e t
STEP 1 DNA DENATURATION
3' H BONDS BREAK 
95°C
5' GENERATION OF1 
SINGLE STRANDS
STEP 2 PRIMER ANNEALING
PRIMER 1 
5' 
3'
P R I M E R  2
STEP 3 PRIMER EXTENSION
dNTPS
PRIMER
MAGNESIUM CHLORIDE
3P 5 TAQ p o l y m e r a s e
P R I M E R  2  PH7-5
5'_______ /V\/\^A/^AAAAAA 3'
3'______________________ B
Figure 4.1 shows a diagrammatic representation of a PCR 
assay. Each assay tube contains a double stranded DNA 
template which is denatured by the employment of high 
temperatures (95°C or higher) to produce two single 
strands (Step 1). The temperature is lowered to allow the 
annealing of an oligonucleotide primer complementary to 
the region to be amplified (Step 2). An increase to 72- 
74°C allows the synthesis of a complementary DNA strand 
using Taq polymerase (Step 3). At the end of each PCR 
cycle 2 double strands of DNA are produced. By repeating 
this the number of target DNA molecules can increase at an 
exponential rate.
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In order to mimic such an inherent cellular metabolism in 
vitro those components present in the cell must also be 
present in PCR assay. The reaction components are as 
follows:
Oligonucleotide primers: The primers are artificially
synthesised as short (17 to 40 nucleotides long) 
oligonucleotide molecules that flank the sequence to be 
amplified, usually between 100 to 2000 bp, and are 
complementary to opposite strands of the target. The 
primers are able to find their target in the reaction 
mixture and specifically anneal to it. In most 
applications it is the sequence and the combination of 
primers that determines the overall assay success. General 
guidelines for primer choice include the following, (i) 
primers should lie within highly conserved regions of the 
sequence, the 3' ends of the primer should not possess 
complementarity to each other in order to avoid template- 
independent artifacts termed as primer-dimers. (ii) 
Primers should not include palindromes and should lack any 
secondary structure, (iii) They should be specific to a 
single member of a gene family and should avoid imbalances 
in the distribution of G/C and A/T rich domains. Both 
oligo d(T) and poly d(C) work well as primers (Saiki,
1992) .
Reaction buffers: Various buffers and inorganic ions aid
the PCR, eg KC1 promotes the activity of the polymerase 
and free magnesium ions are essential for it's function. 
Magnesium influences enzyme activity and forms soluble 
complexes with dNTPs which are essential for dNTP 
incorporation. The concentration of free magnesium depends 
in turn on the concentration of the dNTP, diphospahtes 
(PPi) and EDTA. Each of the above binds stoiciometrically 
with magnesium. Buffers often include bovine serum albumin 
(BSA) for enzyme stabilisation.
Deoxynucleotide triphosphates: The four free dNTPs (dATP, 
dCTP, dGTP and dTTP) are the building blocks for the new 
DNA strands. Stock solutions of dNTPs are neutralised to 
pH 7.0.
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P o ly m e r a s e  en zym es The initial PCR studies used the 
thermosensitive Klenow fragment of Escherichia coli, DNA 
polymerase I to synthesize the DNA. Since this enzyme is 
inactivated after each replication step, each cycle 
requires the opening of the tube and the addition of fresh 
enzyme. This tedious step was eliminated by the isolation 
of a thermostable DNA polymerase enzyme, Taq DNA 
polymerase from the bacterium Thermus aquaticus (Saiki et 
al., 1988), since this enzyme is not denatured under the 
conditions used for PCR. Thus, the use of Taq polymerase 
allows the execution of automated PCR in addition to 
reducing the risk of contamination. A range of polymerase 
enzymes are now available which are more thermostable, 
enabling higher denaturing temperatures and which have 
proof reading abilities to reduce the incorporation of 
errors.
Other factors affecting PCR: PCR amplification can be
adversely or advantageously affected by a large number of 
factors. After complete optimisation of components the 
sensitivity may be increased by the addition of other 
chemicals. Recently it has been demonstrated that the 
addition of cosolvents such as diethyl sulfoxide (DMSO) 
and glycerol enhances the half life of Taq polymerase 
(Rolfs, 1992). These cosolvents also result in more 
complete nucleic acid denaturation and elimination of 
secondary structure. Formaldehyde also acts to improve 
fidelity and correctness while Tween 20, a non-ionic 
detergent, is capable of reversing the inhibitory effects 
of certain ionic detergents such as sodium dodeycl 
sulphate (SDS) (Rolfs, 1992). Each PCR set up however 
remains a unique reaction and optimised conditions may 
only be found by trial and error.
Oil Overlay: Most thermocyclers do not heat the lids of 
the reactant tubes, therefore overlaying of the 
amplification mix with light mineral oil is necessary to 
prevent evaporation. Evaporation would lead to a higher 
reagent concentration and a decrease in temperature.
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Equipment: DNA thermocycler machines, laminar flow
cabinets, electrophoresis and hybridisation equipment are 
the main accessories of a PCR laboratory. Seperate rooms 
should be used for (i) dispensing, storing and preparing 
reagents for PCR, (ii) sample preparation, (iii) DNA 
addition, and (iv) DNA analysis. Each area being equipped 
with designated lab coats and sisposable gloves. Many 
laboratories use specific PCR tube holders and tube 
openers, as well as specific plugged micropipette tips in 
order to prevent cross-contamination and carryover of 
specimens.
Visualisation of the PCR products: A PCR product
(amplicon) may be characterised by various methods 
including:
(I) Electrophoresis by which the characteristic size of 
the product (with or without the digestion of the PCR 
product using REA) can be determined by electrophoresis 
and ethidium bromide staining.
(II) The nucleotide sequence of the product can be 
identified by nucleic acid hybridisation (gene probes) 
using isotopic and non-isotopic methods.
(III) The product can be identified by simple colorimetric 
methods by the use of fluorometric labelled probes.
(IV) Direct sequencing of the PCR product.
The first three methods are rapid while the fourth is 
useful for the confirmation of the correct sequence or for 
looking for base differences within amplified regions. The 
PCR products are rapidly identified by these methods, as 
the results can be read within an hour (electrophoresis) 
or at most several hours (hybridisation).
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4.2 THE DEVELOPMENT OF A PCR ASSAY TO DETECT BHV1
The development of the PCR assay to detect BHV1 will be 
divided into 4 steps
(A) Primer Design
(B) Optimisation of the reaction
(C) Specificity validation
(D) Determination of the sensitivity of the
PCR assay
4.2.1 Primer design
The sequences of five genes (Glycoproteins I, III, IV, and 
regulatory enzymes thymidine kinase and dUTPase gene) were 
the only BHV1 sequence published at the time of primer 
design for this study. All play a role in the 
pathogenicity of BHV1 and were investigated as a suitable 
source of primer sequence for a PCR assay. The functions 
associated with their gene products has been discussed 
(see 1.6 and 1.7). The oligonucleotide primers for this 
assay were chosen from the thymidine kinase (TK) gene for 
several reasons. (I) The TK enzyme has been shown to play 
a role in viral pathogenicity (Kit et al., 1986, Mittal et 
al., 1989) and therefore is likely to be present in all 
pathogenic strains. (II) Regions of the BHV1 TK gene also 
exist which have a different nucleotide sequence to TK 
homologues present in other herpesviruses (Smith et al.,
1993). Primers chosen from these regions would render the 
PCR assay more specific. (Ill) Modified BHV1 mutants 
irreversibly attenuated by deletions in the TK gene 
provide safe and rationally designed vaccines against 
bovine herpes virus diseases (Kit et al, 1986). PCR assay 
using regions of the TK gene as a primer source would not 
detect vaccine virus and therefore could be used as a 
differential test between field and vaccine virus. (IV) 
Part of the TK gene is deleted in BHV5 (Smith et al, 1991) 
thus making the TK gene useful for the differential 
diagnosis of BHV1 and BHV5. (V) Within the target TK
region, base differences between BHV1.1 and BHV1.2 were
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reported by Smith et al.(1990) which, if present, could 
lead to differentiation using the restriction fragment Hae
I I .
The nucleotide sequences of the TK genes of BHV1.1 
strains 6660 and LA (isolated from cases of respiratory 
disease) are highly homologous with only a small number of 
base pair differences (Mittal et al. , 1989 ). The
nucleotide sequence of the TK gene of BHV1.2 strain Q3932 
(Smith et al., 1990) is also highly homologous with BHV1 
virus strain 6660. The primer sequences chosen had 100% 
homology with BHV1.1 and BHV1.2 TK sequences (Mittal et 
al., 1989, Smith et al., 1991) so that they would detect 
both BHV1 genotypes.
Primer choice within the TK gene was influenced by 
the high GC content of the gene with only a limited number 
of 20 bp stretches approaching 50% G+C. Primers were 
designed to amplify a 300 bp region. The location of the 
primer sites was at 403 - 424 bp and 680 - 701 bp on the 
TK gene.
PRIMER CHOICE
PRIMER SEQUENCE % GC TA
Primer 1 5’ GGT GAA TTC CGC AGG CAT 3’ 55% 51°C
Primer IB 5’ GGT GAA TTC CGC AGG CAT GGT 3’ 57% 61°C
Primer 2 5’ GTT GAT CTC GCG GAG GCA GTA 3’ 57% 61°C
The overall %GC content of the target region was 76%.
The annealing temperatures (Ta) were empirically 
determined using the following formulae: Ta = Tm - 5°C, 
where Tm the melting temperature = 2  (A + T) + 4(G + C). 
Primer IB, a variation of primer 1, was synthesised later 
in order to have the same annealing temperature as Primer 
2 .
The overall G+C content of the target region above is 
74% while the G+C contnet of the region excluding the 
primer sequence is 7 6%. Primer sequences were checked for 
complimentarity to all other available sequence using the 
EMBL database and gnebank facilities (see 2.14.8) and no 
significant homologies were found.
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FIGURE 4.2
THE SEQUENCE OF THE BHV1 TARGET REGION
T ACG GAC GAC GCC TTA AGT GGG ATC CTC GCG GCG TCT GCG CGA TGC 45 
GCC GCA GCC TCG CAC GGG AGC GCA CGC GGC GCC GGC GGG CCG GCG 90 
CAC CGC GCA GAC GCG GAC GCG GCG GGC CTG GTT GCG TAC TAC CAG 135 
GCC AGG TTC GCG GCC CCG TAC TTA ATT TTG CAC GCG CGC GTG TCC 160 
GCG CTG CTG GCG CCG CCT GGG CCG GCG CCG GGC GGC ACT GTG ACC 225 
CTC GTG TTC GAC CGC CAC CCC GTG GCC GCG TGC CTC TGC TAC CCC 270 
TTC GCC CGC TAC TGC CTC CGC GAG ATC AAC 300
(Smith et al.,1990)
Figure 4.2 shows the sequence of the selected BHVl. 2 TK 
region. Primer sites are indicated in bold while Hae II 
restriction sites are underlined.
4 . 2 . 2  I n i t i a l  d e v e lo p m e n t  o f  t h e  PCR assay 
No amplification of the target region was obtained in the 
initial attempts with the failure to amplify a product of 
the expected size was finally attributed to the high GC 
content (76%) or secondary structure of the selected 
region. This was confirmed by the amplification of the 
same stock of BHVl DNA using other oligonucleotide primers 
and conditions specific for the BHVl GUI glycoprotein 
kindly provided by Dr. Moussa CNEVA, Lyon, France (Result 
not shown).
Secondary structure can pose problems for successful 
amplification and have many deleterious effects. Complete 
DNA denaturation is more difficult to achieve as greater 
energy is required to break the triple bonds between the 
nucleotides. The formation of "loops" where the 3' end of 
the product anneals somewhere within the product becomes 
a primer structure. If such a structure is elongated once, 
a new primer annealing site is created on the wrong 
strand. In the following cycles, a product with distinct 
length (longer than the original desired one) may be 
created and exponentially amplified with only one primer. 
Similar annealing events at the 3' end of such fragments
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to the same strand of another product with an identical 
sequence may occur with an increase in the concentration 
of fragments. If the newly synthesised sequences prefer 
their own intrastrand secondary structure, shorter 
fragments may be generated (Rolfs, 1992).
In order to overcome this problem two possible 
solutions were examined. (I) The addition of cosolvents 
such as DMSO or glycerol to the PCR reaction. Although the 
exact mode of action of such additives are largely 
unknown, it has been postulated that they act to eliminate 
primer and/or template secondary structure and result in 
more complete denaturation of DNA. This approach has 
already been reported for the successful amplification of 
another region of BHV1 genome (Vilcek et al. , 1993).
(II) Increasing the denaturing temperature - this ensures 
complete denaturation of the GC bonds at each cycle.
Both DMSO and glycerol were added at various 
concentrations to the PCR assay using the following 
components 200 ng of each primer (Primer I B  and Primer 2), 
2 mM dNTPS, 9 mMg Cl2, and 1 U Taq (Promega) with the 
following amplification conditions 95°C for 5 min, 
followed by 40 cycles of 95°C for 30 sec, 50°C for 30 sec, 
7 2°C for 40 sec. Again the PCR assay failed to yield any 
amplification products which were visible after gel 
electrophoresis (results not shown).
Finally the above assay was performed once more with 
an increase in the denaturing temperature to 98°C and a 
more thermostable enzyme used. All other conditions 
remained constant and a PCR product of the expected length 
was generated.
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Comparison of the use of TAP polymerase with PFU at 
different denaturing temperatures
Reaction conditions were as follows - 98°C, for 5 min
followed by 40 cycles of 95°C for 30 sec, 58°C for 30 sec, 
and 72°C for 40 sec.
FIGURE 43
THE AMPLIFICATION OF THE TARGET REGION OF THE BHV1 GENOME 
USING PRIMERS CHOSEN FROM THE TK GENE
1 1  300 bP
LI L2 L3 L4 L5 L6
Lane 1: PFU at 98°C,
Lane 2: Taq at 98°C,
Lane 3: PFU at 9 6°C,
Lane' 4 : Taq at 9 6 ° C,
Lane 5: Negative control (distilled H20),
Lane 6: 0.5 jig 100 bp ladder,
Figure 4.3 shows a comparison of PFU (Stratgene) and Taq 
(Promega) performance using different denaturing 
temperatures. The same reaction concentrations were used 
differing only in polymerase concentration i.e. 5 units of
Taq enzyme was used compared with 1.25 U PFU. The presence
of a product of the expected size in lane 1 and 3 while a
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Comparison of the use of Tag polymerase with PFU at
different denaturing temperatures
Reaction conditions were as follows - 98°C for 5 min, 
followed by 40 cycles of 95°C for 30 sec, 58°C for 30 sec 
and 72°C for 40 sec.
FIGURE 4 .3
THE AMPLIFICATION OF THE TARGET REGION OF THE BHV1 GENOME USING 
PRIMERS CHOSEN FROM THE TK GENE
LI L2 L3 L4 L5 L6
Lane Is PFU at 98°C,
Lane 2: Taq at 98°C,
Lane 3s Taq at 9 6°C,
Lane 4: Taq at 96°C,
Lane 5: Negative control (distilled Hz0),
Lane 6: 0.5 ug 100 bp ladder,
Figure 4.3 shows a comparison of PFU (Stratgene) and Tag 
(Promega) performance using different denaturing 
temperatures. The same reaction concentrations were used 
differing only in polymerase concentration i.e. 5 units of
taq enzyme was used compared with 1.25 U PFU. The presence
of a product of the expected size in lane 1 while a faint
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band may be observed in lane 2. It can be concluded that 
amplification was only possible when a higher denaturation 
temperature was used with a more thermostable enzyme and 
that greater template DNA denaturation occurs at 98°C than 
96° C.
A higher yield of PCR product was generated using the 
enzyme PFU despite using a lower concentration of this 
enzyme. This may be explained by the difference in the 
half-life activity of the enzymes. Tag DNA polymerase has 
a half life activity of 40 minutes at 95°C and 5 minutes 
at 97.2° (Gelfand, 1989) therefore using the above 
programme even if Tag was added after the initial 5 min at 
9 8°C the enzyme would be 50% less active after 10 cycles 
only working at 25% activity after 20 cycles. PFU retains 
95°C activity after 1 hr at 95°C (Stratagene Catalogue, 
1995 page 102) and although no exact data is available on 
PFU activity at 97°C the manufacturers state that it is 
more stable than conventional Taq.
4 . 2 . 3  H ot s t a r t  PCR
In the initial denaturing heating step of a PCR, primers 
that anneal non specifically to a partially single­
stranded template region can be extended and stabilised 
before the reaction reaches 7 2°C for the extension of 
specifically annealed primers. Some of these non- 
specifically annealed and extended primers may be 
orientated with their 3' hydroxyl directed toward each 
other, resulting in the exponential amplification of a non 
specific fragment. If the DNA and the enzyme are allowed 
to come in contact only at, or above, the temperature 
required for activation of the polymerase this problem may 
be overcome. Such an approach is called a 'hot start' 
(Erlich et al.,1991) A hot start was applied to the PCR 
assay due to the appearance of a non specific band of 
about 250 bp in some PCR assays (see Figure 4.2 lanes 1 - 
3). Purified viral DNA (2.12.1) and purified viral DNA 
that had been cut using the restriction enzyme Hind III 
from a laboratory isolate - W135 (2.12.5) were used as DNA
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template. The hot start involved heating samples to 100°C 
for 5 min followed by immediate placement on ice. Samples 
were then added directly to the cocktail which had been 
preheated to 90°C for 2 min and the reaction allowed to 
proceed as described above.
FIGURE 4.4
Lane 1: W35 (34ng),
Lane 2: W35 (68ng),
Lane 3: W35 cut with Hind III (34ng) (2.12.5)/
lane 4: W35 cut with Hind III (68ng) (2.12.5)/
Lane 5 0.5 ug 100 bp ladder,
lane 6s W35 (34ng),
lane 7: W35 (68ng)/
lane 8: W35 cut with Hind III (34ng) (2.12.5),
lane 9: Negative control - distilled water,
Figure 4.4 shows that the inclusion of the hot start 
reduces the formation of a non-specific band within the 
PCR assay. Samples in lanes 1 - 4  did not have a hot start 
applied to samples and a second PCR product may be seen at 
approximately 250 bp. Those in lanes 6 - 9  had a hot start 
applied and only one PCR product of the expected size was 
obtained.
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4 . 2 . 4  The o p t i m i s a t i o n  o f  t h e  PCR A s s a y
Every PCR assay is unique and requires an individual 
optimisation strategy in order to increase its specificity 
and sensitivity. This is particularly important if the 
assay is to be used in the detection of infectious agents. 
Using the guidelines for analytical PCR recommended by et 
Rolfs et al. (1992) and Saiki (1992). The optimisation
strategy adopted for this assay was as follows:
(I) Annealing temperature
(II) [Tag]
(III) [MgCl2]
(IV) [dNTP]
(V) [Primer concentration]
(VI) [DMSO]
(VII) Cycle number
When optimising a reaction component, varying guantities 
of the component were added to a series of tubes. In the 
optimisation of the physical parameters, a range of times 
and temperatures were used. In all optimisation reactions 
DNA template was 90 ng of purified Oxford viral DNA (see
3.2). The starting conditions were those described for 
successful amplification in 4.4.2. Each reaction parameter 
was altered as optimised.
1 0 0
4 . 2 . 4 . 1  P h y s i c a l  p a r a m e te r s
D e t e r m in a t io n  o f  t h e  optim um  a n n e a l i n g  te m p e r a tu r e
The annealing temperature (Ta) is probably the most 
critical step in the optimisation of the specificity of a 
PCR assay. The probability and specificity of primer 
annealing depends on temperature, time, the concentrations 
of single-stranded target and the concentration of the 
primer. The probability of successful primer annealing in 
the first cycle is mainly determined by the target copy 
number and whether there is enough genomic screening time 
to find the target. If the temperature is too high, no 
annealing occurs at all, but if the temperature is too 
low, the occurrence of non specific annealing might rise 
dramatically. The empirical calculation of the Ta was 
determined in 4.2.1 and found to be 61°C. This, however, 
is only a rough estimate and the true Ta can only be found 
by experimentation. The effect of using different 
annealing temperatures on the PCR assay is shown in Figure
4.5.
1 0 1
FIGURE 4.5
Lane Is Ta = 60°C 
Lane 2: Ta = 63°C 
Lane 3: Ta = 65°C 
Lane 4: Ta = 70°C
Lane 5: Negative control (distilled HzO: Ta = 60°C)
Lane 6: 0.5 ng 100 bp ladder
Figure 4.5 shows that the highest annealing temperature 
possible was 63°C. This temperature was therefore chosen 
as the optimum as the highest annealing temperature 
ensures the most specific assay as well as serving to 
minimise priming events due to secondary structure.
1 0 2
Determination of the optimum cycle number 
The optimum number of cycles required depends mainly upon 
starting concentration target sequence. In analytical PCR 
the cycle number should not exceed 40 (Innis and Gelfand, 
1990) and the most appropriate cycle counts are 25 to 35. 
Unwanted amplification artifacts proliferate with 
increasing cycle number. This phenomenon which arises with 
larger cycle numbers depend on (i) stringency and (ii) the 
limiting reaction component which is usually the 
polymerase enzyme. When primers are consumed and there are 
still dNTPs available, amplification products and 
artifacts may start to prime to themselves in subsequent 
cycles often leading to non specific product and smears on 
the gel.
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THE DETERMINATION OF OPTIM UM  CYCLE NUMBER FO R THE PCR ASSAY
FIGURE 4.6.
3 0 0  b p
LI L2 L3 L4 L5 L6
L an e 1 : 0 .5  |ig  lOObp la d d e r  (G ib c o -B R L ),
L an e 2 s 20 c y c l e s ,
L an e 3s 25 c y c l e s ,
L an e 4s 30 c y c l e s ,
L an e 5s 35 c y c l e s ,
L an e 6s 40 c y c l e s ,
Figure 4.6 shows that 35 cycles provided the maximum 
product yield of specific product under the conditions 
used. At 40 cycles, it can be seen that a greater product 
yield was produced but there was also the generation of a 
non specific band at approximately 250 bp. A cycle number 
of 35 was chosen as the optimum for this assay.
104
D e t e r m in a t io n  o f  t h e  optim um  PFU c o n c e n e t r a t i o n  f o r  e a c h  
PCR a s s a y
The amount of polymerase is one of the most important 
factors to be determined for a particular PCR assay. The 
synthesis rate of Taq depends on temperature, 
concentration of magnesium chloride, detergent, template, 
secondary structure and concentration of dNTPs. For most 
assays the optimum quantity of enzyme will be between 0.5 
and 2.5 units (U) in a 50 |il volume. Increased enzyme 
concentrations sometimes lead to decreased specificity 
(Innis and Gelfand, 1992).
FIGURE 4.7
DETERMINATION OF THE OPTIMUM CONCENTRATION OF PFU FOR THE PCR ASSAY
bp
LI L2 L3 L4 L5 L6 L7
4.2.4.2. Reaction conditions
Lane 1: 0.5 units,
Lane 2: 1 units,
Lane 3: 1.5 units,
Lane 4: 2.0 units 
Lane 5: 2.5 units
Lane 6: Negative control (distilled HzO : 1.5 units PFU) 
Lane 7: 0.5 pig 100bp ladder (Gibco-BRL),
It can be seen from figure 4.7 that 1.25 U is sufficient 
to yield visible PCR product and was therefore chosen as 
the optimum concentration required.
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D e t e r m in a t io n  o f  t h e  m agn esiu m  c h l o r i d e  c o n c e n t r a t io n  f o r  
the PCR assay
Magnesium Chloride (MgCl2) concentration may affect all of 
the following: primer annealing, Strand dissociation,
temperatures of both template and PCR product, product 
specificity, formation of primer-dimer artifacts, enzyme 
fidelity and activity. The concentration of free MgCl2 
depends on [dNTP] , [PPj.] and [EDTA] . The optimum 
concentration usually varies between 0.5 and 2.5 mM MgCl2 
(Innis and Gelfand, 1992).
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FIGURE 4.8
DETERMINATION OF THE OPTIMUM CONCENTRATION OF 
M AGNESIUM  CHLORIDE FOR THE PCR ASSAY
300 bp 
250 bp
L I L2 L3 L4 L5 L6 L 7L 8
L an e l ì  0 Mm (0  n i ,  50 Mm MgCl2) ,
L an e 2: 3 Mm (3  n i ,  " ) ,
L an e 3 : 6 Mm (6  ( i l ,  " ) ,
L an e 4 : 9 Mm (9  n i ,  " ) ,
L an e 5 : 12 Mm (1 2  ( i l ,  " ) ,
L an e 6 : 16 Mm (1 6  n i /  " ) r
L an e 7 : n e g a t i v e  c o n t r o l  ( d i s t i l l e d  H20 )
L an e 8 : 0 .5  ng lOObp l a d d e r ,
Figure 4.8 shows that without the addition magnesium 
chloride or the addition of 9 or 12 \xl of 50 Mm MgCl2 a 
specific PCR product is produced. At a concentration of 3 
mM and 6 mM the formation of a non-specific band of 250 bp 
was apparent. The addition of 12 mM (12 \il at 50 mM) was 
chosen as the optimum concentration to be added to each 
reaction.
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Determination of the optimum dNTP concentration for the
PCR assay
Optimal dNTP concentration depends on a number of factors 
including length of primer, magnesium concentration, 
primer concentration and reaction stringency. dNTPs reduce 
concentration of free MgCl2 thus interfering with 
polymerase activity and decreasing primer annealing. 
Imbalances in dNTP mixtures reduce Taq fidelity. In 
general, Taq polymerase catalyses dNTP polymerisation with 
higher fidelity at lower dNTP concentrations (Innis and 
Gelfand, 1992 ) .
FIGURE 4.9
Lane 1: 2.5 mM dNTPS,
Lane 2: 1.25 mM dNTPS,
Lane 3: 0.75 mM dNTPS,
Lane 4: 0.35 mM dNTPS,
Lane 5: 0.00 mM dNTPs
Lane 6: Negative control (distilled H20) 
Lane 7: 0.5ng 100 bp ladder
It was determined from Figure 4.9 that the addition of 
1.25 mM of dNTPs is adequate for the generation of large 
quantities of PCR product.
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Determination of the optimum primer concentration for the 
PCR assay
Primer concentrations between 0.05 and 0.5 jiM are 
generally optimal (Saiki, 1992). Higher primer 
concentrations may promote mispriming and accumulation of 
nonspecific product and may increase the probability of 
generating template-independent artifacts termed primer- 
dimers. Non-specific products and primer-dimer artifacts 
are themselves substrates for PCR and compete with the 
desired product for enzyme, dNTPs, and primers resulting 
in lower yield of the desired product.
FIGURE 4.10
THE DETERMINATION OF THE OPTIMUM PRIMER 
CONCENTRATIONS FOR THE PCR ASSAY
bp
LI L2 L3 L4 L5 L6 L7
Lane 1: 50 ng of each primer,
Lane 2: 100 ng of each primer,
Lane 3: 150 ng of each primer,
Lane 4: 200 ng of each primer
Lane 5: 250 ng of each primer,
Lane 6 negative control,
Lane 7: 100 bp Gibco-BRL,ladder.
Figure 4.10 shows that 100 ng of primer (lane 2) is 
adequate for the generation of large quantities of PCR 
product.
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Determination of the effect of DMSO on the PCR assay 
The effect of the co-solvent DMSO in the PCR assay was 
examined. DMSO was incorporated into the reaction for two 
reasons: (i) In some cases, the use of cosolvents has been 
shown to increase the efficiency of primer extension with 
cloned PFU DNA polymerase (Stratagene, Certificate of 
Analysis - 1993). (ii) DMSO is a strong dénaturant and it 
has been suggested that it results in more complete 
dénaturation of template DNA. DMSO has been used to 
amplify G+C rich viral genomes of Herpes Simplex 1 and 2 
when added at a concentration of 3% (Smith et al., 1990).
FIGURE 4.11
THE EFFECT OF VARYING THE DMSO CONCENTRATION WITHIN THE PCR ASSAY
300 bp
LI L2 L3 L4 L5
Lane 1: 0% DMSO,
Lane 2: 8% DMSO,
Lane 3: 11% DMSO,
Lane 4: 14% DMSO,
Lane 5: 0.05 jiçj 100bp ladder,
Figure 4.11 shows that at a concentration of below fl%, 
DMSO has a minimal effect on PCR product yield. Higher 
concentrations results in lower yields of PCR product so 
therefore 5% DMSO was retained in the assay to ensure 
complete DNA dénaturation of template.
1 1 0
4 . 2 . 4 . 3  E v a lu a t io n  o f  t h e  s e n s i t i v i t y  o f  t h e  PCR a s s a y
Once all the reaction components were determined, the 
sensitivity of the assay could then be evaluated.
To examine the sensitivity of the procedure virus 
supernatant of known titre (105,5 TCID50) was either (i) 
boiled for 8 min or (ii) incubated in 5% Chelex 100 
solution and boiled for 8 min. Dilutions of each were made 
and used as DNA templates in order to determine the 
sensitivity of the assay and the results compared.
Ill
PCR ON A SERIES OF TEN FOLD DILUTIONS OF BHV1 VIRAL 
___________ SUPERNATANT OF KNOWN TITRE
bp
LI L2 L3 L4 L5 L6 L7L8
FIGURE 4.12a
Lane Is 1/40 dilution,
Lane 2: 1/4 xlO'2 dilution,
Lane 3: 1/4 xlO'3
Lane 4: 1/4 xlO'4
Lane 5: 1/4 xlO"5
Lane 6: 1/4 xlO'6
Lane 7: 1/4 xlO-7
Lane 10 : 0.5 ng DNA 100 bp
Figure 4.12a shows results of PCR on a series of ten fold 
dilutions of boiled BHV1 viral supernatant of known titre.
1 1 2
FIGURE 4.12b
PCR ON A SERIES OF TEN FOLD DILUTIONS OF BHV1 VIRAL SUPERNATANT OF 
KNOW N TITRE AFTER BOILING IN THE PRESENCE OF 5% CHELEX 100 SOLUTION.
300 bp
L I L2 L3 L4 L5 L6 L 7 L 8 L 9 L 1 0
L an e 1 : C o n t r o l  n o  DNA ( d i s t i l l e d  H20 ) ,
L an e 2s 1 / 4 0  d i l u t i o n ,
L an e 3 : 1 / 4  x lO '2 d i l u t i o n ,
L an e 4 : 1 / 4  x l O -3
L an e 5s 1 /4  x l O -4
L an e 6 : 1 / 4  x lO -3
L an e 7 s 1 / 4  x lO -6
L an e 8 1 / 4  x lO "7
L an e 9s C o n t r o l  n o  DNA ( C h e le x  c o n t r o l  s o l u t i o n )
L an e 10 : 0 . 5  u g  1 0 0  b p  l a d d e r  ,
Figure 4.12b shows results of PCR on a series of ten fold 
dilutions of BHV1 viral supernatant of known tltre boiled 
In the presence of 5 % Chelex 100.
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Comparing Figure 4.12a and 4.12b it can be seen that the 
inclusion of the Chelex 100 during the DNA preparatory 
step increases the PCR signal to the order of one 10 fold 
dilution. The sensitivity of the assay when using boiling 
alone as a method of DNA preparation was 1 TCID50. This was 
increased to 0.1 TCID30 when DNA was boiled in the presence 
of 5% Chelex 100. As reported by Walsh et al. (1991) the 
Chelex 100 appears to have a protective effect on DNA 
during boiling generating more intact target DNA for 
amplification.
TABLE 4.1 
THE OPTIMISED PCR ASSAY
REACTION COMPONENTS
Primer 1 lOOng
Primer 2 lOOng
PFU 0.5 u
dNTPs 1.25 mM
MgCl2 12 mM
DMSO 8%
REACTION CONDITIONS
98°C 5 min
98°C 30 sec f
63°C 30 sec | x 35
74°C 40 sec J
74°C 5 min
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4 . 2 . 5  THE RESTRICTION ENDONUCLEASE ANALYSIS OF PCR 
PRODUCTS
One reason for the choice of target region was the 
reported single bp differences between BHV1.1 and BHV1.2 
within the selected region (Mittal et al., 1989 and Smith 
et al., 1990). These reports indicated that PCR products 
amplified from BHVl isolates would be cleaved by the 
restriction endonuclease Hae II to generate two fragments 
203 bp and 94 bp (Mittal et al., 1989): while products 
amplified from BHVl.2 isolates would be cleaved into 116 
bp, 96, bp, 75 bp and 15 bp, thus providing a means for 
the differentiation between genotypes.
The Seqaid DNA computer software package was also 
used to determine what enzymes would cut PCR product from 
the selected region (see 2.12.8). Fragment sizes generated 
by restriction enzymes were also predicted. Predictions 
also indicated that BHV5 products could not be cut using 
the enzyme Taq 1. The enzyme Taq I was also shown to be 
suitable for use in the verification of PCR product. 
According to this prediction, amplified products from both 
genotypes would cut with Taq 1 to yield two fragments of 
230 bp and 7 0 bp while those cut with Rsa I would yield 
fragments 123 bp, 147 and 27 bp in length.
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FIGURE 4.13
FIGURE 13A
THE PREDICTED RESTRICTION ENDONUCLEASE DIGEST OF PCR PRODUCTS 
AMPLIFIED FROM KNOWN BHV1 GENOTYPES CUT WITH TAQ I AND HAE II.
Hae II Restriction
75 bp 15 bp 116 bp 96 bp
HAE II HAEII HAE II
Taq I Restriction
70 bp 230 bp
TAQ 1
FIGURE 4.13B
LI L2 L3 L4 L5 L6 L7 L8 L9
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Lane Is 0.5 100 bp ladder,
Lane 2: 300 bp BHV1.1 PCR product,
Lane 3: BHV1.1 PCR product cut with Hae II to yield 
fragments 126 bp, 96 bp and 75 bp in size,
Lane 4 : BHV1.1 PCR product cut with Tag 1 to yield 
fragments approximating to 239bp and 60 bp,
Lane 5: 0.5 pig 100 bp ladder,
Lane 6: 300 bp BHV1.2 PCR product,
Lane 7: BHV1.2 PCR product cut with Hae II to yield
fragments approximating to 126 bp, 96 bp and 75 bp 
Lane 8 : BHV1.2 PCR product cut with Taq 1 to yield 
fragments approximating to 239bp and 60 bp,
Lane 9: 0.5 pg 100 bp ladder,
Figure 4.13A shows the predicted cleavage sites of the 
target sequence selected from the BHV1. 2 TK gene (Smith et 
al.,1990).
Figure 4.13B shows that PCR products amplified from BHV1.1 
and BHV1.2 isolates have similar restriction patterns when 
cut with Hae II (Lane 3, Lane 7).
The presence of bands at approximately 200 bp and 180 
bp indicates that some partial digestion of some PCR 
product took place. However, PCR products from both 
genotypes also produced fragments at approximately 120 bp, 
100 bp, and 80 bp and therefore seems to contain the 
seguence reported by Smith et al., 1990. The patterns from 
PCR products amplified from both genotypes obtained 
corresponded to that predicted from the seguence published 
by Smith et al. (1990). This seems to support his
suggestion that the base differences in the Hae II site 
between this seguence and that of Mittal et al. (1989) may 
have been due to incorrect determinations caused by 
compressions in the regions of high GC content. The 
restriction fragments obtained with Taq I were as 
predicted (lane 4, lane 8) and it was concluded that the 
PCR product was amplified from BHV1. Subsequent partial 
DNA sequencing of the PCR product showed that this was 
indeed the case (Chapter 8).
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4 . 2 . 6  I n v e s t i g a t i o n s  on p r im e r  s p e c i f i c i t y
Examinations on primer specificity for BHV1 were made 
by testing (I) the ability of the primers to amplify a 
range of BHV1 field isolates of known genotype and (II)
the reactivity of primers with DNA extracted from MDBK
cells and the following viruses: BHV2, BHV4, EHV1, EHV4, 
alcephaline herpesvirus 1 and PRV. (DNA from the BHV5 TK 
was also included in the PCR see 4.2.8). Viral 
supernatants were then treated for PCR using the same
procedure as described (2.12.2) for BHV1.
The conditions of the optimised PCR assay were used 
and electrophoretic and visual conditions were as 
described (2.13).
4 . 2 . 6 . 1  A m p l i f i c a t i o n  o f  BHVl i s o l a t e s  o f  known g e n o ty p e
All BHVl strains with the exception of the lab reference 
(Oxford strain) were isolated from diagnostic submissions 
to the VRL. All isolates are identified by their 
laboratory reference number. Multiple negative controls 
were included to ensure that no cross contamination
between positive samples occured.
1 1 8
FIGURE 414.a
THE RESULTS OBTAINED USING TEMPLATE DNA FROM BHV1 ISOLATES Of 
KNOWN GENOTYPE (TABLE 3.1) IN THE PCR ASSAY.
GEL 1
300 bp
LI L2 L3 L4 L5 L6 L7 L8 L9 L10 Lll L12
GEL 2
00 bp
LI L2 L3 L4 L5 L6 L7L8L9
119
G el 1 
L ane 1: 0.5 ng lOObp ladder (Gibco-:
L ane 2: BHV1.2 (579),
L ane 3: BHV1.2 (H607),
L ane 4: BHV1.2 (J302),
L ane 5: BHV1.1 (D46 3),
L ane 6: BHV1.1 (H607),
L ane 7s Negative control (distilled
L ane 8s BHV1.1 (D463),
L ane 9s BHV1.1 (D668),
L ane 10s BHV1.1 (D731),
L ane 11: lOObp :ladder (Gibco-BRL),
L ane 12s Negative control,
L an e 13: BHV1.1 (H984),
L ane 14s BHV1.1 (J702),
L ane 15s BHVl.1 (0909),
L ane 16: BHV1.1 (W145),
L ane 16s BHVl.1 (W199),
L an e 17s BHVl.2 (X35),
L ane 18s BHVl.2 (X313).
Figure 4.14a demonstrates that the assay detects both BHV1 
genotypes and all BHV1 isolates examined.
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The PCR assay was tested on all other bovine 
herpesviruses, Aujeszkys disease virus and equine herpes 
virus using the optimised conditions and the results 
obtained presented in Figures 4.14b and 4.14c. The source 
of these viruses is cited in 2.9
FIGURE 4.14b
4.2.6.2 Specificity to BHV1
Lane 1: MDBK DNA,
Lane 2: BHV2 DNA,
Lane 3: BHV4 DNA,
Lane' 4: PRV DNA,
Lane 5: EHV1 DNA,
Lane 6: EHV4 DNA,
Lane 7 : Positive control
Lane 8: Negative control
Lane 9: 100 bp ladder,
(90 ng BHV1- Oxford DNA), 
(distilled water),
Figure 4.14b shows that the assay does not hybridise with 
the other viral DNAs tested and therefore appears to be 
specific for BHV1.
1 2 1
T E S T  R E S U L T S  F R O M  IG F  P C R  ASSAY U S IN G  D IF F E R E N T  VIRAL DNA TEM PLA TES
FIGURE 4.14c
L I  L2 L3 L4 L5 L6 L7 L8 L9
Lane 2: MDBK DNA,
Lane 3: BHV2 DNA,
Lane 4: BHV3 DNA,
Lane 5: BHV4 DNA,
Lane 6: PRV DNA,
Lane 7: EHV1 DNA,
Lane 8: Negative Control (water),
Lane 9: 0.5 )ig lOObp ladder (Gibco-BRL)
F i g u r e  4 . 1 4 c  s h o w s  t h e  a m p l i f i c a t i o  o f  a 2 0 0  b p  r e g i o n  o f  
t h e  I G F  g e n e  p r e s e n t  i n  b o v i n e ,  e q u i n e  a n d  p o r c i n e  c e l l s .  
I t  w a y  b e  c o n c l u d e d  t h a t  n o  i n h i b i t o r y  s u b s t a n c e s , t h a t  
o t h e r w i s e  m i g h t  p r e v e n t  P C R ,  w e r e  p r e s e n t  i n  o t h e r  
h e r p e s v i r u s  D N A  p r e p a r a t i o n s .
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4.2.7 THE AMPLIFICATION OF MODIFIED VACCINE VIRUS USING 
THE PCR ASSAY
T h e  m o d i f i e d  l i v e  v a c c i n e s ,  T r a c h e r i n e  ( S m i t h k l i n e  
B e e c h a m )  a n d  I n b o v a c  I B R  ( I n t e r v e t ) ,  a r e  c u r r e n t l y  
a v a i l a b l e  o n  t h e  I r i s h  m a r k e t .  In o r d e r  t o  d e t e r m i n e  if 
t h e  d e v e l o p e d  P C R  a s s a y  d e t e c t e d  t h e s e  v a c c i n e  v i r u s e s ,  
b o t h  w e r e  s u b j e c t e d  t o  t h e  a s s a y  as f o l l o w s .  B o t h  v a c c i n e s  
w e r e  r e c o n s t i t u t e d  i n  5 m l  o f  s u p p l i e d  s o l v e n t  ( d i s t i l l e d  
w a t e r )  a n d  p r e p a r e d  f o r  P C R  as d e s c r i b e d  (2 .12. 2) . 
V a c c i n e s  w e r e  t h e n  t e s t e d  f o r  t h e  p r e s e n c e  of B H V 1  a n d  IGF 
g e n e  b y  PCR.
F IG U R E  4.15
P C R  T E S T  R E S U L T S  U S IN G  DNA T E M P L A T E  F R O M  T H E  A VAILABLE LIV E VACCINES
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LI L2 U  L4 L5 L6 L7
L a n e  Is P C R  p r o d u c t  a m p l i f i e d  f r o m  T r a c h e r i n e  D N A
L a n e  2s P C R  p r o d u c t  a m p l i f i e d  f r o m  T r a c h e r i n e  D N A
L a n e  3s P C R  p r o d u c t  a m p l i f i e d  f r o m  I n b o v a c  D N A
L a n e  4: P C R  p r o d u c t  a m p l i f i e d  f r o m  I n b o v a c  D N A
l a n e  5s N e g a t i v e  c o n t r o l  ( d i s t i l l e d  H z0)
L a n e  6 s P o s i t i v e  c o n t r o l  ( R 2 5 4 - d i a g n o s t i c  s a m p l e )  
L a n e  7s 0. 5  n g  10 0  b p  l a d d e r  ( G i b c o - B R L )
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F i g u r e  4 . 1 5  s h o w s  t h a t  a m p l i f i c a t i o n  o f  I n b o v a c  v i r a l  D N A  
o c c u r s  u s i n g  t h e  P C R  a s s a y .  N o  a m p l i f i c a t i o n  o f  t h e  v i r a l  
D N A  e x t r a c t e d  f r o m  T r a c h e r i n e  o c c u r r e d .  T h i s  i s  o f  
s i g n i f i c a n t  v a l u e  f o r  t h e  u s e  o f  T r a c h e r i n e  a s  a v a c c i n e  
a s  i t  e l i m i n a t e s  a n y  u n c e r t a i n t i e s  a s  t o  w h e t h e r  t h e  D N A  
d e t e c t e d  i n  s u b m i s s i o n s  m a d e  t o  d i a g n o s t i c  l a b o r a t o r i e s  i s  
t h a t  o f  f i e l d  o r  v a c c i n e  v i r u s  w h e n  u s i n g  t h e  P C R  a s s a y .
4.2.8 THE AMPLIFICATION OF DNA FROM THE THYMIDINE KINASE 
GENE OF BHV5
A  c o n s t r u c t  c o n t a i n i n g  t h e  B H V 5  T K  g e n e  w a s  s u p p l i e d  b y  D r  
G. S m i t h  ( Q u e e n s l a n d  A g r i c u l t u r a l  B i o t e c h n o l o g y  C e n t r e ,  
Q u e e n s l a n d ,  A u s t r a l i a ) .  p B l u e s c r i p t  K S +  c o n t a i n i n g  th e  
B H V 5  T K  g e n e  (200 ng) w a s  b o i l e d  f o r  5 m i n  a n d  u s e d  as 
t e m p l a t e  i n  t h e  o p t i m i s e d  P C R  r e a c t i o n .  A c c o r d i n g  t o  th e  
s e q u e n c e  of t h e  B H V 5  T K  g e n e  t h e  f r a g m e n t  a m p l i f i e d  w o u l d  
b e  270 b p  ( S m i t h  e t  al., 1991).
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FIGURE 4.16
F ig u re  4.16a
T H E  A M P L IF IC A T IO N  O F  D N A  F R O M  T H E  T H Y M ID IN E  K IN A S E  G E N E  O F
B H V 5
3 0 0  b p  1
■ 2 7 0  b p
L I  L 2  L3 L 4  L 5  L 6
F ig u re  4.16b
T H E  D IF F E R E N T IA T IO N  O F  B H V 1  F R O M  B H V 5  U S IN G  T A Q  1
3 0 0  b p I 1 2  7  0  b p
■  3 0  b p
L I  L 2  L 3 L 4  L 5  L6
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Figure 4.16a
L a n e  2; A m p l i f i c a t i o n  of B H V 1 .1 v i r a l  D N A  (W199),
L a n e  3: A m p l i f i c a t i o n  of B H V 1 .2 v i r a l  D N A  (O xf ord) ,
L a n e  4: A m p l i f i c a t i o n  of p l a s m i d  e n c o d i n g  B H V 5  T K  gene, 
L a n e  5: N e g a t i v e  c o n t r o l ,
L a n e  7: 0.5 n g  l O O b p  l a d d e r  ( G i b c o - B R L ) ,
Figure 4.16b
L a n e  2: P C R  p r o d u c t  a m p l i f i e d  f r o m  B H V 1 .1 T K  ge ne ,
L a n e  3: R E A  of B H V 1 .1 P C R  p r o d u c t  w i t h  T a q  1,
L a n e  4: P C R  p r o d u c t  a m p l i f i e d  f r o m  B H V 5  T K  gene,
L a n e  5: R E A  of B H V 1 .1 P C R  p r o d u c t  w i t h  T a q  1,
L a n e  7: 0.5 |ig l O O b p  l a d d e r  ( G i b c o - B R L ) ,
F i g u r e  4 . 1 6 a  s h o w s  t h e  r e s u l t s  o f  u s i n g  B H V 1 . 1 , B H V 1 . 2  a n d  
p l a s m i d  e n c o d i n g  t h e  T K  g e n e  o f  B H V 5  i n  t h e  P C R  a s s a y .  
F i g u r e  4 . 1 6  s h o w s  t h a t  B H V 5  m a y  b e  d i f f e r e n t i a t e d  f r o m  
B H V 1  g e n o t y p e s  o n  t h e  b a s i s  o f  R E A  w i t h  t h e  r e s t r i c t i o n  
e n z y m e  T a q  1. T h i s  e n z y m e  c l e a v e s  B H V 1  i n t o  f r a g m e n t s  o f  
a p p r o x i m a t e l y  2 7 0  b p  a n d  3 0  bo. T h e  t a r g e t  s e q u e n c e  o f  t h e  
B H V 5  B H V 5  T K  g e n e  l a c k s  t h e  T a q  1 r e s t r i c t i o n  s i t e  a n d  
t h e r e f o r e  r e m i a n s  u n c u t .
It c a n  b e  c o n c l u d e d  f r o m  f i g u r e  4.16 t h a t  t h e  P C R  a s s a y  
d e t e c t s  t h e  B H V 5  T K  g e n e  w h i c h  c a n  b e  d i f f e r e n t i a t e d  f r o m  
B H V 1  g e n o t y p e s  o t h e  b a s i s  of p r o d u c t  size.
4.3 DISCUSSION
T h i s  c h a p t e r  d e s c r i b e s  t h e  d e v e l o p m e n t  of a P C R  a s s a y  to 
d e t e c t  B H V 1  D N A  u s i n g  o l i g o n u c l e o t i d e  p r i m e r s  
c o m p l e m e n t a r y  to a r e g i o n  of t h e  B H V 1  t h y m i d i n e  k i n a s e  
gene . P r i m e r  s e q u e n c e s  c h o s e n  w e r e  p r e s e n t  in  b o t h  B H V 1 . 1  
a n d  B H V 1 .2 t h y m i d i n e  k i n a s e  s e q u e n c e s  ( M i t t a l  e t  al., 
1989, S m i t h  e t  a l . , 1991). G i v e n  t h e  h i g h  d e g r e e  of
h o m o l o g y  (95%) b e t w e e n  t h e  T K  g e n e s  of B H V l .1 a n d  B H V 1 .2 
(Seal e t  al., 19 85 ), it w a s  a s s u m e d  t h a t  t h i s  p r i m e r  p a i r  
w o u l d  b e  c a p a b l e  of d e t e c t i n g  m o s t  if n o t  a l l  B H V l 
s t r a i n s .
A m p l i f i c a t i o n  of t h e  s e l e c t e d  r e g i o n  i n  t h e  T K  g e n e
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w a s  i n i t i a l l y  d i f f i c u l t  t o  o b t a i n .  D e s p i t e  t h e  v a r i a t i o n  
of t h e  t y p i c a l  p a r a m e t e r s  i n c l u d i n g ,  a n n e a l i n g  
t e m p e r a t u r e ,  m a g n e s i u m  c h l o r i d e ,  p r i m e r  c o n c e n t r a t i o n  a n d  
e n z y m e  c o n c e n t r a t i o n ,  P C R  p r o d u c t  w a s  n o t  p r o d u c e d .  In 
a d d i t i o n ,  v a r i o u s  d i l u t i o n s  of p u r i f i e d  v i r a l  D N A  w h i c h  
h a d  b e e n  u s e d  in r e s t r i c t i o n  e n d o n u c l e a s e  a n a l y s i s  w e r e  
u s e d  as t e m p l a t e  DNA, b u t  a l s o  r e s u l t e d  in a f a i l u r e  of 
t h e  a s s a y  to g e n e r a t e  P C R  p r o d u c t .  T h i s  s e e m e d  to s u g g e s t  
t h a t  t h e  p r o b l e m  w a s  n o t  a s s o c i a t e d  w i t h  t e m p l a t e  D N A  
p r e p a r a t i o n .  T h e  p o s s i b i l i t y  r e m a i n e d  t h a t  t h e  p r o b l e m  m a y  
b e  r e l a t e d  t o  t h e  h i g h  G C  c o n t e n t  of t h e  r e g i o n .  In o r d e r  
t o  a d d r e s s  t w o  a p p r o a c h e s  w e r e  a d o p t e d  i n  o r d e r  t o  e n s u r e  
f u l l  d e n a t u r a t i o n  of D N A  t e m p l a t e ,  t h e  f i r s t  w a s  to 
i n c r e a s e  t h e  d e n a t u r i n g  t e m p e r a t u r e  w h i l e  t h e  s e c o n d  
i n v o l v e d  t h e  a d d i t i o n  of a c o - s o l v e n t  - DMSO.
A m p l i f i c a t i o n  w a s  o b t a i n e d  b y  i n c r e a s i n g  th e  
d e n a t u r i n g  t e m p e r a t u r e  to 9 8 ° C  w i t h  a n  i n c r e a s e d  p r o d u c t  
y i e l d  o b t a i n e d  w h e n  a m o r e  t h e r m o s t a b l e  e n z y m e ,  PFU, w a s  
u s e d  i n s t e a d  of t h e  t h e n  c o n v e n t i o n a l  T a g  p o l y m e r a s e .  T h e  
m o s t  l i k e l y  r e a s o n  f o r  t h i s  w a s  t h a t  a h i g h e r  d e n a t u r i n g  
t e m p e r a t u r e  w a s  r e q u i r e d  t o  b r e a k  t h e  t r i p l e  h y d r o g e n  
b o n d s  b e t w e e n  G  a n d  C n u c l e o t i d e s . T h e  u s e  of t h e  h i g h e r  
d e n a t u r i n g  t e m p e r a t u r e  n e c e s s i t a t e d  t h e  u s e  of a m o r e  
t h e r m o s t a b l e  e n z y m e  - PFU. T h i s  e n z y m e  is d e r i v e d  f r o m  
P v r o c o c c u s  f u r i o s u s . T h i s  e n z y m e  a l s o  h a s  a 3' t o  5' p r o o f  
r e a d i n g  a b i l i t y .  T h e  m u t a t i o n  f r e q u e n c y  r a t e  is 1.6 x 1 0 ' 6 
w h i c h  h a s  a 12 f o l d  h i g h e r  f i d e l i t y  of D N A  s y n t h e s i s  t h a n  
T a q  D N A  p o l y m e r a s e .
A n  i m p o r t a n t  a s p e c t  to t a k e  i n t o  a c c o u n t  w h e n  
d e v e l o p i n g  a r e p r o d u c i b l e  P C R  a s s a y  is t h a t  t h e  e x a c t  i n ­
w e l l  d e n a t u r i n g ,  a n n e a l i n g  a n d  e l o n g a t i o n  t e m p e r a t u r e s  a r e  
r e p o r t e d  so t h a t  t h e  a s s a y  m a y  b e  r e p r o d u c e d  e a s i l y  o n  a n y  
c o m m e r c i a l l y  a v a i l a b l e  t h e r m o c y c l e r .  T h i s  a s p e c t  w a s  
h i g h l i g h t e d  d u r i n g  t h e  p r e s e n t  st ud y. It w a s  f o u n d  t h a t  
o p t i m i z a t i o n  e x p e r i m e n t s  w e r e  i m p o s s i b l e  to s t a n d a r d i s e  o n  
t h e  H y b a i d ' s  P r e m  m a c h i n e  d u e  t o  w e l l  t o  w e l l  t e m p e r a t u r e  
v a r i a t i o n .  T h i s  w a s  o f t e n  as m u c h  as 4 ° C  a t  t e m p e r a t u r e s  
a b o v e  90°C. R e a c t i o n  c o n d i t i o n s  w e r e  o r i g i n a l l y  d e r i v e d
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u s i n g  a n  O m n i g e n e  t h e r m o c y c l e r  s u p p l i e d  b y  H y b a i d  a n d  all 
of t h e  t e m p e r a t u r e s  u s e d  a b o v e  r e f e r  t o  t h i s  m a c h i n e .  
H y b a i d ' s  O m n i g e n e  w a s  m o r e  r e l i a b l e  w i t h  l i t t l e  w e l l  to 
w e l l  v a r i a t i o n  ( n e v e r  m o r e  t h a n  1°C). T h e  t e m p e r a t u r e  
r e a d i n g  o n  t h e  m a c h i n e  w a s  a p p r o x i m a t e l y  1° C  l o w e r  t h a n  
t h a t  g i v e n  b y  a t h e r m o c o u p l e  (E i r e l e c - I R L )  w h e n  t h e  
r e g u i r e d  r e a d i n g  w a s  b e t w e e n  55 °C a n d  6 5 °C a n d  2°C w h e n  
a t e m p e r a t u r e  of 70° w a s  r e g u i r e d .  T h e  t e m p e r a t u r e  
d i s c r e p a n c y  b e t w e e n  t h e r m o c o u p l e  a n d  m a c h i n e  r e a d i n g  
i n c r e a s e d  t o  b e t w e e n  2°C a n d  3°C w h e n  t h e  t e m p e r a t u r e  w a s  
a b o v e  9 5 °C. T h e r e f o r e  t h e  f i n a l  s a t i s f a c t o r y  d e n a t u r i n g  
t e m p e r a t u r e  w a s  d e t e r m i n e d  t o  b e  9 8 ° C  w h e n  u s i n g  t h i s  
m a c h i n e .  A  D N A  t h e r m o c y c l e r  48 0 ( P e r k i n  Elmer) 
d e m o n s t r a t e d  o c c a s i o n a l  if a n y  w e l l  t o  w e l l  t e m p e r a t u r e  
v a r i a t i o n  (< 0.2 °C). T h e r m o c o u p l e  t e m p e r a t u r e s
c o r r e s p o n d e d  e x a c t l y  t o  t h o s e  r e g i s t e r i n g  o n  th e  
t h e r m o c y l e r  m a c h i n e .  T h e s e  f i n d i n g s  d e m o n s t r a t e d  t h a t  th e  
c h o i c e  of a r e l i a b l e  a n d  a c c u r a t e  t h e r m o c y c l e r  is of 
p a r a m o u n t  i m p o r t a n c e  w h e n  d e v e l o p i n g  a P C R  a s s a y  a n d  
r e l y i n g  o n  o n e  f o r  d i a g n o s t i c  use.
D u r i n g  t h e  i n i t i a l  r e a c t i o n s  a n o n - s p e c i f i c  b a n d  w a s  
o b s e r v e d .  T h i s  w a s  e l i m i n a t e d  b y  t h e  i n t r o d u c t i o n  of a 
"hot s t a r t "  w h i c h  i n v o l v e d  t h e  b o i l i n g  of s a m p l e  D N A  a n d  
t h e n  f l a s h  c o o l i n g  b y  p l a c i n g  it i m m e d i a t e l y  o n  ic e  a n d  
t h e n  a d d i n g  s a m p l e  D N A  t o  t h e  P C R  c o c k t a i l  p r e - h e a t e d  to 
8 5 °C. P r i m e r  is t h e r e f o r e  n o t  in c o n t a c t  w i t h  s a m p l e  D N A  
b e l o w  t h e  c o r r e c t  a n n e a l i n g  t e m p e r a t u r e .  A  h o t  s t a r t  is 
o f t e n  i n t r o d u c e d  to  e l i m i n a t e  n o n - s p e c i f i c  b a n d s  p r e s e n t  
in  t h e  P C R  p r o d u c t .  T h e  r e s u l t s  of t h e  i n c l u s i o n  of t h e  
h o t  s t a r t  ( F i g u r e  4.4) s h o w s  t h e  i m p o r t a n c e  of b o i l i n g  all 
s a m p l e s  b e f o r e  t h e i r  a d d i t i o n  t o  t h e  P C R  c o c k t a i l .
A l l  p a r a m e t e r s  of t h e  P C R  r e a c t i o n  w e r e  o p t i m i s e d  
( F i g u r e s  4. 5  - 4. 1 1 ) .  T h e  o p t i m u m  c y c l e  n u m b e r  w a s  f o u n d  
t o  b e  35 c y c l e s ,  as 40 c y c l e s ,  a l t h o u g h  g e n e r a t i n g  a 
g r e a t e r  p r o d u c t  y i e l d  g e n e r a t e d  a n o n  s p e c i f i c  band. B y  
r e p l a c i n g  t h e  o r i g i n a l  p r i m e r  1 w i t h  p r i m e r  IB w h i c h  w a s  
l o n g e r  b y  3 b a s e s  (see 4 . 2 . 1 ) ,  t h e  a n n e a l i n g  t e m p e r a t u r e  
of t h e  a s s a y  w a s  i n c r e a s e d  b y  3 d e g r e e s  t h e r e f o r e
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i n c r e a s i n g  t h e  s p e c i f i c i t y  of t h e  a s s a y  (r es ul t n o t  
s h o w n) . T h e  h i g h e s t  a n n e a l i n g  t e m p e r a t u r e  w h i c h  p e r m i t t e d  
a n n e a l i n g  w a s  6 3 ° C  ( F i g u r e  4.5). T h e  a d d i t i o n  of c e r t a i n  
c o n c e n t r a t i o n s  (3 m M  a n d  6 mM) of M g C l 2 to t h e  a s s a y  
g e n e r a t e d  a n o n  s p e c i f i c  b a n d  w h i c h  w a s  e l i m i n a t e d  b y  
e i t h e r  o m i t t i n g  t h i s  c o m p o n e n t  o r  b y  a d d i n g  h i g h e r  
c o n c e n t r a t i o n s  (9 m M  o r  12 mM; F i g u r e  4.8) of M g C l 2. Th e  
e f f e c t  of t h e  c o - s o l v e n t  D M S O  in t h e  P C R  a s s a y  w a s  
e x a m i n e d .  N o  i n h i b i t o r y  e f f e c t s  o n  t h e  P C R  w e r e  f o u n d  t h a t  
a t  c o n c e n t r a t i o n s  b e l o w  8 %, a l t h o u g h  h i g h e r  c o n c e n t r a t i o n s  
r e s u l t e d  in c o r r e s p o n d i n g  l o w e r  p r o d u c t  y i e l d s  (F ig ur e 
4. 10 ). D M S O  w a s  r e t a i n e d  in t h e  P C R  a s s a y  to e n s u r e  
c o m p l e t e  d e n a t u r a t i o n  of a l l  s a m p l e  t e m p l a t e  DNA.
T h e  P C R  p r o d u c t  w a s  v e r i f i e d  t o  h a v e  b e e n  g e n e r a t e d  
f r o m  B H V 1  D N A  b y  t h e  u s e  of r e s t r i c t i o n  e n d o n u c l e a s e  
a n a l y s i s  of t h e  p r o d u c t  u s i n g  H a e  II a n d  T a q  I ( F i g u r e  
4 . 1 3 ) . H o w e v e r ,  it w a s  n o t  p o s s i b l e  t o  d i f f e r e n t i a t e  
B H V 1 .1 f r o m  B H V 1 .2 u s i n g  H a e  II r e s t r i c t i o n  a n a l y s i s .
T h e  s e n s i t i v i t y  of t h e  r e a c t i o n  w a s  d e t e r m i n e d  in 
t e r m s  of T C I D 50, as t h e  e x p r e s s i o n  of t h e  s e n s i t i v i t y  in 
t e r m s  of D N A  w a s  t h o u g h t  t o  b e  u n r e l i a b l e  f o r  t w o  r e a s o n s ;
(I) s p e c t r o p h o t o m e t e r  r e a d i n g s  of D N A  a r e  o f t e n  u n r e l i a b l e  
a n d  (II) t h e  p r e s e n c e  of b o v i n e  D N A  i n  v i r a l  p r e p s  m a y  
o v e r e s t i m a t e  t o t a l  B H V 1  DNA. W h e n  r e p r e s e n t i n g  th e  
s e n s i t i v i t y  of t h e  P C R  a s s a y  in t e r m s  of T C I D 50 it m u s t  b e  
b o r n e  i n  m i n d  t h a t  t h e  a s s a y  d e t e c t s  v i r a l  D N A  t h a t  is n o t  
p a r t  of v i a b l e  v i r u s . V i r a l  s u p e r n a t a n t  of k n o w n  t i t r e  w a s  
u s e d  as t e m p l a t e  f o r  t h e  P C R  ass a y .  T w o  m e t h o d s  fo r  th e 
p r e p a r a t i o n  of v i r u s  s u p e r n a t a n t  w e r e  c o m p a r e d .  O n e  m e t h o d  
i n v o l v e d  t h e  b o i l i n g  of v i r a l  s u p e r n a t a n t  in o r d e r  to 
r e l e a s e  t h e  v i r a l  DNA. T h e  s e c o n d  a l s o  i n v o l v e d  b o i l i n g  
v i r a l  s u p e r n a t a n t  of k n o w n  t i t r e  e x c e p t ,  t h i s  time , in t h e  
p r e s e n c e  of a C h e l e x  100. C h e l e x  100 is a c h e l a t i n g  r e s i n  
t h a t  h a s  a h i g h  a f f i n i t y  fo r  p o l y v a l e n t  m e t a l  i o n s a n d  
a c t s  as a c h e l a t i n g  g r o u p .  It ha s  b e e n  p o s t u l a t e d  (S i n g e r -  
Sam, 19 89 ), t h a t  t h e  p r e s e n c e  of C h e l e x  d u r i n g  b o i l i n g  
p r e v e n t s  t h e  d e g r a d a t i o n  of D N A  b y  c h e l a t i n g  m e t a l  ions 
t h a t  m a y  a c t  as a c a t a l y s t  in t h e  b r e a k d o w n  of D N A  at h i g h
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t e m p e r a t u r e s  in l o w  i o n i c  s o l u t i o n s .  T h e  u s e  of C h e l e x  100 
as a m e a n s  of i n c r e a s i n g  t h e  s i g n a l  f r o m  t h e  P C R  
a m p l i f i c a t i o n  of s m a l l  a m o u n t s  of D N A  r e l e a s e d  f r o m  sm al l  
n u m b e r s  of t i s s u e  c u l t u r e  c e l l s  t h a t  h a v e  b e e n  b o i l e d  has 
b e e n  r e p o r t e d  ( S i n g e r - S a m ,  1989). T h e  s e n s i t i v i t y  of the 
a s s a y  w h e n  b o i l i n g  w a s  u s e d  as a m e t h o d  fo r the 
p r e p a r a t i o n  of D N A  w a s  f o u n d  t o  b e  1 T C I D 50 (see F i g u r e  
4. 1 2 a )  w h i l e  t h e  i n c l u s i o n  of C h e l e x  100 in the 
p r e p a r a t i o n  s t e p  i n c r e a s e d  t h e  s e n s i t i v i t y  t o  0.1 T C I D 50 
f o l d  ( F i g u r e  4 . 1 2 b ) . T h e r e f o r e  i t  m a y  b e  c o n c l u d e d  t h a t  b y  
t h e  i n c l u s i o n  of 5% C h e l e x  100 i n  t h e  b o i l i n g  of v i r a l  
s u p e r n a t a n t  m o r e  t a r g e t  D N A  r e m a i n s  i n t a c t  t h e r e f o r e  
p r o v i d i n g  a g r e a t e r  n u m b e r  of D N A  m o l e c u l e s  a v a i l a b l e  for 
a m p l i f i c a t i o n .  T h i s  h a s  i m p o r t a n t  i m p l i c a t i o n s  w h e n  the 
s t a r t i n g  c o n c e n t r a t i o n  of t a r g e t  D N A  m a y  b e  low, s u c h  as 
in d i a g n o s t i c  s u b m i s s i o n s  a n d  f o r  t h i s  r e a s o n  t h e  C h e l e x  
1 0 0 r e s i n  w a s  i n c o r p o r a t e d  i n t o  t h e  e x t r a c t i o n  p r o c e d u r e  
f o r  s u c h  s a m p l e s .
T h e  e x t r a c t i o n  of D N A  f r o m  t h e  s u p e r n a t a n t  of v i r u s  
i n f e c t e d  c e l l s  u s i n g  t h e  C h e l e x  100 m e t h o d  w a s  s i m p l e  a n d  
fast. It i n v o l v e s  l e s s s t e p s  t h a n  p h e n o l :c h l o r o f o r m  b a s e d  
m e t h o d .  A t  s u c h  a s e n s i t i v i t y  t h e  P C R  d e s c r i b e d  in t h is 
s t u d y  is o n e  of t h e  m o s t  s e n s i t i v e  a s s a y s  r e p o r t e d  to 
d a t e .
A s  e x p e c t e d  t h e  P C R  a s s a y  d e t e c t e d  b o t h  B H V 1  s u b t y p e s  
( F i g u r e  4 . 1 4 a ) .  T h e r e  w a s  n o  c r o s s  r e a c t i o n  of p r i m e r s  
w i t h  o t h e r  b o v i n e  h e r p e s v i r u s e s  o r  b o v i n e  c e l l s  ( F igur e 
4 . 1 4 b ) .  It w a s  a l s o  s h o w n  t h a t  w e r e  n o  i n h i b i t o r y  f a c t o r s  
in t h e s e  s a m p l e s  b y  p e r f o r m i n g  c o n t r o l  P C R  a s s a y  u s i n g  IGF 
p r i m e r s  t h a t  a m p l i f y  a p o r t i o n  of t h e  IG F  g e n e  (F ig ur e 
4 . 1 4 c ) .
L i v e  B H V 1  v a c c i n e s  m a y  b e  u s e d  i n  t h e  f a c e  of an 
o u t b r e a k  of r e s p i r a t o r y  d i s e a s e  t o  r e d u c e  t h e  d e v a s t a t i n g  
e f f e c t s  of B H V 1  i n f e c t i o n s  i n  f e e d l o t  s i t u a t i o n s .  This, 
h o w e v e r ,  m a y  p o s e  p r o b l e m s  f o r  c o r r e c t  d i a g n o s i s  i n  the 
l a b o r a t o r y  as t o  w h e t h e r  t h e  v i r u s  d e t e c t e d  f r o m  
s u b m i s s i o n s  u s i n g  v i r u s  i s o l a t i o n ,  F A T  o r  P C R  m a y  b e  f i e l d  
o r  v a c c i n e  v i r u s . T h i s  p r o b l e m  is f u r t h e r  a c c e n t u a t e d  as
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B H V 1  c a n  e s t a b l i s h  l a t e n t  i n f e c t i o n ,  i n f e c t i o n  b y  o t h e r  
r e s p i r a t o r y  d i s e a s e - c a u s i n g  p a t h o g e n s  m a y  l e a d  to t h e  r e ­
e x c r e t i o n  of v a c c i n e  B H V 1  w h i c h  m a y  t h e n  b e  d i a g n o s e d  as 
t h e  c a u s e  of t h e  o u t b r e a k  w h e n  i n  a c t u a l  f a c t  th e  
c a u s a t i v e  a g e n t  is a n o t h e r  p a t h o g e n .
W h e n  t h e  P C R  a s s a y  w a s  u s e d  t o  e x a m i n e  its c r o s s  
r e a c t i v i t y  w i t h  t h e  s e g u e n c e  of t h e  t w o  l i v e  v i r u s  
v a c c i n e s  c u r r e n t l y  a v a i l a b l e  o n  t h e  I r i s h  M a r k e t ,  it wa s  
f o u n d  t h a t  it d i d  d e t e c t  o n e  (I n b o v a c ) b u t  d i d  n o t  d e t e c t  
t h e  o t h e r  ( T r a c h e r i n e )  ( F i g u r e  4. 16 ). T h e r e  is no 
i n f o r m a t i o n  a v a i l a b l e  f r o m  t h e  m a n u f a c t u r i n g  c o m p a n i e s  on 
g e n o m i c  d i f f e r e n c e s  b e t w e e n  t h e s e  v a c c i n e s  a n d  v i r u l e n t  
v i r u s . B o t h  v a c c i n e s  w e r e  d e v e l o p e d  f r o m  f i e l d  i s o l a t e s
w h i c h  h a d  c a u s e d  m i l d  c l i n i c a l  s i g n s  a n d  l i t t l e
i n f o r m a t i o n  h a s  b e e n  m a d e  a v a i l a b l e  o n  t h e i r  b i o l o g i c a l
p r o p e r t i e s .  In t h e  c a s e  of T r a c h e r i n e ,  t h e  v i r u s  wa s  
a d a p t e d  t o  g r o w  o n l y  a t  3 2 ° C  a n d  t h e r e f o r e  a c t s  as a 
m a r k e r  v a c c i n e  w h i c h  c a n  b e  d i f f e r e n t i a t e d  f r o m  f i e l d
v i r u s  w i t h i n  t h e  l a b o r a t o r y  u s i n g  v i r u s  i s o l a t i o n  at 
d i f f e r e n t  t e m p e r a t u r e s .  B y  it s  i n a b i l i t y  t o  d e t e c t  
T r a c h e r i n e ,  t h i s  P C R  a s s a y  w i l l  n o t  p r o n o u n c e  a n i m a l s  t h a t  
a r e  o n l y  v a c c i n a t e d  as b e i n g  i n f e c t e d  w i t h  B H V 1 . T h i s  
m a k e s  t h e  p o s s i b l e  u s e  of t h e  P C R  a s s a y  o n  a r o u t i n e  b a s i s  
i n  c o n j u n c t i o n  w i t h  t h e  l i v e  v a c c i n e  T r a c h e r i n e  v e r y  
f a v o u r a b l e .
T h e  P C R  t e s t  w a s  a l s o  d e s i g n e d  t o  d e t e c t  B H V 1 . 3 , 
w h i c h  h a s  a n  85% h o m o l o g y  w i t h  B H V 1  s t r a i n s  a n d  h a s  b e e n  
r e f e r r e d  t o  as B H V 5  ( R o i z a m n  a n d  B a i n e s ,  1991) - a n d  is 
a s s o c i a t e d  w i t h  e n c e p h a l i t i s  i n  c a l v e s  ( S m i t h  et al., 
19 93 ). D u e  t o  t a  d e l e t i o n  i n  t h e  B H V 5  T K  P C R  p r o d u c t  
a m p l i f i e d  f r o m  B H V 5  (270 bp) c o u l d  b e  d i s t i n g u i s h e d  f r o m  
t h a t  a m p l i f i e d  f r o m  B H V 1  (300 bp) o n  t h e  b a s i s  of p r o d u c t  
s i z e  a n d  b y  r e s t r i c t i o n  a n a l y s i s  w i t h  T a g  I. O u t b r e a k s  of 
e n c e p h a l i t i s  c a u s e d  b y  B H V 5  h a v e  b e e n  r e p o r t e d  f r o m  
A u s t r a l i a ,  C a n a d a ,  A r g e n t i n a  a n d  H u n g a r y  (Strau b, e t  a l ., 
19 90 ). T h e r e  h a v e  b e e n  n o  r e p o r t e d  i s o l a t i o n s  of t h e  v i r u s  
w i t h i n  t h e  E u r o p e a n  U n i o n  i n  t h e  l i t e r a t u r e  t o  date. 
H o w e v e r  w i t h  t h e  p r e s e n c e  of t h e  v i r u s  o n  m a i n l a n d  E u r o p e
131
it r e m a i n s  a t h r e a t  to a n i m a l s  w i t h i n  t h e  E u r o p e a n  
C o m m u n i t y .
F i n a l l y ,  t h e  e n t i r e  P C R  p r o g r a m m e  t a k e s  2 h r  15 m i n  
w i t h  t h e  p r e p a r a t i o n  of v i r a l  s u p e r n a t a n t  t a k i n g  45 min, 
h e n c e  r e s u l t s  of d i a g n o s t i c  s u b m i s s i o n s  c a n  b e  m a d e  
a v a i l a b l e  w i t h i n  o n e  day.
D u r i n g  a n d  a f t e r  t h e  d e v e l o p m e n t  of t h e  a b o v e  P C R  
a s s a y  a n u m b e r  of o t h e r  P C R  a s s a y s  w e r e  a l s o  r e p o r t e d  for 
t h e  d e t e c t i o n  of B H V l , W i e d m a n n  e t  al., 1993, V a n  
E n g e l e n b u r g  e t  a l . , 1993, Y a s o n  e t  al., 1994, V i l e c k  et 
a l ., 1994, K i b e n g e  a t  a l ., 1 9 9 4  a n d  m o s t  r e c e n t l y  M w e e n e  
e t  al. (1996) a n d  S a n t r u d e  e t  a l . (1996). Of t h e s e  Y a s o n
a n d  K i b e n g e  a l s o  s e l e c t e d  t h e  T K  g e n e  as a t a r g e t  f o r  P C R  
(for t h e  s i m i l a r  r e a s o n s  as t h i s  r e p o r t ) .  T h e  o t h e r s  c h o s e  
gl (V il ec k, 1994) ( S n a t r u d e  e t  al., 19 9 6 ) ,  g i l l  (gC) (Van 
E n g e l e n b u r g ,  19 93 ), g I V  ( W i e d m a n n  1993) a n d  t h e  o r i  g e n e  
(Mweene, 19 96 ). V a n  E n g e l e n b u r g  c h o s e  g C  b e c a u s e  th e  
g l y c o p r o t e i n  a n d  i t ' s  n u c l e o t i d e  s e g u e n c e  s h o u l d  be 
p r e s e n t  i n  c o n s e r v e d  r e g i o n s  of D N A  in al l  s t r a i n s  of 
B H V l . N o  r e a s o n  f o r  p r i m e r  c h o i c e  w a s  s t a t e d  i n  t h e  o t h e r  
p a p e r s .  H o w e v e r  it is p r e s u m e d  t h a t  t h e  c h o i c e  of 
g l y c o p r o t e i n s  w a s  t h e  f a c t  t h e y  w e r e  i n v o l v e d  i n  th e  
p a t h o g e n i c i t y  of B H V l  a n d  w o u l d  t h e r e f o r e  b e  p r e s e n t  in 
a l l  p a t h o g e n i c  s t r a i n s . D e s p i t e  t h e  u s e  of a n e s t e d  P C R  
W i e d m a n n  e t  al., (1993) r e p o r t e d  o n l y  a s e n s i t i v i t y  of 103 
T C I D 50. V i l e c k  a n d  E n g e l e n b u r g  r e p o r t e d  s e n s i t i v i t i e s  e g u a l  
to t h a t  of t h i s  P C R  a s s a y  w h i l e  t h e  a s s a y  of Y a s o n  e t  a l . 
(1994) f o r  t h e  d e t e c t i o n  of B H V l  i n  s p i k e d  s e m e n  w a s  
r e p o r t e d  t o  b e  0 . 01 T C I D 50 w h e n  u s e d  in c o n j u n c t i o n  w i t h  a 
d o t  b l o t  h y b r i d i s a t i o n .  T h e  u s e  of P C R  o n  r o u t i n e  
d i a g n o s t i c  s a m p l e s  a n d  t h e  c o m p a r i s o n  w i t h  o t h e r  m e t h o d s  
is d i s c u s s e d  i n  t h e  f o l l o w i n g  c h a p t e r .
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CHAPTER 5
DETECTION OF BHV1 IN DIAGNOSTIC SAMPLES
5.1 INTRODUCTION: The detection of BHV1 in clinical
s u b m i s s i o n s  a t  t h e  V R L
P r e l i m i n a r y  d i a g n o s i s  of B H V 1  as t h e  c a u s a t i v e  a g e n t  
of d i s e a s e  m a y  b e  m a d e  o n  t h e  b a s i s  of c l i n i c a l ,  
p a t h o l o g i c a l  a n d  e p i d e m i o l o g i c a l  g r o u n d s . H o w e v e r  
c o n f i r m a t o r y  l a b o r a t o r y  e x a m i n a t i o n s  a r e  r e q u i r e d  t o  m a k e  
a d e f i n i t i v e  d i a g n o s i s .
T r a d i t i o n a l  d i a g n o s t i c  m e t h o d s  f o r  B H V 1  d e t e c t i o n  
s u c h  as p a i r e d  s e r o l o g y  a n d  v i r u s  i s o l a t i o n  a r e  u s u a l l y  
u s e d  as a r e t r o s p e c t i v e  d i a g n o s t i c  t e c h n i g u e s  (due t o  th e  
t i m e  r e q u i r e d  t o  o b t a i n  a r e s u l t ) ,  w h i c h  m a y  b e  p r i m a r i l y  
of h i s t o r i c a l  i m p o r t a n c e  t o  h e r d  o w n e r s  b u t  m a y  a l s o  
p r o v i d e  g u i d e l i n e s  f o r  p r e v e n t a t i v e  m e a s u r e s  i n  th e  
f u t u r e .
T h e  a d v e n t  of l i v e  i n t r a n a s a l  v a c c i n e s  w h i c h  m a y  be 
u s e d  i n  t h e  f a c e  of a n  I B R  o u t b r e a k  h a s  p l a c e d  
c o n s i d e r a b l e  e m p h a s i s  o n  t h e  d e v e l o p m e n t  of r a p i d  a n d  
r e l i a b l e  d i a g n o s t i c  t e s t s  f o r  B H V 1  d e t e c t i o n .  T h e s e  
v a c c i n e s  i n d u c e  a r a p i d  l o c a l  i m m u n i t y  i n  t h e  r e s p i r a t o r y  
t r a c t  ( K u c e r a  e t  al., 19 78 ), a l l o w i n g  t h e  u s e  of f a st 
i n t e r v e n t i o n  s t r a t e g i e s  w h i c h  c a n  r e d u c e  a n d  c o n t r o l  th e  
d e v a s t a t i n g  e f f e c t s  of v i r u s  sp re ad .
T h e  c l i n i c a l  d i s e a s e  s i g n s  c a u s e d  b y  B H V 1  ar e  
r e f l e c t e d  in  t h e  n a t u r e  of d i a g n o s t i c  s u b m i s s i o n s  t h a t  are 
t a k e n  o n  a r o u t i n e  b a s i s . S a m p l e s  a r e  s u b m i t t e d  t o  th e  
d i a g n o s t i c  l a b o r a t o r y  f r o m  a n i m a l s  w i t h  r e s p i r a t o r y  
d i s e a s e  i n  t h e  f o r m  of n a s a l  o r  o c u l a r  d i s c h a r g e  o n  swabs, 
n a s a l  s e c r e t i o n s ,  o r  i n  t h e  c a s e  of d e a t h ,  t i s s u e  s a m p l e s  
f r o m  t h e  l u n g  a n d / o r  t h e  t r a c h e a .  T h e  s u c c e s s  of m a n y  
d i a g n o s t i c  t e s t s  d e p e n d s  o n  t h e  g u a l i t y  of t h e  s a m p l e s .
C u r r e n t  m e t h o d s  f o r  B H V 1  d e t e c t i o n  h a v e  b e e n  o u t l i n e d  
i n  1 .1 0 . 2  a n d  i n c l u d e  t h e  m o s t  f r e q u e n t l y  u s e d  m e t h o d s  for 
B H V 1  d e t e c t i o n  i n  t h e  V R L .
(I) V i r u s  I s o l a t i o n  (VI): T h i s  is t h e  'g old s t a n d a r d '
t e c h n i q u e  r e s u l t i n g  in t h e  i s o l a t i o n  a n d  c u l t u r e  of th e 
c a u s a t i v e  v i r u s  (see 1 . 1 0 . 2 . 1 ) .  A s  a d i a g n o s t i c  t e c h n i q u e
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it is r e l i a b l e ,  as B H V l  f i e l d  s t r a i n s  g r o w  w e l l  in s o m e  
t i s s u e  c u l t u r e  c e l l  lines. A  p r e l i m i n a r y  d i a g n o s i s  ca n  
u s u a l l y  b e  c o n f i r m e d  b y  c h a r a c t e r i s t i c  C P E  a f t e r  48 t o  72 
hr. T h e  t e c h n i q u e  a l s o  p r o p a g a t e s  t h e  c a u s a t i v e  a g e n t  of 
t h e  d i s e a s e  w h i c h  m a y  t h e n  b e  c l a s s i f i e d  a n d  u s e d  for 
r e s e a r c h  o r  e p i d e m i o l o g i c a l  p u r p o s e s . T h e  d i s a d v a n t a g e  of 
t h e  t e c h n i q u e  is t h a t  it m a y  t a k e  a w e e k  to t e n  d a y s  to 
o b t a i n  a d e f i n i t i v e  r e s u l t  p a r t i c u l a r l y  if t h e  v i r u s  t i t r e  
i n  s a m p l e s  is low. A s  a r e s u l t  t h e  t e s t  is r a r e l y  of v a l u e  
to d e t e r m i n e  t h e  c o u r s e  of t r e a t m e n t  t o  b e  a d o p t e d  i n  t h e  
f a c e  of a n  o u t b r e a k .  N a s a l  a n d  o c u l a r  s e c r e t i o n s  o n  s w a b s  
f o r  t e s t i n g  b y  V I  m u s t  r e m a i n  m o i s t  t o  r e t a i n  v i a b l e  
v i r u s .  D e l a y s  b e f o r e  a n d  d u r i n g  t r a n s m i s s i o n  to t h e  
l a b o r a t o r y  r e d u c e  t h e  c h a n c e  of v i r u s  d e t e c t i o n .
(II) F l u o r e s c e n t  A n t i b o d y  T e s t  (FAT): T h e  F A T  is a s l i d e  
b a s e d  i m m u n o f l u o r e s c e n t  t e s t  (see 1 . 1 0 . 2 . 1 ) .  T h e  i m p o r t a n t  
a d v a n t a g e  of F A T  is t h a t  it is a v e r y  r a p i d  t e s t  w i t h  
r e s u l t s  o f t e n  a v a i l a b l e  w i t h i n  h o u r s .  T h e  t e s t  m a y  
t h e r e f o r e  p l a y  a r o l e  in w h a t  c o n t r o l  m e a s u r e s  ar e  
a d o p t e d .
A  n u m b e r  of c r i t e r i a  a r e  r e q u i r e d  fo r s u c c e s s f u l  
d e t e c t i o n  of v i r u s  i n  t h e s e  s a m p l e s  (Gunn, 1994).
F i r s t l y ,  i n  t h e  f a c e  of a n  I B R  o u t b r e a k  n a s a l  o r  
o c u l a r  s e c r e t i o n s  s h o u l d  b e  t a k e n  i n  t h e  e a r l y  s t a g e s  
( f i r s t 2-3 d a y s )  of t h e  c l i n i c a l  d i s e a s e  w h e n  v i r u s  is 
b e i n g  e x c r e t e d  a t  h i g h  t i t r e s  a n d  b e f o r e  s e c r e t i o n s  b e c o m e  
p u r u l e n t  d u e  t o  b a c t e r i a l  g r o w t h .  T o  o b t a i n  c e l l s  w i t h  
i n f e c t e d  v i r u s  f o r  t h e  F A T  te st, s e c r e t i o n s  s h o u l d  be 
c o l l e c t e d  f r o m  t h e  u p p e r  r e g i o n  of t h e  n a r e s  e i t h e r  b y  
a s p i r a t i o n  o r  b y  u s i n g  a l o n g  s h a f t e d  swab. T i s s u e  f r o m  
p o s t  m o r t e m  e x a m i n a t i o n  s h o u l d  i d e a l l y  b e  f r o m  a n  a n i m a l  
w h e r e  d e a t h  o c c u r r e d  as a r e s u l t  of v i r a l  i n f e c t i o n  
w i t h o u t  s e c o n d a r y  b a c t e r i a l  i n f e c t i o n .  T i s s u e  s h o u l d  b e  
i n t a c t  w i t h  n o  s i g n s  of g r o s s  a u t o l y s i s .
S e c o n d l y ,  p r o p e r  p r e p a r a t i o n  a n d  a t t a c h m e n t  of c e l l s  
o n t o  g l a s s  m i c r o s c o p e  s l i d e s  is a l s o  of p a r a m o u n t  
i m p o r t a n c e  t o  t h e  s u c c e s s  of t h e  te st. A n  a d e q u a t e  n u m b e r  
of c e l l s  o f  g o o d  q u a l i t y  w i t h  o r  w i t h o u t  s i t e s  of
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i n t r a c e l l u l a r  a n t i g e n  f r o m  t h e  r e s p i r a t o r y  t r a c t  m u s t  b e  
p r e s e n t  o n  s l i d e s  in o r d e r  t o  m a k e  a d e f i n i t i v e  p o s i t i v e  
o r  n e g a t i v e  d i a g n o s i s . S e c r e t i o n s  s h o u l d  b e  r u b b e d  o n t o  a 
g l a s s  s l i d e  i n  a c i r c u l a r  f a s h i o n .  T h e s e  m u s t  t h e n  b e  
a l l o w e d  t o  d r y  a t  a m b i e n t  t e m p e r a t u r e  a n d  t h e n  f i x e d  in 
a c e t o n e  f o r  30 m i n  at r o o m  t e m p e r a t u r e  (Gunn, 1995). A n y  
d e v i a t i o n s  f r o m  t h i s  p r o c e d u r e  m a y  r e s u l t  in  p o o r  q u a l i t y  
s l i d e s  o r  s l i d e s  w i t h  t o o  f e w  c e l l s  w h i c h  a r e  u n s u i t a b l e  
f o r  t e s t i n g .  A s  a g e n e r a l  r u l e  a p p r o x i m a t e l y  300 
c e l l s / s l i d e  w a s  c o n s i d e r e d  a d e g u a t e  t o  m a k e  a n e g a t i v e  o r  
p o s i t i v e  d i a g n o s i s .
Thirdly, this test reguires adeguate laboratory 
facilities including an epifluorescent microscope, a 
specific labelled antiserum and experienced personnel to 
perform the microscopic examination.
(Ill) P a i r e d  s e r o l o g y :  P a i r e d  b l o o d  s a m p l e s  m a y  a l s o  be 
s u b m i t t e d  f o r  s e r o l o g i c a l  e x a m i n a t i o n  a n d  t e s t e d  f o r  t h e  
p r e s e n c e  of B H V 1  a n t i b o d i e s  b y  s e r u m  n e u t r a l i s a t i o n  t e s t s  
o r  E L I S A  b a s e d  m e t h o d s  (see 1 . 1 0 . 2 . 3 ) .  T h e s e  d o  n o t  
p r o v i d e  a r a p i d  m e a n s  of d i a g n o s i s ,  i n s t e a d  t h e y  a r e  
a p p l i e d  t o  d i a g n o s e  i n f e c t i o n  as d e m o n s t r a t e d  b y  a 
s i g n i f i c a n t  r i s e  i n  a n t i b o d y  t i t r e  b e t w e e n  a t i m e  i n t e r v a l  
of a p p r o x i m a t e l y  2 t o  4 w e e k s . S e r o l o g i c a l  r e s u l t s  m a y  
a l s o  d e m o n s t r a t e  an  a b s e n c e  of B H V 1  i n f e c t i o n ,  t h e  
p r e v a l e n c e  of i n f e c t i o n  in g r o u p s  of c a t t l e ,  o r  m a y  a l s o  
b e  u s e d  i n  t h e  f r a m e w o r k  of e r a d i c a t i o n  p r o g r a m m e s  a n d  
s u b s e g u e n t  s u r v e i l l a n c e .
During the past decade there has been a move away 
from these conventional techniques and methods to 
demonstrate viral DNA in clinical samples have been 
described. These include DNA-DNA hybridisation and PCR. 
While dot blot hybridisation techniques have also been 
reported (Belak et al., 19 88 ), such methods have not been 
used on a routine basis. PCR assays have been reported for 
a range of human and animal viruses (Belak et a l ., 1993). 
The use of such DNA based tests have the distinct 
advantage of indicating the presence or absence of viral 
DNA in a sample, hence non-viable virus and sample quality
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m a y  n o t  a f f e c t  t h e  t e s t  r e s u l t .  T h e  a d v a n t a g e s  of P C R  
a s s a y s  h a v e  b e e n  o u t l i n e d  i n  c h a p t e r  1 .
T h i s  c h a p t e r  d e s c r i b e s  t h e  a p p l i c a t i o n  of t h e  
o p t i m i s e d  P C R  a s s a y  d e s c r i b e d  e a r l i e r  (see T a b l e  4.1) to 
r o u t i n e  s a m p l e s  s u b m i t t e d  to  t h e  d i a g n o s t i c  l a b o r a t o r y .  
T h e  r e s u l t s  o b t a i n e d  a r e  c o m p a r e d  t o  t h o s e  o b t a i n e d  b y  F A T  
a n d  v i r u s  i s o l a t i o n .
5 . 2  R E S U L T S
5 . 2 . 1  T h e  d e t e c t i o n  o f  B H V 1  i n  d i a g n o s t i c  s a m p l e s  f r o m  
r e s p i r a t o r y  d i s e a s e  o u t b r e a k s  u s i n g  V I ,  P C R  a n d  F A T
A  r o u t i n e  d i a g n o s t i c  s e r v i c e  f o r  t h e  d i a g n o s i s  of 
v i r a l  a g e n t s  a s s o c i a t e d  w i t h  o u t b r e a k s  of r e s p i r a t o r y  
d i s e a s e  is p r o v i d e d  b y  t h e  V i r o l o g y  D i v i s i o n  a t  th e  
V e t e r i n a r y  R e s e a r c h  L a b o r a t o r y  (VRL) f o r  v e t e r i n a r y  
p r a c t i t i o n e r s  s t r a t e g i c a l l y  l o c a t e d  t h r o u g h o u t  t h e  c o u n t r y  
a n d  f o r  t h e  f i v e  R e g i o n a l  V e t e r i n a r y  L a b o r a t o r i e s  (RVLs).
A  s e l e c t i o n  of o n e  h u n d r e d  a n d  f i v e  s a m p l e s  f r o m
a n i m a l s  e x h i b i t i n g  r e s p i r a t o r y  d i s e a s e ,  s u b m i t t e d  b y
v e t e r i n a r y  p r a c t i t i o n e r s  t o  t h e  V R L  o v e r  a s e v e n  m o n t h  
p e r i o d  w e r e  c h o s e n  f o r  t h i s  i n v e s t i g a t i o n .  S u b m i s s i o n s  
c h o s e n  f o r  a n a l y s i s  w e r e  i n  f o u r  f o r m s  (I) n a s a l  
s e c r e t i o n s  (II) n a s a l  s w a b s  w i t h  (III) a c o r r e s p o n d i n g  
n a s a l  s e c r e t i o n  f i x e d  o n  g l a s s  m i c r o s c o p e  s l i d e s  o r  (IV) 
b o v i n e  t i s s u e  o b t a i n e d  o n  p o s t  m o r t e m  e x a m i n a t i o n .  O n l y  
s a m p l e s  w h i c h  w e r e  s u i t a b l e  f o r  t e s t i n g  b y  a l l  t h r e e
m e t h o d s  w e r e  c h o s e n  i.e. t i s s u e  o r  s w a b s  t h a t  h a d  b e e n
s u b m i t t e d  i n  c o n j u n c t i o n  w i t h  s l i d e s .  A l l  s a m p l e s  w e r e  
t e s t e d  f o r  t h e  p r e s e n c e  of B H V 1  b y  V I  ( 2 .1 1. 1a ) a n d  F A T  
(2 .1 1 . 2 ) .  D N A  t e m p l a t e s  f o r  P C R  w e r e  p r e p a r e d  b y  
i n c u b a t i n g  h o m o g e n a t e s  p r e p a r e d  f o r  V I  ( C h a p t e r  2.12 .2 ) 
w i t h  C h e l e x  100. A l l  s a m p l e s  w h i c h  w e r e  n e g a t i v e  b y  P C R  
w e r e  a l s o  t e s t e d  f o r  t h e  p r e s e n c e  of i n h i b i t o r y  s u b s t a n c e s  
u s i n g  a n o t h e r  P C R  a s s a y  w i t h  p r i m e r s  c o m p l e m e n t a r y  to  t h e  
b o v i n e  I G F  g e n e  (2 .1 4. 7) .
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TA B LE 5.1
T H E  T O TA L  N U M B E R  O F  BHV1 P O S IT IV E  S U B M IS S IO N S  BY VI, P C R  AND FA T
S am p le  type V I P C R FA T
T issues (44) 7 8 4
S w abs/slides (46) 6 7 6
N asa l secre tions (15) 0 0 0
T o ta l positives 13 15 10
It c a n  b e  s e e n  f r o m  T a b l e  5. 1  t h a t  t h e  g r e a t e s t  n u m b e r  of 
p o s i t i v e  B H V 1  s a m p l e s  w e r e  i d e n t i f i e d  b y  P C R  (80%) 
f o l l o w e d  b y  V I  (60%) a n d  t h e n  b y  F A T  (50%). A  d e t a i l e d  
a c c o u n t  o f  t h e  s a m p l e s  p o s i t i v e  b y  a n y  of t h e s e  m e t h o d s  is 
g i v e n  i n  T a b l e  5.2 (A c o m p l e t e  l i s t  of t h e  s a m p l e s  t e s t e d ,  
t h e  s a m p l e  t y p e  a n d  t h e  r e s u l t  is g i v e n  i n  t h e  A p p e n d i x  
A).
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TABLE 5.2
C O M P A R IS O N  O F  BHV1 P O S IT IV E  SA M PLES O N  105 D IA G N O ST IC  S U B M IS S IO N S
LAB R E F S A M P L E  TY PE FA T VI P C R
D469 slide/sw ab P Q + +
D 703 slide/sw ab + - +
E 140 o cu lar sw ab - + +
E 230 slide/sw ab T F C - +
E465 slide/sw ab + - -
E 467 slide/sw ab + - -
E 766 slide/sw ab + + +
E 795 slide/sw ab T F C - +
E830 slide/sw ab + +
H 274 slides/sw ab - + +
J683 slides/sw abs + + +
E463 tissue + - +
D680(4x) tissue + + +
F313 tissue + + +
G780 tissue - + +
G 677 tissue + + +
G 770 tissue P Q + +
H 8 tissue D R - + +
H 443/44 tissue P Q + +
H 499 tissue + - -
T o ta l su itab le  fo r  te sting 14 20 20
T o ta l positive 20 11 13 16
P erce n tag e  positive 55% 65% 80%
* Positive on  tissu e  cu ltu re  su p e rn a tan t (P assage 1) 
P Q  P o o r quality
T F C  T o o  few  cells fo r re liab le  read ing .
N D  N o  slide availab le fo r te sting
138
I
T a b l e  5 . 2  l i s t s  t h e  s a m p l e s  w h i c h  w e r e  f o u n d  p o s i t i v e  b y  
a n y  o r  a l l  o f  t h e  d e t e c t i o n  m e t h o d s  e m p l o y e d .  T h i r t y  p e r  
c e n t  o f  s a m p l e s  s u b m i t t e d  w e r e  a r e  n o t  s u i t a b l e  f o r  
t e s t i n g  b y  F A T .  I n  o r d e r  t o  a l l o w  a v a l i d  a s s e s s m e n t  o f  
F A T  t h e  T a b l e  5 . 2  w a s  a d j u s t e d  t o  e x c l u d e  a n y  s a m p l e s  ( s e e  
T a b l e  5 . 3 )  t h a t  w e r e  u n s u i t a b l e  f o r  t e s t i n g  b y  FAT. 
H o w e v e r  u s i n g  T a b l e  5 .2, a c o m p a r i s o n  b e t w e e n  V I  a n d  P C R  
m a y  b e  m a d e .
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TABLE 53
C O M P A R IS O N  O F  P O S IT IV E  D IA G N O ST IC  SA M PL E S BY A LL M E T H O D S
LAB R E F S A M P L E  TY PE FA T VI P C R
D 703 slide/sw ab + - +
E 140 o cu lar swab + +
E463 tissue + - +
E 465 slide/sw ab + - *
E 467 slide/sw ab + - *
E 766 slide/sw ab + + +
E830 slide/sw ab + + -*
H 274 slides/sw ab * + +
H 499 tissue + - “
D 680 tissue + + +
F313 tissue + + +
G677 tissue + + +
H 8 tissue - + +
J683 slides/sw abs + + +
T o ta l positive 13 10 9 10 (1 TC )
P erce n tag e  positive 78% 69% 78%
T a b l e  5 . 3  e x c l u d e s  s a m p l e s  D 4 6 9 ,  G 7 7 0  a n d  H 4 4 3 / 4 4  w h i c h  
w e r e  o f  p o o r  q u a l i t y ,  s a m p l e s  E 2 3 0  a n d  E 7 9 5  w h i c h  h a d  t o o  
f e w  c e l l s  f o r  r e l i a b l e  t e s t i n g  a n d  s a m p l e  G 7 8 0  w h i c h  h a d  
n o  c o r r e s p o n d i n g  s l i d e .  A l l  o f  t h e s e  w e r e  p o s i t i v e  b y  P C R .
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TABLE 5.4
(A) C O M P A R I S O N  OF P C R  W I T H  VI A N D  FAT
Correlation of P C R  Positive samples with FAT and VI
60%  positive b y  F A T  
82%  positive by  V I 
18%  positive by  P C R  only
Correlation of VI Positive samples with FAT and PC R
55%  positive by  F A T  
93%  positive by  P C R  
7%  positive  by  V I only
Correlation of FAT Positive samples with P C R  and VI
50%  positive b y  V I 
60%  positive b y  P C R  
33%  positive by  F A T  only
(B)
T a b l e  5 . 4 A  C o m p a r e s  s a m p l e s  t h a t  w e r e  p o s i t i v e  b y  a l l  
t h r e e  m e t h o d s .
5 . 4 B  C o m p a r e s  s a m p l e s  b y  w h i c h  w e r e  p o s i t i v e  b y  a l l  
t h r e e  m e t h o d s  u s i n g  V e n n  D i a g r a m .
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5.2.2 The evaluation of the sensitivity and specificity of 
the PCR assay
T h e  t e s t  s y s t e m  s h o w n  b e l o w  ( B r i d s o n  e t  al., 1993), 
w a s  u s e d  to e v a l u a t e  t h e  P C R  a s s a y .  T h e  s e n s i t i v i t y  a n d  
s p e c i f i c i t y  of P C R  w a s  e v a l u a t e d  a s s u m i n g  V I  as t h e  g o l d  
s t a n d a r d .
T E S T A
{VI}
P ositive  N egative
T e s t B P ositive a  b a  +  b
{PC R } N egative c d c +  d
a + c  b + d
T h e  te s t assum es th a t te s t A  is th e  a c ce p te d  go ld  s ta n d a rd  te s t i.e  closest to  th e  ac tua l tru th .
T h e  sensitivity o f th e  te s t is d e fin e d  as th e  p ro p o rtio n  o f positive resu lts  to  tru ly  positive sam ples:
a /a  +  c.
T h e  specificity  o f th e  te s t is d e fin e d  as th e  p ro p o rtio n  o f negative resu lts  to  tru ly  negative results: 
d /d  +  b.
T h e  false positive ra te  is th e  p ro p o rtio n  b /b  +  d.
T h e  false negative ra te  is th e  p ro p o rtio n  c/a +  c.
T h e  positive p red ic tive  value (P P V ) is a /a  +  b.
T h e  p red ic tiv e  negative value  (P N V ) is d /c  +  d.
T ab le  5.3 app lies th ese  c r ite r ia  to  th e  resu lts  fo u n d  in  th is study  an d  shows th e  evaluation o f the 
P C R  assay against v irus iso la tio n  o n  tissue cu ltu re  ("gold standard").
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TABLE 5.5
THE EVALUATION OF PCR AS A DIAGNOSTIC TEST
Sensitivity o f P C R  assay =  92%  
Specificity  o f th e  P C R  assay =  97%  
F alse  positive ra te  =  2%
F alse  negative r a te  =  7%
Positive p red ic tive  value =  80%  
N egative p red ic tive  value =  98%
T a b l e  5 . 5  s h o w s  t h e  e v a l u a t i o n  o f  t h e  s e n s i t i v i t y  a n d  
s p e c i f i c i t y  o f  P C R  a s  a d i a g n o s t i c  a s s a y .
5.3 DISCUSSION: PCR as a routine diagnostic test
T h e  a p p l i c a t i o n  of t h e  o p t i m i s e d  P C R  a s s a y  to 
d i a g n o s t i c  s a m p l e s  w a s  i n v e s t i g a t e d  i n  t h i s  st ud y. T h e  P C R  
a s s a y  w a s  a l s o  c o m p a r e d  t o  V I  a n d  F A T  o n  r o u t i n e  
s u b m i s s i o n s  as a m e a n s  of B H V 1  d e t e c t i o n .  T h e  c o m p a r i s o n  
w a s  m a d e  o n  o n e  h u n d r e d  a n d  f i v e  d i a g n o s t i c  s u b m i s s i o n s  
o b t a i n e d  f r o m  c a t t l e  e x h i b i t i n g  r e s p i r a t o r y  d i s e a s e  
t h r o u g h o u t  t h e  R e p u b l i c  of I r e l a n d  w h i c h  h a d  s a m p l e s  
s u b m i t t e d  f o r  VI, P C R  a n d  i n  m o s t  c a s e s  FAT. S u b m i s s i o n s  
w e r e  m a d e  b y  v e t e r i n a r y  p r a c t i t i o n e r s  a n d  t h e  R V L s  b e t w e e n  
O c t o b e r  1993 a n d  A p r i l  1994 i.e. a t i m e  p e r i o d  d u r i n g  
w h i c h  r e s p i r a t o r y  d i s e a s e  is m o s t  p r e v a l e n t  in h o u s e d  
c a t t l e .
T h e  l i m i t a t i o n s  t o  t h e  l a b o r a t o r y  d i a g n o s i s  of B H V 1  
i n f e c t i o n s  m u s t  b e  c o n s i d e r e d  w i t h  r e g a r d  to t h i s  study. 
M o s t  s u b m i s s i o n s  a r e  m a d e  b y  v e t e r i n a r y  p r a c t i t i o n e r s  w h o  
t a k e  s a m p l e s  f r o m  h e r d s  w i t h  c l i n i c a l  s i g n s  of r e s p i r a t o r y  
d i s e a s e .  In o r d e r  t o  m a x i m i s e  t h e  c h a n c e  of B H V 1  
d e t e c t i o n ,  s a m p l i n g  of c a t t l e  a n d  s l i d e  p r e p a r a t i o n  s h o u l d  
b e  p e r f o r m e d  f o l l o w i n g  t h e  c r i t e r i a  as o u t l i n e d  in 5.1.
W h e n  r e s u l t s  f r o m  a l l  t h r e e  t e s t s  w e r e  c o m p a r e d  a 
t o t a l  of 16 w e r e  B H V 1  p o s i t i v e  b y  PCR, 13 w e r e  p o s i t i v e  b y
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t i s s u e  c u l t u r e  a n d  11 w e r e  p o s i t i v e  b y  FAT. A s  c a n  b e  s e e n  
f r o m  T a b l e  5.1 30% of t h o s e  s a m p l e s  w e r e  t e s t e d  p o s i t i v e  
b y  V I  a n d / o r  P C R  w e r e  u n s u i t a b l e  f o r  t e s t i n g  b y  F A T  a n d  
t h i s  h i g h l i g h t s  t h e  p r e v a l e n c e  of p o o r  s a m p l i n g  in t h e  
f i e l d  o r  t h e  s a m p l i n g  of a n i m a l s  w h i c h  a r e  s e c r e t i n g  
i n s u f f i c i e n t  c e l l s  f r o m  t h e i r  r e s p i r a t o r y  tr ac ts . 
S i m i l a r l y ,  s u b m i s s i o n s  f o r  V I  m u s t  i n  v i r a l  t r a n s p o r t  
m e d i a  o r  b e  o n  d a m p  s w a b s  w h i c h  m u s t  n o t  a l l o w e d  t o  d r y  
o u t  p r i o r  t o  r e a c h i n g  t h e  l a b o r a t o r y .
W h e n  u s i n g  t h e  P C R  a s s a y  o n  d i a g n o s t i c  s a m p l e s  s t r i c t  
c o n t r o l  m e a s u r e s  w e r e  a l w a y s  a p p l i e d  (2 .1 4.3). T h e s e  
i n c l u d e d  t w o  n e g a t i v e  c o n t r o l s ,  o n e  of w h i c h  w a s  d i s t i l l e d  
p u r i f i e d  w a t e r  w h i c h  m o n i t o r e d  t h e  g u a l i t y  of t h e  
e n v i r o n m e n t  a n d  i n d i c a t e d  if a n y  r e a g e n t s  w e r e  
c o n t a m i n a t e d .  T h e  s e c o n d  w a s  a s a m p l e  w h i c h  w a s  p r e v i o u s l y  
f o u n d  t o  b e  n e g a t i v e  - t h u s  p r o v i d i n g  a c o n t r o l  f o r  th e  
h a n d l i n g  p r o c e d u r e s .
M e t h o d s  of D N A  e x t r a c t i o n  f r o m  a v a r i e t y  of 
b i o l o g i c a l  m a t e r i a l s  f o r  P C R  t e s t i n g  h a v e  i n c l u d e d  
s e p a r a t i o n  a n d  p u r i f i c a t i o n  s t e p s  u t i l i s i n g  
p h e n o l :c h l o r o f o r m  e x t r a c t i o n s  a n d / o r  e t h a n o l  
p r e c i p i t a t i o n ,  ( S a m b r o o k  e t  a l . , 1 9 8 9  I n n i s  et a l . , 1 9 9 0 ) .  
I n o r g a n i c  e x t r a c t i o n  p r o c e d u r e s  h a v e  u s e d  e x c e s s  s a l t s  an d  
p r o t e i n a s e  K  d i g e s t i o n .  A l t h o u g h  t h e s e  m e t h o d s  ar e  
s u c c e s s f u l  i n  r e c o v e r i n g  h i g h  m o l e c u l a r  w e i g h t  D N A  f r o m  
l a r g e  s t a r t i n g  v o l u m e s , t h e y  i n c l u d e  s e v e r a l  s t e p s  a n d  m a y  
r e g u i r e  t r a n s f e r  of D N A  e x t r a c t s  t o  a d d i t i o n a l  c o n t a i n e r s  
o r  w a s h i n g / d e s a l t i n g  p r o c e d u r e s  u s i n g  c o m m e r c i a l  f i l t e r s  
o r  c o l u m n s .  T h e s e  a d d i t i o n a l  s t e p s  i n c r e a s e  t h e  
o p p o r t u n i t i e s  f o r  t e c h n i c a l  h a n d l i n g  e r r o r ,  s a m p l e  c a r r y ­
o v e r  o r  t h e  i n t r o d u c t i o n  of c o n t a m i n a n t s . T h e  u s e  of 
C h e l e x  100 as a m e a n s  of i n c r e a s i n g  t h e  s i g n a l  f r o m  P C R  
a m p l i f i c a t i o n  o f  s m a l l  a m o u n t s  of D N A  r e l e a s e d  f r o m  b o l i e d  
c e l l s ,  h a s  b e e n  r e p o r t e d ,  ( W al s h e t  al., 1991) a n d  a l s o  
f o u n d  t r u e  in t h i s  s t u d y  (see F i g u r e  4 . 1 2 b ) .  T h i s  m e t h o d ,  
h a v i n g  w o r k e d  e f f i c i e n t l y  o n  v i r a l  s u p e r n a t a n t s  of k n o w n  
t i t r e ,  w a s  a p p l i e d  t o  d i a g n o s t i c  s a m p l e s .
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Comparison of PCR and VI
T h e  e v a l u a t i o n  of t h e  P C R  a s s a y  as a d i a g n o s t i c  t e s t  
u s i n g  a t e s t  s y s t e m  d e s c r i b e d  b y  B r i d s o n  (1993) r e s u l t e d  
i n  h i g h  s e n s i t i v i t y  a n d  s p e c i f i c i t y  v a l u e s  ( S e n s i t i v i t y  
92%; S p e c i f i c i t y  97%). A s  t h e  s y s t e m  a s s u m e s  t h a t  th e  
s e n s i t i v i t y  of v i r u s  i s o l a t i o n  is 1 0 0 % a f u n d a m e n t a l  f l a w  
is i n t r o d u c e d  t o  t h e  s y s t e m  a n d  d o e s  n o t  a l l o w  fo r  th e  
t e s t  b e i n g  e v a l u a t e d  to b e  b e t t e r  t h a n  t h e  t e s t  p r o c e d u r e  
u n d e r  e x a m i n a t i o n .  A s  t h e  4 s a m p l e s  p o s i t i v e  b y  P C R  b u t  
n e g a t i v e  b y  V I  (E230, E463, E 7 9 5  a n d  D703) w e r e  a l s o
p o s i t i v e  b y  FAT, it a p p e a r s  t h a t  t h i s  a s s u m p t i o n  m a y  n o t  
b e  c o r r e c t  a n d  e x p l a i n s  t h e  f a l s e  n e g a t i v e  r a t e  of 7%.
A  h i g h  c o r r e l a t i o n  w a s  f o u n d  b e t w e e n  V I  a n d  P C R  t e s t  
r e s u l t s .  T w e l v e  o u t  of 13 s a m p l e s  w h i c h  w e r e  B H V 1  p o s i t i v e  
b y  v i r u s  i s o l a t i o n  w e r e  p o s i t i v e  b y  PCR. T h e  s a m p l e  
(E830), f r o m  a n a s a l  s w a b  w h i c h  w a s  p o s i t i v e  b y  V I  w a s  
a s s u m e d  t o  c o n t a i n  i n h i b i t o r y  s u b s t a n c e s  t o  P C R  as no 
a m p l i f i c a t i o n  o c c u r r e d  in t h e  b o v i n e  IGF P C R  a s s a y  ( r es ul t  
n o t  s h o w n ) .  T h i s  s a m p l e  w a s  l a t e r  f o u n d  t o  b e  P C R  p o s i t i v e  
u s i n g  t h e  v i r u s  s u p e r n a t a n t  f r o m  t h e  f i r s t  p a s s a g e  on 
t i s s u e  c u l t u r e  as a s o u r c e  of D N A  t e m p l a t e .  T h e  p o s i t i v e  
r e s u l t  w a s  p r o b a b l y  e i t h e r  d u e  t o  m o r e  v i r u s  b e i n g  p r e s e n t  
o r  d u e  t o  t h e  d i l u t i o n  m a d e  u p o n  v i r u s  i s o l a t i o n  (1 :1 0 ). 
T h i s  d e m o n s t r a t e s  t h e  n e e d  fo r  c a u t i o n  w i t h  n e g a t i v e  
r e s u l t s  a n d  t h e  n e e d  fo r  a p p r o p r i a t e  c o n t r o l s  t o  d e t e c t  
P C R  i n h i b i t i o n .  It a l s o  g u e s t i o n s  t h e  u s e  of C h e l e x  100 in 
c e r t a i n  i n s t a n c e s  a n d  i m p l i e s  t h a t  i n  s o m e  i n s t a n c e s  a 
m o r e  c o m p l e x  p r o c e d u r e  fo r  D N A  e x t r a c t i o n  m a y  b e  n e c e s s a r y  
e.g. p h e n o l  c h o r o f o r m  e x t r a c t i o n .
F o u r  s a m p l e s  w e r e  B H V 1  p o s i t i v e  b y  P C R  b u t  n e g a t i v e  
b y  v i r u s  i s o l a t i o n .  T h e s e  w e r e  p a s s a g e d  t w i c e  m o r e  on 
t i s s u e  c u l t u r e  a n d  m o n i t o r e d  f o r  CPE. N o  s u c h  e f f e c t  w a s  
o b s e r v e d .  T w o  of t h e s e  s a m p l e s  (E463, D7 03) w e r e  a l s o  BHV1 
p o s i t i v e  o n  FAT. A l l  f o u r  s u b m i s s i o n s  (E463, D7 03 , E 2 30 
a n d  E 9 7 5 ) ) w e r e  f r o m  r e s p i r a t o r y  d i s e a s e  o u t b r e a k s  w h i c h  
r e p o r t e d  c l a s s i c a l  I B R  i n c l u d i n g  c o n j u n c t i v i t i s .  T h i s  
e v i d e n c e  s u g g e s t s  t h a t  p o s i t i v e  d i a g n o s i s  b y  P C R  w a s  
c o r r e c t  a n d  n o t  d u e  t o  s p o r a d i c  c r o s s - c o n t a m i n a t i o n  d u r i n g
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t h e  p r e - P C R  p r e p a r a t i o n .  T h e  f a i l u r e  of V I  t o  d e t e c t  v i r u s  
i n  t h e s e  t w o  s a m p l e s  m a y  b e  e x p l a i n e d  b y  t h e  n a t u r e  of 
t h e s e  s u b m i s s i o n s .  B o t h  w e r e  s u b m i t t e d  as s w a b s  a n d  it is 
r e g o g n i s e d  t h a t  s u c h  s a m p l e s  t a k e n  b y  p r a c t i t i o n e r s  m a y  
n o t  a r r i v e  a t  t h e  l a b o r a t o r y  u n t i l  2 - 3  d a y s  a f t e r  
s a m p l i n g  a n d  m a y  h a v e  d r i e d  o u t  a n d  as a r e s u l t  v i r u s  m a y  
b e  n o t  b e  v i a b l e  a n d  t h e r e f o r e  u n s u i t a b l e  f o r  t e s t i n g  b y  
VI. T h i s  h i g h l i g h t s  o n e  a d v a n t a g e  of PCR, w h i c h ,  u n l i k e  
v i r u s  i s o l a t i o n ,  d o e s  n o t  d e p e n d  o n  l i v e  v i r u s  b u t  o n  t h e  
p r e s e n c e  of i n t a c t  t a r g e t  n u c l e i c  acid . D e f i n i t i v e  
c o n f i r m a t i o n  of t h e s e  p o s i t i v e s  s a m p l e s  c o u l d  b e  m a d e  o n l y  
b y  s e r o l o g i c a l  e x a m i n a t i o n  of t h e  i n f e c t e d  c a t t l e  a n d  a 
d e m o n s t r a b l e  r i s e  in B H V 1  a n t i b o d y  t i t r e . U n f o r t u n a t e l y ,  
d u e  t o  t h e  n a t u r e  of t h e  s o u r c e  of d i a g n o s t i c  s u b m i s s i o n s  
t h i s  w a s  n o t  p o s s i b l e .
C o m p a r i s o n  o f  P C R  a n d  F A T
P r o b l e m s  a s s o c i a t e d  w i t h  p o o r  q u a l i t y  s l i d e  
p r e p a r a t i o n s  s u c h  as l a c k  of s u f f i c i e n t  c e l l  n u m b e r s  for 
m i c r o s c o p i c  e x a m i n a t i o n  a n d  p o o r  d r y i n g  o r  f i x i n g  
p r o c e d u r e s  m a y  h a m p e r  t h e  e f f i c i e n t  d e t e c t i o n  of B H V 1  
a n t i g e n  b y  FAT. A  t o t a l  of 6 s a m p l e s  w e r e  c o n s i d e r e d  
u n s u i t a b l e  f o r  t e s t i n g  in  t h i s  st ud y. H o w e v e r  w h e n  t h e s e  
s a m p l e s  w e r e  e x c l u d e d  f r o m  t h e  st udy, 10 s a m p l e s  w e r e  
p o s i t i v e  b y  F A T  (one m o r e  t h a n  VI) i n d i c a t i n g  t h a t  w h e n  
g o o d  q u a l i t y  s a m p l e s  a r e  s u b m i t t e d  t h e  F A T  is a r a p i d  a n d  
s e n s i t i v e  te st . T h r e e  s a m p l e s ,  E 1 4 0  ( o c u l a r  sw a b ) ,  H 8 
(tis sue) a n d  H 2 7  4 ( s w a b s / s l i d e s )  w e r e  d e t e c t e d  as p o s i t i v e  
b y  P C R  b u t  n e g a t i v e  b y  FAT. A l l  w e r e  a l s o  p o s i t i v e  b y  VI 
s u p p o r t i n g  t h e  P C R  d i a g n o s i s .  In a d d i t i o n ,  t h e  s o u r c e  of 
E 1 4 0  w a s  f r o m  o c u l a r  s e c r e t i o n s .  C o n j u n c t i v i t i s  w i t h  
r e s p i r a t o r y  d i s e a s e  s i g n s  is h i g h l y  s u g g e s t i v e  of 
i n f e c t i o n  b y  B H V 1 . H 8 w a s  f o u n d  n e g a t i v e  o n  e x a m i n a t i o n  b y  
t h e  a u t h o r .  T h i s  m a y  h a v e  b e e n  d e e m e d  p o s i t i v e  h a d  a m o r e  
e x p e r i e n c e d  r e a d e r  e x a m i n e d  t h e  s l i d e s  a n d  e m p h a s i s e s  t h e  
n e e d  f o r  s k i l l e d  a n d  e x p e r i e n c e d  t e c h n i c i a n s  w h e n  u s i n g  a 
F A T  as a d i a g n o s t i c  test . H2 7  4 w a s  s u b m i t t e d  as a s l i d e  
w i t h  c o r r e s p o n d i n g  s w a b s  w h i c h  w e r e  t e s t e d  b y  P C R  a n d
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v i r u s  i s o l a t i o n .  S w a b s  w e r e  u s u a l l y  p o o l e d  t o g e t h e r  a n d  
t h e r e f o r e  c o n t a i n e d  s a m p l e s  f r o m  a n u m b e r  of s i c k  a n i m a l s . 
T h e  s l i d e  t e s t e d  b y  FAT, a l t h o u g h  t a k e n  f r o m  t h e  s a m e 
h e r d ,  m a y  o n l y  r e p r e s e n t  o n e  s i c k  a n i m a l .  T h i s  a n i m a l ,  
d e p e n d i n g  o n  t h e  s t a g e  of i n f e c t i o n  m a y  n o t  h a v e  b e e n  
s h e d d i n g  v i r u s  a n d  t h e r e f o r e  n o t  b e  r e p r e s e n t a t i v e  of the 
h e r d .
A  t o t a l  of 3 s a m p l e s ,  E4 65 , E 4 6 7  (s l i d e s / s w a b s ) a n d  
H 4 9 9  ( t i s s u e ) , w e r e  d i a g n o s e d  as B H V 1  p o s i t i v e  b y  F A T  
o n ly . A g a i n  i d e a l l y  a c o n f i r m a t i o n  of a l l  r e s u l t s  c o u l d  be 
m a d e  b y  t h e  e x a m i n a t i o n  of t h e  s e r u m  a n t i b o d i e s  l e v e l s  of 
t h e  a n i m a l s .  A s  E 4 6 5  a n d  E 4 6 7  w e r e  s w a b s  v i r u s  m a y  no t  
h a v e  b e e n  v i a b l e  o r  t h e r e  m a y  s i m p l y  h a v e  b e e n  n o  v i r u s  
p r e s e n t  o n  t h e  s w a b  t h u s  e x p l a i n i n g  t h e  n e g a t i v e  r e s u l t  b y  
V I  a n d  P C R .
P C R  c o n t r o l s  u s i n g  p r i m e r s  t h a t  a m p l i f y  g e n e  
s e q u e n c e s  f r o m  t h e  IGF g e n e  w e r e  p e r f o r m e d  o n  a l l  n e g a t i v e  
s a m p l e s .  T h e  n e e d  t o  p e r f o r m  s e p a r a t e  P C R  a s s a y s  o n  e a c h  
s a m p l e  w o u l d  b e  l a b o r i o u s  o n  a r o u t i n e  b a s i s . A t t e m p t s  to 
o p t i m i s e  b o t h  P C R  a s s a y s  i n  t h e  s a m e  t u b e  f a i l e d  (r es u l t s  
n o t  s h ow n)  as c o n d i t i o n s  f o r  t h e  a m p l i f i c a t i o n  of b o t h  D N A  
f r a g m e n t s  w a s  n o t  p o s s i b l e ,  s e e m i n g l y  d u e  to  t h e  d i v e r g i n g  
r e q u i r e m e n t s  of r e a c t i o n  c o m p o n e n t s .
T h i s  P C R  a s s a y  m a y  b e  c o m p a r e d  t o  o n e  o t h e r  r e p o r t e d  
a s s a y  f o r  t h e  d e t e c t i o n  of B H V l  i n  n a s a l  s w a b s  ( V i l e c k  et 
al., 19 94 ).  ( O t h e r  r e p o r t s  b y  Y a s o n  e t  a l ., 1994, K i b e n g e  
e t  a l , . 1 9 9 4 ,  w h i c h  d e s c r i b e  t h e  d e t e c t i o n  of B H V l  in 
s u p e r n a t a n t s  f r o m  t i s s u e  c u l t u r e  v i r u s  i n f e c t e d  c e l l s  (Van 
E n g e l e n b u r g  e t  al., 1 9 93 a n d  V i l e c k  e t  al., 1992) 
d e s c r i b e d  a P C R  a s s a y  t o  d e t e c t  B H V l  i n  s e m e n  s a mp le s ) .  
T h e  P C R  a s s a y  r e p o r t e d  b y  V i l e c k  e t  al. (1994) s h o w e d  a 
g o o d  c o r r e l a t i o n  b e t w e e n  v i r u s  i s o l a t i o n  a n d  P C R  o n  n a s a l  
s w a b s  t a k e n  f r o m  c a t t l e  t h a t  h a d  b e e n  a r t i f i c i a l l y  
i n f e c t e d .  H o w e v e r ,  t h i s  c o r r e l a t i o n  o n l y  o c c u r r e d  w h e n  
s a m p l e s  w e r e  d i l u t e d  5 0 - 1 0 0  f o l d  b e f o r e  a d d i t i o n  t o  th e  
P C R  a s s a y .  It w a s  c o n c l u d e d  t h a t  t h i s  w a s  d u e  t o  th e  
p r e s e n c e  of i n h i b i t o r y  s u b s t a n c e s  i n  t h e  n a s a l  s e c r e t i o n s . 
U s i n g  t h e  C h e l e x  m e t h o d  a n y  s u c h  i n h i b i t o r s  c o u l d  be
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d i l u t e d  out. F o r  t h i s  r e a s o n  a m e t h o d  of D N A  p r e p a r a t i o n  
c o m p a r e s  m o r e  f a v o u r a b l y  t o  t h e  p r o t e i n a s e  
K / p h e n o l / c h l o r o f o r m ,  D N A  p r e c i p i t a t i o n  m e t h o d  e m p l o y e d  b y  
V i l e c k  e t  al. (1994) i n  t e r m s  of s p e e d  a n d  t h e  r e d u c e d  
l i k e l i h o o d  of c r o s s  c o n t a m i n a t i o n .  T w o  o t h e r  s t u d i e s  
r e p o r t i n g  t h e  d e v e l o p m e n t  of P C R  as a d i a g n o s t i c  t e s t  
( K i b e n g e  e t  al., 1994 a n d  Y a s o n  e t  a l ., 1994) h a v e
c o m p a r e d  p h e n o l :c h l o r o f o r m  e x t r a c t i o n  to a c o m m e r c i a l l y  
a v a i l a b l e  k i t  ( G e n e R e l e a s e r ; A m e r s h a m  C o r p o r a t i o n )  f o r  D N A  
p r e p a r a t i o n  f r o m  B H V 1  s u p e r n a t a n t s . B o t h  r e p o r t e d  t h e  k i t  
t o  g r e a t l y  i n c r e a s e  t h e  s e n s i t i v i t y  of t h e  P C R  assay. 
D e t a i l s  of t h e  e x a c t  c o m p o n e n t s  of t h e  k i t  a r e  n o t  m a d e  
a v a i l a b l e  b u t  a c c o r d i n g  t o  t h e  m a n u f a c t u r e r ,  th e  
G e n e R e l e a s e r  f a c i l i t a t e s  t h e  r e l e a s e  of v i r a l  D N A  b y
i n c u b a t i o n  of s a m p l e  w i t h  a D N A  r e l e a s i n g  c o c k t a i l  at 
1 0 0 ° C  f o r  8 - 1 0  m i n ,  a f t e r  w h i c h  t i m e  t h e  s a m p l e  is
s u i t a b l e  f o r  a m p l i f i c a t i o n .  T h e  p r o c e d u r e  i n v o l v e s  th e  
r e m o v a l  of a m p l i f i c a t i o n  i n h i b i t o r s  b y  s e q u e s t e r i n g  i o ns 
i n v o l v e d  i n  D N A  d a m a g e .  T h e  p r i n c i p l e  of t h i s  m e t h o d  is 
s i m i l a r  t o  t h a t  of t h e  C h e l e x  100 m e t h o d  u s e d  i n  t h is 
st udy. T h e  u s e  of t h e  C h e l e x  m e t h o d  h a s  a n  o b v i o u s  
a d v a n t a g e  i n  t h e  d i a g n o s t i c  l a b o r a t o r y  of b e i n g  m u c h
c h e a p e r  t h a n  p u r c h a s i n g  a c o m m e r c i a l  kit.
In c o n c l u s i o n ,  f r o m  t h i s  s t u d y  t h e  P C R  a s s a y  
d e s c r i b e d  h e r e  o f f e r s  a r e l i a b l e  m e a n s  of r a p i d  d e t e c t i o n  
of B H V 1  i n  d i a g n o s t i c  s a m p l e s  w h i c h  is m o r e  i n d e p e n d e n t  of 
s a m p l e  q u a l i t y  t h a n  t h e  F A T  a n d  f a s t e r  t h a n  V I  a n d  
t h e r e f o r e  c a n  b e  u s e d  as a r a p i d  d i a g n o s t i c  t e s t  to
p r o d u c e  r e s u l t s  w h i c h  w i l l  i n f l u e n c e  t h e  c o n t r o l  m e a s u r e s  
a d o p t e d  in t h e  f a c e  of a n  o u t b r e a k  of I B R - a s s o c i a t e d  
r e s p i r a t o r y  d i s e a s e .
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5.4 THE DETECTION OF BHV1 IN BOVINE SEMEN
T h e  u s e  of a r t i f i c i a l  i n s e m i n a t i o n  (AI) in c a t t l e  
s i n c e  t h e  1 9 3 0 s  h a s  f a c i l i t a t e d  t h e  w i d e s p r e a d  
d i s s e m i n a t i o n  of d e s i r e d  g e n e t i c  c h a r a c t e r i s t i c s  a n d  t h e  
c o n t r o l  of s e x u a l l y  t r a n s m i t t e d  d i s e a s e s  ( A f s h a r  et al., 
19 9 0 ) .  U n f o r t u n a t e l y  e v e n  A I  p o s e s  s o m e  r i s k s  for t h e  
t r a n s m i s s i o n  of b o v i n e  p a t h o g e n s ,  e s p e c i a l l y  v i r u s e s .
B H V 1  is c o n s i d e r e d  t o  b e  t h e  m o s t  c o m m o n  v i r a l  
p a t h o g e n  f o u n d  i n  b o v i n e  s e m e n  ( A f s h a r  e t  al., 1990) a n d  
c a n  b e  w i d e l y  t r a n s m i t t e d  t h r o u g h  a r t i f i c i a l  i n s e m i n a t i o n  
(Ka h r s  e t  al., 1980, K u f e r s c h m i e d  et a l . , 1986, V a n
O i r c h o t  e t  a l ., 1993).
S u b c l i n i c a l  o u t b r e a k s  h a v e  b e e n  r e p o r t e d  o n  s t u d  
f a r m s  w h e r e  a l a r g e  n u m b e r  of a n i m a l s  h a v e  b e c o m e  i n f e c t e d  
y e t  n o  c l i n i c a l  d i s e a s e  s i g n s  h a v e  b e e n  r e p o r t e d  (Van 
O i r s h o t  e t  al., 19 9 3 ) .  B H V 1  i n f e c t e d  s e m e n  n o t  o n l y  
s p r e a d s  d i s e a s e  b u t  is a l s o  a s s o c i a t e d  w i t h  r e d u c e d  
f e r t i l i t y  a n d  a b n o r m a l  f o e t a l  d e v e l o p m e n t  ( S t r a u b  e t  a l ., 
1990, W y l e r  e t  a l., 1989).
I n f e c t i o n  of t h e  s e m e n  u s u a l l y  o c c u r s  d u r i n g  
e j a c u l a t i o n ,  a n d  r e s u l t s  in f r e e  v i r u s  in t h e  s e m i n a l  
p l a s m a  (K ah rs e t  a l ., 1977, S t r a u b  1991). T h e  r e a c t i v a t e d  
v i r u s  m a y  b e  r e - e x c r e t e d  f r o m  t h e  m u c o s a e  of t h e  p r e p u c e ,  
p e n i s  a n d  p o s s i b l y  t h e  d i s t a l  p a r t  of t h e  u r e t h r a  (Van 
E n g e l e n b u r g  e t  al., 1993). B H V 1  in t h e  s e m e n  m a y  be 
d e t e c t e d  f o r  l o n g  p e r i o d s  a f t e r  i n f e c t i o n ,  o n e  r e p o r t  
i n d i c a t e d  t h a t  v i r u s  c o u l d  b e  d e t e c t e d  f o r  44 d a y s  p o s t  
i n f e c t i o n  (Van E n g e l e n b u r g  e t  al., 1995). In a d d i t i o n ,  the 
r e p r o d u c t i v e  t r a c t  of t h e  m a t u r e  m a l e  is a n  
i m m u n o l o g i c a l l y  p r i v i l e g e d  s i t e  w h i c h  a l l o w s  t h e  n o r m a l  
e x p r e s s i o n  of s p e r m  a n t i g e n s  in t h e  t e s t e s  a n d  e f f e r e n t  
d u c t s  w i t h o u t  t h e  d e v e l o p m e n t  of a n t i s p e r m  a n t i b o d i e s . 
T h i s  i n h e r e n t  p r o p e r t y  m a y  a l s o  p r e d i s p o s e  t h e s e  s i t e s  to 
p e r s i s t e n t  v i r u s  i n f e c t i o n  ( L i t t l e  e t  a l ., 1991).
T h e  p o t e n t i a l  e c o n o m i c  i m p a c t  of s e m e n  c o n t a m i n a t i o n  
is e m p h a s i s e d  b y  t h e  f a c t  t h a t  a s i n g l e  e j a c u l a t e  is 
e x t e n d e d  a n d  u s e d  t o  i n s e m i n a t e  m a n y  f e m a l e s  t h e r e f o r e  
i n c r e a s i n g  t h e  c h a n c e s  of B H V 1  t r a n s m i s s i o n  n o t  o n l y  to
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t h e  f e m a l e  b u t  a l s o  t o  t h e  o f f s p r i n g .  M o r e o v e r ,  s e m e n  
p r e p a r e d  f o r  AI u s e  m a y  b e  d i s t r i b u t e d  i n t e r n a t i o n a l l y .  
V i r u s  c a n  a l s o  s u r v i v e  in s e m e n  s t o r a g e  c o n t a i n e r s  b e l o w  - 
6 5 ° C  (Drew, 1987) w h e r e  it c a n  c o n t a m i n a t e  v i r u s - f r e e  
s e m e n  (Krp at a, 1982).
In a n  a t t e m p t  t o  e l i m i n a t e  A I  as a m e a n s  of BHV1 
t r a n s m i s s i o n  w i t h i n  t h e  E u r o p e a n  U n i o n ,  t h e  d i r e c t i v e  
E U / 8 8 / 4 0 7  d e c l a r e d  t h a t  t r a d e  i n  s e m e n  w i t h i n  th e  
c o m m u n i t y  s h o u l d  b e  e i t h e r  f r o m  b u l l s  w h i c h  a r e  B H V 1  free, 
o r  t h o s e  w h i c h  a r e  s e r o n e g a t i v e  a t  e n t r y  to t h e  A I  c e n t r e  
a n d  a r e  s u b s e q u e n t l y  v a c c i n a t e d .  T h e  u s e  of s e m e n  f r o m  
s e r o p o s i t i v e  b u l l s  w h i c h  a r e  n o t  k n o w n  t o  h a v e  b e e n  
s e r o n e g a t i v e  o n  e n t r y  t o  t h e  c e n t r e ,  h a s  b e e n  p e r m i t t e d  in 
s o m e  m e m b e r  s t a t e s  p r o v i d e d  it p a s s e s  a n e g a t i v e  t i s s u e  
c u l t u r e  v i r u s  i s o l a t i o n  test.
S e r o l o g i c a l  e x a m i n a t i o n  f o r  B H V 1  a n t i b o d i e s  s h o u l d  
d e t e c t  m o s t  i n f e c t e d  b u l l s  h o w e v e r  in c e r t a i n  c a s e s  th is 
s h o u l d  n o t  b e  r e l i e d  up o n :
(I) It h a s  b e e n  p o s t u l a t e d  t h a t  c a l v e s  w i t h  p a s s i v e  
m a t e r n a l  i m m u n i t y  m a y  b e c o m e  l a t e n t l y  i n f e c t e d  w i t h  BHVl 
w i t h o u t  d e v e l o p i n g  c l i n i c a l  d i s e a s e  a n d  w i t h o u t  s h o w i n g  
s e r o l o g i c a l  r e s p o n s e  ( L e m a i r e  e t  al., 1995). S u c h  c a r r i e r s  
a r e  a p o t e n t i a l  s o u r c e  of B H V l  i n f e c t i o n ,  p a r t i c u l a r l y  to 
o t h e r  c o m r a d e s  if p r e s e n t  o n  s t u d  farms.
(II) I d e n t i f i c a t i o n  of l a t e n t  c a r r i e r s  b y  s e r o l o g i c a l  
m e a n s  m a y  n o t  b e  a p p r o p r i a t e  w h e n  e r a d i c a t i o n  p r o g r a m m e s  
( w h e n  m a r k e r  v a c c i n e s  h a v e  n o t  b e e n  u s e d )  u s i n g  
v a c c i n a t i o n  h a v e  b e e n  i m p l e m e n t e d ,  s u c h  as in c o u n t r i e s  
l i k e  H o l l a n d  a n d  F r a n c e .
(III) B u l l s  h a v e  b e e n  s h o w n  t o  s h e d  B H V l  f o r  u p  t o  si x 
w e e k s  p r i o r  t o  s e r o c o n v e r s i o n  (De G e e  et al., 1995).
T h e s e  f i n d i n g s  i n d i c a t e  t h a t  s e r o l o g i c a l  t e s t i n g  
a l o n e  m a y  n o t  b e  s u f f i c i e n t  t o  e n s u r e  B H V l - f r e e  semen. In 
t h e  a b o v e  c a s e s  s e m e n  is t e s t e d  fo r t h e  p r e s e n c e  of v i r u s  
u s i n g  t h e  f o l l o w i n g  t e c h n i q u e s .
(A) V i r u s  I s o l a t i o n .  V i r u s  I s o l a t i o n  is t h e  m o s t  
r o u t i n e l y  u s e d  t e s t  t o  d e t e c t  B H V l  in se me n ,  h o w e v e r  t h is 
t e c h n i q u e  m a y  n o t  b e  a l w a y s  p o s s i b l e  d u e  t o  t h e  n a t u r a l
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c y t o t o x i c i t y  of s e m i n a l  p l a s m a  o f t e n  m a k i n g  v i r u s  
i s o l a t i o n  d i f f i c u l t  ( S h e f f y  e t  al., 19 7 7 s , K a h r s  e t  al., 
1 9 77 ). V I  t a k e s  a t  l e a s t  s e v e n  d a y s  f o r  a r e s u l t .  T h e  
s e n s i t i v i t y  of t h e  t e s t  f o r  t h i s  p u r p o s e  is a l s o  in do u b t.  
S e m e n  is u s u a l l y  e x t e n d e d  t o  h i g h  d i l u t i o n s  b e f o r e  i t  is 
s t o r e d  i n  s t r a w s . B e c a u s e  o n l y  1 to  2 s e m e n  s t r a w s  p e r  
e j a c u l a t e  a r e  e x a m i n e d  s m a l l  a m o u n t s  of B H V 1  m a y  n o t  be 
d e t e c t e d .  In b u l l s  w i t h  s u b c l i n i c a l  B H V 1  i n f e c t i o n  v i r u s  
t i t r e s  i n  9 s t r a w s  m a y  v a r y  b e t w e e n  10 a n d  1 0 0 , 0 0 0  T C I D 50 
i n d i c a t i n g  t h a t  n o t  a l l  s t r a w s  f r o m  t h e  s a m e  e j a c u l a t e  
c o n t a i n  v i r u s ,  p a r t i c u l a r l y  w h e n  t h e  t i t r e  is l o w  (Van 
O i r c h o t  e t  al., 1993).
(B) T h e  C o r n e l l  S e m e n  T e s t  T h i s  t e s t  ( S c h u l t z  et  a l . , 
1982) m a y  a l s o  b e  u s e d  as a n  a l t e r n a t i v e .  It i n v o l v e s  t h e  
p o o l i n g  of a p p r o x i m a t e l y  1 0 0  s e m e n  s a m p l e s  f o l l o w e d  b y  t h e  
i n o c u l a t i o n  of s u s c e p t i b l e  c a l v e s  o r  sheep. S e r o l o g i c a l  
t e s t i n g  is t h e n  u s e d  t o  i d e n t i f y  t h e  t y p e s  of p a t h o g e n s  
t h a t  a r e  p r e s e n t  i n  t h e  se me n. T h e  C o r n e l l  t e s t  h a s  t h e  
a d v a n t a g e  of b e i n g  a b l e  to  s c r e e n  f o r  a w i d e  v a r i e t y  of 
d i f f e r e n t  v i r a l  p a t h o g e n s .  T h e s e  i n c l u d e  b o v i n e  v i r a l  
d i a r r h o e a  v i r u s  (BVDV), b l u e  t o n g u e  v i r u s  (BTV) a n d  b o v i n e  
l e u c o s i s  v i r u s  ( B L V ) . H o w e v e r  t h e  t e s t  h a s  s e v e r a l  
d i s a d v a n t a g e s .  F i r s t l y ,  o n  a s i n g l e  t e s t  it is i m p o s s i b l e  
t o  p i n p o i n t  a s i n g l e  c a r r i e r  s i n c e  u s u a l l y  m o r e  t h a n  1 0 0  
s e m e n  s a m p l e s  a r e  p o o l e d  t o g e t h e r .  S e c o n d l y ,  a n i m a l  
i s o l a t i o n  f a c i l i t i e s  a r e  r e g u i r e d  a n d  s u b s e g u e n t l y  t h e  
o v e r a l l  c o s t s  of t h i s  t e s t  a r e  high. T h i r d l y ,  
s e r o c o n v e r s i o n  of a n i m a l s  i n o c u l a t e d  w i t h  s p i k e d  s e m e n  
t a k e s  u p  t o  3 w e e k s  ( S c h u l t z  e t  a l , 1 9 8 2 ) .
T h e r e  is c l e a r l y  a n e e d  f o r  a f a s t  a n d  i n e x p e n s i v e  
d i a g n o s t i c  t e s t  f o r  t h e  d e t e c t i o n  of B H V 1  in seme n. T h e  
f o l l o w i n g  d e s c r i b e s  t h e  e v a l u a t i o n  of t h e  u s e  of P C R  as an 
a l t e r n a t i v e  t o  v i r u s  i s o l a t i o n  f o r  t h e  d e t e c t i o n  of BH V l  
i n  s p i k e d  s e m e n  s a m p l e s .
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5.6 The use of PCR for the detection of BHV1 in semen
B o v i n e  s e m e n  m a y  b e  s u b m i t t e d  t o  a l a b o r a t o r y  for 
t e s t i n g  i n  t w o  f o r m s  - r a w  o r  e x t e n d e d  se m e n .  A t  t h e  V R L  
a l l  s e m e n  s a m p l e s  r e c e i v e d  a r e  e x t e n d e d  se men. E x t e n d e d  
s e m e n  c o n t a i n s  r a w  s e m e n  a n d  a n u m b e r  of c o m p o n e n t s  s u c h  
as e g g  y o l k  a n d  a l b u m i n  w h i c h  a c t  t o  p r o t e c t ,  s t a b i l i s e  
a n d  e x t e n d  t h e  e j a c u l a t e .  T h e s e  c o m p o n e n t s  h a v e  a h i g h  
p r o t e i n  c o n t e n t  w h i c h  m a k e s  s e m e n  ( a l r e a d y  of a h i g h l y  
v i s c o u s  n a t u r e )  m o r e  d i f f i c u l t  to m a n i p u l a t e .  A  n u m b e r  of 
m e t h o d s  f o r  B H V 1  D N A  e x t r a c t i o n  f r o m  s e m e n  h a v e  a l r e a d y  
b e e n  r e p o r t e d  (Van E n g e l e n b u r g  et  al., 1993; W e i d m a n n  et 
a l ., 1993; X i a  e t  a l . , 1 9 9 5  a n d  S a n t r u d e  e t  al., 1996) m o s t  
of w h i c h  r e q u i r e d  m a n y  m a n i p u l a t i o n s . T h e  d e v e l o p m e n t  of 
a D N A  e x t r a c t i o n  p r o t o c o l  f o r  u s e  w i t h  t h e  d e v e l o p e d  P C R  
a s s a y  w a s  a p p r o a c h e d  w i t h  t h e  v i e w  to h a v i n g  t h e  s i m p l e s t  
p r o t o c o l  p o s s i b l e .  T h r e e  d i f f e r e n t  s a m p l e  p r e p a r a t i o n  
p r o t o c o l s  w e r e  e x a m i n e d  f o r  t h e  d e t e c t i o n  of B H V 1  in 
s e m e n .
T h e  p r o t o c o l s  e x a m i n e d  f o r  t h e  d e t e c t i o n  of B H V 1  i n  s e m e n  
a r e  as f o l l o w s :
(I) D i r e c t  C h e l e x  100 m e t h o d  ( v a r i a t i o n s  o n  t h i s  
m e t h o d  w e r e  i n v e s t i g a t e d )
C h e l e x  100 m e t h o d  w i t h / w i t h o u t  SDS
C h e l e x  100 m e t h o d  w i t h  a p r e c i p i t a t i o n  
s t e p .
C h e l e x  100 m e t h o d  u s i n g  SD S w i t h  
p h e n o l :c h l o r o f o r m  e x t r a c t i o n
(II) A  g u a n i d i n i u m  t h i o c y a n a t e  e x t r a c t i o n  p r o c e d u r e
(III) A  c o m m e r c i a l l y  a v a i l a b l e  D N A  e x t r a c t i o n  k i t  
(S n a p - O - S o l )
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5.6.1 Semen
S e m e n  u s e d  in t h i s  i n v e s t i g a t i o n  w a s  f r o m  a b u l l  k n o w n  to 
b e  B H V 1  f r e e  a n d  o b t a i n e d  f r o m  a s t u d  f a r m  as e x t e n d e d  
s e m e n .
5.6.2 The preparation of spiked semen
T h e  e f f i c i e n c y  of a n u m b e r  of v i r a l  D N A  e x t r a c t i o n  
t e c h n i q u e s  w a s  a s s e s s e d  b y  a d d i n g  k n o w n  d e c r e a s i n g  a m o u n t s  
of B H V 1  f r o m  1 0 5,5 t o  l0,5 T C I D 50 /50 |il t o  d u p l i c a t e  
g u a n t i t i e s  of e x t e n d e d  s e m e n .  A l l  v i r u s  d i l u t i o n s  w e r e  
m a d e  i n  M E M  5. T h e s e  w e r e  a d d e d  to 40 p.1 of e x t e n d e d
s e me n . S e m e n  w a s  t h e n  i n c u b a t e d  a t  18 °C f o r  1 h r  to 
s i m u l a t e  n a t u r a l  c o n d i t i o n s  ( K r u et z  e t  al., 1994). The 
s p i k e d  s e m e n  w a s  t h e n  c e n t r i f u g e d  a t  1 2 , 0 0 0 g  f o r  30 sec 
a n d  t h e  s e m i n a l  f l u i d  r e m o v e d .  D N A  w a s  r e c o v e r e d  f r o m  
s e m i n a l  f l u i d  u s i n g  t h e  p r o t o c o l s  o u t l i n e d  a b o v e .  Th e  
e f f i c i e n c y  of e a c h  t e c h n i q u e  w a s  d e t e r m i n e d  b y  t h e  l o w e s t  
d i l u t i o n  of s p i k e d  s e m e n  w h i c h  c o u l d  b e  d e t e c t e d  o n  PCR.
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5.4.4 DNA extraction techniques
TA BLE 5.6
E X T R A C T IO N  M E T H O D P R IN C IP L E  O F  M E T H O D
D irec t C helex M e th o d
5%  Chelex,
0.5 m g/m l p ro te in ase  K )
30 m M  D T T ,
M O D IF IC A T IO N S  O N  ABOVE
U sin g  5%  SD S
U sin g  5 %  SD S w ith  a  sod ium  ch lo ride  e th an o l/ 
p re c ip ita tio n  step .
U sin g  th e  above inc lud ing  a 
p h e n o l ch lo ro fo rm  p ro c e d u re
see  4.2.4.3.
B reaks o p en  cells to  re le ase  D N A .
C leaves d isu lph ide linkages in  po lypeptides and  
fac ilita te  p ro te in  d én a tu ra tio n .
D isru p ts  cell m em branes.
D issoc ia tes nu cle ic  ac id -p ro te in  com plexes.
S odium  ch lo ride  also  allows SDS to  rem ain  
so lub le a n d  n o t co -p rec ip ita te  w ith  the  nucleic 
acids.
R em oves excess p ro te in .
G u an id in e  th io c y an a te  ex tra c tio n  p ro c e d u re G u an id in e  th iocyana te  unfo lds an d  separates 
p ro te in s  to  th e ir  po lypep tides. P ro to co l ou tlined  
below
S nap-O -S o l (com m erc ia l DNA ex tra c tio n  k it) R ev erse  o rgan ic  ex traction . 
P ro to c o l o u tlin ed  below
T a b l e  5 . 6  s h o w s  s o m e  of t h e  D N A  e x t r a c t i o n  t e c h n i q u e s  u s e d  
t o  e x t r a c t  P C R - q u a l i t y  D N A  f r o m  B H V 1  s p i k e d  se men.
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Protocol I
P r o t o c o l  I w a s  b a s e d  o n  a m e t h o d  p r e v i o u s l y  d e s c r i b e d  b y  
W i e d m a n n  e t  al ., 19 93 . T h i s  i n v o l v e d  t h e  i n c u b a t i o n  of 
B H V l - s p i k e d  s e m e n  w i t h  f i f t y  m i c r o l i t r e s  of t h e  5% C h e l e x  
100, 3 0 m M  D T T , 0 . 5  m g / m l  p r o t e i n a s e  K. In t h i s  c a s e  a n  
a d j u s t m e n t  o f  t h i s  s o l u t i o n  t o  5% S D S  w a s  e x a m i n e d .  T h e  
e x t r a c t i o n  m i x  w a s  a d d e d  t o  50 ^ 1  B H V 1  s p i k e d  s e m i n a l  
f l u i d / e x t e n d e r .  T u b e s  w e r e  i n c u b a t e d  a t  5 5 °C f o r  2 h r  a n d  
b o i l e d  f o r  8 m i n .  S a m p l e s  w e r e  t h e n  c e n t r i f u g e d  a t  1 2 , 0 0 0 g  
f o r  3 m i n .  T e n  m i c r o l i t r e  a l i q u o t s  of t h e  t r e a t e d  s e m i n a l  
f l u i d  w e r e  u s e d  d i r e c t l y  in t h e  P C R  a s s a y .
FIGURE 5.1
THE DETECTION OF BHV1 IN SPIKED SEMEN USING A 
CHELEX 100 PROCEDURE WITH 5% SDS
300 bp
LI L2 L3 L4 L5 L6 L7 L8 L9
L a n e Is N e a t  B H V 1  v i r u s ,
L a n e 2 : S e m e n  s p i k e d  w i t h v i r u s of t i t r e io 5-5,
L a n e 3: S e m e n  s p i k e d  w i t h v i r u s of t i t r e io A-5,
L a n e 4: S e m e n  s p i k e d  w i t h  v i r u s of t i t r e io 3-5,
L a n e 5s S e m e n  s p i k e d  w i t h v i r u s of t i t r e io 2-5,
L a n e 6 : S e m e n  s p i k e d  w i t h v i r u s of t i t r e io 1-5,
L a n e 7: S e m e n  s p i k e d  w i t h v i r u s of t i t r e io 0-5,
L a n e 8 s 1 0 0  b p  l a d d e r ,
L a n e 9s n e g a t i v e  c o n t r o l  -- w a t e r ,
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F i g u r e  5 . 1  s h o w s  t h a t ,  b y  t h e  i n c l u s i o n  o f  5% S D S  i n  t h e  
e x t r a c t i o n  m i x ,  s o m e  P C R  p r o d u c t  a p p r o x i m a t i n g  t o  3 0 0  b p  
w a s  f o r m e d  i n  a l l  l a n e s .
S D S  i n  t h e  e x t r a c t i o n  m i x t u r e  h a d  t h e  e f f e c t  of 
t r a n s f o r m i n g  t h e  s e m e n  s o l u t i o n s  to a h o m o g e n e o u s  s o l u t i o n  
n o t  o b t a i n e d  w i t h  D T T  a n d  p r o t e i n a s e  K  al one. P C R  
a m p l i f i c a t i o n  of B H V 1  T K  D N A  s e g u e n c e  a p p e a r e d  t o  o c c u r  
w i t h  a b a n d  a p p r o x i m a t i n g  t o  300 b p  v i s i b l e  o n  t h e  gel. 
H o w e v e r ,  t h e  d i r e c t  u s e  of t h i s  m i x t u r e  i n  t h e  a s s a y  seems 
t o  h a v e  d i s t o r t e d  D N A  m i g r a t i o n .  T h e  p r o d u c t  o b t a i n e d  
h o w e v e r  is d i s t o r t e d  p r o b a b l y  d u e  t o  t h e  p r e s e n c e  of SDS 
in  t h e  P C R  r e a c t i o n .  T h e  p r o t o c o l  w a s  d e e m e d  to be 
u n s u i t a b l e .
P r o t o c o l  II
P r o t o c o l  II w a s  b a s e d  o n  a m e t h o d  d e s c r i b e d  b y  C h o m c z y n s k i  
a n d  S a c c h i  (1987). T h e  p r o t o c o l  i n v o l v e d  t h e  u s e  of 
g u a n i d i n e  t h i o c y a n a t e  - a s t r o n g  p r o t e i n  d e n a t u r a n t  t h a t  
c a u s e s  p r o t e i n s  t o  u n f o l d  a n d  s e p a r a t e  i n t o  t h e i r  
c o n s t i t u e n t  p o l y p e p t i d e  c h a i n s .
T h i s  w a s  f o l l o w e d  b y  p h e n o l :c h l o r o f o r m  e x t r a c t i o n  e t h a n o l  
p r e c i p i t a t i o n .
S a m p l e s  w e r e  s p i k e d  as n o r m a l  a n d  d i l u t e d  t o  200 p.1 
(50m-1 s e m i n a l  f l u i d  a n d  150 p.1 M E M  0). T h e  f o l l o w i n g  w e r e  
a d d e d  t o  e a c h  sa m p l e ,  500 |il of s o l u t i o n  D (4M  g u a n i d i n e  
t h i o c y a n a t e  25 m M  s o d i u m  c i t r a t e  p H  7.0, 0 . 5 %  s a r c o s y l ,  
0.1 M  2- m e r c a p t o e t h a n o l ), 50 |il 2M s o d i u m  a c e t a t e ,  500 (il 
b u f f e r e d  p h e n o l  (pH 7.5) a n d  100 jil c h l o r o f o r m - i s o a m y l  
a l c o h o l  a n d  t h e  m i x t u r e  l e f t  o n  ice f o r  15 m i n. F o l l o w i n g  
c e n t r i f u g a t i o n  a t  1 2 , 0 0 0  g f o r  20 m i n  t h e  a g u e o u s  p h a s e  
w a s  t r a n s f e r r e d  t o  a 1.5 m l  e p p e n d o r f  a n d  D N A  w a s  
p r e c i p i t a t e d  w i t h  500 (J.1 c o l d  i s o p r o p a n o l  a t  - 7 0 ° C  f o r  1 
hr. D N A  w a s  r e s u s p e n d e d  i n  100 (il s t e r i l e  H zO a n d  10(j.l u s e d  
p e r  P C R  as s a y .
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FIGURE 52
T H E  DE TE CT IO N O F  BHV1 IN SPIKED S E M E N  USING A  GUANIDINE THIOCYANATE 
M E T H O D  O F  D N A  EX TR AC TI ON F R O M  S E M E N
L l L2 L3 L4 L5 L6 L7 L8 L9
L a n e Is s e m e n s p i k e d  w i t h 1Q5.5 t c i d 50,
L a n e 2 s s e m e n s p i k e d  w i t h 10*. 5 t c i d 50,
L a n e 3: s e m e n s p i k e d  w i t h io 3-5 TCIDso,
L a n e 4s s e m e n s p i k e d  w i t h 1Q2.5 t c i d 50,
L a n e 5s s e m e n s p i k e d  w i t h i o 1-5 T C I D 50,
L a n e 6 : s e m e n s p i k e d  w i t h 10°.5 T C I D 50,
L a n e  7 s n e g a t i v e  c o n t r o l  - p r o c e s s e d  u n s p i k e d  s a m p l e ,
L a n e  8 : n e g a t i v e  c o n t r o l  - w a t e r ,
L a n e  9: 0. 5  u g  l O O b p  l a d d e r .  u s i n g  t h e  c o n t r o l  IG F
p r i m e r s .
F i g u r e  5 . 2  s h o w s  t h a t ,  u s i n g  t h i s  e x t r a c t i o n ,  t h e  P C R  
a s s a y  h a d  a s e n s i t i v i t y  o f  1 0 3'5 T C I D 30 ( s e e  l a n e  2). T h e  
v o l u m e  a d d e d  t o  t h e  P C R  a s s a y  m a d e  a  f u r t h e r  1 : 1 0  
d i l u t i o n .
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P R O T O C O L  III.
T h e  p r o t o c o l  of t h i s  c o m m e r c i a l  k i t  w a s  b a s e d  on  a 
r e v e r s e  o r g a n i c  e x t r a c t i o n  o r i g i n a l l y  d e s c r i b e d  b y  
M a j u m d a r  et a l . ( 1 9 9 1 ) .  T h e  k i t  p e r m i t t e d  fo r t h e  
s i m u l t a n e o u s  a n d  r a p i d  e x t r a c t i o n  of b o t h  D N A  a n d  R N A  
b a s e d  o n  t h e  p r i n c i p l e  t h a t  i n  a p h e n o l i c  l y s a t e  o n l y  R N A  
r e m a i n s  i n  t h e  a q u e o u s  p h a s e  if t h e  p h  is a c i d i c  w h i l e  
b o t h  R N A  a n d  D N A  a r e  i n  t h e  a q u e o u s  p h a s e  if t h e  p H  is 
a l k a l i n e .  F o l l o w i n g  t h e  r e m o v a l  of R N A  b y  t h e  s e p a r a t i o n  
o f  t h e  a q u e o u s  a n d  o r g a n i c  p h a s e s  D N A  w a s  e x t r a c t e d  f r o m  
t h e  i n t e r p h a s e  a n d  o r g a n i c  p h a s e  b y  c h a n g i n g  t h e  p H  f r o m  
a c i d i c  t o  a l k a l i n e  b y  r e v e r s e  e x t r a c t i o n  w i t h  h i g h l y  
a l k a l i n e  t r i s .
S e v e n  h u n d r e d  m i c r o l i t r e s  of i c e  c o l d  s o l u t i o n  1 
l y s i s  r e a g e n t  (5% t r i t o n  X, 100 m M  E D T A  - M a j u m d a r  et al. 
(1991) w a s  a d d e d  t o  200 p.1 c o l d  s p i k e d  s e m i n a l  f l u i d  a n d  
m i x e d  u s i n g  a v o r t e x  f o r  10 sec. S a m p l e s  w e r e  t h e n  l e f t  o n  
i c e  f o r  5 m i n. T w o  h u n d r e d  m i c r o l i t r e s  of c o l d  
c h l o r o f o r m : i s o a m y l  a l c o h o l  (24:1) w a s  a d d e d  a n d  m i x e d  for 
10 sec. T u b e s  w e r e  p l a c e d  o n  i c e  f o r  5 m i n  a n d  m i x e d  a g a i n  
a n d  c e n t r i f u g e d  a t  1 2 , 0 0 0  g a t  4° C  f o r  15 m i n. T o  t h e  
o r g a n i c  l a y e r  250 (il of s o l u t i o n  4 r e v e r s e  e x t r a c t i o n  
r e a g e n t  (1 M  u n c a l i b r a t e d  T r i s  b a s e  e x t r a c t e d  t w i c e  - 
M a j u m d a r  e t  al., 1991) w a s  a d d e d  a n d  m i x e d  g e n t l y  fo r  3 
m i n  a n d  c e n t r i f u g e d  a t  1 3 , 0 0 0  r p m  f o r  15 mi n. T h e  a q u e o u s  
p h a s e  w a s  t r a n s f e r r e d  t o  a n e w  tu be . T h e  r e v e r s e  
e x t r a c t i o n  of t h e  o r g a n i c  p h a s e  w a s  r e p e a t e d  a n d  t h e  
a q u e o u s  p h a s e  t r a n s f e r r e d  to a n o t h e r  tube. D N A  w a s  
e x t r a c t e d  w i t h  a n  e q u a l  v o l u m e  of c o l d  c h l o r o f o r m : i s o a m y l  
a l c o h o l  (24:1) a n d  e t h a n o l  u s i n g  p r e c i p i t a t e d .  T h e  p e l l e t  
w a s  t h e n  r e s u s p e n d e d  in  a v o l u m e  e q u a l  t o  t h e  o r i g i n a l  
v o l u m e  of s e m i n a l  fl ui d.
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FIGURE 53
T H E  DETECTION O F  BHV1 IN SPIKED S E M E N  USING A  SNAP-O-SOL 
NUCLEIC ACID EX TR AC TION KIT
300 bp
LI L 2 L 3 L 4 L 5 L 6 L 7 L 8 L 9
L a n e  Is s e m e n  s p i k e d  w i t h  1 0 5-5 T C I D so/ 5 0 n l ,
L a n e  2: s e m e n  s p i k e d  w i t h  1 0 4,5 T C I D 5O/ 5 0 n l ,
L a n e  3: s e m e n  s p i k e d  w i t h  1 0 3,5 T C I D 5o/ 5 0 n l ,
L a n e  4: s e m e n  s p i k e d  w i t h  1 0 2-5 T C I D 50 / 50pil,
L a n e  5: s e m e n  s p i k e d  w i t h  1 0 1,5 T C I D 50 / 50|il,
L a n e  6 : s e m e n  s p i k e d  w i t h  1 0 0,5 T C I D 5o/ 5 0 n l ,
L a n e  7s n e g a t i v e  c o n t r o l  - p r o c e s s e d  u n s p i k e d  sa m p l e ,
L a n e  8 : n e g a t i v e  c o n t r o l  - w a t e r ,
L a n e  9: 0. 5  jag l O O b p  l a d d e r .
F i g u r e  5 . 3  s h o w s  t h e  r e s u l t s  o f  P C R  o n  D N A  e x t r a c t e d  u s i n g  
S n a p - O - S o l  e x t r a c t i o n  k i t  f r o m  s e m i n a l  f l u i d  s p i k e d  w i t h  
B H V 1  . A m p l i f i c a t i o n  o f  B H V 1  T K  g e n e  c a n  b e  s e e n  i n  l a n e s  
1 - 4  c o r r e s p o n d i n g  t o  a s e n s i t i v i t y  o f  1 0 2m5 T C I D 50/50\il.
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T a k i n g  i n t o  a c c o u n t  t h e  Is 10 d i l u t i o n  t h i s  e x t r a c t i o n  
p r o c e d u r e  r e s u l t s  i n  a s e n s i t i v i t y  of l e s s  t h a n  1 0 1,5 T C I D 50 
e g u a l  t o  t h a t  o n  v i r u s  i n f e c t e d  s u p e r n a t a n t .  T h i s  w a s  t h e  
m o s t  e f f i c i e n t  o f  t h e  e x t r a c t i o n  p r o c e d u r e s  i n v e s t i g a t e d  
a n d  w a s  a d o p t e d  f o r  t h e  d e t e c t i o n  of B H V l  i n  semen. 
S i m i l a r  s e n s i t i v i t y  w a s  f o u n d  w h e n  t h e  a b o v e  p r o c e d u r e  w a s  
r e p e a t e d  u s i n g  r a w  s e m e n  ( R e s u l t  n o t  s h o w n ) .
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5.5 RESULTS
TABLE 5.7
S U M M A R Y  O F  T H E  PR OC ED UR ES F O R  T H E  EXTRACTION O F  BHV1 D N A  F R O M  
SPIKED S E M E N  SAMPLES
EXTRACTION
M E T H O D RESULT
SUITABILITY 
O N  ROUTINE BASIS
(I) D ire c t C helex  100 M e th o d
(5%  C helex  100, 30 m M  D T T , 
0.5 m g/m l p ro te in ase  K)
N o am plifica tion  
o f B H V 1  sp iked  
sem en
U n su itab le
C helex  100 m e th o d  using  SDS 
(A ) w ith
A m plification  of B H V 1 T K  
seq u en ce
H ow ever p ro d u c t d is to rte d
N o t su itab le  
S ee F ig u re  5.1
(B) w ithou t a n  e th an o l 
p rec ip ita tio n  step .
N o am plification
N o t su itab le
C helex  100 m e th o d  u sing  SDS 
w ith  pheno l: ch lo ro fo rm  
ex trac tion
A m plification  o f  B H V 1 T K  
seq u en ce
H ow ever resu lts  w ere  
inconsisten t
N o t su itab le
m
G u an id in e  th iocyana te  
ex trac tion  p ro c e d u re
A m plification  of B H V 1 T K  
seq u en ce
Sensitivity o f  th e  m e th o d  is 103 
T C ID 50
S uitab le  
S ee F ig u re  5.2
(HI)
S nap-O -S o l (co m m erc ia l D N A  
ex trac tio n  kit)
A m plification  o f B H V 1 T K
seq u en ce
Sensitivity o f th e  m e th o d  is 101 
T C ID 50
S uitab le  
S ee  F ig u re  5.3
F r o m  T a b l e  5 . 7  i t  c a n  b e  s e e n  t h a t  t h e  m o s t  s e n s i t i v e  a n d  
r e p r o d u c i b l e  m e a n s  o f  D N A  e x t r a c t i o n  f r o m  s p i k e d  s e m e n  i s  
p r o t o c o l  I I I -  t h e  S n a p - O - S o l  m e t h o d .
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5.6 DISCUSSION: PCR as a detection method for BHV1 in
semen
S e r o l o g i c a l  t e s t i n g  f o r  t h e  p r e s e n c e  of B H V 1  
a n t i b o d i e s  is a r e l i a b l e  m e t h o d  f o r  t h e  d e t e c t i o n  of b u l l s  
i n f e c t e d  w i t h  B H V 1  a n d  is a t  p r e s e n t  a c c e p t a b l e  f o r  th is 
p u r p o s e  u n d e r  t h e  E U  d i r e c t i v e  4 0 7 / 8 8 / E C .  H o w e v e r  t h e r e  
a r e  s o m e  s i t u a t i o n s  w h e r e  it m a y  n o t  a l w a y s  b e  d e p e n d e d  on 
as d e s c r i b e d  in  s e c t i o n  5.5. In s u c h  c a s e s  t h e  s e m e n  f r o m  
t h e s e  b u l l s  m u s t  b e  t e s t e d  f o r  t h e  p r e s e n c e  of B H V 1  vi r u s .  
P C R  a s s a y s  h a v e  r e c e n t l y  b e c o m e  w i d e l y  u s e d  fo r t h e  
d e t e c t i o n  of B H V 1  i n  s e m e n  of P C R  a s s a y s  (Vil ce k, et al., 
1 9 9 4 : ,  W e i d m a n n  e t  a l ., 1993: V a n  E n g e l e n b u r g  et  a l .,
19 9 3 : ,  Y a s o n  e t  a l . , 19 95 a n d  m o s t  r e c e n t l y  S a n t u r d e  et 
al., 199 6 a n d  M a s a r i  e t  al., 1996). A l l  h a v e  r e p o r t e d  
a s s a y s  w h i c h  h a v e  s h o w n  h i g h e r  s e n s i t i v i t i e s  t h a n  
c o n v e n t i o n a l  v i r u s  i s o l a t i o n  t e c h n i q u e s . A s  a m e a n s  of 
i d e n t i f i c a t i o n  of B H V l - i n f e c t e d  s e m e n  it o f f e r s  m a n y  
a d v a n t a g e s  o v e r  t h e  C o r n e l l  S e m e n  T e s t  a n d  V I .
T h e  t e s t s  d e s c r i b e d  w e r e  p e r f o r m e d  o n  e x t e n d e d  (Tris- 
e g g  y o l k - g l y c e r o l ) a n d  r a w  s e m e n  s a m p l e s  w h i c h  w e r e
a r t i f i c i a l l y  i n f e c t e d  w i t h  B H V 1 . A r t i f i c i a l l y  i n o c u l a t e d  
s e m e n  is a g o o d  m o d e l  f o r  t h e  s i t u a t i o n  f o u n d  in n a t u r a l l y  
i n f e c t e d  s e m e n  s i n c e  n a t u r a l  i n f e c t i o n  of t h e  s e m e n  
u s u a l l y  o c c u r s  w h e n  s e m e n  p a s s e s  d o w n  t h e  m a l e  
r e p r o d u c t i v e  t r a c t  a n d  r e s u l t s  in f r e e  v i r u s  in t h e
s e m i n a l  p l a s m a  (K ahrs e t  al., 1977, S t r a u b  1991).
T h e  s a m p l e  m a n i p u l a t i o n  f o r  D N A  t e m p l a t e  p r e p a r a t i o n  
f r o m  s e m e n  d i f f e r s  t o  t h a t  of t h e  o t h e r  d i a g n o s t i c  s a m p l e s  
d i s c u s s e d  in  5.5. T h i s  is d u e  to t h e  n a t u r e  of s e m e n  w h i c h  
is h i g h l y  v i s c o u s  a n d  c o n t a i n s  t w o  c o m p o n e n t s ,  s e m i n a l  
f l u i d  a n d  s p e r m a t o z o a .  A s  a r e s u l t  s i m p l e  D N A  e x t r a c t i o n  
is d i f f i c u l t .  A l s o  s e m e n  is s u b m i t t e d  t o  t h e  l a b o r a t o r y  
as e x t e n d e d  s e m e n  i . e  in a n  e x t e n d e r  w h i c h  c o n t a i n s
a l b u m i n  a n d  e g g  y o l k  m a k i n g  a l i q u o t i n g  a n d  D N A  e x t r a c t i o n  
of s a m p l e s  e v e n  m o r e  c u m b e r s o m e .
T h e  s p e r m  h e a d  f r a c t i o n  of B H V 1  c o n t a m i n a t e d  s e m e n  
h a s  b e e n  r e p o r t e d  n o t  t o  c o n t a i n  a s u b s t a n t i a l  f r a c t i o n  of 
v i r a l  D N A  a n d  i t ' s  p r e s e n c e  h a s  b e e n  r e p o r t e d  to i n h i b i t
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P C R  (Van E n g e l e n b u r g ,  1993). A  10 f o l d  i n c r e a s e  in 
s e n s i t i v i t y  c o u l d  b e  o b t a i n e d  w h e n  a c e n t r i f u g a t i o n  s t e p  
w a s  i n c l u d e d  t o  r e m o v e  t h e  s p e r m a t o z o a  ( W i e d m a n n  et  al., 
19 93 ). T h e  i n c r e a s e  i n  s e n s i t i v i t y  w a s  a t t r i b u t e d  to  a 
d i l u t i o n  i n  i n h i b i t o r y  s u b s t a n c e s  p r e s e n t  in  t h e  semen. 
T h e r e f o r e  a s i m i l a r  a p p r o a c h  w a s  u n d e r t a k e n  i n  t h i s  s t u d y  
a n d  t h e  s p e r m  h e a d  f r a c t i o n  r e m o v e d  f o l l o w i n g  s p i k i n g  a n d  
p r i o r  t o  s a m p l e  m a n i p u l a t i o n .
A s  w a s  p r e d i c t e d  t h e  u s e  of b o i l i n g  a l o n e  w a s  n o t  
s u f f i c i e n t  f o r  D N A  p r e p a r a t i o n  f r o m  s e m i n a l  f l u i d  (W a l sh  
e t  al., 19 91 ). T h e  u s e  of d e t e r g e n t s  ( SD S  a n d  DTT) for 
c e l l  l y s i s  a n d  p r o t e i n  d é n a t u r a t i o n  of s e m e n  t o  p r e p a r e  
D N A  f o r  P C R  w a s  i n v e s t i g a t e d .  T h r e e  p r o t o c o l s  w e r e  
a t t e m p t e d  b e f o r e  a s a t i s f a c t o r y  m e t h o d  w a s  found.
T h e  f i r s t  p r o t o c o l  w a s  b a s e d  o n  a p r o t o c o l  d e s c r i b e d  
b y  W e i d m a n n  et  al., 1 9 9 3  a n d  w a s  u s e d  o n  r a w  a n d  e x t e n d e d  
s e me n .  T h i s  e m p l o y e d  t h e  C h e l e x  100 m e t h o d  u s e d  i n  c h a p t e r
5. 2  w i t h  t h e  a d d i t i o n  of p r o t e i n a s e  K  a n d  D T T  t o  b r e a k  
d o w n  t h e  a d d i t i o n a l  p r o t e i n s . T h i s  m e t h o d  f a i l e d  t o  
p r o d u c e  a m p l i f i c a t i o n  ( r e s u l ts  n o t  s h o w n ) .  A  p o s s i b l e  
r e a s o n  f o r  t h i s  w a s  t h a t  e v e n  a f t e r  t w o  h o u r s  i n c u b a t i o n  
w i t h  p r o t e i n a s e  K, a h o m o g e n e o u s  s o l u t i o n  of s e m i n a l  f l u i d  
w a s  n o t  o b t a i n e d .
A n o t h e r  r e a s o n  m a y  h a v e  b e e n  t h a t  c o m p o n e n t s  
i n h i b i t o r y  t o  t h e  P C R  a s s a y  m a y  h a v e  b e e n  p r e s e n t  in t h e  
s e m e n .  B o v i n e  s e m e n  c o n t a i n s  3.5 m M  M g C l 2 a n d  h a s  a p H  of
6.4 - 7.8. It is p o s s i b l e  t h a t  h i g h  M g C l 2 c o n c e n t r a t i o n s  in 
n e a t  b o v i n e  s e m e n  m a y  h a v e  i n h i b i t e d  t h i s  P C R  ass a y .  O t h e r  
c o m p o n e n t s  in  b o v i n e  s e m e n  s u c h  as K + a n d  C a 2+ o r  i n  t h e  
e x t e n d e r  m i g h t  a l s o  i n f l u e n c e  t h e  y i e l d  of P C R  p r o d u c t .  
A l t e r n a t i v e l y  a n  e x c e s s  of p r o t e i n  (in t h i s  c a s e  e g g  
l i p o p r o t e i n s )  m a y  i n t e r f e r e  w i t h  D N A  p o l y m e r i s a t i o n  
( S t r a t u r d e  e t  al., 199 6 ) w h i c h  i n  t u r n  m a y  h a v e  e f f e c t e d  
t h e  p r o d u c t  y i e l d .
A t t e m p t s  t o  p r e p a r e  D N A  f r o m  s e m e n  u s i n g  t h e  a b o v e  
p r o t o c o l  h a d  b e e n  r e p o r t e d  b y  W i e d m a n n  e t  al. (1993) w h o  
f o u n d  t h a t  i t  h a d  a s e n s i t i v i t y  of 5 x 1 0 3 T C I D 50 p e r  0.5 
m l  c o m p a r e d  t o  v i r u s  i s o l a t i o n  w h i c h  w a s  b e t w e e n  1 0 3 t o  1 0 4
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T C I D 50 p e r  0.5 m l  semen. T h e  d i s a d v a n t a g e  of t h a t  m e t h o d  
w a s  t h a t  o n l y  6 |al of s u p e r n a t a n t  c o u l d  b e  a d d e d  t o  th e  
C h e l e x  100 c o c k t a i l  a n d  o n l y  10 |Jil of a t o t a l  of 225 p.1 
w a s  t h e n  a d d e d  t o  t h e  PCR, t h u s  o n l y  a l l o w i n g  a v e r y  s m a l l  
p r o p o r t i o n  of s e m e n  (0.02 |il) t o  b e  t e s t e d .  T h e r e f o r e ,  th e  
T C I D 50 of i n f e c t e d  w o u l d  h a v e  to b e  a t  l e a s t  103 a s s u m i n g  
t h e  s e n s i t i v i t y  of t h e  P C R  w a s  1 T C I D 50. In t h is 
i n v e s t i g a t i o n  a t t e m p t s  w e r e  m a d e  a t  a d d i n g  t h e  g r e a t e s t  
p o s s i b l e  v o l u m e  of s e m e n  t o  t h e  P C R  a s s a y  i n  o r d e r  to 
i n c r e a s e  t h e  s e n s i t i v i t y .  T h i s  i n c r e a s e d  v o l u m e  p r o b a b l y  
a c c o u n t e d  f o r  t h e  i n c r e a s e d  s e n s i t i v i t y  w i t h  as l i t t l e  as 
1 T C I D 50 d e t e c t e d .
T h e  e f f e c t  of SDS, a p o w e r f u l  i o n i c  d e t e r g e n t ,  o n  
s e m e n  b r e a k d o w n  w a s  i n v e s t i g a t e d  b y  it s  i n c o r p o r a t i o n  i n t o  
t h e  D N A  r e l e a s i n g  c o c k t a i l .  T h i s  a p p e a r e d  t o  w o r k  a n d  a 
P C R  p r o d u c t  w a s  v i s i b l e  u s i n g  s a m p l e s  s p i k e d  a t  1 T C I D 50 
( F i g u r e  5.1). H o w e v e r  t h e  S D S  s e e m e d  t o  h a v e  a s m e a r i n g  
e f f e c t  o n  t h e  s a m p l e s  o n  g e l s  w h i c h  w a s  p r o b a b l y  d u e  to 
e x c e s s  S D S  p r e s e n t  d u r i n g  e l e c t r o p h o r e s i s .  T h e  
d i s a d v a n t a g e  of u s i n g  S D S  i n  t h e  p r e p a r a t i o n  of D N A  fo r  
P C R  is t h a t  t h e  c o n c e n t r a t i o n  of SD S  r e q u i r e d  o f t e n  h a s  an 
i n h i b i t o r y  e f f e c t  o n  PCR. A t t e m p t s  to d e c r e a s e  th e  
c o n c e n t r a t i o n  of SD S  in t h e  P C R  a s s a y  f a i l e d  t o  p r o d u c e  
P C R  p r o d u c t .  S D S  w a s  t h e n  r e m o v e d  a f t e r  p h e n o l :c h l o r o f o r m  
e x t r a c t i o n  b y  e t h a n o l  p r e c i p i t a t i o n  u s i n g  s o d i u m  c h l o r i d e .  
T h e s e  a t t e m p t s  fa i l e d .  It w a s  b e c o m i n g  o b v i o u s  a t  th is 
p o i n t  t h a t  a d i r e c t  m e t h o d  ,a l t h o u g h  f a s t  a n d  u s e r  
f r i e n d l y  w o u l d  n o t  w o r k  in t h i s  case. F a i l u r e  m a y  h a v e  
b e e n  a s s o c i a t e d  w i t h  t h e  l o s s  of D N A  t h r o u g h o u t  t h e  
m a n i p u l a t i o n  o r  p o s s i b l y  t h e  r e t e n t i o n  of s o m e  i n h i b i t o r y  
s u b s t a n c e s  i n  p r e p a r a t i o n .  A t t e m p t s  t o  r e m o v e  S D S  b y  
p h e n o l / c h l o r o f o r m  a n d  e t h a n o l  p r e c i p i t a t i o n  p r o d u c e d  
i n c o n s i s t e n t  r e s u l t s .  T h e  r e a s o n  f o r  t h i s  w a s  p r o b a b l y  
b e c a u s e  of D N A  l o ss d u r i n g  e a c h  m a n i p u l a t i o n  w i t h  loss 
b e i n g  v a r i a b l e  i n  a l l  t u b e s .
D u e  t o  t h e  l a c k  of s u c c e s s  u s i n g  t h e  s t a n d a r d  
p r o c e d u r e s  as d e s c r i b e d  a b o v e  m o r e  c o m p l e x  e x t r a c t i o n  
m e t h o d s  w e r e  a t t e m p t e d .  In o r d e r  to o v e r c o m e  t h e  p r o b l e m
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of D N A  l o s s  a t  e a c h  s t e p  s e m i n a l  f l u i d  w a s  d i l u t e d  in 
l a r g e r  q u a n t i t i e s . A  g u a n i d i n e  m e t h o d  u s i n g  a r e v e r s e  
e x t r a c t i o n  ( L i t t l e  e t  al, 1991) w a s  e x a m i n e d  a n d  th e  
m e t h o d  g a v e  i m p r o v e d  r e s u l t s  s h o w i n g  a s e n s i t i v i t y  of 
a p p r o x i m a t e l y  1 0 3 T C I D 50 ( F i g u r e  5.2). H o w e v e r  t h e  u s e  of 
a c o m m e r c i a l l y  a v a i l a b l e  S n a p - O - S o l  D N A / R N A  e x t r a c t i o n  ki t  
p r o v e d  t o  b e  t h e  m o s t  s e n s i t i v e  m e t h o d  w i t h  a d e t e c t i o n  
l e v e l  of 1 T C I D 50 w h i c h  w a s  a l m o s t  e q u a l  t o  t h a t  of the 
t e s t  o n  v i r u s  s u p e r n a t a n t  ( s e e  F i g u r e  5.3). T h e  m e t h o d  
i n v o l v e d  a r e v e r s e  e x t r a c t i o n  of D N A  f o l l o w e d  b y  D N A  
p r e c i p i t a t i o n .  O n e  p r o b a b l e  r e a s o n  w h y  t h i s  t e c h n i q u e  
w o r k e d  is b e c a u s e  of t h e  l a r g e r  d i l u t i o n  w h i c h  w a s  m a d e  
(40 |Jil of s e m e n  w a s  d i l u t e d  t o  200 |il w i t h  M E M O ,  t h i s  w a s  
t h e n  d i l u t e d  t o  950 p.1 i n  t h e  f i r s t  s t a g e  of the
e x t r a c t i o n  p r o c e d u r e )  a n d  t h e r e f o r e  a n y  l o s s e s  of D N A  
d u r i n g  o r g a n i c  e x t r a c t i o n  a n d  D N A  p r e c i p i t a t i o n  w e r e  m u c h  
less. T h e  t e c h n i q u e  a l s o  h a d  t h e  a d v a n t a g e  t h a t  s e m e n  wa s 
r e a d y  f o r  u s e  fo r  t h e  d e t e c t i o n  of o t h e r  D N A  a n d  R N A  
v i r u s e s . O n e  d r a w b a c k  of t h e  t e c h n i q u e  w a s  t h e  n u m b e r  of 
d i f f e r e n t  m a n i p u l a t i o n s  t h a t  w e r e  r e q u i r e d  t o  p r e p a r e  the 
D N A  t h u s  i n c r e a s i n g  t h e  p o s s i b i l i t y  of c r os s 
c o n t a m i n a t i o n .  T h i s  a l s o  m a d e  t h e  e x t r a c t i o n  p r o c e d u r e  
m o r e  t i m e  c o n s u m i n g  m a k i n g  t h e  t o t a l  t i m e  t o  o b t a i n  a 
r e s u l t  a t  l e a s t  t w o  d a y s .
T h e  P C R  a s s a y  u s i n g  t h e  S n a p - O - S o l  m e t h o d  c o m p a r e s  
f a v o u r a b l y  w i t h  o t h e r  m e t h o d s ,  al l  of w h i c h  r e p o r t  
s e n s i t i v i t i e s  of a p p r o x i m a t e l y  1 T C I D 50. V a r i o u s  
s e n s i t i v i t i e s  f o r  t h e  d e t e c t i o n  of B H V 1  b y  V I  h a v e  b e e n  
r e p o r t e d  i n c l u d i n g  2 0 , 0 0 0  T C I D 50 (Xia et al., 1995) 250
T C I D 50 ( M a s a r i  e t  al, 1996) w h i l e  t h a t  of t h e  C o r n e l l  S e m e n  
t e s t  h a s  b e e n  d e t e r m i n e d  t o  b e  b e t w e e n  5 x l 0 3 t o  2.5x104 
T C I D 50. T h i s  P C R  a s s a y  is as s e n s i t i v e  as a l l  t h o s e  
r e p o r t e d  t o  d a t e  e x c e p t  f o r  t h e  w o r k  of S a n t r u d e  e t  al. 
(1996) (0.1 T C I D 50) a n d  X i a  e t  al. (1995) (0.1 T C I D 50) w h o  
u s e d  a d o t - b l o t  PCR. H o w e v e r ,  t h e  D N A  e x t r a c t i o n  m e t h o d  
f o r  t h e  l a t t e r  a s s a y  w a s  t i m e  c o n s u m i n g .  T h i s  m a y  n o t  be 
p r a c t i c a l  f o r  p r o c e s s i n g  l a r g e  a m o u n t s  of s a m p l e s  for 
m o n i t o r i n g  s e m e n  b a n k s .  T h i s  P C R  a s s a y  f o r  B H V 1  d e t e c t i o n
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i n  s e m e n  w a s  s l i g h t l y  l e s s  s e n s i t i v e  ( a p p r o x i m a t e l y  1 
T C I D 50) t h a n  t h a t  d e s c r i b e d  b y  S a n t r u d e  e t  a l . (1996). T h a t  
r e p o r t  d e s c r i b e d  a C h e l e x  10 0 e x t r a c t i o n  p r o c e d u r e  the 
s i m i l a r  t o  p r o t o c o l  I i n  t h i s  study. F o l l o w i n g  s i m i l a r  
i n i t i a l  d i f f i c u l t i e s  w i t h  P C R  i n h i b i t i o n  as f o u n d  in t h i s  
s t u d y  d u e  t o  e x t e n d e d  s e me n , t h e s e  w e r e  e l i m i n a t e d  b y  th e  
u s e  of a c h r o m a t o g r a p h y  c o l u m n  S e p h a c r y l  S - 4 0 0  as a 
p r e v i o u s  s t e p  t o  D N A  e x t r a c t i o n  b y  C h e l e x  100. A  t r i a l  of 
t h i s  t e c h n i q u e  w i t h  t h e  p r e s e n t  P C R  a s s a y  is r e c o m m e n d e d  
w i t h  t h e  p r e s e n t  a s s a y  i n  o r d e r  t o  e n s u r e  m a x i m u m  
s e n s i t i v i t y  w i t h  t h i s  PCR.
U s i n g  t h e  S n a p - S o l  m e t h o d  as a m e a n s  of D N A  
p r e p a r a t i o n ,  t h e  P C R  a s s a y  m a y  b e  r e a d i l y  a p p l i e d  to 
d e t e c t  B H V 1  in semen.
A l t h o u g h  a m o r e  e x t e n s i v e  c o m p a r i s o n  m a y  b e  n e e d e d ,  
p a r t i c u l a r l y  w i t h  n a t u r a l l y  i n f e c t e d  s e m e n  s a m p l e s ,  th is 
m e t h o d  is m u c h  m o r e  s e n s i t i v e  t h a n  e x i s t i n g  t e c h n i q u e s  an d  
it s u s e  o u g h t  t o  e n s u r e  t h a t  t h e  I B R - f r e e  s t a t u s  of AI 
s t a t i o n s  i n  I r e l a n d  r e m a i n s  u n c h a n g e d .
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CHAPTER 6
INVESTIGATIONS ON THE BHV1 FIELD ISOLATE (W199)
6.1 INTRODUCTION
B H V 1  w a s  f i r s t  r e c o r d e d  as t h e  c a u s a t i v e  a g e n t  of 
s e v e r e  p h a r y n g i t i s  i n  n e o n a t a l  d a i r y  c a l v e s  i n  I r e l a n d  in 
1987 w i t h  f u r t h e r  i s o l a t i o n s  inade f r o m  s i m i l a r  c l i n i c a l  
c a s e s  i n  1 9 9 1  a n d  1992 ( L a b o r a t o r y  d a t a ) .  A l l  d i s e a s e  
o u t b r e a k s  o c c u r r e d  in t h e  S o u t h  W e s t  of I r e l a n d  a n d  al l  
w e r e  a s s o c i a t e d  w i t h  a h i g h  m o r t a l i t y  ra te . S e v e r e  
g e n e r a l i s e d  s y s t e m i c  i n f e c t i o n  i n  n e o n a t a l  c a l v e s  as a 
r e s u l t  of B H V l  i n f e c t i o n  h a d  n o t  b e e n  p r e v i o u s l y  r e c o r d e d  
i n  I r e l a n d  a n d  is d e s c r i b e d  i n  o n l y  a f e w  r e p o r t s  in th e  
e x t e n s i v e  l i t e r a t u r e  a v a i l a b l e  o n  B H V l  (Kahrs e t  a . , 1977., 
R o s s  1983; H i g g i n s  a n d  E d w a r d s ,  1986). A  h i g h l y  f a t a l  f o r m  
of I B R  h a d  b e e n  d e s c r i b e d  i n  n e o n a t a l  a n i m a l s  (K ah rs et 
al., 1977), t h e  l e s i o n s  c o n s i s t i n g  of n e c r o t i s i n g  f o c i in 
m u l t i p l e  o r g a n s  i n c l u d i n g  t h e  u p p e r  r e s p i r a t o r y  tr ac t, 
s p l e e n ,  l y m p h  n o d e  a n d  k i d n e y .  N e o n a t a l  c a l v e s  h a v e  a l s o  
b e e n  s h o w n  t o  d e v e l o p  d i s e a s e  f o l l o w i n g  i n t r a m u s c u l a r  l i ve 
B H V l  v a c c i n e  a d m i n i s t r a t i o n  ( B r y a n  et al., 1994).
P o s t  m o r t e m  e x a m i n a t i o n s  p e r f o r m e d  b y  t h e  R e g i o n a l  
V e t e r i n a r y  L a b o r a t o r y  (RVL) i n  C o r k  o n  c a l v e s  f r o m  th e  
1 9 92 o u t b r e a k  r e v e a l e d  n e c r o s i s  of t h e  p h a r y n x  a n d  th e  
l i v e r  w i t h  l e s i o n s  s i m i l a r  t o  t h o s e  i n  t h e  1987 a n d  1991 
o u t b r e a k s . T h e  p h a r y n x  w a s  c o v e r e d  w i t h  a d i p h t h e r i c  
m e m b r a n e  a n d  t h e  p h a r y n g e a l  e p i t h e l i a l  l e s i o n s  w e r e  
c o n t i n u o u s  w i t h  l e s i o n s  o n  t h e  e p i t h e l i u m  of t h e  l a r y n x  of 
t h e  s a m e  d e g r e e  of s e v e r i t y .  In c a l v e s ,  w h i c h  h a d  a 
r e l a t i v e l y  l o n g  c o u r s e  of i l l n e s s ,  t h e  l i v e r  w a s  s w o l l e n  
a n d  t h e r e  w e r e  m u l t i p l e  p i n p o i n t  y e l l o w  n e c r o t i c  f o ci 
s c a t t e r e d  t h r o u g h o u t  t h e  l i v e r  ( P o w e r  1996, p e r s o n a l  
c o m m u n i c a t i o n ) .  B H V l  ( l a b o r a t o r y  r e f e r e n c e  W 1 9 9 )  w a s  
i d e n t i f i e d  as t h e  c a u s a t i v e  a g e n t  b y  t h e  f l u o r e s c e n t  
a n t i b o d y  t e s t  (FAT) a n d  t h e  v i r u s  w a s  i s o l a t e d  f r o m  lung, 
p h a r y n x  a n d  l i v e r  t i s s u e  of t h e s e  c a l v e s .  S u b s e q u e n t  
r e s t r i c t i o n  e n d o n u c l e a s e  a n a l y s i s  of t h e  i s o l a t e  r e v e a l e d  
it t o  b e  g e n o t y p e  B H V l .1 ( C h a p t e r  3s T a b l e  3.1).
T h e r e  h a v e  b e e n  m a n y  r e p o r t s  of a r t i f i c i a l  
i n o c u l a t i o n  of c a t t l e  w i t h  B H V l  f o r  a v a r i e t y  of 
i n v e s t i g a t i v e  r e a s o n s . T h e s e  i n c l u d e  t h e  e x a m i n a t i o n  of
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t h e  v i r u l e n c e  of v a r i o u s  i s o l a t e s  ( M s o l l a  e t  al., 1983; 
E d w a r d s  e t  al., 1991), t h e  s t u d y  of t h e  v a r i a b i l i t y  in 
r e s t r i c t i o n  e n d o n u c l e a s e  a n a l y s i s  of i s o l a t e s  w h e n  t h e y  
h a v e  p a s s e d  t h r o u g h  c a t t l e  ( W h e a t s t o n e  et al., 1989; 
W h e a t s t o n e  e t  a l., 1993), s t u d i e s  of t h e  i m p a c t  of n e w  or 
r a r e  i s o l a t e s  o n  c a t t l e  (Van O i r s c h o t  e t  a l . , 1995) a n d
t h e  e v a l u a t i o n  of d i a g n o s t i c  t e c h n i q u e s  to d e t e c t  B H Vl 
f r o m  a r t i f i c i a l l y  i n f e c t e d  c a t t l e  ( V i l c e k  et  al., 1994; 
M w e e n e  e t  a l ., 1996).
In t h i s  i n v e s t i g a t i o n  c a l v e s  w e r e  i n o c u l a t e d  w i t h  
i s o l a t e  W 1 9 9  a n  a p p r o a c h  w h i c h  w a s  h o p e d  t o  a l l o w  m o r e  
p r e c i s e  a n a l y s i s  of t h e  v i r u s  i s o l a t e  (W199 i n  t e r m s  of: 
(i) t h e  v i r u l e n c e  of t h i s  B H V l  i s o l a t e  a n d  c l i n i c a l  
d i s e a s e  s i g n s  a r i s i n g  p o s t - i n f e c t i o n ,  u n d e r  a c o n t r o l l e d  
i n v e s t i g a t i o n ,  (ii) t o  m o n i t o r  t h e  s e r o l o g i c a l  a n d  
h a e m a t o l o g i c a l  r e s p o n s e  of i n f e c t e d  ca t t l e .  T h e  s t u d y  a l s o  
p e r m i t t e d  (iii) a c o m p a r i s o n  of t h r e e  m e t h o d s  (FAT, V I  a n d  
PCR) f o r  t h e  d e t e c t i o n  of B H V l  in n a s a l  s e c r e t i o n s ;  an d  
(iv) a n  e x a m i n a t i o n  of w h i t e  b l o o d  c e l l s  a n d  s e r u m  f o r  th e 
p r e s e n c e  o f  B H V l  d u r i n g  t h e  e a r l y  s t a g e s  of i n f e c t i o n  
u s i n g  P C R  a n d  v i r u s  i s o l a t i o n .
6.2 ANIMAL INOCULATION
6.2.1 Animals and accommodation used: A  t o t a l  of e l e v e n  
c a l v e s  w e r e  u s e d  in t h e  i n v e s t i g a t i o n .  A n i m a l s  r a n g e d  f r o m  
4 t o  8 m o n t h s  i n  a g e  a n d  a l l  w e r e  F r i e s i a n s  o r  F r i e s i a n  
c r o s s e s  of m i x e d  s e x e s  ( T a b le  6.3). F o u r  l o o s e  b o x e s  in 
l i n e  f a c i n g  e a s t  w e r e  u s e d  t o  h o u s e  t h e  a n i m a l s . Th e  
d i f f e r e n t  g r o u p s  of c a l v e s  w e r e  k e p t  in s t r i c t  i s o l a t i o n  
f r o m  e a c h  o t h e r  a n d  t h o r o u g h  d i s i n f e c t i o n  p r o c e d u r e s  w e r e  
m a i n t a i n e d  b y  p e r s o n n e l  p a s s i n g  b e t w e e n  t h e  p e n s  w e r e  
m a i n t a i n e d  a t  a l l  tim e s .  A l l  b o x e s  w e r e  t h e  s a m e  s i z e  w i t h  
a f l o o r  a r e a  of 9.7 6 m 2 a n d  a v o l u m e  of 2 9 . 8 9  m 2. T h e  a i r  
s p a c e  a t  t h e  d o o r  e n t r a n c e  w a s  0 . 6 2 4  m 2. T h e s e  w e r e  w i t h i n  
t h e  r e c o m m e n d e d  m e a s u r e m e n t s  (Dod d e t  al., 1992). B o x  I 
c o n t a i n e d  t w o  c a l v e s ,  w h i c h  w e r e  u n i n f e c t e d  a n d  a c t e d  as 
n e g a t i v e  c o n t r o l s ,  b o x  II, III a n d  I V  e a c h  c o n t a i n e d  t h r e e
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c a l v e s  t w o  of w h i c h  w e r e  i n o c u l a t e d  w i t h  v i r u s  a n d  th e  
o t h e r  r e m a i n e d  u n i n o c u l a t e d .  A n i m a l s  w e r e  g r o u p e d  i n  b o x e s  
as f o l l o w s  B o x  I (10, 11,) B o x  II ( 1, 2, 3>, B o x  III {4, 
5, 6 }, B o x  IV {7, 8 , 9}, T h e  b o l d  i n d i c a t e s  t h e  n u m b e r
a s s i g n e d  to t h e  s e n t i n e l  i n  e a c h  box.
6 . 2 . 2  P r e - i n f e c t i o n  t r i a l s :  A l l  c a l v e s  w e r e  p u r c h a s e d  f r o m  
a c o m m e r c i a l  farm. B l o o d  s a m p l e s  w e r e  t a k e n  f r o m  th e  
c a l v e s  o n e  m o n t h  p r i o r  to  v i r u s  i n o c u l a t i o n  a n d  a g a i n  just 
b e f o r e  i n o c u l a t i o n .  A l l  c a t t l e  w e r e  B H V 1  a n t i b o d y -  
n e g a t i v e  o n e  m o n t h  p r i o r  t o  i n f e c t i o n .  N e i t h e r  d i d  t h e y  
p o s s e s s  a n t i b o d i e s  t o  o t h e r  r e s p i r a t o r y  p a t h o g e n s  s u c h  as 
p a r a i n f l u e n z a  3 v i r u s  (PI3) n o r  r e s p i r a t o r y  s y n c y t i a l  
v i r u s  ( R S V ) . T h e  a n i m a l s  d i d  h a v e  a n t i b o d i e s  to b o v i n e  
v i r a l  d i a r r h o e a  v i r u s  (BVDV) a t  a t i t r e  of 1/8. H o w e v e r ,  
a s  e x p e c t e d  n o  a n i m a l s  w e r e  v i r a e m i c . F o r  t h e  w e e k  
p r e c e d i n g  i n f e c t i o n  a l l  t h e  a n i m a l s '  t e m p e r a t u r e s  an d  
r e s p i r a t o r y  r a t e s  w e r e  m e a s u r e d  e a c h  d a y  a t  a p p r o x i m a t e l y  
t h e  s a m e  ti me . W e i g h i n g  of a l l  c a l v e s  t o o k  p l a c e  i n  th e  
p o s t -  i n f e c t i o n  p e r i o d  u s i n g  a h y d r a u l i c  w e i g h i n g  scales.
6 . 2 . 3  F o r a g e :  A l l  c a l v e s  i n  t h e  i n v e s t i g a t i o n  r e c e i v e d  
a p p r o x i m a t e l y  1.5 k g  n u t s  (see A p p e n d i x  B) a n d  1.5 k g  h a y  
d a i l y  w h i l e  w a t e r  w a s  s u p p l i e d  o n  a n  a d - l i b  b a s i s .
6 . 2 . 4  V i r u s :  T h e  c h o s e n  B H V 1  i s o l a t e  (W199) fo r
i n o c u l a t i o n  w a s  p a s s a g e d  o n c e  o n  F B K  c e l l s  f o l l o w e d  b y  
t h r e e  p a s s a g e s  o n  M D B K  c e ll s.  S i x  c a l v e s  (two c a t t l e  p e r  
sh ed) w e r e  a r t i f i c i a l l y  i n o c u l a t e d  w i t h  8 x 1 0 6’ 3 T C I D 50 of 
B H V 1  s t r a i n  W 1 9 9 ,  (4x 1 0 6,5 T C I D 50 i n t r a n a s a l l y , 4x 1 0 6’ 3
T C I D 50 o r a l l y )  .
6.3 COLLECTION OF BIOLOGICAL SAMPLES
A  s t a n d a r d  p r o c e d u r e  w a s  a d o p t e d  f o r  c l i n i c a l  m o n i t o r i n g  
a n d  s a m p l i n g .
6 . 3 . 1  N a s a l  s a m p l i n g :  N a s a l  s a m p l e s  w e r e  c o l l e c t e d  in
d u p l i c a t e  f r o m  c a t t l e  e v e r y  d a y  u s i n g  w o o d e n  s h a f t e d
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c o t t o n  w o o l  s w a b s . S w a b s  w e r e  f u l l y  i n s e r t e d  u p  e a c h  
n o s t r i l  a n d  l e f t  t h e r e  f o r  10 sec t o  e n s u r e  t h o r o u g h  
s o a k i n g  a n d  t h e n  w i t h d r a w n .  O n e  s w a b  f r o m  e a c h  a n i m a l  w a s  
s u s p e n d e d  in 2.5 m l  M E M O .  T h e  m e d i u m  w a s  t h e n  s p l i t  i n t o  
a p p r o x i m a t e l y  1 m l  a l i q u o t s  a n d  s t o r e d  a t  - 7 0 °C t o  b e  u s e d  
i n  v i r u s  i s o l a t i o n  a n d  PCR. T h e  s e c o n d  s w a b  w a s  u s e d  to 
m a k e  s m e a r s  o n  g l a s s  s l i d e s  w h i c h  w e r e  t h e n  d r i e d ,  f i x e d  
i n  a c e t o n e  f o r  30 m i n  a n d  s t o r e d  at  4 ° C  f o r  F A T  te s t i n g .  
O n  d a y s  w h e n  t h e  a n i m a l s  w e r e  e x c r e t i n g  l a r g e  q u a n t i t i e s  
of n a s a l  d i s c h a r g e  n a s a l  s e c r e t i o n s  w e r e  o b t a i n e d  w i t h  the 
a i d  of a m e c h a n i c a l  a s p i r a t o r .
6 . 3 . 2  Blood sampling: J u g u l a r  b l o o d  s a m p l e s  w e r e  a l s o
t a k e n  d a i l y  f o r  s e r o l o g y  a n d  h a e m a t o l o g i c a l  
i n v e s t i g a t i o n s ,  V I  a n d  PCR. S e r a  w e r e  t e s t e d  a n d  t i t r a t e d  
t o  d e t e c t  a n t i b o d y  l e v e l s  u s i n g  t h e  S N T  (see 2 . 1 1 . 3 ) .  S e ra  
f r o m  c a l v e s  o n  d a y s  2-5 p o s t  i n f e c t i o n  w e r e  a l s o  e x a m i n e d  
f o r  B H V 1  b y  V I  a n d  PCR. W h i t e  b l o o d  c e l l s  w e r e  e x t r a c t e d  
f r o m  w h o l e  b l o o d  (see 2 . 1 2 . 3 )  a n d  t e s t e d  f o r  t h e  p r e s e n c e  
of v i r u s  b y  V I  a n d  PCR. T h e  f o l l o w i n g  h a e m a t o l o g i c a l
i n v e s t i g a t i o n s  w e r e  p e r f o r m e d  o n  w h o l e  b l o o d  f r o m  d a y  0 to 
d a y  9 pi: R e d  b l o o d  c e l l  (RBC) co unt, H a e m o g l o b i n  (Hb) , 
P a c k e d  c e l l  v o l u m e  (PCV), M e a n  c e l l  v o l u m e  ( M C V ) , McH, 
M c H C ,  T o t a l  w h i t e  c e l l s  (TWC), P l a t e l e t s  (Pits),
N e u t r o p h i l s  ( N eu ts), L y m p h o c y t e s  ( L ym ph s) .
6.4 CLINICAL ASSESSMENTS
E a c h  c a l f  w a s  e x a m i n e d  c l i n i c a l l y  a t  a p p r o x i m a t e l y  th e  
s a m e  t i m e  d a i l y  f o r  1 w e e k  p r i o r  to i n o c u l a t i o n ,  e v e r y  d a y  
f o r  1 2 d a y s  p o s t  i n o c u l a t i o n  (p.i.) a n d  e v e r y  s e c o n d  d a y  
u n t i l  d a y  23 pi. A n i m a l s  w e r e  i n s p e c t e d  f o r  t h e  c l i n i c a l
s i g n s  l i s t e d  i n  T a b l e  I. A  s c o r e  (as s h o w n  i n  T a b l e  I)
g r a d e d  a c c o r d i n g  t o  t h e  s e v e r i t y  of e a c h  c l i n i c a l  sign, 
w a s  a s s i g n e d  to  e a c h  c a l f  e a c h  day.
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TABLE 6.1
SCORING SYSTEM F O R  T H E  CLINICAL ASSESSMENT OF CATTLE
CLINICAL SIGN S C OR E  R A N G E  US ED W EIG HT IN G
A P A T H Y 0 - 2 5
A N O R E X I A 0 - 2 5
D I A R R H O E A 0-3 2
D Y S P N O E A 0 - 2 2
C O U G H 0 - 2 2
A D E N I T I S 0-3 2
R H I N I T I S 0 1 OJ 2
N A S A L  D I S C H A R G E 0-3 2
O C U L A R  D I S C H A R G E 0-3 2
C O N J U N C T I V I T I S 0-3 1
R E S P I R A T O R Y  R A T E < 30=0
3 0 - 3 9 = 1
4 0 - 4 9 = 2
5 0 - 5 9 = 3
P H A R Y N G I T I S
C
N1
O
3
R E C T A L  T E M P E R A T U R E 0.1 f o r  e v e r y  1° C  > 3 9 ° C 10
T a b l e  6 . 1  s h o w s  a s c o r i n g  s y s t e m  f o r  t h e  e v a l u a t i o n  o f  
c l i n i c a l  d i s e a s e  i n  i n f e c t e d  c a t t l e .
T h i s  s t r a t e g y  w a s  d e r i v e d  f r o m  t h a t  of T h o m a s  e t  al. 
(1977) a n d  E d w a r d s  e t  al. (1991) a n d  m o d i f i e d  t o  i n c l u d e  
p h a r y n g i t i s  as a c l i n i c a l  sign. In a s s e s s i n g  t h e  s c o r e s  
f o r  a p a t h y  a n d  a n o r e x i a  a k n o w l e d g e  of t h e  i n d i v i d u a l  
c a l v e s '  g e n e r a l  b e h a v i o u r  g a i n e d  d u r i n g  t h e  p r e i n o c u l a t i o n  
m o n i t o r i n g  w a s  u s e f u l .  I n f o r m a t i o n  o n  t h e  f e e d i n g  
b e h a v i o u r  a n d  a p p e t i t e  w a s  a l s o  c o l l a t e d .  A t  t h e  e n d  of 
t h e  i n t e n s i v e  m o n i t o r i n g  p e r i o d ,  t h e  r a w  c l i n i c a l  s c o r i n g  
d a t a  w e r e  t r a n s f o r m e d  t o  g i v e  a n u m e r i c a l  a s s e s s m e n t  of 
t h e  c l i n i c a l  s e v e r i t y  of t h e  d i s e a s e  in e a c h  c a l f  b y  
m u l t i p l y i n g  t h e  s c o r e  f o r  e a c h  c l i n i c a l  s i g n  b y  a 
w e i g h t i n g  f a c t o r  ( s h o w n  in T a b l e  I).
T h e  o n l y  q u a n t i t a t i v e  m e a s u r e  of t h e  c a l v e s '  c l i n i c a l  
r e s p o n s e  w a s  t h e  r e c t a l  t e m p e r a t u r e  a n d  t h e r e f o r e  i t  w a s  
c o n s i d e r e d  to b e  a n  i m p o r t a n t  i n d i c a t o r  of t h e  ca lv es ' 
g e n e r a l  w e l l  b e i n g  a n d  w a s  g i v e n  a c o n s i d e r a b l e  w e i g h t i n g
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(a s c o r e  of 1 b e i n g  a l l o w e d  t o  e v e r y  0.1 °C a b o v e  39°C). 
S c o r e s  d u e  t o  e l e v a t e d  t e m p e r a t u r e s  w e r e  p r e s e n t e d  
s e p a r a t e l y  a n d  t h e n  a d d e d  t o  t h e  t o t a l  g a i n e d  b y  a l l  th e  
o t h e r  c l i n i c a l  signs.
T h e  r e s p i r a t o r y  r a t e s  of t h e  c a l v e s  w e r e  o f t e n  
e l e v a t e d  d u r i n g  t h e  p r e i n o c u l a t i o n  p e r i o d .  In a d d i t i o n ,  
c a t t l e  i n  t h e  c o n t r o l  b o x  o f t e n  h a d  h i g h e r  r e s p i r a t o r y  
r a t e s  t h a n  t h e  i n f e c t e d  o n e s . T h e r e f o r e  t h e  c o n t r i b u t i o n  
g i v e n  t o  t h e  r e s p i r a t o r y  r a t e s  i n  t h e  o v e r a l l  c l i n i c a l  
s c o r e  w a s  v i e w e d  w i t h  c a u t i o n .  In t h e  f i n a l  t a b l e  th e 
s c o r e s  d u e  to  i n c r e a s e d  r e s p i r a t o r y  r a t e s  w e r e  p r e s e n t e d  
a f t e r  t h e  t o t a l  (Ta b l e  6.2) s c o r e s  f o r  a l l  o t h e r  c l i n i c a l  
s i g n s  as t h i s  w a s  t h e  m o s t  d i f f i c u l t  t o  a s se s s .
6.5 R E S U L T S
T h e  r e s u l t s  a r e  d i v i d e d  i n t o  f o u r  d i s t i n c t  p a r t s  as 
f o l l o w s
(I) C L I N I C A L  I N V E S T I G A T I O N S
(II) C O M P A R I S O N  O F  VI, P C R  A N D  F A T  F O R  T H E  
D E T E C T I O N  O F  B H V 1  IN T H E  F A C E  O F  A N  O U T B R E A K
(III) I M M U N E  R E S P O N S E
(IV) T H E  D E T E C T I O N  O F  B H V 1  IN W H I T E  B L O O D  C E L L S
6 . 5 . 1  C L I N I C A L  I N V E S T I G A T I O N S
6 . 5 . 1 . 1  C l i n i c a l  d i s e a s e  si g n s : A l l  a n i m a l s ,  w i t h  the 
e x c e p t i o n  of t h e  t w o  i s o l a t e d  c o n t r o l  a n i m a l s ,  d e v e l o p e d  
c l i n i c a l  s i g n s  of IBR. A l t h o u g h  t h e r e  w a s  n o  o b j e c t i v e  
e v i d e n c e  of s e v e r e  p h a r y n g i t i s ,  s o m e  a n i m a l s  s t o o d  w i t h  
s t r e t c h e d  t h r o a t s  (calf 3 o n  d a y  5 pi, c a l f  2 o n  d a y  6 pi) 
a n d  p h a r y n g e a l  l y m p h  n o d e s  w e r e  s w o l l e n  (calf 6 d a y  5 pi, 
c a l f  9 o n  d a y  6 pi) i n d i c a t i n g  l o c a l  i n f l a m m a t i o n  of t h e  
p h a r y n x .  H o w e v e r ,  t h e s e  a n i m a l s  c o n t i n u e d  t o  e a t  so 
p h a r y n g i t i s ,  if p r e s e n t ,  w a s  q u i t e  m i l d .  T h e  d i s e a s e  
p r o g r e s s i o n  f o l l o w e d  a t y p i c a l  c o u r s e  f o r  I B R  ( W y l e r  et 
al., 19 89 ).  T h e  c l i n i c a l  s i g n s  v a r i e d  b e t w e e n  c a t t l e ,  w i t h
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s o m e  a n i m a l s  d e v e l o p i n g  m o r e  s e v e r e  s i g n s  of d i s e a s e  t h a n  
o t h e r s  (see T a b l e  6.2).
T h e  g e n e r a l  p a t t e r n  h o w e v e r  w a s  as f o l l o w s ;  i n f e c t e d  
c a t t l e  b e g a n  to  s h o w  a r i s e  in t e m p e r a t u r e  2 d a y s  a f t e r  
i n f e c t i o n .  B y  d a y  3 t e m p e r a t u r e s  h a d  r e a c h e d  3 9 °C a n d  
r e m a i n e d  h i g h  u n t i l  d a y  9 (see F i g u r e  6.1). T h e  h i g h e s t  
t e m p e r a t u r e  r e c o r d e d  f o r  a n y  a n i m a l  w a s  4 0 . 5 ° C .  B y  d a y  
t h r e e  o r  f o u r  p o s t  i n f e c t i o n ,  a n i m a l s  b e g a n  t o  s e c r e t e  a 
n a s a l  d i s c h a r g e  w h i c h  i n i t i a l l y  w a s  c l e a r  b u t  u s u a l l y  
b e c o m e  p u r u l e n t  o n  d a y  8 p i  r e m a i n i n g  so t o  d a y  10 pi. 
M o s t  of t h e  c a t t l e  h a d  o c u l a r  d i s c h a r g e  o n  d a y  6 pi, th e  
a m o u n t  v a r y i n g  b e t w e e n  a n i m a l s  a n d  g e n e r a l l y  th is 
d i s c h a r g e  w a s  o n l y  p r e s e n t  f o r  1-2 d a y s  ( F i g u r e  6.3). 
R h i n i t i s  w a s  c o m m o n  i n  m o s t  a n i m a l s  i n  t h e  e a r l y  s t a g e s  of 
d i s e a s e  a n d  l a t e r  d e v e l o p e d  i n t o  u l c e r a t i v e  l e s i o n s  o n  th e  
n o s e  ( F i g u r e  6.2).
C o u g h i n g  w a s  m i l d  if a t  a l l  p r e s e n t  a n d  i n  s o m e 
c a l v e s ,  p a r t i c u l a r l y  t h e  y o u n g e r  o n e s  ( a n i m a l s  9 a n d  7) 
w h i c h  a p p e a r e d  to d e v e l o p  m o r e  s e v e r e  c l i n i c a l  signs, the 
u p p e r  r e s p i r a t o r y  c h a n g e s  w e r e  s e v e r e  e n o u g h  to i n d u c e  
v e r y  n o i s y  r e s p i r a t i o n  a k i n  to  s n o r i n g  a n d  w a s  c l a s s e d  as 
d y s p n o e a .  L i s t l e s s n e s s  a n d  a p a t h y  w e r e  i n c o n s i s t e n t  in th e  
a n i m a l s  a n d  o n l y  s o m e  a p p e a r e d  to  e x p e r i e n c e  a r e d u c e d  
a p p e t i t e .
T h e  s e n t i n e l  a n i m a l s  a l s o  s h o w e d  s i m i l a r  r e s p i r a t o r y  
d i s e a s e  s i g n s  as t h e i r  i n f e c t e d  c o m p a n i o n s .  H o w e v e r ,  t h e i r  
d i s e a s e  p a t t e r n  f o l l o w e d  t w o  d a y s  l a t e r  t h a n  t h a t  of th e 
i n o c u l a t e d  a n i m a l s ,  i n d i c a t i n g  t h a t  t r a n s m i s s i o n  f r o m  
a r t i f i c i a l l y  i n o c u l a t e d  c a t t l e  t o  t h e  u n i n o c u l a t e d  
s e n t i n e l s  t o o k  2-3 d a y s .  B y  d a y  12, w i t h  t h e  e x c e p t i o n  of 
a s l i g h t  n a s a l  d i s c h a r g e ,  a l l  c l i n i c a l  s i g n s  of d i s e a s e  
h a d  a b a t e d  i n  b o t h  d i r e c t l y  a n d  i n d i r e c t l y  i n f e c t e d  
c a l v e s .
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TABLE 6.2
CU MU LA TI VE 12 DAY CLINICAL SCORES IN CALVES INOCULATE1 
ISOLATE W199
AN I M A L
N U M B E R
CLINICAL
SIGNS
T E M P E R A T U R E  TOTA L RESPIRATION T 
RATE
1 18 37 55 39
2 61 48 99 43
3 56 21 77 39
4 18 27 45 24
5 66 27 93 45
6 49 43 84 28
7 80 47 119 2 0
8 59 24 83 38
9 1 0 2 50 152 44
10 0 0 0 31
11 0 1 1 37
94
142
116
69
138 
112
139
121
196
31
38
T a b l e  6 . 2  p r e s e n t s  t h e  c u m u l a t i v e  s c o r e  f o r  e a c h  a n i m a l  a t  
t h e  e n d  o f  t h e  m o n i t o r i n g  p e r i o d .  S e n t i n e l s  a r e  i n d i c a t e d  
i n  b o l d .
T h e  c o n t r i b u t i o n  of t e m p e r a t u r e  t o  t h e  t o t a l  c l i n i c a l  
s c o r e  f o r  e a c h  a n i m a l  w a s  l i s t e d  s e p a r a t e l y  b e c a u s e  t h i s  
w a s  t h e  m o s t  a c c u r a t e  q u a n t i f i a b l e  p a r a m e t e r  i n d i c a t i v e  of 
d i s e a s e .  T h e  c o n t r i b u t i o n  of i n c r e a s e d  r e s p i r a t i o n  w a s  
m a d e  l a s t  d u e  to t h e  d i f f i c u l t y  a n d  i n c o n s i s t e n t  r e s u l t s  
o b t a i n e d  w h i l e  m e a s u r i n g  r e s p i r a t o r y  r a te s.  T h e  o r d e r  of 
d e c r e a s i n g  c l i n i c a l  s c o r e s  r e m a i n e d  a l m o s t  t h e  s a m e  (with 
t h e  e x c e p t i o n  of t h e  i n t e r c h a n g i n g  of t h e  s e c o n d  a n d  t h i r d  
p o s i t i o n  ( a n i m a l  7 a n d  2) a n d  t h e  f i f t h  a n d  s i x t h  p o s i t i o n  
( 8  a n d  3) a f t e r  t h e  r e s p i r a t o r y  r a t e  is a c c o u n t e d  for.
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T E M P E R A T U R E  C H A N G E  IN CONTROL, INFECTED A N D  SENTINELS 
CALVES O N  DAYS 1 - 18 POST INFECTION
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F i g u r e  6.1 s h o w s  t h e  t e m p e r a t u r e  c h a n g e  p o s t  i n f e c t i o n  o f  
a l l  c a t t l e  t h r o u g h o u t  t h e  i n v e s t i g a t i o n  p e r i o d .  F i g u r e  la 
s h o w s  t h e  a v e r a g e  t e m p e r a t u r e  o f  t h e  c o n t r o l  a n i m a l s  w h e r e  
t h e r e  w a s  n o  s i g n i f i c a n t  r i s e  i n  t e m p e r a t u r e .  F i g u r e  l b  
s h o w s  t h e  a v e r a g e  t e m p e r a t u r e  o f  t h e  a r t i f i c i a l l y  i n f e c t e d  
c a t t l e  o v e r  t h e  s a m e  p e r i o d .  I t  c a n  b e  s e e n  t h a t  t h e  
a v e r a g e  t e m p e r a t u r e  r o s e  o n  d a y  3 p o s t  i n f e c t i o n  to 40. 5° C  
w h i c h  i s  i n d i c a t i v e  o f  i n f e c t i o n  a n d  f e l l  t h e r e a f t e r  
r e a c h i n g  n o r m a l  t e m p e r a t u r e s  o n  d a y  1 0  p i .  F i g u r e  l c  s h o w s  
t h e  a v e r a g e  i n c r e a s e  i n  t e m p e r a t u r e  o f  t h e  s e n t i n e l  
c a l v e s .  T h e i r  t e m p e r a t u r e  i n c r e a s e  w a s  s i m i l a r  t o  t h a t  o f  
t h e  n a t u r a l l y  i n f e c t e d  c a t t l e .  H o w e v e r  t h i s  i n c r e a s e  d i d  
n o t  t a k e  p l a c e  u n t i l  t w o  d a y s  l a t e r  s u g g e s t i n g  t h a t  t h e s e  
a n i m a l s  c o n t r a c t e d  i n f e c t i o n  f r o m  t h e  e x p e r i m e n t a l l y  
i n f e c t e d  c a t t l e .
FIGURE 6.2
F i g u r e  6 . 2  s h o w s  a n i m a l  No. 7 o n  d a y  8 p o s t  i n f e c t i o n .  
H e r p e t i c  l e s i o n s  c a n  b e  s e e n  o n  t h e  n o s e  a n d  w i t h i n  t h e  
n a s a l  p a s s a g e s .
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FIGURE 63
F i g u r e  6 . 3  s h o w s  a n i m a l  No. 7 o n  d a y  6 p o s t  i n f e c t i o n .  
O c u l a r  s e c r e t i o n s  a r e  v i s i b l e  b e l o w  t h e  l e f t  e y e  ( s e e  
a r r o w )  .
Ill
6 . 5 . 1 . 2  W E I G H T  G A I N
TABLE 63A
AN IM AL W E I G H T  GAIN 28/02 - 5/04
AN IMAL
(Sex)
DATE OF 
BIRTH
84 days PI 
W T  (Kg)
119 days PI 
W T  (Kg)
AVERAGE 
DAILY 
W T  GAIN 
(Kg)
1 ¥ 28/6/94 225 248 0.657
2 26/6/94 223 258 1.0
3 ¥ 26/5/94 220 252 0.914
4 <j* 14/7/94 179 204 0.711
5 <? 2/8/94 200 240 1.141
6 ¥ 29/7/94 163 182 0.542
7 ¥ 27/6/94 176 196 0.571
8 d1 4/8/94 169 191 0.628
9 ¥ 27/6/94 176 196 0.571
10 d> 4/6/94 240 274 0.971
11 c? 30/5/94 285 335 1.428
TABLE 63B
A V E R A G E  W E I G H T  G A I N  O V E R  A  35 D A Y  P E R I O D  P O S T  I N F E C T I O N
S e n t i n e l s 0 . 6 4 6  ± 0 . 7 0  K g / d a y
A r t i f i c i a l l y  i n f e c t e d 0 . 9 0 9  ± 0 . 23  K g / d a y
C o n t r o l 1. 1 8 8  ± 0 . 32  K g / d a y
T a b l e  6. 3 A  s h o w s  t h e  a g e  a n d  t h e  a v e r a g e  d a l l y  w e i g h t  g a i n  
o f  t h e  c a l v e s  i n  t h e  i n v e s t i g a t i o n  o v e r  a 3 5  d a y  p o s t ­
i n f e c t i o n  p e r i o d  ( D a y  8 5  - D a y  1 1 9 ) .  S e n t i n e l s  a r e
i n d i c a t e d  i n  b o l d  typ e .
U n f o r t u n a t e l y  it w a s  n o t  p o s s i b l e  t o  w e i g h  t h e  c a l v e s  
d u r i n g  t h e  i n f e c t i o n  p e r i o d  as t h e r e  w e r e  no  m e a n s  of 
d i s i n f e c t i n g  t h e  s c a l e s .  N o  c o r r e l a t i o n  c o u l d  b e  m a d e
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b e t w e e n  t h e  w e i g h t  g a i n  of e a c h  i n d i v i d u a l  c a l f  a n d  th e  
c l i n i c a l  s c o r e  a t t r i b u t e d  t o  it i n  T a b l e  6.2. T h e  a v e r a g e  
d a i l y  w e i g h t  g a i n  f o r  n o r m a l  c a l v e s  u n d e r  t h e s e  c o n d i t i o n s  
is 600 - 750 g / d a y  (Harte, 1985). T h e  a r t i f i c i a l l y
i n f e c t e d  a n d  s e n t i n e l  c a l v e s  i n  t h i s  s t u d y  g a i n e d  a b o v e  
a v e r a g e  w e i g h t  i n  t h e  t i m e  p e r i o d  e x a m i n e d .  T a b l e  6 . 3B 
c o m p a r e s  t h e  a v e r a g e  w e i g h t  g a i n  in t h e  c o n t r o l ,  s e n t i n e l  
a n d  a r t i f i c i a l l y  i n f e c t e d  c a l v e s .  T h e  c o n t r o l  a n i m a l s  h a d  
a g r e a t e r  t h a n  a v e r a g e  w e i g h t  g a i n  t h a n  t h e  a r t i f i c i a l l y  
i n f e c t e d  a n i m a l s  w h o  in t u r n  h a d  a g r e a t e r  w e i g h t  g a i n
t h a n  t h o s e  t h a t  c o n t r a c t e d  I B R  i n f e c t i o n  f r o m  t h e i r
c o l l e a g u e s .  D e s p i t e  t h e  s m a l l  n u m b e r  of a n i m a l s  i n v o l v e d  
t h e  d i f f e r e n c e  in w e i g h t  g a i n  b e t w e e n  t h e  s e n t i n e l s  a n d  
c o n t r o l s  w a s  s i g n i f i c a n t  (P > 0.05).
6 . 5 . 1 . 3  R e s t r i c t i o n  e n d o n u c l e a s e  a n a l y s i s  o f  B H V 1  (W199) 
a f t e r  p a s s a g e  i n  v i t r o  a n d  i n  v i v o
T h e  s t a b i l i t y  of t h e  B H V 1  g e n o m e  a f t e r  p a s s a g e  in c e ll
c u l t u r e  h a s  b e e n  r e p o r t e d  (M i s ra  e t  al., 1981) a l t h o u g h  
c h a n g e s  in B H V 1  g e n e  s e q u e n c e  u s i n g  R E A  f o l l o w i n g  p a s s a g e  
i n  c a t t l e  h a s  b e e n  d o c u m e n t e d  ( W h e a t s t o n e  e t  al., 1989; 
W h e a t s t o n e  e t  a l ., 19 93 ).  T h i s  s t u d y  w a s  i n i t i a t e d  in
o r d e r  to d e t e r m i n e  w h e t h e r  t h e  g e n o t y p e  of t h e  B H V1 
i s o l a t e  W 1 9 9  r e m a i n e d  c o n s t a n t  u p o n  p a s s a g e  i n  a n i m a l s  
f r o m  a n  e x p e r i m e n t a l l y  i n f e c t e d  c a l f  a n d  a n  u n i n o c u l a t e d  
c o n t a c t  s e n t i n e l  w e r e  s u b j e c t e d  to REA.
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FIGURE 6.4
REA OF  BHV1 ISOLATE W199 AFTER PASSAGE T H R O U G H  CATTLE
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6,557
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L a n e  1: H i n d  III l a m b d a  l a d d e r  ( f o r  l a d d e r  s i z e s  s e e  
F i g u r e  3.1: l a n e  1),
L a n e  2: W 1 9 9  f o l l o w i n g  p a s s a g e  o n  c  1 c u l t u r e  ( p r i o r  to 
i n o c u l a t i o n ),
L a n e  3: W 1 9  9 f o l l o w i n g  p a s s a g e  t h r o u g h  a n  e x p e r i m e n t a l l y  
i n f e c t e d  c a l f  (Calf 10: d a y  7 p i ),
L a n e  4: W 1 9 9  f o l l o w i n g  p a s s a g e  t h r o u g h  a n a t u r a l l y  
i n f e c t e d  s e n t i n e l  ( c a l f  7: d a y  5 p i ),
F i g u r e  6 . 4  s h o w s  t h a t  t h e  g e n o t y p e  o f  W 1 9 9  r e m a i n e d  t h e  
s a m e  ( B H V 1 . 1 )  f o l l o w i n g  p a s s a g e  t h r o u g h  n a t u r a l l y  a n d  
e x p e r i m e n t a l l y  i n f e c t e d  c a t t l e .
T h i s  s t u d y  s h o w s  t h a t  t h e  m i l d  c l i n i c a l  s i g n s  of 
r e s p i r a t o r y  d i s e a s e  o b s e r v e d  i n  b o t h  n a t u r a l l y  a n d  
e x p e r i m e n t a l l y  i n f e c t e d  c a t t l e  w e r e  n o t  d u e  t o  a c h a n g e  
o f  B H V 1  W 1 9 9  i s o l a t e  t o  B H V 1 . 2  w h i c h  is n o r m a l l y  
a s s o c i a t e d  w i t h  m i l d  IBR. T h i s  p r o v i d e s  e v i d e n c e  t h a t ,  in
180
d e l e t i o n s  a l o n g  t h e  g e n o m e  m a y  h a v e  o c c u r r e d .  O n l y  b y  
f u r t h e r  R E A  u s i n g  a r a n g e  of e n z y m e s  ( i n c l u d i n g  P s t  I a n d  
B a m  HI) o r  b y  t h e  g e n o m e  s e q u e n c e  a n a l y s i s  c o u l d  t h i s  b e  
d e f i n i t e l y  e l u c i d a t e d .
6 .5 . 1 . 4  D I S C U S S I O N :  c l i n i c a l  o u t c o m e  o f  t h e  i n v e s t i g a t i o n  
T h e  B H V 1  i s o l a t e  W 1 9 9  w h i c h  h a d  b e e n  p r e v i o u s l y  i s o l a t e d  
f r o m  c a l v e s  s u f f e r i n g  f r o m  p h a r y n g e a l  l e s i o n s  w a s  u s e d  to 
i n o c u l a t e  s i x  6 t o  8 m o n t h s  o l d  c a l v e s  b e t w e e n  fo r  th e  
i n v e s t i g a t i v e  p u r p o s e s  o u t l i n e d  i n  6.1. T h e  c l i n i c a l  
o u t c o m e  of t h e  e x p e r i m e n t  d i d  n o t  i n d i c a t e  e v i d e n c e  of 
s e v e r e  p h a r y n g i t i s  w h i l e  R E A  s t u d i e s  s h o w e d  t h a t  th e  
g e n o t y p e  r e m a i n e d  t h a t  of B H V 1 .1 ( a s s o c i a t e d  w i t h  m o r e  
s e v e r e  c l i n i c a l  d i s e a s e  si gn s )  f o l l o w i n g  p a s s a g e  t h r o u g h  
t h e  c a l v e s .  T h e  r e s p i r a t o r y  d i s e a s e  w h i c h  d e v e l o p e d  a f t e r  
i n o c u l a t i o n  w a s  m i l d  (the g e n e r a l  g u i d e l i n e  u s e d  in 
c h a p t e r  t h r e e  t o  d i s t i n g u i s h  s e v e r i t y  w a s  t h e  i n c i d e n c e  of 
m o r t a l i t y  i n  a n  o u t b r e a k ) .  A p a r t  f r o m  t h e  d i f f i c u l t y  of 
r e p r o d u c i n g  d i s e a s e  m a n i f e s t a t i o n s  i n  c a t t l e  u n d e r  c o n t r o l  
c o n d i t i o n s  t h e r e  m a y  b e  a n u m b e r  of r e a s o n s  w h y  a s t r a i n  
i s o l a t e d  f r o m  a n  o u t b r e a k  of s e v e r e  p h a r y n g i t i s  c a u s e d  
o n l y  m i l d  d i s e a s e  s i g n s  w h e n  i n o c u l a t e d  i n t o  a n i m a l s .
F i r s t l y ,  B H V 1  i s o l a t e s  d o  n o t  a l w a y s  c a u s e  t h e  same 
c l i n i c a l  si gn s. T h e  c l i n i c a l  d i s e a s e  m a y  d e p e n d  o n  t h e  
r o u t e  of i n f e c t i o n  (S ea l e t  al., 1985). It is p o s s i b l e  
t h a t  as a p o r t i o n  of t h i s  i n o c u l a n t  w a s  a d m i n i s t e r e d  
i n t r a n a s a l l y  it p r e d i s p o s e d  t h e  c a l v e s  t o  r e s p i r a t o r y  
d i s e a s e  (it w a s  a n t i c i p a t e d  t h a t  o r a l  a d m i n i s t r a t i o n  w o u l d  
i n c r e a s e  t h e  l i k e l i h o o d  of t h e  d e v e l o p m e n t  of 
p h a r y n g i t i s ) .  S e c o n d l y  t h e  a g e  of t h e  e x p e r i m e n t a l  a n i m a l s  
m a y  h a v e  b e e n  t o o  old: i n  t h e  o r i g i n a l  o u t b r e a k  i n f e c t e d  
a n i m a l s  w e r e  n e o n a t a l  c a l v e s ,  w h e r e a s  i n  t h i s  e x p e r i m e n t  
t h e  a n i m a l s  w e r e  b e t w e e n  6 a n d  8 m o n t h s  old. S e v e r e  
g e n e r a l i s e d  d i s e a s e  of n e o n a t a l  c a l v e s  h a s  b e e n  r e p o r t e d  
(Ka h r s  e t  al., 1977) w h i l e  o u t b r e a k s  of s i m i l a r  d i s e a s e  in 
y o u n g  c a l v e s  h a d  b e e n  r e p o r t e d  in B r i t a i n  ( H i g g i n s  et al., 
1986, R e e d  e t  al, 1 9 7 3 . ) T h e  o l d e r  c a l v e s  w o u l d  be  m o r e  
l i k e l y  t o  e x h i b i t  a g e - r e s i s t a n c e  to s e v e r e  d i s e a s e  a n d  to
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have had a better developed specific and non-specific 
immune systems and therefore ought to be more efficient at 
overcoming disease. Thirdly, the passage of the virus 
through MDBK cells three times may have reduced the 
virulence of the isolate although this is unlikely at such 
a low passage number (three passages). However, the 
reduced weight gain in the contact-infected sentinel 
animals may indicate that passage of W199 through calves 
might lead to increased virulence. Finally, an important 
link may exist between the environmental conditions and 
the development of disease. In this case cattle were 
housed in well ventilated sheds which were not overcrowded 
and were fed twice daily, and were therefore unlikely to 
have suffered any stress. This scenario would be far less 
likely to be found in found in the farms on which the 
clinical condition of pharyngitis occurred.
6.5.2 Detection of BHV1 throughout the investigation
6.5.2.1 Comparison of FAT, PCR and VI in the
detection of BHVl throughout the investigation.
Virus isolation, PCR and FAT were used to examine nasal 
swabs taken from the calves during the investigation. The 
results are presented in Table 6.4A and Table 6.4B.
The results obtained when nasal secretions taken from each 
artificially infected animals between day 2 and day 16 
were tested by VI, PCR and FAT and are listed in Table 
6.4A. The fourth row describes the presence (+) or absence 
(-) of clinical signs (above a score of 3).
The design of Table 6.4B is similar to that of table 6.4A 
and describes the detection of BHVl isolate W199 in nasal 
secretions taken from the sentinels over the same time 
period.
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The following describes the notation used in the tables 
below.
+ = BHV1 detected in sample
= BHV1 not detected in sample 
° = Slide not suitable for testing
■ = Not tested
VI Virus Isolation 
PCR Polymerase Chain Reaction 
FAT Fluorescent Antibody Test 
CDS Clinical Disease Sign
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THE DETECTION OF BHVl IN NASAL SWABS FROM ARTIFICIALLY INFECTED CALVES ON DAY 2 -  
DAY 16 P I USING V I,PC R  AND FAT AND THE PRESENCE OF CLINICAL DISEASE SIGNS ON THE SAME DAYS
DAY 2 3 4 5 6 7 8 9 10  12 14 16
ANIMAL NO.
_ + + + + + + -  - -  
i -o i t z° : : : :
+ + + + + _ _ _
+ + + + + — — — —
■ + + + + + + +
-  -  +  +  +  +  +  -
+ + + + + + -  -
+ + + + + + -  -
■  - o  +  +  - +  -  -  
+ + + + + + +
-  -  + + + + -  -
+ + + + + + -  -
■ + _ _  + + +
+ + + + + +
  + + + — — — — — —
10 PCR + + + -  + + + -  -~  ■ + + + + + +
-  +  +  +  +  +  +
-  +  +  +  +  +  -
8 PCR -  -  ■ + Î I Î Î  I I  I
p S 5
+
+
+
+
FAT ■ ■
CDS .
V I + +
PCR + —
FAT ■ H
CDS
VI +
PCR — +
FA T ■ ■+
CDS
V I _ +
PCR + —
FAT ■ ■
CDS — —
V I + t
FAT ■ ■
CDS “ —
V I — -
PCR — —
FAT
CDS
■ ■
184
TABLE 6.4B
THE DETECTION OF BHV1 IN NASAL SWABS TAKEN FROM SENTINEL CALVES DAY 2 - DAY 16 USING  
VI,PCR AND FAT USING AND THE PRESENCE OF CLINICAL DISEASE SIGNS ON THE SAME DAYS
DAY 2 3 4 5 6 7 8 9 10 12 14 16
ANIMAL NO.
V I
_ _ _ _ . + + + +
P C R - - - + + - + + + + + -
F A T ■ ■ ■ + -
_  o _  o + - - - —
C D S - - - - + + + + + - - -
VI - - - - + + + + + — — —
4 PCR _ _ + + + + + __FAT u ■ ■ + _ _ o _  o _ o _CDS + + + + + _
V I - - - + + + - + + - - -
7 P C R - - + + + + + + + - - -
FAT ■ ■ - + + _  o _  o + + + - -
C D S - - + + + + + + + + + -
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FIGURE 6.5
TOTAL POSITIVE SAMLES
1 2 3 4 5  6 7  5 9  10 12
DAYS POST INFKTION 
E888 PCR VI V //A  FAT fvVI PCR.V1.FAT
Figure 6.5 shows the total number of nasal swabs from 
artificially infected animals which were found to contain 
BHV1 by each individual method. It also shows the total 
detected by any of the three methods examined. It may be 
concluded thatf in general, PC* and VI are best employed 
between days 2 - 9  while FAT seems to best used in the
later stages of infection.
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6 . 5 . 2 . 2  DISCUSSION: The u s e  o f  PCR i n  t h e  f a c e  o f  an
o u t b r e a k
This part of the investigation compared the use of three 
diagnostic tests for the detection of BHV1 in artificially 
infected and sentinel calves. In general, using a 
combination of all three diagnostic tests, the average 
excretion period per infected animal was 8 days. There was 
some variation in excretion times between animals (Table 
6.3A and 6.3B) and this was also reflected in the number 
of days when clinical disease signs were present. Similar 
excretion periods of BHV1 from infected cattle were 
reported when a similar inoculation titre of a BHV1 
isolate was used to inoculate cattle in other such 
investigations (Vileck et al., 1994). Longer excretions 
periods (up to 21 days) were reported when animals were 
infected with virus of higher titres (108TCID5O) (Vileck et 
al., 1994; Mweene et al., 1996).
All swabs taken from the control calves were negative 
by VI, PCR and FAT indicating that the stringent measures 
taken when passing between pens were effective and no 
cross contamination arose (Data not shown in Table 6. 4A 
and 6.4B).
A total of 49/108 samples were detected as positive 
by VI (see Table 6.5). Results indicated that virus 
excretion could be detected using virus isolation for 6 - 
7 days (day 2 to day 8 post infection for those 
artificially infected) and 4 days (day 6 to day 9 for 
sentinels). Using VI, 24 samples were detected as positive 
on the first passage on tissue culture while an equal 
number were detected on the second passage. Most of those 
samples detected as positive on the first passage were 
taken on days 5 -8, while those that were positive on the 
second pass were taken on days 3, 9, 10 and 12
postinfection. Therefore although the exact titres of the 
virus in the positive samples were not determined this 
evidence suggests that virus was excreted in highest 
concentrations on days 5 - 8  post-infection. Therefore
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this time period would be the most suitable for sampling 
during a field outbreak if VI is the test in use. Samples 
submitted on the other days would be detected only after 
the second pass and therefore it would take up to two 
weeks to obtain a result.
Like other reports which compared VI and PCR for the 
detection of BHV1 in from swabs taken from artificially 
infected animals (Mweene et al., 1996; Vilcek et al.,
1994) the greatest number of positive results were 
obtained (total of 61) using PCR. This suggests that this 
is the most sensitive method of detecting BHV1 in nasal 
secretions throughout the course of an outbreak. Those 
samples positive on day 2 pi from the artificially 
infected calves were probably the inoculant while virus 
excretion probably began between day 3 and day 5 post 
infection, depending on the individual calf. PCR detected 
virus earlier in the case of 3 animals and longer in the 
case of 2 animals than VI.
However some inconsistent results were obtained by 
PCR and a total of 9 were originally negative but later 
positive when 1:10 dilutions of the original samples were 
added as template to the PCR assay. These samples had to 
be either diluted tenfold or extracted with phenol- 
chloroform before BHV1 could be detected. The source of 
this inhibition was possibly a substance in the excreted 
mucus. Mucus consists of water and carbohydrates and has 
at least two purposes in animals (i) it protects the cell 
surface from drying out by keeping the trachea and bronchi 
moist under dry environmental conditions and (ii) the 
mucus is also sticky and airborne particles are collected 
and the trapped particles expelled. Therefore the mucous 
contains much dirt and dust that can be found in the 
environment. This increases if animals are housed in dusty 
environments.
All samples tested on nasal secretions obtained using 
the vacuum pump were positive.
The need for internal controls has already been 
reported (Edwards, 1994) and although a control was used
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using primers to detect the IGF gene present in bovine 
samples such endogenous controls have some disadvantages. 
These disadvantages include, (i) they fail by definition, 
to detect random failures in unspiked reactions, a 
potentially important cause of false negatives (random 
failure is not often reported in the literature but has 
been frequently reported during informal discussions with 
colleagues in other laboratories), (ii) they fail to 
identify problems in the test cocktail such as defective 
reagents or mistakes in setting up the cocktail and (iii) 
in addition, the use of parallel controls doubles the work 
and time involved in obtaining a definitive result. Such 
a procedure may be impractical on a routine basis. All 
attempts by the author to optimise the standard BHV1 PCR 
reaction to amplify bovine DNA and BHV1 DNA in the same 
tubes failed (Data not shown). An internal control that 
could be amplified within the same tube may be an 
alternative and more reliable means of detecting false 
negatives. The development of such an internal control is 
the subject of the following chapter.
The least number of positive results were detected 
using the FAT. There may be several reasons for this. 
Firstly fewer samples were tested using this method due to 
the low volume of nasal secretions (a total of 7 2 whereas 
108 samples were tested using the other two methods). 
Excluding the days when samples were not tested by FAT the 
total number positive by VI was 38 and by PCR was 48. This 
was because on days 2-4 post infection there were no nasal 
secretions and slides made from swabs contained too few 
cells. Had these been suitable for testing virus may well 
have been detected. The number of slides which were 
unsuitable for testing also reflects the problem 
associated with the sampling protocol even in a controlled 
experiment and demonstrates how low concentrations of 
nasal discharge may hinder successful BHV1 detection. The 
days when FAT was most useful as a means of viral 
detection were days 5 - 1 2 .  It was also noted that all 
samples taken with a mechanical aspirator (which was used
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when nasal secretions were copious) were positive by FAT, 
stressing the advantage of this sampling technique over 
the use of swabs alone. If this technigue had been used on 
other days it may have improved the BHV1 detection rate. 
However the use of such a means of nasal excretions on a 
routine basis is not always practical in a field 
situation. In addition, the use of such a technigue is 
only an appropriate means of sampling for PCR testing if 
disposable materials are used for secretion collection to 
ensure there is no possibility of cross contamination 
between samples.
In summary, the results of the investigation suggest 
that the use of the developed PCR assay is the most 
sensitive means of detecting BHV1 in the face of an 
outbreak. However the use of internal controls are 
paramount for reliable results. VI is useful to facilitate 
virus detection between days 3 - 12 post infection
although it is more valuable as a retrospective diagnosis. 
FAT, although not as sensitive, is a rapid and inexpensive 
means of BHV1 detection which can be effectively used on 
days 5 - 1 0  post infection and may best be employed on an 
animal group basis.
6.6 STUDIES ON THE IMMUNE RESPONSE OF THE ANIMALS
6.6.1 Serological studies
In order to substantiate the evidence of BHV1 infection in 
the animals sera were screened for the presence of 
antibodies to BHV1, and if present the titres were 
determined using the serum neutralisation test (2.11.3). 
The geometric mean formula was used to calculate mean 
titres as a few samples with very high or very low titres 
will give an unreasonable arithmetic mean which can be 
misleading when the results are interpreted. The geometric 
mean (GM) titre therefore gives a more representative view 
of results.
The formula for the calculation of the Geometric mean is
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as follows
Where x = the titre of an individual observation 
n = number of observations.
The geometric mean was calculated for the infected and 
sentinel animals over a period of 65 days and plotted on 
a graph (see Figure 6.6).
GM = n V xl. x2.x3..... xn
Figure 6.6 shows the mean serological responses of the 
Infected calves and sentinels to BHV1. Antibodies to BHV1 
were detected In serum on day 10 or 11 after Infection. 
Antibody tltres then followed the predicted kinetic 
patterns for BHVl Infection. These results also Indicated 
that sentinels became Infected approximately 2 days after 
those that were artificially inoculated as they 
seroconverted 2 days or 3 days later. The highest levels 
of antibodies produced in cattle varied between titres of 
1/64 to 1/256, the highest being produced in animal 52 
which also had the highest clinical score. However, in 
general, the antibody level produced in each animal did 
not relate to the clinical score. Antibodies were still 
present in the blood until the last blood samples were 
taken on day 120.
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GM = n /xl. x2.x3.....  xn
Where x = the titre of an individual observation 
n = number of observations.
The geometric mean was calculated for the infected and 
sentinel animals over a period of 65 days and plotted on 
a graph (see Figure 6.6).
FIGURE 6.6
BOVINE ANTIBODY RESPONSE TO BHV1 POST INFECTION
D ays post—In fe ctio n  
□  Sentinels  t*  In fected
Figure 6.6 shows the mean serological responses of the 
infected calves and sentinels to f “72. Antibodies to BHV1 
were detected in serum on day 1C r 11 after infection. 
Antibody titres then followed the predicted kinetic 
patterns for BHV1 infection. These results also indicated 
that sentinels became infected approximately 2 days after 
those that were artificially inoculated as they 
seroconverted 2 days or 3 days later. The highest levels 
of antibodies produced in cattle varied between titres of 
1/64 to 1/256, the highest being produced in animal 52 
which also had the highest clinical score. However, in 
general, the antibody level produced in each animal did 
not relate to the clinical score. Antibodies were still 
present in the blood when the last blood samples were 
taken on day 120.
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6.6.2 Haematological studies: As part of cell mediated and 
antibody immunity in response to BHV1 infection, 
lymphocytes, through their antigen-specific receptors are 
triggered to differentiate and secrete soluble mediators 
such as interleukin-2 and T-cell replacing factors by T- 
lymphocytes or antibody to BHV1 antigens by B lymphocytes 
(Splitter et al., 1992). This investigation was undertaken 
in order to study the lymphocyte response to this BHV1.1 
strain. In addition the total white blood cell response 
and the neutrophil response was also examined. The mean 
values of each were assessed in all cattle for the initial 
10 day post-infection period: red blood cells,
haemoglobin, packed cell volume, mean cell volume, total 
white cells, platelets, neutrophils, lymphocytes. The 
arithmetic mean was calculated for the following groups: 
infected, sentinel and control calves. Results were 
plotted against time (see Figure 6.6, Figure 6.7 and 
Figure 6.8).
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AVERAGE TOTAL WHITE BLOOD CELL COUNT (TWC) COUNT FOLLOWING BHV1 
INFECTION
FIGURE 6.7
Days post infection  
□  sentinel +  infected O control
Figure 6. 7 shows the Total White Blood Cell (TWC) count 
over the first ten days, the increase of TWC in the 
artificially inoculated animals can be seen to begin on 
day 3 post infection, peak on day 4 and begin to drop 
again on day 5. The sentinels show a similar TWC count 
pattern 3 days later and peaking on day 8 and falling 
thereafter. The uninfected calves showed no dramatic 
alteration in white cell counts on any day.
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FIGURE 6.8
AVERAGE LYMPHOCYTE COUNT FOLLOWING BHV1 INFECTION
Lymphocyte Count (Lymphs)
Days post infection 
□ Sentinel +  Infected O Control
Figure 6.8 shows the lymphocyte count over the first 10 
days pi. The lymphocyte count also increased on day 4 in 
the artificially inoculated animals and fell thereafter.
H o w ev er , t h e  s e n t i n e l  r e s p o n s e  o c c u r r e d  a t  t h e  same 
t i m e .  B e c a u s e  t h e  c o n t r o l s  b e h a v e d  i n  t h e  sam e m anner  
l i t t l e  c o u ld  b e  c o n c lu d e d  from  t h e s e  r e s u l t s .
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FIGURE 6.9
AVERAGE NEUTROPHIL COUNT FOLLOWING BHV1 INFECTION
NEUTROPHIL COUNT (Neuts)
Days post infection 
□  Sentinel +  Infected O Control
Figure 6.9 shows the neutrophil count in the blood over 
the first 10 days pi. It can be seen that there was a 
dramatic decrease on day 4 - 5  suggesting a migration of 
neutrophils to the point of infection. The pattern from 
the sentinels and infected animals appeared to be similar.
1 9 6
6.6.4 DISCUSSION
This study was undertaken to confirm BHV1 infection in the 
animals by serological means and to look at the immune 
response of these calves to BHV1.1. What is known of the 
bovine immune response is well documented (Wyler et al., 
19 89) although many guestions on the exact mechanisms of 
the bovine response to BHV1 remain unanswered (Babiuk,
1995). The results found in this investigation showed that 
antibodies were produced in all infected cattle 10-11 days 
after infection while the control animals remained BHV1 
seronegative throughout the course of the investigation. 
From the studies obtained in this investigation no 
definitive or new responses were observed.
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6.7 THE EXAMINATION OF WHITE BLOOD CELLS FOR CELL 
ASSOCIATED VIRAEMIA
6.7.1 The white blood cells of cattle were examined in the 
2 - 5  day post-inoculation period for the presence of 
BHVl. It has been reported that Equine herpesvirus 1 
another alpha herpesvirus can induce cell-associated 
viraemia (Hannant et al., 1993: Dolby et al. , 1995). It 
was also anticipated if the infection became systemic then 
BHVl would be found in the blood on these days as this 
would be the means of viral dissemination.
6.7.2 PCR assays were performed on white blood cells as 
described in chapter 2.12.4. White blood cells were used 
for virus isolation as described in chapter 2.12.3.
TABLE 6.6
THE DETECTION OF BHVl IN WHITE BLOOD CELLS USING PCR
62
2 3 4 5
33 - - -
69 - - -
77 - - -
65 - - -
68 - - -
62 - - -
61 - - -
64 - - -
Table 6.6 shows that BHVl was not detected in the white 
blood cells using PCR on any of the days examined.
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DISCUSSION
Virus was not detected in the white blood cells on any day 
using VI or PCR indicating that BHV1 it is not associated 
with white blood cells. Another investigation whereby the 
white blood cells of cattle that had antibodies to BHV1 
were examined for the presence of BHV1 DNA using PCR were 
all negative (Data not shown). This evidence suggests that 
BHV1 is not associated with the white blood cells.
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CHAPTER 7
THE DEVELOPMENT OF AN INTERNAL PCR CONTROL
7 .1  THE DEVELOPMENT OF A PCR INTERNAL CONTROL
The use of PCR assays have revolutionised diagnostic 
procedures for a wide range of medical and veterinary 
purposes. However, despite the many advantages offered by 
PCR systems of diagnosis, there are some problems 
associated with such assays on a routine diagnostic basis, 
including the occurrence of false positive and false 
negative results. Both possibilities must be considered, 
and provisions for their detection must be in-built in the 
test procedure should PCR be used as a diagnostic 
technigue. False positives are usually the result of PCR 
product carryover or cross contamination, and can usually 
be eliminated by meticulous laboratory technigue (chapter 
2.14). Egually important is the identification of false 
negative results. False negative results may arise for a 
number of reasons including: defective PCR reagents,
technical error, the presence of inhibitors in individual 
samples or random PCR failure.
Negative results for many tests can, correctly or 
not, imply that the organism responsible for the disease 
has not been detected thus eliminating the infectious 
agent from a differential diagnosis. The conseguences may 
be especially profound if the result is used to determine 
the course of treatment which in turns affects the 
ultimate health of the herd. The presence of inhibitory 
substances in nasal secretions collected during the 
controlled investigation highlighted the need for controls 
to eliminate false negative results. The use of exogenous 
controls which allow the amplification of a piece of 
target DNA within the same tube as the test PCR assay have 
been reported and are becoming an essential part of PCR 
assays in a diagnostic laboratory. This chapter describes 
the development of an exogenous internal control using a 
technigue described by Pallen et al. (1992).
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FIGURE 7 .1
THE SCHEMATIC GENERATION OF AN INTERNAL CONTROL
300 bp PCR Product Amplified from BHV1
Hae II Restriction 
I
75 bp 15 bp 116 Bp 96 bp
HAE XI HAEII
Hae II cuts the PCR product into four fragments 
of 75 bp, 15 bp, 116 bp and 96 bp
I
Gel purification of 75 bp and 96 bp fragments
4*
Ligation of 75 bp and 96 bp fragment
J.
75 bp 96 bp
Re-amplification to generate internal control
I
Gel Purification of 190 bp ligated fragment
4*Re-amplification of the 1 0 bp product
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Figure 7.1 is a schematic diagram showing the construction 
of the internal control template by creating a deletion in 
the central portion of the BHV1 PCR product. This was 
achieved by cutting the PCR product with a restriction 
enzyme which yielded four DNA fragments. The outer DNA 
fragments (fragment sizes corresponding to 75 bp and 96 bp 
containing the primer sequence) were removed and gel 
purified. These were then ligated to each other using TA 
DNA ligase and re-amplified using the standard PCR 
conditions for BHV1 (Chapter 4. 2. 4. 3) .
The generated internal control containing the primer 
sequence is 170 bp in length. As the same PCR primers can 
be used to amplify BHV1 target DNA and the internal 
control co-amplification using the standard PCR assay 
conditions was possible. BHV1 PCR product could be 
distinguished from that of the internal control by its 
size on agarose gels.
Using such an approach there were three possible 
outcomes to a PCR test. They are as follows; (i) no DNA is 
amplified in the tubes (the PCR assay has failed), (ii) 
the control but not the test is positive (the assay has 
worked, the sample was negative) and (iii) a test 
fragment, with or without the control fragment is obtained 
(the assay has worked, the sample is positive).
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7 . 2  R E SU L TS
FIGURE 12
Lane 1: 100 bp ladder
lane 2: PCR product from a 1:10 dilution of gel purified 
ligated product, 
lane 3: PCR product from a 1:100 dilution of gel purified 
ligated product.
Lane 4: PCR product amplified from BHV1 Oxford strain. 
Lane 5: Negative control - sterile water
Figure 7.2 shows the amplification of a PCR product from 
the ligation mix of bands of 116 bp and 75 bp 
approximating to 190 bp (lanes 2 and 3).
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THE RESTRICTION ENDONUCLEASE ANALYSIS OF THE 170 bp FRAGMENT
FIGURE 73
b p
LI L2 L3
Lane 1: Uncut 190 bp fragment.
Lane 2: 190 bp fragment cut with Hae II.
Lane 3: 100 bp ladder.
Figure 7.3 shows that the 170 bp fragment appears to have 
been cut into the original two bands of 96 bp and 75 bp 
fragments thus further verifying that it is the required 
internal control.
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The determination of lowest dilution of internal control
possible to production PCR product
The amplification of PCR product using the same set of 
primers as in the original PCR can led to a smearing 
effect that has now been refereed to as the Ampli-Schultz 
effect (Hengen, 1995). The effect is due high 
concentrations of DNA and can only be removed by the high 
dilution of the starting PCR DNA template.
FIGURE 7.4
Lane Is PCR generated from 10'1 dilution
control,
Lane 2s PCR generated from 10'2 dilution
Lane 3s PCR generated from IO"3 dilution
Lane 4: PCR generated from 10"4 dilution
Lane 5: PCR generated from IO’5 dilution
Lane 6s PCR generated from 10"6 dilution
Lane 7s PCR generated from 10‘7 dilution
Lane 8: PCR generated from 10"8 dilution
Lane 9: Positive control (90 ng purified
Lane 10 s 0.!5 ng 100 bp ladder
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Figure 7.4 shows the amplification of a clean 190 bp PCR 
product when the re-amplified ligated product was added to 
a standard PCR assay at a dilution of 10~7. At lower 
dilutions an example of the Ampli-Schultz can be seen 
whereby a large amount of streaking is evident with no 
amplification of the desired product occurring at 10'1 to 
10~3 dilutions. The high dilution of the internal control 
product also ensured that any of the original PCR product 
amplified from the TK gene ought to be completely diluted 
from the stock solution.
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The examination of the effect of the incorporation of the
internal control on the sensitivity of the PCR assay
Ten microlitres of each dilution was processed under 
standard PCR conditions. Results indicate that only at 
dilutions of 10'5, 10'6 and 10~7 can amplification occur. 
Higher dilutions of DNA in the PCR appear to inhibit 
product production. The least DNA smearing and the limit 
of detection occurred at a 10~7 dilution. This was then 
chosen as the dilution of internal control to be used in 
each reaction.
FIGURE 7.5
THE EFFECT OF THE INCORPORATION O F THE INTERNAL CONTROL ON 
THE SENSITIVITY OF THE REACTION
L l 2 3 4 5 6 7 8 9 10 11 12 13 14 !
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Lane 1: 10 4-75 tcid50,
lane 2 10 3,75 TCID50,
Lane 3 10 2-75 tcid50,
Lane 4: 10 1>75 tcid50,
Lane 5: 10 °-75 tcid50,
Lane 6 : 10 0,07 tcid50,
Lane 7: Negative control (no DNA)
Lane 8: 104.75 Tcid50, with 10 ni of internal control,
Lane 9: 103-75 TCID50, with 10 ni of internal control,
Lane 10 102-75 TCID50, with 10 iii of internal control
Lane 11 101'75 TCID50, with 10 iii of internal control
Lane 12 1 0 °.75 TCID50, with 10 ]Xl of internal control
Lane 13 1 0 °.07 TCID50, with 10 Hi of internal control,
Lane 14 Negative control (distilled Hz0 DNA) .
Figure 7.5 shows the detection of BHV1 supernatant at a 
series of ten fold dilutions compared to the detection of 
BHV1 using the same series of dilutions when a standard 
amount of internal control was included in the reaction. 
The result shows that the incorporation of the internal 
control decreases the sensitivity of detection by 10 to 
100 fold.
7.3 DISCUSSION: The use of an internal PCR control
The occurrence of some negative results (nine in 
total) using PCR assays on nasal samples taken from 
animals used in the study outlined in chapter 6 gave some 
cause for concern on the reliability of the PCR assay as 
a diagnostic test. These samples were BHV1 positive by VI 
suggesting that there was a problem with the PCR assay. 
When the IGF PCR assay primers were used on these samples
there was a failure of amplification suggesting that the
problem was associated with substances present in the
samples. In the previous comparison of PCR, VI and FAT
(chapter 5.1) for the detection of BHV1 on a selection of 
samples submitted for diagnostic purposes a good
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correlation was found between PCR and VI with only one 
sample negative by PCR that was positive by VI and again 
this was also negative using the IGF PCR assay. A similar 
experiment was described by Vileck et al. (1995) which
involved the inoculation of cattle with BHV1 and 
subseguent sampling and testing for the presence of BHV1 
in nasal secretions using another PCR assay. The report 
described obtaining some inconsistent results, with a 
number of samples being negative on PCR, which were later 
found to be positive when samples were diluted 10 to 100 
fold. Dilution of the samples seemed to eliminate the 
problem which was reported to be attributed to inhibitory 
factors present in the nasal secretions, although the 
exact source of this inhibition was not discussed.
The use of the IGF PCR assay for the detection of 
inhibitory substances in the test sample was useful and 
necessary. However the technigue had a number of 
disadvantages including the following; (i) despite many 
variations of reaction parameters it was impossible to 
perform the two PCR assays within the same tube using the 
same thermo-profile hence two PCR assays had to be 
performed on each test sample. This increased the time to 
obtain a definitive negative result as well as making the 
test system more impractical on a routine basis, (ii) this 
kind of control essentially only detects the presence of 
an inhibitory substance in the DNA preparation and does 
not detect the presence of errors in the cocktail 
preparation and (iii) endogenous control target sequences 
may be degraded. Furthermore as the quantity of cells and 
free virus per submission varies, particularly in nasal 
secretions, adequate DNA may not be present for 
amplification. It was anticipated that the use of a known 
concentration of internal control DNA that could be used 
within the same tube would overcome the above.
The internal control was obtained by using the method 
outlined in Figure 7.1 The use of the enzyme Hae II was 
chosen for the generation of an internal control due to 
the fragment sizes (116 bp, 15 bp, 96 bp, 75 bp) it
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generated. This resulted in the relatively easy visibility 
and excision of fragments corresponding to 75 bp and 96 bp 
in length from the gel which were ligated together to give 
an internal control of 17 0 bp. The enzyme also generated 
sticky ends and were therefore easy to ligate together. 
The DNA sequence of the internal control was verified by 
cutting it back into its original fragments with Hae II 
(Figure 7.3). The lowest concentration of internal control 
necessary to generate PCR product was determined by making 
a series of 10 fold dilutions of the amplified product 
using each dilution as DNA template for PCR assays (see 
Figure 7.4; lane 7). The limit of detection occurred at 
the 10‘7 dilution. This was then chosen as the dilution of 
internal control to be used in each reaction. The 
inclusion of the internal control was found to have the 
effect of lowering the sensitivity of the PCR assay by 10 
-100 fold (Figure 7.5). The disadvantage of including the 
internal control within the same tube is that it decreases 
the sensitivity of the PCR test assay. Therefore it is 
recommended that for each test sample two PCR assays 
should be used. One should include the internal control to 
detect any technical errors and the presence of inhibitory 
substances while the other one without the internal 
control would detect any virus present at a titre of 0.1 - 
1 TCID50 that may not be detected when the internal control 
was used. Using this technigue a more reliable internal 
control is used with the assay while still retaining the 
sensitivity of the test assay.
2 10
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CHAPTER 8
DNA SEQUENCE ANALYSIS OF THE BHV1 TK PCR PRODUCT
8.1 INTRODUCTION
Restriction endonuclease analysis of BHV1 PCR 
products obtained in his study using Hae II and Taq I gave 
the predicted fragments according to the published 
sequence for the target region (Young et al., 1990). This 
chapter describes the attempts to (i) further validate 
that the PCR product was amplified from BHV1 DNA, and (ii) 
to seguence PCR products from 13 BHV1 isolates on which 
REA had been performed and the genotype elucidated (see 
Table 3.1).
The determination of DNA seguences using the chain- 
termination method of Sanger et al., 1977 is now a well 
established technigue in molecular biology. The method 
involves the synthesis of a DNA strand by a DNA polymerase 
in vitro using a single stranded DNA template. Synthesis 
is initiated at the site where the oligonucleotide primer 
anneals to the template in the presence of 
deoxynucleotides (dNTPs) and dideoxynucleotides (ddNTPs). 
The dideoxynucleotide (chain terminating nucleotide) 
analogs are 2'3 '-dideoxynucleotides which lack the 3 ' -OH 
group necessary for DNA chain elongation. When mixtures of 
the dNTPS and one of the four ddNTPs (dATP, dCTP, dTTP, 
dGTP) are used, enzyme-catalysed polymerisation will be 
terminated in a fraction of the population of chains at 
each site where a ddNTP is incorporated. The fragments 
produced are then separated by gel electrophoresis. Four 
separate reactions, each with a different ddNTP, will give 
complete seguence information. The seguence of the 
template DNA is determined from the sizes of the 
fragments. Detection of the DNA fragments in the seguence 
ladder has been traditionally accomplished by 
incorporating radiolabelled deoxynucleotide (either 35S- or 
32P-labelled) into newly synthesised DNA and performing 
autoradiography on the dried electrophoresis gel. 
Radioisotopic labelling affords high sensitivity, sharp 
bands (particularly with 35S) excellent resolution, and low 
background. However, there are also drawbacks to
211
radioisotopes. Their use requires special handling, safety 
precautions, facilities and procedures for the disposal of 
any radioactive waste as well as licences. Isotopes decay 
within a relatively short period and must be continually 
recorded. In addition, expenses associated with the 
disposal of radioactive waste continue to escalate.
To overcome this, non-isotopic methods for research 
technigues such as Southern blotting, Northern blotting 
and DNA seguencing are increasingly being investigated. As 
a result there is an increasing availability of sensitive, 
easy-to-use and cost competitive non-isotopic kits.
Three such commercially available kits were used in this 
study to seguence amplified PCR product from the BHV1.
(I) NON ISOTOPIC SEQUANASE IMAGES KIT (USB)
(II) CYCLE SEQUENCING KIT (STRATAGENE)
(III) SILVER SEQUENCING (PROMEGA)
(I) NON ISOTOPIC SEQUANASE IMAGES KIT (USB)
The USB™ Sequenase Images non Isotopic DNA seguencing 
system utilises the high affinity of the bacterial protein 
strepavidin for the vitamin biotin and is based on the 
detection of biotinylated DNA fragments on a nylon 
membrane using chemiluminescence (see Figure 8.1). Biotin 
is incorporated in the DNA fragments generated in the 
seguencing reactions either by using a 5'-bioinylated 
primer or by performing a labelling step during which a 
biotinylated nucleotide is incorporated. Seguencing 
reactions are performed with Seguenase version 2.0 T7 DNA 
polymerase and the seguencing protocol produces a series 
of biotinylated DNA fragments.
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FIGURE 8.1
Principle of Sequenase Images 
Non-lsotoplc DNA Sequencing Kit
Q 0
e r a
Strepavidin
== DNA Sequencing product with biotin attached 
Alkaline Phosphatase
= Strepavidin-Alkaline Phosphatase Conjugate 
lumi-phos 530
light
Membrane
Figure 8.1 shows the principle of the Sequenase Images 
Kit. Following electrophoretic separation of the DNA 
fragments on a polyacylamide denaturing gel a simple 
blotting protocol is employed to transfer a significant 
portion (50-80%) of the DNA from the gel onto a sheet of 
nylon membrane. The membrane is allowed to dry, placed in 
a hybridisation bag and following blocking is treated with 
a strepavidin-alkaline phosphatase conjugate (SAAP). 
Strepavidin binds to biotin thus indirectly linking 
alkaline phosphatase to each DNA fragment. After excess 
SAAP is washed away, Lumni-PhosR 530 a chemiluminescent
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substrate for alkaline phosphatase, is applied to the 
membrane. The membrane is then placed in contact with X- 
ray film in an X-ray cassette and exposed for 
approximately 1 hr. The chemi luminescent detection 
chemistry is based on the removal of the phosphate group 
from phenylphospho-substituted 1,2-dioxetane. This 
reaction is catalysed by alkaline phosphatase and results 
in the decomposition of the 1,2-dioxetane which triggers 
the subsequent production of light. The Lumni-Phos 530 
used in the Seguenase Images emission is maximum at 
approximately 530 nm. This chemiluminescence can be 
detected using standard X-ray film in a format similar to 
that of standard isotopic detection.
(II) CYCLE SEQUENCING KIT (STRATAGENE)
The technique of cycle sequencing is also known as linear 
amplification seguencing and is a variation of the 
polymerase chain reaction (PCR). The components of the 
seguencing reaction are similar to those in the PCR assay 
with the following exceptions, (A) The presence of 
dideoxynucleotide triphosphates (ddNTPs) in the seguencing 
reactions, which are responsible for chain termination 
reguired for DNA seguencing. (B) The presence of only one 
primer in the cycle sequencing reaction is used to prime 
synthesis of one strand of the DNA. The resultant linear 
amplification of the PCR product leads to an increase in 
the signal generated during the seguencing reaction. (C) 
The use of a labelled primer which would allow the 
identification of the seguenced strand. In this case, for 
the seguencing of BHV1 PCR product, a biotinylated PCR 
primer (which was also used with the USB kit) was used for 
amplification reactions. Chain-termination seguencing 
reactions are cycled through a temperature profile 
consisting of a heat-denaturation step, an annealing step 
and extension step. The generated fragments are then 
separated using electrophoresis as described above. The 
biotinylated fragments are identified using a strepavidin 
alkaline phosphatase (SAAP) -Lumni-Phos 530 chronographic
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detection as used with the Sequanase Images kit (Figure
8.1). Cycle sequencing has many advantages: (i) The amount 
of template necessary for the seguencing reaction is 
greatly reduced because multiple seguencing products are 
formed from each template molecule, (ii) the addition of 
smaller amounts of template minimises impurities and 
therefore reduces the amount of template preparation 
reguired, (iii) double stranded templates such as PCR and 
plasmids can be sequenced without separate denaturation 
and annealing steps because of the high temperature at 
which the sequencing reactions are run and the multiple 
heat-denaturation steps, (iv) seguencing at elevated 
temperatures reduces template secondary structure, 
resulting in fewer strong stops and (v) high annealing 
temperatures may be used to increase the stringency of 
primer hybridisation.
The latter system of DNA seguencing was chosen in 
this investigation for all of the above reasons and in 
particular the reduction of potential template secondary 
structure. Since the optimised conditions of the PCR assay 
would be repeated it was thought that the linear 
amplification of BHV1 PCR product would be successful.
(Ill) SILVER SEQUENCING
The Silver Seguence DNA seguencing system combines thermal 
cycle seguencing with a staining protocol to detect bands 
in a DNA sequencing gel. The system incorporates the 
advantages of Cycle Sequencing as outlined above. 
Following standard seguencing reactions and 
electrophoresis the gel is stained in a solution 
containing silver nitrate and formaldehyde. DNA fragments 
are visualised directly as brown bands following the 
reduction of silver ions to metallic silver by 
formaldehyde in an alkaline solution.
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8 . 2 . 1  DIRECT SEQUENCING OF THE PCR PRODUCT AMPLIFIED FROM 
BHV1 USING DYNABEADS AND THE USB IMAGES KIT
Initial attempts at sequencing BHV1 DNA using the 
Silver sequencing kit failed to produce any clear sequence 
data. The sequence data obtained from the control template 
was not equivalent in quality to that obtained with 
isotopic methods. In addition, the procedure was difficult 
and extremely cumbersome to perform and the technique was 
rejected.
The USB Images kit was used under conditions 
described in 2.16 and PCR product was sequenced from both 
ends using the PCR primers both of which were 
biotinylated. Single stranded DNA had been obtained using 
Dynabeads (2.17).
FIGURE 8 .2
The following sets of four lanes show the sequence 
obtained in the order GATC
Lanes 1 - 4s M13 Control plasmid ss-DNA,
Lanes 5 - 8 :  Bovine Viral Diarrhoea virus (BVDV),
Lanes 9 - 1 2 :  BHV1 (W199 field isolate) biotinylated
strand sequenced using biotinylated PCR 
primer 1,
Lanes 13 - 16: BHV1 (Oxford PCR product) neutralised
strand sequenced using biotinylated PCR 
primer 2,
Lanes 17 - 20: BHV1 (Oxford PCR product) biotinylated
strand sequenced using biotinylated PCR 
primer 1,
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FIGURE
Figure 8.2 shows the results obtained in the initial 
sequencing reactions using the Sequeanse Images kit 
(conditions as described in 2.16) when PCR product 
amplified from the Oxford strain and field isolate W199 
were used as DNA template. The control plasmid gave a 
clear readable sequence (lanes 1 - 4) as did the
sequencing of the PCR product amplified from BVDV (lanes 
5 - 8). However, the reactions on BHVl PCR product
amplified from the Oxford strain produced four bands 
across the top of the gel (lanes 17 - 20). No DNA was 
observed in the neutralised strand (lanes 13 - 16). This 
may have been due to an incorrect pH of the neutralised 
strand which may be difficult to obtain due to the small 
quantities of NaoH and HCL that are used. Blocks were also 
observed in the sequence of BHVl isolate W199 at 
approximately 102 bp, 140 bp 150 bp and 160 bp along the 
BHVl sequence (13 - 116).
The problem did not appear to be systematic as the 
control template generated a sequence that was comparable 
to that obtained with isotopic methods. This pointed to 
the problem being template-specific. Most template- 
specific problems have one of five causes (I) The presence 
of contaminating DNA (usually bacterial chromosome). This 
was not the case as the template had not been cloned. (II) 
The presence of residual polyethylene glycol or high 
concentrations of EDTA in the preparation, again these 
problems are related to cloned DNA fragments. (Ill) Low 
concentrations of template DNA in the chain termination 
reaction. This was not possible as the DNA concentration 
had been checked on an agarose gel (not shown). (IV) The 
absence of a primer site, as the primer used for 
sequencing was the same as that used in the PCR reaction 
the site should have been present on the template. (V) The 
sequence of the template. GC rich regions can cause 
secondary structures which create problems at different 
stages of the polymerisation e.g. (i) denaturation of 
template (ii) annealing temperature (iii) extension of 
template. Regions of high GC, or for that matter high AT,
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have less variation than those of equal number of all four 
bases. This leads to a greater chance of single-strand 
template being complementary to itself and therefore 
folding over and forming hydrogen bonds which form 
hairpins. This then causes blocks which impede the 
progression of the polymerase. If polymerase stalling 
occurs during the extension, bands in all four lanes 
(BAFLS) are seen during denaturing gel electrophoresis. 
The stall point or arrest site on the film occurs with the 
loss of DNA bands past the point on the gel thus obscuring 
any bands that should have been readable past the 
nucleotide position (Hengen, 1996).
Compressions are another consequence of secondary 
structure. They can be seen as bands at a particular 
location within the gel crowding together and resulting in 
unreadable sequence. In the region of the gel above the 
compression the space between the bands freguently becomes 
overloaded. When this occurs, the regular pattern of 
migration of DNA fragments is interrupted. Usually the 
bands are spaced closer than the normal or "compressed" 
together, although occasionally the bands migrate further 
apart than normal. When this happens the seguence is lost.
8.2.2 TECHNIQUES EMPLOYED IN AN ATTEMPT TO OVERCOME 
PROBLEMS IN SEQUENCING GC RICH DNA
A number of technigues have been reported to overcome 
problems associated with high GC content in template DNA. 
These are outlined in Table 8.1. In addition many 
researchers still find seguencing PCR products difficult 
particularly those of high GC content (Hengen, 1996, Krall 
et al., 1992). The recommended means of overcoming 
problems associated with sequencing PCR products are 
outlined in Table 8.2. The effects obtained from the 
incorporation of these technigues are outlined in Table 
8.3.
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TABLE 8.1
METHODS FOR OVERCOMING PROBLEMS CAUSED BY GC RICH SEQUENCES IN DNA SEQUENCING REACTIONS
TECHNIQUE
Higher termination temperatures: Glycerol tolerant gels
Glycerol has a stabilising effect on Taq polymerase increasing its half life. This permits termination reactions to be carried out at temperatures of up to 60°C. Polymerisations may be more rapid 
at elevated temperatures and some template secondaiy structures may be eliminated above 50°C (Pisa-Williamson and Fuller, 1992).
The use of glycerol in sequencing reaction necessitated the use of glycerol tolerant gels
The use of di l  l's
Compressed regions of gels may be resolved using a nucleotide analog such as dITP (2’-deoxyinosine 5’triphosphate) or 7-deaza-dGTP (7-deaza-2’-deoxyguanosine-5’-triphosphate) (Barnes et 
al.,1983; Gough et al., 1983). These analogs pair weakly with conventional bases and are good substrates for the polymerases. dITP is recommended over dGTP as it does not affect the sharpness 
of DNA bands in the sequencing gel (Sambrook et al., 1989).
The use of SSB
Single stranded binding protein (SSB-protein) binds co-operatively to single stranded DNA destabilising and removing intrastrand secondary structures that form barriers to the progression of 
these Taq polymerase (Sambrook et al., 1989). They also allow the DNA to enter the sequencing gel and prevent smearing of bands.
The use of formamide
The effect of formamide on sequencing reactions was reported to dramatically improve the PCR sequencing of GC rich regions when included in the annealing and sequencing reactions (Zhang 
e al.,1992).
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TABLE 8.2
METHODS FOR OVERCOMING PROBLEMS ARISING WHEN SEQUENCING PCR PRODUCTS
TECHNIQUE
Dynabeads
Dynabeads provide a simple and rapid means for generating 100% single stranded
DNA without interference from PCR components eg buffer, primer, dNTPS (L ew s et al., 1992, Krall 1992). 
The use o f fonnamide
As described in Table 8.1; formamide has also been shown to be beneficiary 
when PCR primers are used in the DNA sequencing reactions (Zhang et al.,1992).
Cycle Seqnenctng
See advantages o f cycle sequencing in 8.1 
Internal Primer
Internal primers are recommended by the manufacturers of dynabeads for the sequencing of PCR 
products. Their use permit and ensure the annealing of primers to intact target DNA within 
the ss-strand which may not be always present at the extremities of the PCR product (Personal 
communication, ACCU SCIENCE; Green and Vaudin, 1993).
Cloning the PCR product
Difficulties associated with intrastrand annealing may be eliminated by 
subcloning the PCR fragment. This has the effect o f reducing the 
possibility erf the single stranded PCR product re-annealing on itself.
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TABLE 83
3
RESULTS OBTAINED USING THE TECHNIQUES OUTLINED IN TABLE 8.1 AND &2 FOR SEQUENCING PGR. PRODUCES WITH A  HIGH GC CONTENT
TECHNIQUE EFFECT
Termination Temperatures
Reactions were carried out as in chapter 2.16
37°C Bands across all 4 lanes (Figure 8.2)
39°C Bands across all 4 lanes
42°C Some readable sequence but blocks after a short stretch (Figure 8.3)
45°C, 55°C, 65°C, As at 42°C
dITP
Reactions were carried out as described in chapter 2.16 No improvement
Single Stranded Binding; protein SSB
Reactions normal (2.16) with the inclusion of 0.1 mg/ml SSB in the
annealing reactions No improvement
Formamide
Sequencing reactions were carried as described in 2.16 with the No improvement
addition of 10% formamdie to reactions.
Internal primer
The sequence of the internal primer was Bands in all four lanes
5’ CTGGTTGCGTACTACCAG 3’
The primer was used with SSB and formamide as described above
Cyclc scqucndna No improvement, Poor quality
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FIGURE 8.3
SEQUENCING PCR PRODUCT AMPLIFIED FROM ISOLATE W199 USING 
SEQUENASE IMAGES AND VARYING THE TERMINATION TEMPERATURES
The following sets of four lanes show the seguence 
obtained in the order GATC
Lanes 1 - 4 :  BHV1 (W19 9 field isolate) biotinylated
strand sequenced with biotinylated PCR 
primer 1
Lanes 5- 8: BHV1 (W199 field isolate) biotinylated
strand sequenced with biotinylated PCR 
primer 3 (HPLC purified)
Lanes 9 - 12: Ml3 Control plasmid DNA
Figure 8.3 shows results obtained by increasing the 
polymerisation temperature when standard reaction 
procedures were used as outlined in 2.16. Some partial 
seguence was obtained when the polymerisation temperatures 
were increased to 42° C (there was no improvement in 
seguence above this temperature). The biotynlated strands 
of PCR product amplified from BHV1 - W199 were included in 
the sequencing reaction. More sequence was visible in 
lanes 5-8 than in lanes 1-4, this may have been due to the 
biotinylation of primer 3 had been HPLC purified while 
primer 1 had not. There may have been more labelled primer 
3 than primer 1 thus explaining the better sequence. 
Partial sequence elucidated is as presented in Figure 8.4A 
while those stretches of DNA sequence which corresponded 
to that published by Smith et al. (1990) is shown in 
Figure 8.4B.
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FIGURE 8.3
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FIGURE 8.4A
CAGCCTCAGCTCGGG7GCHCACGCMCGGCGGGCCGB
CCGCGCGBCHCGBCGCGGCHCCGTABTTGCGTCTCCT
AGGCCAGGTCTCGB
FIGURE 8.4B
T ACG GAC GAC GCC TTA AGT GGG ATC CTC GCG GCG TCT GCG CGA TGC ,5 
GCC GCA GCC TCG CAC GGG AGC GCA CGC GGC GCC GGC GGG CCG GCG 90 
CAC CGC GCA GAC GCG GAC GCG GCG GGC CTG GTT GCG TAC TAC CAG 135 
GCC AGG TTC GCG GCC CCG TAC TTA ATT TTG CAC GCG CGC GTG TCC 1B0 
GCG CTG CTG GCG CCG CCT GGG CCG GCG CCG GGC GGC ACT GTG ACC 225 
CTC GTG TTC GAC CGC CAC CCC GTG GCC GCG TGC CTC TGC TAC CCC 270 
TTC GCC CGC TAC TGC CTC CGC GAG ATC AAC 300
Smith et al., 1990
Figure 8.4A shows the partial readable sequence obtained 
using standard conditions with a polymerisation 
temperature of 42°C. Figure 8.4B shows where this seguence 
corresponded to the published BHVl TK sequence. Underlined 
bases = uncertain of the presence of a base, ■ = blocks or 
Bands in all four lanes (BAFLs). Bold indicates 
corresponding sequence.
It is apparent from these Figure 8.4A and 8.4B that 
many parts of the sequence obtained in this study were 
present in the published sequence and therefore provides 
further evidence that the amplified PCR product was 
amplified from BHVl. Unfortunately due to the inability to 
completely sequence the PCR product no attempts were made 
to sequence PCR product from different BHVl isolates in 
order to elucidate any base pair differences that may 
exist between them.
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FIGURE 8.5
SEQUENCING PCR PRODUCT AMPLIFIED FROM ISOLATE W199 USING 
SEQUENASE IMAGES AND AN INTERNAL PRIMER
The following sets of four lanes show the sequence 
obtained in the order GATC
Lanes 1 - 4: BHV1 biotinylated strand seguenced with
biotinylated PCR primer 3 
Lanes 5- 8: BHV1 (neutralised strand seguenced with
internal biotinylated primer (HPLC purified) 
Lanes 9 - 12: BHV1 biotinylated strand seguenced with
biotinylated PCR primer 1
Figure 8.5 shows the sequence obtained when an internal 
primer was used to sequence one strand of PCR product 
amplified from the Oxford strain of BHV1. The sequence 
pattern obtained using the internal primer only generated 
BAFLs were obtained suggesting that this method would not 
overcome the problem.
2 2 6
FIGURE 8.5
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8 . 2 . 3  CLONING AND SEQUENCING THE PCR PRODUCT
PCR product from BHV1 field isolate D868 and W148 was 
cloned into the unique Sma I site of the plasmid pGEM 
3z(+) as described in 2.15
FIGURE 8.6A
THE RESTRICTION MAP OF pGEM3Z( + )
1 start 
5 
15 
21 
21 
23 
26 
32
38
39
40 
48 
54 
56 
69
Figure 8. 6A shows the genomic map of pGEM3Z(+). The enzyme 
taq I was used to analyse recombinant plasmids (Taken from 
the Promega Tools to explore new worlds catalog 1994 - 
1995, page 94).
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FIGURE 8.6B
THE ANALYSIS OF MINIPREPS USING THE RESTRICTION ENZYM E TAQ 1
W B 'in *  ‘amÊ k t f  l ì r i H i M i l i  4^
■ ____  -
300 bp
« f t  m m  mm
L 1 L 2 L 3 L 4 L 5 L 6 L 7 L 8 L 9  L10
Lane 1 ladder
Lane 2 Plasmid with cloned PCR product from BHV1 W145
Lane 3 Plasmid with cloned PCR product from BHV1 W145
Lane 4 Plasmid with cloned PCR product from BHV1 W145
Lane 5 Plasmid with cloned PCR product from BHV1 D868
Lane 6 Plasmid with cloned PCR product from BHV1 D868
Lane 7 Plasmid with cloned PCR product from BHVl D868
Lane 8 pGEM 3Z(+) Plasmid DNA cut with Taq I
Lane 9 PGEM 3Z(+) Plasmid DNA cut with Taq I
Lane 10 100 bp ladder
F i g u r e  8 .6B  shows an i n s e r t  o f  a p p r o x i m a t e l y  270  bp i n  
l a n e s  2,  3,  4 and 7 ( s e e  a r r o w s )  i n d i c a t i n g  t h e  p r e s e n c e  
o f  PCR p r o d u c t  a m p l i f i e d  from  BHV1 i s o l a t e s  D868 and  W145. 
In  t h i s  a n a l y s i s  Taq I  s i t e s  on e i t h e r  s i d e  o f  t h e  Sma I  
r e s t r i c t i o n  s i t e  m ea n t  t h a t  t h e  PCR p r o d u c t  may h a v e  been  
c l o n e d  i n  e i t h e r  o r i e n t a t i o n .  F u r t h e r  r e s t r i c t i o n  p a t t e r n s  
w i t h  t h e  enzym es  H i n f  I ,  c o n f i r m e d  t h e  p r e s e n c e  o f  t h i s  
i n s e r t i o n  ( n o t  sh o w n ) .
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TABLE 8.4
EFFECT OBTAINED BY USING OTHER TECHNIQUES IN SEQUENCING REACTIONS ON CLONED PCR PRODUCTS
TECHNIQUE EFFECT
SSB No improvement, BAFLs and
compressions
Formamide No improvement, BAFLs and
compressions
Internal primer BAFLs
Cycle seouencina Partial sequence - poor quality
Table 8.4 shows that the sequencing of the cloned fragment did not yield any significantly 
better results than obtained when directly sequencing BHV1 PCR product (results not shown) 
despite making all by the modifications as described to overcome problems associated with 
secondary structure.
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GENERAL DISCUSSION
The number of reported BHV1 infections per annum in 
Ireland has been increasing since the first recorded 
isolation in 1971. This increase has been particularly 
noticeable since the mid 1980s (laboratory data at the 
VRL) and may be attributed to various factors including 
the changing trends in agriculture towards more intensive 
farming as well as a greater awareness of IBR on the part 
of the farming and veterinary profession.
In addition, the development of an improved 
diagnostic technique - a Fluorescent Antibody Test (FAT) - 
which, unlike virus isolation or serological tests, 
facilitates BHV1 detection in the early stages of an 
outbreak (usually within one day). Rapid diagnosis, in 
turn, permits control measures such as live vaccination 
programmes which may be used in the face of an outbreak, 
thus permitting control measures, such as live vaccination 
programmes to be implemented. However the test does have 
some drawbacks, notably its dependence on proper sampling 
procedures which may be difficult to achieve in the field 
situation. The use of PCR, the DNA based test which is 
rapidly becoming common place in diagnostic laboratories, 
offers as an alternative and/or an adjunct to the FAT as 
well as the possibility of an even better diagnostic 
service to veterinary practitioners and farmers. A PCR 
assay which is as rapid as FAT is less dependant on 
sampling procedures. Its use would also reduce problems 
s associated with delayed transport to the laboratory 
and/or poor sampling procedures.
Initially epidemiology studies using restriction 
endonuclease analysis (REA) were performed on BHV1 
isolates that had been made in Ireland. The presence of 
both BHVl genotypes (BHV1.1 and BHV1.2) has been 
documented in Europe (Engels et al., 1981; Metzler et al., 
1985; Edwards et al., 1990). Studies on a number of BHVl 
isolates from Northern Ireland showed that only the 
genotype associated with less severe clinical disease 
signs (BHVl.2) was present while there was no evidence for
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the presence of genotype BHV1.1 which is associated with 
more severe disease (Edwards et al., 1990). Whether or not 
BHV1.1 had been responsible for the more severe outbreaks 
of respiratory disease in Ireland in the late 1980s 
remained unknown as it was generally assumed that BHV1.1 
was not present. This study undertook to characterise a 
number of isolates that had been made at the laboratory 
over the period 1971-1992. In order to do this, large 
guantities of these viruses were grown in the laboratory, 
purified and DNA extractions performed. Purified viral DNA 
was subjected to REA using the restriction enzyme Hind 
III. This enzyme allowed the simple differentiation of 
BHV1 into BHV1.1, BHV1.2a and BHVl.2b on the basis of the 
size of fragments I, L, and K upon digestion.
The REA of thirteen isolates clearly showed that both 
BHVl genotypes were present in Ireland. It also showed 
that some of the more severe outbreaks that have been 
reported in Ireland in the late 1980s have been caused by 
genotype BHVl.1.
DNA, from all of these typed isolates, was retained 
for PCR to ensure that the oligonucleotide primers would 
hybridise to and detect viral DNA of each genotype.
Oligonucleotide primers were chosen from a region in 
the thymidine kinase (TK) gene for reasons outlined in 
chapter 4.2. The entire seguence of BHVl has been 
elucidated (Schwyzer, 1995). Had this information been 
available at the time of primer choice, genes that are 
possibly unique to BHVl i.e. the circ, ULO.5 and US1.5. 
may have been used as an option for primer selection. Such 
a choice should increase and ensure the specificity of the 
PCR assay.
When choosing primers from the TK gene, the choice 
was limited due to the presence of a high percentage GC 
content and only a limited numbers of potential primers 
would adhere to the 40%:60% AT:GC recommendation for 
primer sequence. Ten primers were chosen and their 
suitability assessed using recommended guidelines and 
their specificity evaluated using Genebank facilities in
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EMBL. The two most suitable were used to amplify a 300 bp 
region in the TK gene. The initial attempts at PCR 
amplification were hampered by what was later found to be 
incomplete denaturation of the template DNA at 95°C. This 
was determined due to the failure of all other variations 
of reaction components and reaction parameters and by the 
fact that extracted DNA in another PCR assay described by 
Dr. Moussa, CNEVA, Lyon, France (personal communication, 
1994) produced amplification. Eventually by increasing the 
denaturing temperature to 98°C the GC rich target region 
was denatured and amplification of a 300 bp product was 
achieved. In order to ensure complete DNA denaturation 
DMSO was incorporated in the reaction components. A 
similar denaturation problem was reported for other PCR 
assays (Vilcek et al. , 1993) and in these cases the
problem was overcome by the addition of glycerol, the 
effect of which in a PCR assay is similar to that of DMSO.
Due to problems associated with well to well 
variation in thermocyclers used in this study the 
validation of thermocyclers for PCRs assays using a 
thermocouple is strongly recommended on a routine basis.
Following the optimisation of the PCR assay described 
in this study the sensitivity was determined to be 1 TCID50 
making it one of the most sensitive methods for the 
detection of BHV1 (a sensitivity of less than 1 TCID) 
reported to date and only superseded by one which included 
a post-PCR dot-blot, the combination of which led to a 
sensitivity of 0.1 TCID50 (Van Engelenburg et al.,1993).
The PCR assay developed in this study was also shown 
to detect BHV1 virus isolates of known genotype including 
that of BHV1.1 and BHV1.2. In addition to epidemiological 
studies a knowledge of the BHV1 genotype may be useful as 
a basis for advice on control measures. For instance if 
either BHV1 genotype is shown to be responsible for an IBR 
outbreak it can facilitate a decision as to whether or not 
it may be economically feasible to vaccinate the herd in 
question. However the amplified product from both subtypes 
could not be differentiated as expected. Published
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sequence data from the TK gene of BHV1.1 (Mittal et al., 
1991) and BHV1.2 (Smith et al, 1990) differed in some 
bases which should have led to the ability to 
differentiate them using the restriction endonuclease Hae 
II. Using the enzyme to cut all the products amplified 
from BHV1.1 and BHV1.2 no difference in restriction 
pattern was obtained and all patterns seemed to correlate 
with the seguence that was published by Smith et al. 
(1990). The seguence differences which were reported for 
BHV1.1 is most likely due to seguencing errors which can 
occur when a seguence with such a high GC content is being 
elucidated. These errors often arise from compressions in 
the seguence caused by the strong secondary structure. No 
other report on a PCR assay to date allows for the 
differentiation of BHV1 genotypes.
The developed PCR assay did not detect the other 
bovine or eguine herpesviruses or the closely related 
Aujeszky's disease virus (PRV).
The assay was also designed to detect BHV5 or what 
was formerly called BHV1.3, a strain that causes a highly 
fatal form of encephalitis in young calves. BHV1.3 has 
been reported in Australia, Argentina and Hungary however 
there have been no published reports of BHV5 within the 
EU. The TK gene of BHV5 has been seguenced and found to 
contain a deletion of 10 amino acids (30 bp) that are 
present in the TK gene of BHV1.1 and BHV1.2. This 30 bp 
coding sequence is absent in the amplified product of BHV5 
therefore allowing a means of differentiation between BHV1 
and BHV5 on the basis of product size. Further 
differentiation may be obtained on the basis of 
restriction endonuclease analysis using Taq I which 
cleaves PCR product amplified from the BHV1.1 and BHV1.2 
TK gene into a 270 bp and 30 bp fragment while it does not 
cut product amplified from the BHV5 TK gene. The PCR assay 
therefore may be used to detect and identify BHV5 should 
it enter the country.
Both of the live BHV1 vaccines available in the 
Republic of Ireland, Tracherine and Inbovac, were included
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in the PCR assay. Multiple testing indicated that the PCR 
assay detected viral DNA extracted from Inbovac but did 
not detect DNA extracted from Tracherine. As a result 
Tracherine may be used as a "negative marker" vaccine in 
conjunction with this test. This may be useful as the 
vaccine virus may be detected by FAT. The technique could 
be used to resolve queries which arise on occasion when a 
vaccinated herd develops respiratory disease the causative 
agent of which is BHV1 and the competency of the vaccine 
is queried.
Once the sensitivity, specificity and optimised 
conditions of the assay had been determined, it was used 
in an attempt to detect BHV1 in routine diagnostic samples 
submitted from cattle exhibiting respiratory disease.
PCR has an important role to play in many aspects of 
BHV1 detection in the laboratory.
Firstly the use of PCR as a diagnostic test offers an 
alternative technique which is sensitive, specific and 
fast thus facilitating the rapid implementation of control 
programmes.
Secondly, as a diagnostic test PCR is more 
independent of sample quality than VI or FAT for routinely 
submitted samples such as nasal secretions, nasal swabs 
and tissue from animals which had exhibited respiratory 
disease.for BHV1 in routinely submitted samples such as 
nasal secretions, nasal swabs and tissue from animals 
which had exhibited respiratory disease.
As regards FAT, inappropriate smearing of nasal secretions 
and inadequate fixation may also inhibit proper testing. 
Furthermore the time of nasal sampling is important for 
virus detection (see 6.5.2.2) and the Veterinary 
practitioner may not always be summoned to the farm on the 
most suitable day for sampling. As a result, if samples 
are taken too early or too late in the course of infection 
nasal secretions with few cells containing viral antigen 
may be submitted at the laboratory. Finally the use of FAT 
requires the presence of intracellular antigen in infected 
cells, free virus in secretions may go undetected. This
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should not occur with PCR or VI test systems.
As regards submissions for VI, viral transport medium 
may not always be available to veterinary practitioners 
and swabs may dry out during transport to the laboratory. 
This is very likely to occur as the most freguently used 
means of submission is by the postal service. As PCR 
detects the presence of viral DNA, viable virus is not 
required.
Because of the above, many BHV1 positive submissions 
may not be detected and while methods such as FAT and VI 
are sensitive and specific the use of PCR should guarantee 
the detection of all BHVl positive submissions. The use of 
ELISA technigues for the detection of BHVl infection, 
although not discussed in depth in this thesis, are not 
routinely used at the VRL as they are generally only cost- 
effective when large numbers of samples are being 
processed at one time.
Thirdly, the sale of semen for artificial 
insemination is important for bull owners with an EU 
directive demanding BHVl free semen. PCR may be readily 
applied to the detection of BHVl in semen and has may 
advantages over the most freguently used virus isolation 
or Cornell semen test in terms of sensitivity, cost and 
speed.
The use of Chelex 100 which had been reported to 
improve the recovery of DNA from a range of sample types 
(Walsh et al., 1991) was also found to improve the 
recovery of DNA from viral supernatant in this study. For 
this reason the resin was also used in the extraction 
procedure from diagnostic submissions.
This study compared the use of PCR, FAT and VI as
methods for the detection of BHVl in 105 diagnostic 
submissions submitted to the laboratory over a winter
period. The PCR assay was found to detect the greatest 
number of BHVl positive samples (15 in total, Table 5.1) 
followed by VI (13) and FAT (10). There was a higher
correlation between VI and PCR than between PCR and by 
FAT. However, this was partly due to the large number of
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(30%) submissions that were deemed to be unsuitable for 
testing by FAT due to poor quality of submissions. When 
these samples were removed from the comparison the 
correlation between PCR and FAT was higher, demonstrating 
that the test system is sensitive when adequate sampling 
procedures are followed.
A further comparison between FAT, PCR and VI was 
performed when cattle were artificially inoculated with 
BHV1 strain W199 and nasal swabs were examined for up to 
18 days. Again in this study PCR detected BHV1 in more 
samples (61) than VI (49) or FAT (24). In addition, 50% of 
virus isolated on tissue culture were only detected on the 
second pass highlighting the length a result by VI make 
take. The low number of positive samples identified by FAT 
in this investigation may have been due to the mild nature 
of the disease which ensued, nasal secretions were slight 
and therefore the volume of cells being shed was also low 
reducing the chances of detecting virus.
The study also gave an indication on when the best 
times for nasal sampling following infection. In general 
VI was most efficient for BHV1 detection on days 3 through 
10, FAT was more suitable on days 5 - 1 0  while PCR was 
efficient throughout the study. However, even though PCR 
detected the greatest number of positive BHVl samples one 
worrying aspect of the results was that on a number of 
occasions some samples were found to score negative but 
positive when diluted. This indicated the presence of some 
inhibitory substance in the nasal secretions. The 
inhibition appears to have arisen on days when secretions 
become purulent usually days around 7 - 8  post infection. 
This was confirmed by the generation of an internal 
control which was used on these samples. The need for 
internal controls has been recommended when using PCR as 
a diagnostic test (Edwards, 1995). Their use however leads 
to a reduction in the sensitivity of the assay, in this 
case 10-100 fold. A possible likely solution to the 
problem may be the duplication of each diagnostic test 
where one sample would include an internal control in
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order to detect the presence of inhibitory substances 
while the other would not, thus maximising the chances of 
virus detection. In cases where inhibition is found these 
samples should be re-extracted using the phenol: 
chloroform or the Snap-O-Sol DNA extraction kit.
It is doubtful if VI will be replaced in diagnostic 
virology, particularly in a laboratory like the VRL as it 
generates the causative isolate which may then be used for 
further investigations or epidemiological studies. PCR 
does however offer a means of rapid diagnosis which may be 
used to dictate control procedures. PCR may also be used 
to confirm the VI results in cases where the CPE is either 
doubtful or uncharacteristic and where specific 
classification is needed.
As to whether PCR will replace FAT as a rapid method 
of BHVl detection will be decided by personnel at the 
laboratory in view of the costs, time input etc. Evidence 
found in the investigations here suggests that it will 
have a major role to play in particular circumstances. The 
cost of PCR assays have fallen dramatically in the past 
few years, this is largely due to the continuing reduction 
in the price of polymerase. Following the initial expenses 
of laboratory set-up for PCR costs per test are as low as 
£0.75 for reagents while the cost in time is dependant on 
the number of samples being processed. One advantage that 
remains with the FAT system of diagnosis is that multiple 
tests e.g. those for the detection of RSV, PI3 and BHVl 
may be performed on the same microscope slide submitted 
for the detection of respiratory pathogens. One 
recommendation is that all those submissions which are 
found to contain too few cells on microscope slides or 
which are not suitable for testing (approximately 30% of 
the total submissions to the laboratory) would be tested 
by PCR. In this case all BHVl positive samples would be 
detected in the laboratory as the correlation between PCR 
and FAT was high (when samples were suitable for FAT 
testing).
If PCR were to replace FAT or virus isolation as a
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routine diagnostic test it is highly recommended that an 
international standard would be established whereby all 
PCR assays could be standardised using known viral DNA 
concentrations. A comparison that was made of serological 
diagnostic procedures used for infectious bovine 
rhinotracheitis in the European Community revealed 
considerable variation between tests in the "doubtful" 
category of sera (Perrin et al. , 1993) thus emphasising 
the need for an international standards.
The method of extraction reported in chapter 5 using 
the commercial DNA extraction kit, Snap-O-Sol, provided a 
reliable means of DNA extraction from semen with the 
elimination of any inhibitory substances which may have 
affected the success of the assay. Using this extraction 
technique the PCR assay is strongly recommended over virus 
isolation for the detection of BHVl in semen. The virus 
isolation technique had many disadvantages mostly due to 
the cytotoxicity of semen to bovine tissue culture cells. 
The test also ensures the implementation While the EU 
directive EC/88/407 does not cite PCR as being an 
appropriate test for semen this will probably change in 
the future. The Snap-O-Sol kit also provides a means of 
extracting RNA as well as DNA, therefore it could be used 
in the screening of semen for a number of viruses.
The use of a BHVl isolate which had been associated 
with of severe pharyngitis in young calves to establish 
infection in cattle under control conditions resulted in 
the infected cattle developing a mild respiratory disease. 
The possible reasons of this were discussed in chapter 6 
and demonstrated that natural infections may not always be 
easily reproduced and that different clinical signs may be 
caused by the same isolate. In this study the clinical 
sign seemed to be related to the age of the cattle i.e in 
general younger calves developed higher clinical scores to 
the older ones. The results also may support the view that 
systemic infection caused by BHVl infection is more 
associated with neo-natal calves that have less evolved 
immune systems.
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Finally attempts to sequence the entire PCR product 
using non-radioactive methods failed and only partial 
sequence information was obtained. However the partial 
sequence obtained correlated with that of the published 
sequence and regions where blocks and compression were 
evident corresponded to high stretches of GC content in 
the reported sequence. Much difficulty was encountered in 
obtaining any readable sequence. This may be attributed to 
the fact that the DNA template was PCR product which in 
itself has been previously reported to be often very 
difficult to sequence (Krall, 1992). In addition the 
template was also GC rich which also poses problems for 
sequencing. Magnetic beads which allow the immobilisation 
and subsequent isolation of one DNA strand have been 
reported to be useful for DNA template preparation of PCR 
products for sequencing (Lewis et al. , 19 92). These were 
found to work very efficiently for PCR product amplified 
from BVDV but their use for BHVl template preparation did 
not lead to clear sequencing data. The use of the Non- 
Isotopic USB Sequenase Images kit was found to be an 
attractive alternative to isotopic methods as regards 
safety and high quality sequence data. A range of trouble­
shooting methods have been reported to solve the problems 
of band blocks and band compressions (Table 8.1 and Table
8.2) including the use of higher polymerisation
temperatures, more thermostable polymerases, cycle 
sequencing, co-solvents such as DMSO and formamide to
decrease secondary structure were investigated in the hope 
of overcoming this problem. When all these various 
combination of these techniques failed PCR product was 
cloned and although this did produce some partial
sequence, compressed bands remained and there was no 
significant improvement to the direct sequencing. An
attempt was also made to sequence PCR product amplified 
from BHVl isolate W19 9 was also attempted to be sequenced 
at another laboratory using automated sequencing again 
this did not yield any readable sequence. Finally it was 
concluded that the product could not be fully sequenced
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using the chain termination method. The only technique 
that had not been attempted but which may have produced 
results was the Maxim and Gilbert method which is a 
chemical degradation method that is not influenced by high 
GC content (Sambrook et al., 1989). This however this 
technique is complicated and the facilities for its 
execution were not available at the laboratory.
With regard to the future development of this work 
possible projects could include
(I) A DNA probe test system for the differentiation 
of BHVl genotypes. Due to the nature of the procedure for 
the extraction, purification and restriction endonuclease 
analysis of viral DNA, such a technique for BHVl genotype 
differentiation is not practical on a routine basis. In 
addition, the recovery of pure intact viral DNA is quite 
difficult and the REA of a number of other isolates failed 
to produce clean viral DNA preps which may have been due 
to poor viral yield and/or the integrity of extracted DNA. 
A suggestion for overcoming this in the future could be 
the preparation of viral DNA from isolates from both 
genotypes followed by their cleavage using Hind III and 
Southern blotting onto a nitrocellulose membrane. The 
subsequent cloning of the variable regions I, J and K and 
their labelling by radioactive or non-radioactive means 
would provide for highly specific probes for
differentiating between BHVl subtypes by hybridisation. 
This technique would allow for a simpler viral DNA
preparation procedure and would be less dependant on
highly purified and large quantities of viral DNA.
(II) Future development of the PCR assay could 
involve a more automated assay performed on microtitre 
plates (MTPs) using a PCR ELISA for product detection. A 
number of variations are possible and one such technique 
is outlined in Figure 1. This method is becoming more
popular than dot blots which use radioactive or non 
radioactive probes for the detection of PCR product based 
on the principle of Hybridisation. The main advantages of 
the PCR ELISA technique are that it is useful for
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screening large numbers of samples as well as increasing 
the sensitivity of DNA detection.
Fears of problems with contamination seem unfounded when 
proper precautions are under taken.
FIGURE 1 
PCR ELISA
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Figure 1 shows the principle of one method of PCR ELISA 
(adopted from the Boehringer Mannheim: PCR applications 
manual 1995: Chapter 4 page 69). During the DIG labelling 
step (a), Tag DNA polymerase incorporates digoxigenin-11- 
dUTP (DIG) into the target DNA during 25-35 amplification 
cycles. During the DIG detection step (b), a biotin- 
labelled oligonucleotide probe "capture" the DIG-labelled 
PCR products (target DNA). The probe-PCR product hybrid 
is immobilised on a strepavivdin-coated microtiter plate 
and detected with peroxidase-conjugated anti-dioxigenein 
antibody and ABTS* colorimetric substrate.
PCR product is amplified using the standard procedure 
with the incorporation of dioxigenin-ll-dUTP (DIG) during 
PCR (Figure la).
Alternatively another method, using the biotinylated 
primer already synthesised for DNA seguencing using the 
Sequenase Images kit (USB) (chapter 8.1) could also be 
employed. Microtitre plates coated with a double stranded 
DNA binding protein would bind PCR product while primer 
would remain unbound. Double stranded DNA would then be 
denatured by the addition of high salt concentrations. A 
biotinylated probe complementary to a region within the 
PCR product would be applied which if bound could be 
detected using the strepavidin linked alkaline-phosphatase 
detection method as used for DNA seguencing. The use of 
the internal control could be incorporated into this test 
system by the design of another biotinylated probe 
flanking the ligation junction. This seguence would not be 
present in the PCR product. Aliguots from the PCR assay 
could then be applied in duplicate in the microtitre wells 
allowing for one well to be probed using the probe 
complementary to the PCR product while the other probe 
would be complementary to the internal control. Numerous 
variations of the test such as the probe label (horse 
radish peroxidase) and subseguent detection system could 
be also be applied.
From this study it may be concluded that
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(I) Both BHV1 genotypes are present in Ireland. The first 
Irish isolate of BHV1 was from a case of conjunctivitis 
and has been designated as BHV1.2. BHVl. 1 has been in 
Ireland since at least 1988 and has been associated with 
some of the more severe outbreaks of respiratory disease 
in the past eight years.
( I I )  A PCR assay has been developed, optimised and 
validated to detect BHVl in viral tissue culture 
supernatants and is thus available for confirming the 
presence of BHVl 1 in cell cultures. The assay has also 
been shown to detect BHVl from of both BHVl genotypes as 
well as a large number of field isolates.
( I I I )  The assay compares favourably with the other two 
diagnostic procedures, VI and FAT, currently available for 
BHVl detection in diagnostic samples. Its use may be as 
part of surveillance against the entry of new more 
virulent stains of BHVl which may become more prevalent 
since the introduction of free movement of cattle within 
member states of the EU.
( I V )  An extraction procedure using the chelating resin 
Chelex 100 provides a simple and rapid method for viral 
DNA extraction from diagnostic submissions. However the 
use of an internal control with this extraction procedure 
is recommended.
(V) The inoculation of calves with the BHVl isolate W199 
associated with pharyngitis caused only a mild respiratory 
disease in infected cattle. The genotype of the inoculant 
(BHV1.1) remained the same after passage in cell culture 
and after passage in the infected cattle indicating that 
age and farm conditions may be important in the course of 
disease.
( V I )  Finally the study also compared the use of several 
Non-Isotopic sequencing kits for the sequencing of the 
BHVl PCR product. While the use of such techniques in 
particular USBs Non-Isotopic sequenase images kit gives 
sequence data comparable to that obtained using isotopic 
techniques only partial sequence of the BHVl PCR product 
using this technique was possible despite the inclusion of
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a wide range of techniques recommended for overcoming 
problems associated with sequencing PCR products and DNA 
template of high GC content. It was therefore concluded 
that by the nature of the template sequence the product 
could not be sequenced using Sanger dideoxy method.
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APPENDIX
Appendix A:
Appendix A lists samples tested by FAT,VI and PCR, the sample 
type and the result obtained. Other viral pathogens if detected 
are indicated in brackets
LAB REF (Sample type) FAT VI PCR
D325 Swab) - -
D346 Nasal 
secretion)
- - -
D405 Nasal
secretion)
- - -
D427 (Swab) - - -
D433 Tissue) - - -
D437 Swab) NS - -
D438 Swab) NS - -
D465 Swab) - - -
D469 Swab) PQ + +
D497 Swab) - - -
D498 Swab) - - -
D499 Swab) - -
D517 Tissue) - - -
D550 Swab) - - -
D568 Swab) - - -
D588 Swab) - - -
D590 Swab) NS - -
LAB REF (Sample type) FAT VI PCR
D646 Nasal 
secretion)
- -
D647 Nasal
secretion)
- - -
D678 Tissue) + (RSV) + -
D678 Tissue)
+ (RSV)
+ +
D680 Tissue)
+ (RSV)
+ +
D681 Tissue) + (RSV) + +
D685 Swab) - - -
D703 Swab) + - +
D714 Swab) - - -
D716 Swab) - - -
D718 Swab) - - -
D7 34 Swab) — _ -
D783 Swab) — - D
E830 Swab) + + -/+TC
E436 Nasal 
secretion)
- - -
E140 (Ocular 
secretion)
- + +
LAB REF (Sample type) FAT VI PCR
E133 (Tissue) - (RSV) — -
E134 (Tissue) - (RSV) - -
E135 (Tissue) — — -
E138 (Swab) - (RSV) — -
E139 (Swab) - -
E143 (Swab) — - -
E171 (Swab) - - -
E17 3 (Swab) — - -
E222 (Swab) - (RSV) - -
E230 (Swab) TFC — +
E266 (Swab) - (PI3) - -
E301 (Tissue) - (PI3) — -
E338 (Swab) - (RSV) — -
E340 (Swab) - - -
E345 (Swab) — - -
E364 (Tissue) — - -
E419 (Tissue) - - -
E427 (Swab) - (PI3,RSV) - -
E431 (Swab) - - -
E453 (Tissue) - - -
E457 (Tissue) — - -
E458 (Tissue) - (PI3) - -
E459 (Swab) — - -
E463 (Tissue) - - -
LAB REF (Sample type) FAT VI PCR
E457 Tissue) - - -
E458 Tissue) - - -
E459 Tissue) - — -
E463 Swab) + — +
E464 Swab) - (PI3) - -
E465 Swab) + — -
E467 Swab) + — -
E470 Swab) - - -
E474 Swab) - - -
E485 Tissue) — — -
E486 Tissue) -(RSV) - -
E489 Swab) — - -
E766 Swab) + + +
E795 Swab) TFC - -
LAB REF (Sample type) FAT VI PCR
F313 (Swab) + + +
F973 (Nasal
secretion)
NS - -
F985 (Nasal
secretion) -(PI3)
- -
F986 (Nasal
secretion) “ (PI3) —
-
F987 (Nasal
secretion) “ (PI3)
- -
F988 (Nasal
secretion) ~(PI3)
- -
J683 (Swab) - -
LAB REF FAT VI PCR
G7 80 (Tissue) NS + +
G677 (Tissue) + + +
G7 67 (Swab) - - -
G770 (Tissue) PQ + +
G835 (Tissue) - - -
G837 (Swab) - (PI3) - -
G841 (Tissue) - (RSV) - -
G842 (Tissue) - - -
G844 (Swab) - (RSV, PI3) - -
G87 6 (Tissue) - (PI3 , RSV) - -
G878 (Tissue) - (PI3, RSV) — -
G879 (Nasal Secretion) — - -
G907 (Tissue) - - -
H8 (Swab) - + +
H168 (Tissue) - - -
H131 (Swab) - - -
H186 (Swab) - -
H46 (Swab) - - -
H405 (Swab) - - -
H423 (Swab) — - -
H437 (Swab) - - -
H439(Tissue) — - -
H27 4 (Tissue) — + +
H441 (Tissue) - - -
H443/44 (Tissue) + - -
PQ Poor Quality
TFC Too few cells
NS No corresponding slide
TC Postive on supernatant of first passage
O'Hare Animal Feed
Appendix B:
Protein 16 % Vitamin A 6,000 U/ Kg
Oil 5 % Vitamin D 3,200 U/ Kg
Fibre 9.0 % Copper 40 mg/ Kg
Ash 8.0 %
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